

1_ONCODNA-COM-FOR-HEALTHCARE-INSTITUTIONS-ONCODEEP-OUR-COMPREHENSIVE-CANCER-BIOMARKER-TE

OncoDEEP®SolidBiopsyTestforPersonalizedCancerCare

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogleTagManager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDEEP® : Our comprehensive cancer biomarker test 

Turn deep insights into personalized cancer treatment strategies 

CANCER TYPE: Solid tumors, incl. CUP cancer

SAMPLE TYPE: FFPE tumor tissue

BIOMARKERS: 638 DNA, 20 RNA and cancer-specific proteins

GENOMIC SIGNATURES: HRD, MSI, TMB, LOH

TURNAROUND TIME: <2 weeks 

COMPREHENSIVE BIOMARKER TEST DESIGNED TO GUIDE ONCOLOGISTS IN THEIR TREATMENT OF SOLID TUMORS

When your patients are diagnosed with a rare cancer type, when chemotherapy doesn’t work or when cancer comes back, OncoDEEP can help you unlock the molecular insights that you need to plan your treatment strategies.

Compared to single-gene tests, is a comprehensive biomarker test that screens for a very wide range of cancer biomarkers in parallel. This 360-degree approach reduces the costs of testing and delivers faster results in the selection of appropriate cancer treatment options.

OncoDEEP is the most comprehensive biomarker test available on the market. The test targets cancer biomarkers carefully selected for their clinical relevance, and it offers a unique combination of analyses that proved to maximize the clinical benefits for cancer patients.

In one simple biomarker test and in less than two weeks, OncoDEEP can help you to: 

Identify the cancer treatment options that match your patient's tumor profile;

Reveal early indication of treatment resistance and spare nonresponders the toxicity of a treatment with no therapeutic benefit;

Consider appropriate oncology clinical trials that are currently recruiting;

Understand why chemotherapy stopped working.

Stage 3-4 solid tumors in adults
Glioblastoma in children
Cancer of unknown primary

Recurrence of cancer
Highly aggressive or rare cancer
Cancer of unknown primary

Choose your OncoDEEP formula : 3 versions available 

FeaturesTherapeutic predictionAt DNA and RNA level according to international guidelinesNGS panels638 genes DNA + 20 genes RNAGenomic signatures (MSI, TMB, HRD)IncludedTERT promotorIncludedMethylation (MGMT, MLH1)Not includedAdditional BiomarkersNot includedClinical UtilityTargeted therapyBased on NGSImmunotherapyBased on NGS (TMB & MSI)Hormone therapyBased on NGS (ESR1/AR genes & ARv7)Clinical trials (II & III)Based on NGSChemotherapyToxicity based in NGSSample RequisitionsSample typeBlock or if not possible 7 slides of 10 μm Non-Superfrost™ Plus

OncoDEEP 

FeaturesTherapeutic predictionAt DNA, RNA and protein level according to international guidelines and or scientific evidenceNGS panels638 genes DNA + 20 genes RNAGenomic signatures (MSI, TMB, HRD)IncludedTERT promotorIncludedMethylation (MGMT, MLH1)Included for specific cancer typesAdditional BiomarkersIncludedTumor-specific IHC Supported by clinical and/or scientific evidenceClinical UtilityTargeted therapyBased on NGS + IHCImmunotherapyBased on NGS (TMB & MSI) +Based on IHC : PD-L1, CD-8Hormone therapyBased on NGS (ESR1/AR genes & ARv7) + IHC markersClinical trials (II & III)Based on NGS + IHC markersChemotherapyToxicity based in NGSSample RequisitionsSample typeBlock or if not possible: 15 slides (7 slides of 10 μm Non-Superfrost™ Plus and 8 slides of 5 μm Superfrost™ Plus) excepted for Breast HR+ cancer : 20 slides (7 slides of 10 μm Non-Superfrost™ Plus and 13 slides Superfrost™ Plus) Block mandatory for CUP

Download our brochure to have list of genes and product specifications of the OncoDEEP 

Consent(Required) I agree to the privacy policy.

OncoDEEP: Turn deep insights into personalized treatment strategies

Precision medicine has changed the way cancer is treated. With OncoDEEP biomarker test, clinicians can obtain deep insights into a patient’s solid tumor and receive a report with all the appropriate cancer treatment options, such as chemotherapy, immunotherapy, targeted therapy, hormonal therapy, and oncology clinical trials. 

The role of fusion genes for cancer screening and therapy selection

With advances in precision medicine, there now exist therapies that target gene fusion in solid tumors. Unlike most common biomarkers, gene fusions are complex biomarkers that are visible at both DNA and RNA levels. Our Senior Scientist explains why it is so important to screen for fusion genes and what the methods available are. 

Discover the molecular profile of a tumour​Thanks to biomarker testing, it is now possible to examine the therapeutic vulnerabilities of a solid tumor. Running one single comprehensive biomarker test is often cheaper and faster than deploying multiple genomic cancer tests on small NGS cancer panel. It is also less likely to exhaust a tumor tissue biopsy. OncoDEEP uniquely combines IHC testing and NGS testing, targeting a large cancer panel of over 600 genes and cancer-specific biomarkers. It reveals patients' response to targeted therapy, immunotherapy, hormonal therapy, chemotherapy and oncology clinical trials - screening for cancer gene mutations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers.Obtain patient-specific clinical recommandations​OncoDEEP biomarker test comes with a clinical interpretation of the complex genomic and molecular data. The interpretation is supported by OncoDNA’s proprietary curated database that matches your patient’s tumor profile with relevant cancer treatment options. Our database is kept up to date with all the latest developments in cancer treatment. The final report will be made available in less than two weeks on OncoSHARE, our secure clinical decision support software. On OncoSHARE, you will be able to visualize your patient report, download it in PDF format, and discuss your patient case with other healthcare professionals through virtual meetings and tumor boards.Benefit from an individual support every step of the wayFrom the selection of the appropriate biomarker test to the collection of the tumor tissue sample and the interpretation of the clinical report, our teams are at hand to assist you every step of the way. You can request support at any time. Should you need assistance on whether biomarker testing is relevant for your patient, on how to order an OncoDEEP test, how to prepare the tumor tissue and ship the specimen, how to navigate through our clinical decision support platform, or how to read the final report with clinical recommendations, we are here to help!​ 

Carcinoma of Unknown Primary 

Carcinomas of unknown primary are a diagnostic and therapeutic challenge for oncologists. They account for 3%–5% of newly diagnosed advanced malignancies, with chemotherapy as standard of care. By definition, patients diagnosed with CUP cancer have metastatic disease, but the specific site of the primary cancer is unknown. Consequently, traditional treatment approaches, which rely on the site of origin being known, are often ineffective.

At OncoDNA, we can help identify the cancer type of your patients by running a set of IHC tests based on ESMO guidelines. The technology has proven successful, with oncologists observing treatment response and prolonged overall survival rates in their CUP cancer patients.

While biomarker testing does not always succeed in identifying the primary origin of a cancer, OncoDEEP comprehensive biomarker test can help you identify cancer treatment options likely to improve clinical outcomes, deliver the right treatment at the right time and avoid your patient the toxicity of an ineffective standard chemotherapy. 

	I think biomarker testing with broad NGS panel should be used more frequently at initial diagnosis. If we run such a test before the first-line treatment, we can map the entire treatment journey for a patient and choose the best options for the first and following lines of therapy. When patients lack treatment options, biomarker testing enables us to screen for options beyond standard treatments. Comprehensive biomarker testing covers not only molecular markers for targeted therapy but also predictive biomarkers for immunotherapy. 	

Dr ShapochkaMolecular Pathologist, Kiev, Ukraine 

	The challenge with cancer of unknown primary is to identify the best treatment for a patient. I found a solution in OncoDNA test. It tells me exactly which chemotherapy is best for my patients. Since I started using the biomarker test, a third of them have had a complete response. Actually, the overall cancer survival rate is the highest among all the stage 4 cancer patients that I treat. I absolutely recommend OncoDNA test to oncologists.	

Dr D'ErricoHospital Universitario Quirónsalud, Madrid 

	The amount of tumor tissue is very limited in some cancer types. Running one biomarker test after the other is a problem. The solution is to run all the biomarker tests together, thus combining NGS with IHC testing for protein expression and RNA expression.	

Prof ErAcıbadem University Medical Faculty, Istanbul 

	I think we have to move comprehensive biomarker testing at diagnosis in order to be able to map out the best treatment options for our cancer patients. We should not delay the test until the end. We are living a revolution in oncology. Precision medicine is the present and the future, and I recommend all oncologists to embrace it and use such biomarker tests.	

Dr FuscoLa Milagrosa Hospital, GenesisCare, Madrid 

What is comprehensive biomarker testing?

Comprehensive biomarker testing – also known as comprehensive genomic profiling or genomic cancer test or molecular diagnostic test – is a next-generation sequencing (NGS) approach that uses a single assay to detect relevant cancer biomarkers, alterations in genes that are known to drive cancer growth, as established in guidelines and clinical trials, for therapy guidance. OncoDEEP goes one step further by integrating tumor-specific biomarker analyses to maximize the clinical benefit for the patients.

Why combine DNA, RNA and protein analyses?

Combining different biomarker analyses is the key to maximize the clinical benefit for the patients. A study demonstrated the clinical utility of integrating DNA, RNA and proteins in one single biomarker test. The trial was led on 1,057 advanced cancer patients in 30 countries on 4 continents that had already experienced treatment failure(s).

Which assays does the OncoDEEP include?

The OncoDEEP comprehensive biomarker test combines NGS with IHC testing to screen for genomic alterations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers of response to targeted therapies, immunotherapy, hormonal therapy and chemotherapy. The technology is robust and accurate, and the genes of the panel were carefully selected based on their biological and therapeutical relevance.

Why is important to look at mutations at the RNA level?

Analyses of RNA genes enable the identification of gene fusion and unusual splicing variants that are present in solid tumors and that may predict a patient’s sensivitity to targeted therapy or homorne therapy. An example is the targeted therapy “larotrectinib”. A pan-cancer drug that targets abnormal TRK gene proteins in patients with NTRK fusion cancer.

Do you analyze RNA genes for all solid tumors?

The OncoDEEP panel includes 20 RNA genes (e.g. NTRK gene, FGFR gene, BRAF gene) that are associated with personalized medicines. Those personalized medicines can be a targeted therapy, a hormonal therapy, or an oncology clinical trial that is currently recruiting. We do not make any distinction between solid tumor types and we run RNA sequencing for all patient cases, be they diagnosed with a breast cancer, ovarian cancer, NSCLC, prostate cancer or a glioblastoma to name a few.

For which cancer types can I use OncoDEEP?

Comprehensive biomarker testing is recommended for adults with stage 3 cancer or stage 4 cancer with solid tumors – such as metastatic breast cancer, stage 4 lung cancer, stage 3 colon cancer, metastatic prostate cancer, stage 4 ovarian cancer – or for children with brain cancer. In case of cancer of unknown primary (CUP cancer), OncoDEEP can help decipher the primary origin of the tumor and guide clinicians towards approved therapies or drugs currently in development in oncology clinical trials.

When is the best time to use OncoDEEP?

OncoDEEP can be used at diagnosis or at disease progression to identify biomarker-matched targeted therapies or biomarker-stratified clinical trials. It can also provide physicians with extra therapeutic guidance when chemotherapy does not work; when new biomarkers are required for second-line treatment; when cancer comes back; or when patients are diagnosed with highly aggressive cancer or a rare cancer type like a cancer of unknow primary.

What are the specimen requirements for OncoDEEP?

OncoDEEP can be performed on tissue biopsy, fine needle biopsy​ or bone marrow aspirate.​ The quality of laboratory test results is highly dependent on proper specimen collection and handling procedures. Our teams can guide you through our sample preparation protocol in case of any questions. All histologic samples will be reviewed by a pathologist after reception at OncoDNA.

Is OncoDEEP accredited and certified?

The ISO 15189 (Medical laboratories-Requirements for quality and competence), CE-IVD (In vitro diagnostic devices complied to be sold in Europe), ISO 27001 (Information security management) and ISO 13485:2016 (Quality Management System) apply to our OncoDEEP comprehensive biomarker test.

How can I order an OncoDEEP biomarker test?

Ordering a solution is very simple: Just log in to OncoSHARE and select the biomarker test(s) you are interested in. If you do not have a kit for the collection of the FFPE tissue sample, we will send you one.

Are OncoDEEP biomarker tests available across the world?

You can order an OncoDEEP from anywhere in the world. In the United States, OncoDEEP can be used for academic projects only. The test cannot be used for molecular diagnostics yet.

How do I get the results of my OncoDEEP test?

After FFPE tissue sample processing and data interpretation, a comprehensive and interactive report will be made available for you on OncoSHARE, our secure clinical decision support software. It will help you select the most appropriate treatments based on the unique signature of your patient’s tumor. You will also be able to share the report with your colleagues.

How long does it take to receive the results from an OncoDEEP test?

It takes about 10 working days from the FFPE tissue sample quality control check to reporting on our clinical decision support system.

What is the price of an OncoDEEP biomarker test?

For information regarding the price of our OncoDEEP® biomarker test in your respective country, please contact our sales team.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712094398



2_ONCODNA-COM-FOR-CLINICAL-RESEARCH-TRANSCRIPTOMIC

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedby Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

The transcriptome is comprised of all RNA molecules including mRNA, rRNA, tRNA, and other non-coding RNA transcribed in one cell or a population of cells. OncoDNA is a leading expert in the study of the transcriptome and the measure of RNA expression. 

RNA-Seq uses deep sequencing technologies for transcriptome profiling that provides more precise measurement of levels of transcripts and their isoforms than other methods. OncoDNA is an expert with RNA-Seq and can assist researchers to design and implement a wide variety of RNA-Seq related studies.Experience across a full range of RNA-Seq study types.We also offer clinical grade RNA-Seq for personalized medicine studies.Cutting-edge, constantly updated bioinformatic pipelines.We can provide you with advice on experimental design.from study design through tertiary biostatistical analysis.

We have developed a powerful workflow to access cancer gene expression signatures. Dowload our paper to discover the technical features of our 3’ RNA-seq protocol for accurate gene transcriptomic analysis of challenging tumor samples. 

OncoDNA has developed and streamlined a process for measuring small RNA expression in tissue samples and liquid biopsies (serum or plasma) via next generation sequencing. We offer researchers a small RNA sequencing service for examining gene regulation at both the transcriptional and post-transcriptional level.

We offer a proprietary protocol for small RNA-SEQFully optimized process – from extraction to bioinformatics.Start with either frozen or FFPE tissue, circulating blood cells, or liquid biopsies.Able to extract total RNA from either plasma or serum.Library prep uses random adapters via in-house developed protocolReduces bias representationProvides better correlation.State-of-the-art analysis using snRNAbench mutational signatures. 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712114957



3_ONCODNA-COM-SUBMIT-COMPLAIN

OncoDNA:SubmitaComplaint

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

If you have any general concerns, comments or complaints regarding our products or services, please use this form to submit a complaint to our QA department. The complaint will be processed within two working days and we will contact you back. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

IntegraGen S.A.Genopole Campus 1 – Bât. 85, Rue de Henri DesbruèresFR-91000 Evry

+33 (0) 1 60 91 09 00 

BioSequence S.L.Avenida Amado Granell Mesado nº75, oficina 8BES-46013 Valencia

+34 (0)96 071 91 34 

If you have questions or need assistance, please contact us. Our teams are available from Monday to Friday, 9 AM to 5 PM CET. 

"*" indicates required fields

First name :* Email :*

DD slash MM slash YYYY

I would like to receive regular updates about OncoDNA products, services, activities and educational material.
Consent* I confirm that I have read the and I agree the personal data that I have provided will be used by OncoDNA according to the .EmailThis field is for validation purposes and should be left unchanged.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Privacy Policy

Privacy Policy

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712101739



4_ONCODNA-COM-FOR-PHARMA-COMPANIES-KNOWLEDGE-DRIVEN-MEDICINE

Knowledge-DrivenMedicineforClinicalTrials

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

A unique data interpretation pipeline, from patient to trials meta-analyses 

OncoKDM is the first personalised bioinformatic assistant that can be customised to your specific needs and your bioinformatics pipeline. It is a highly-secured platform, accessible through the web which will turn your data into useful knowledge, without investment in hardware or IT staff.

OncoKDM can integrate sequencing data from any platform with any other test performed in the laboratory. Through proprietary algorithms, OncoKDM can analyse and integrate the information to enable relevant biological and clinical interpretation. 

OncoKDM: Make it your data interpretation pipeline, from patient to trials meta-analyses

Based on its expertise in giving sense to molecular data obtained from individual cancer patient tested in routine, OncoDNA has developed a specific environment to allow clinical data integration and interpretation. Clinical background, treatment history, molecular characterisation data, treatment arm, clinical outcomes, … so many different types of data OncoDNA can extract knowledge from. 

Integrate genomics, molecular pathology, IHC test results, and clinical data.

DNA (Ion Torrent, Illumina,…), RNA (microarray, transcriptome), protein (IHC, MS,…) 

Compatible with third party data sets QC and biomarker calling.

Customise the bioinformatics pipeline, personalise the report according to your needs and specifications 

Secure and robust web portal giving access to data and interpretation to every eligible partner.

Standardise your data to simplify further meta-analyses. 

Connect with one or a list of collaborators and share and discuss the report remotely and securely to make the right decision. 

They trust our expertise 

	Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions.	

M.D. PH.D ANTONIO GUALBERTOHead of Development and Chief Medical Officer, Kura Oncology - USA 

	The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)	

DR. ALAN L. HOOncologist, Memorial Sloan Kettering Cancer Center - USA 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712110917



5_ONCODNA-COM

OncoDNA:YourOncologyLabPortalforhealthcare

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solutions

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Precision medicine solutions for healthcare institutions, pharmaceutical companies and academic researchers 

	A unique dedicated portal with high-value scientific materials and major updates in the field of oncology, genetics and precision medicine.	

 Case of the Month
March: 42-year-old male with a metastatic colorectal cancer

Here we will describe the case of a man of 42 years old diagnosed in 221 with metastatic colorectal cancer. 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Press Release
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.Feb 28th

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.   Gosselies, Belgium and Paris,...Read more → Article
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing servicesFeb 23rd

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...Read more → Case of the Month
February: 4-year-old male with a stage IV glioma cancer2 min readingFeb 2th

OncoDEEP® identifies rare mutations & personalizes treatment for a 4-year-old male with a stage IV glioma cancerRead more → Webinar
Advancing personalized cancer treatment: Webinar ReplayFeb 19th

Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...Read more → Poster
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer5 min readingJan 22nd

Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...Read more →

 Webinar
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinarJan 22nd

Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...Read more →

 Press Release
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccineJan 17th

Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...Read more →

 Case of the Month
January: 45-year-old male with an intrahepatic cholangiocarcinoma2 min readingJan 16th

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...Read more → Poster
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers5 min readingJan 8th

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...Read more → 

They trust us, we trust them 

Years of trust, countless tests run, genes, and trials explored. 

0

Of knowledge that matters

0

0

0

OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.  

Stay in the know​

Get the latest resources, news and more.	

monthly
NameThis field is for validation purposes and should be left unchanged.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712130453



6_ONCODNA-COM-FOR-PHARMA-COMPANIES-PRECISION-ENROLLMEN

PrecisionEnrollmentforClinicalTrials

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Meet your recruitment targets and deadlines by granting treatment access to fully characterised patients 

	Many targeted clinical trials are not solely related to gene alterations but also depend on the expression of a specific protein, the presence of a novel mRNA transcript, the occurrence of a methylation event or the expression of a checkpoint inhibitor biomarker.

Hence, the best treatment options cannot be established by relying merely on DNA analysis. OncoDNA characterises patients by NGS and searches for specific SNVs, CNVs, indels and translocations. We also rely on molecular pathology tools to monitor the expression of specific receptors or biomarkers using IHC and by assessing methylation status.

This approach offers the highest chances to find a match between a patient looking for an effective treatment and a biopharma company recruiting patients for their trial.	

Meet your recruitment targets & deadlines by granting treatment access to fully characterised patients

More and more oncology clinical trials do not meet enrollment deadlines and sometimes fail to meet recruitment targets. The increase in the number of clinical trials and in the complexity of recruiting patients has made patient enrollment a crucial aspect of clinical trials in oncology. Thanks to its extensive oncology network and patient testing services, OncoDNA can bring together patients searching access to treatment and recruiting clinical trials. 

Reduce delays and costs

OncoDNA characterises patients from all over the world.
Access a pool of patients fully characterised to serve you R&D and clinical trials.

In some cases, the best or only treatment options left are compounds which are still under clinical development. 

Fast growing oncologist numbers

Some patients tested by OncoDNA are in desperate need to get access to these clinical trials.

Our job? To help patients and biopharmas with targeted recruitment.

Our program is driven by the fast-growing number of patients and oncologists using OncoDNA solutions. 

They trust our expertise 

	Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions.	

M.D. PH.D ANTONIO GUALBERTOHead of Development and Chief Medical Officer, Kura Oncology - USA 

	The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)	

DR. ALAN L. HOOncologist, Memorial Sloan Kettering Cancer Center - USA 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712109564



7_ONCODNA-COM-FOR-HEALTHCARE-INSTITUTIONS-ONCOSELECT-OUR-BIOMARKER-TEST-ON-LIQUID-BIOPSY

LiquidBiopsyforHealthcareProviders

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogle Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solutions

Solid Biopsy (Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Our pan-cancer biomarker test on liquid biopsy 

Liquid biopsy

2 blood samples 

Targeted Liquid Biopsy to Your Clinical Decisions

OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for all advanced cancer patients.

When patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT is the perfect alternative to help in treatment strategies optimization and to support clinical decisions. It can be used as a tool to detect treatment resistance to targeted therapies and hormone therapies (before first line to assess the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations or to inform on the patient’s response to chemotherapy in neoadjuvant settings) as well as determine patient potential eligibility to clinical trials. 

SAMPLE TYPE: 

All types of stage III and IV solid tumors in adults 

58 genesSNVs, IndelsGene translocations, unusual splicingTERT promoter

MATERIAL: 

2 blood samples (2x10ml Streck tubes) 

The Added Value of ctDNA 

Identify sensitivity/resistance to therapy

OncoSELECT detects potential sensitivity or resistance to targeted therapies and hormone treatments by targeting 58 genes associated with treatment response (SNVs, indels, translocations and TERT promoter).

It is recommended for patients whose tissue sample is not available or is limited, when it is challenging or not possible to perform a solid biopsy, or if the tumor tissue sample is too old. 

	OncoDNA scientific team regularly publishes studies in peer-reviewed international journals. We have selected for you the key scientific publications that highlight the clinical impact of our biomarker tests.

	Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization	

	Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN	

	The clinical impact of using complex molecular profiling strategies in routine oncology practice	

	The combined analysis of solid and liquid biopsies provides additional clinical information to improve patient care	

	J. of Cancer Metastasis and Treatment	

OncoDEEP® 

Comprehensive biomarker test to support clinical decisions

OncoDEEP® offers a unique combination of DNA, RNA and protein biomarker tests on solid biopsies. In less than two weeks, OncoDEEP is able to pinpoint the therapeutic vulnerabilities of an advanced, metastatic tumor and to recommend appropriate treatment options. The test screens for genomic alterations (DNA & RNA), genomic signatures (MSI, TMB, HRD) and protein biomarkers of response to targeted therapies, immunotherapies, hormone therapy and chemotherapy. 

Personalised liquid biopsy for patient monitoring

OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.

This assay is customised for each patient, as it analyses variants previously identified in the tumour of the patient.

In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test. 

How can I order an OncoSELECT biomarker test?

Ordering a solution is very simple: Just log in to OncoSHARE and select the solution(s) you are interested in. If you do not have a kit for sample collection, we will send you one.

How do I get the results of an OncoSELECT biomarker test?

After sample processing and interpretation by our expert team, a comprehensive report will be available for you on OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient’s tumour. Moreover, you will be able to share the report with your colleagues.

 What is the price of an OncoSELECT biomarker test?

For information regarding the price of our OncoSELECT biomarker test in your respective country, please contact our sales team.

Cannot find what you are looking for? ! Our Scientific Support Teams are available to answer all your questions from Monday to Friday. 

 us

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

Contact

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712110914



8_ONCODNA-COM-AWARD

AwardsandRecognitions-PioneeringPrecisionOncology

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySite Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

	Since our early days in 2012, we have established a proven track record in precision oncology. Local and international institutions have recognised our continuous growth, empowering our team to redouble efforts to make precision medicine in oncology a reality. Whatever the challenges, we will continue to set the bar high and to disrupt technology in personalised cancer therapy.

Winner of Deloitte’s 2020 Technology Fast 50

Deloitte Belgium granted us for the second time the award of the fastest growing tech company headquartered and founded in Belgium in the biotech and pharma category. “Winning the award multiple times is very rare, as each year the challenge to grow our turnover is more and more difficult”, said Jean-Pol Detiffe, Founder of OncoDNA. 

Winner of Deloitte’s 2018 Technology Fast 50

We won Deloitte Belgium’s Fast 50 Technology Competition in the healthcare and life sciences category for the first time in 2018. The award recognised OncoDNA as the fastest growing tech company in the field in terms of percentage of growth in turnover over the past four years. 

Winner of the AWEX’s Tremplin Export Prize

The Wallonia Export-Investment Agency (AWEX) awarded us the Tremplin Prize “Grande Exportation”. The prize recognised our successful export performance, following our global expansion into over 60 countries most notably beyond Europe. Mr. Paul Magnette, former Wallonia’s Minister-President, was present at the award ceremony. 

Interview with Jean-Pol Detiffe

Winner of Deloitte’s Most Disruptive Innovator Award

OncoDNA was named “Most Disruptive Innovator” in the rising star category of Deloitte Belgium’s Fast 50 Technology Competition in 2015. The award recognises fast growing companies that have developed a product or services that make very high-end technology accessible for wide application and use. 

Winner of EY Entrepreneur of the Year Award

Ernst & Young celebrated our entrepreneurial achievement by electing us as the Most Promising only three years after our foundation in 2012. The global program supports companies that demonstrate vision, leadership and success. 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

Company 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129202



9_ONCODNA-COM-PRESS_RELEASE-REVOLUTIONARY-TREATMENT-FOR-COLORECTAL-CANCER-ONCODNA-JOINS-THE-PDCNEO-PROJECT-FOR-A-PERSONALISED-THERAPEUTIC-VACCINE

PDC*neo+Project:PersonalizedVaccineforColorectalCancer

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine 

Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA) analysis, this project, supported by the Walloon Region and the Wallonia BioWin Health Cluster, heralds a new era in cancer immunotherapy.
What is the PDC*neo+ project?

The PDCneo+ project focuses on the development of a personalised therapeutic vaccine for colorectal cancer, called PDCneo+. Using PDC*line Pharma’s innovative technology, this vaccine targets unique neoantigens in each colorectal cancer patient. This approach represents a revolutionary development in the field of cancer immunotherapy.

OncoDNA brings its expertise in neoantigen identification and ctDNA analysis. Jean-Pol Detiffe, founder and scientific director of OncoDNA, expresses his enthusiasm: “We are thrilled to be a part of this cutting-edge project and clinical trial at OncoDNA. It acknowledges our expertise in uncovering neoantigens and our robust track record in liquid biopsy monitoring through the detection of circulating tumor DNA (ctDNA)“
The importance of regional support

The selection of the PDC*neo+ project by the Walloon Region and the BioWin health cluster underlines the importance of supporting innovative initiatives in the field of biotechnology. This strategic partnership is crucial to advancing research and the development of revolutionary treatments.

 To find out more about the PDC*neo+ project, we invite you to read the full press release. 

Read the full Press Release

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Poster
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers5 min readingJan 8th

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...Read more →

 Press Release
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncologyDec 16th

The Appolo study will assess the impact of biomarker testing on access to precision medicines and on posttreatment surveillance for cancer patients across the sounth of France. OncoDNA, a genomic and theranostic company specializing in...Read more →

 White paper
White Paper: Homologous Recombination Deficiency (HRD) Assessment for Clinical Management using the OncoDEEP® Kit2 min readingMay 14th

The Homologous Recombination Repair (HRR) pathway repairs DNA double-strand breaks (DSB). HRR deficiency leads to the accumulation of genomic aberrations and genomic instability which can promote malignant transformation. This phenotype of loss of the HRR...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712095488



10_ONCODNA-COM-CONTENT-UPLOADS-2024-01-COLORECTAL-CANCER-PERSONALISED-THERAPEUTIC-VACCINE-JPG

 JFIF       Comprssed by jpe-recompress Exif  II*                V       ^   (              i    f       `      `            010�      �    0100�      �    �  �           'http://ns.adobe.com/xap/1.0/ xpacet begin'﻿' id='W5M0MpCehiHzreSzNTczkc9d'?

2

Templates Posts Website - colorectal-cancer-personalised-therapeutic-accine

  
    �j\jP(a�j�@P �%  �)"(�8yw  �   "�( @ Y@� � ,X�K  @       �� c�B�@(@ &B��B���E�XPC(��"���  �q�    @  	@ U� �b,� P ��Q`"�  �@   

�Af\
E�D�@ a��:���   �_���Pg�V�� +(H� ��L ^_>�X�Ŗ4�`h	2bO�

�

	�

�

r�





�

����� �6U[��]�C/���<��|oc�ߖ���ջ���u�� �&��a�=�>^y�jJ�⋽υ�	�:uՂ����_��~.ɫ�1�p�� Q�M�����ƹ+��=�7͏���1u��6�I��	󱺂�FՌ��gUL�O���/���u�zO�O?J�?��~S ���]Qb�;uSL�٨h�,J��.*Kdt	_�_�x0{,+�)�

e���

�Mtà��)y��`3���� ���G�r Hy�\
��H`h�����Y� �^�e��ۉT�ή1d�in�,�m���-�΃[� �o,���~��H"[E9��ye�}��6!��~�|�n2���yv�a��\~�-:��	�X�g(cP��&���g�sa)�)�f#�:���|�v[�

�

�
i;�J6�qH�镾X����d����!ƅd1FF�Ri�n�4�� B�6c:�,W�7�K!\s�?�K�bp'[�Fa �(�2��5��@�d����a2cl�jJ��Pk�[9��ʌ7�#�e}�F6q#R	�Y"G����d0�@��*6�<�����C�ް��I�cػ&	�&�pq0�=�����T�IP?��tŶ��E�%�ƪ�Ԑ0&�c�V`RD�ū�k2@�ƽ2��0C

�Bd2��*�efq#�jxѵ�8��"x��9�1�3;��%���hki��S�X�]�",�:�#���X��|WD� �cb=�h�ʎi�w �- Cx�w���ϡk;��>CV2M*l�ۻ{�J�r�

��

S�E�xgd�?�'[O�F6Y��K�X�dpJ�79\�9����P1��a��z��WPS�i.F'�38w��9�W9ʮ����X��(ɶ����ָЖK֧�MQd�N��uuc3�N<���e�"kd�E�q=3|��� e���>/�_/�۲�ml��;�Gv7Т�\�~��~�d�E�{��]o�g۵��5�[�ԉ�˱=���t�-n����>�wbz5���[kd�}9���|�3�6���� =*zU��;}-�����]���o�W�m��л�<�"�v'�][&�� q�ºMq�'D��m�v]q��5��E��/�wby{���x�
����

�b���jמ�@QE�  ����\�� 	QU5��B�4��4�`Ɓ`��&������.�%}���ّBґQ�񰬎"58���5�J�؞�~=a;gp�

��e



��
�m�D�� ��6���\FcZ��r��W�V����ѻw	��}t����C�yE�5����5%�tY�H��",9/��	(�y	a���aK�� �ǭ

k

�+
�U}�Jƽq��=Bn���s��Ñ�5=� � n}�<���z�}�<�Ly��H �M� � .�	 yE$`A2�4��+��D!K_;���{fX��r�"�

������

X��8����f{6��}
1��u>j�(\�	�:�C@EZ�lhO�~؝�Zɧ�	o�1�Z	���s0���I��S��c� �߱�=�z���S��v#S؃b:

��(6G,j��^ �r����l��tw����)��fr#�=�RT���������h��ىbvA���.�硊�#��� ��v9��)�1P�(�ʢ��L'�3�5B8��j�U� �;T5l��(]�j�V�T����ܶ��JJ��x�C �Ubt�[�Q����Z�

�

v
�

��8g

�K&��U#�)����mͅ82|*�j�Bb��������	�(�E���4x|}5�����;���o�����y+qlm�o�N�Z��?#:�^2�[����b ǈJ1%��ON�������

Us�1=�$"��p!��8	ߤE���F�	�p�n]#��f�導������"��������Ǐ ��a=

���
}�

�i���

��

�:�\D�G>t��f�dM+��?n�*�ͩ�Q�"�;���c~I`��L.B�\���w�}5�|�O�1�u��H@;��UJ�%J�pp� �2+1Q�*_� p JH�(J� �� m� 6���w�P�{ʀ��E� �� (M������A�i^y����:��b� u0���#o o

��U�

��h�

^� @A���;�2ҦɎ��TψP*�K��B��PO�`lj�x���F�lk�[D�W�bb׀�	���m�#�gQs2ddoY}�U"��!���� u>�q�e���� �e�*&�X�_��1��9�]φf}dψ�t����1�w�ve��	!#2ԽD.�ԭ�,�

�?

��P

"�t|���a�P	Bq/����(ۗ�#�D�0�B$�@+��|�%J�,	r� �bD�g�

L�����;�g{<{�% �k��ƝN�"�Q����FCG����u9q&�H�t�@�0ɺ(l�>�XA˄�A��t,���E#���X��g�����"�`�m�G?�O���	��Ln\�,�@|~�26��	E��>i�C��]�s��&7����� ̺�Dʡ\�Ma��2���Q`�@|k���Q7�� �A��t��rK6�~���X����&"~�������6��FG�3�\�͇��

�=
���d��

����

��t�s�+h8��Y���u�����V�d�2���z���Y\�r�rJ�dQAf�p�/�GR6�h�,PZE#�	R�9�W�9������� �؄@��0�.ߴq88��+����v�;�*ϵZ�&|�5v\��js�<˨���2�3a�f���fa�B����vQ�yG�������0��� 7(K���>@0��T�R��.��ϔ�N��������



11_ONCODNA-COM-POSTER-GENOME-WIDE-CIRCULATING-TUMOR-DNA-FOR-MONITORING-TREATMENT-RESPONSE-AND-METASTATIC-RELAPSE-IN-BLADDER-CANCER

AdvancingMIBCTreatment:WGSforMRDDetection

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer 

Figure 1. Schematic of Clinical Sample Collection

Molecular and data analysis Protocol

Genomic DNA from tumor/germline pairs (n=67) and cfDNA from 510 plasma samples were isolated.
WGS of tumor/germline pairs followed by genome-wide integration of somatic mutations, enriched by

signal processing and AI-based error suppression, were used to generate patient-specific tumor

signature (Figure 2).
Patient-specific somatic variants were used for detecting ctDNA levels in about 15 ng cfDNA from plasma

WGS data by the MRDetect5 algorithm (Figure 2)
Clinical data, such as pathological evaluation and radiographic imaging, were first unblinded after

analysis and compared directly to the MRDetect5 plasma call results.

Figure 2. Schematic of Workflow

Figure 3. Concordance between independent laboratories - United States vs. Denmark

Figure 4. Prognostic value of circulating tumor DNA (ctDNA)

Kaplan-Meier survival analysis of recurrence-free survival (RFS)(A+B) and overall survival (OS) (C) stratified by ctDNA status before chemotherapy (or at diagnosis), before cystectomy, and any time after cystectomy.

(A) The follow-up time set to one year after last plasma sample fore each patient if prior to relapse, last CT scan or death.

(B+C) shows Kaplan-Meier analysis for the maximum follow-up time where patients without events were censored at end of follow-up.

Figure 5. Disease courses and longitudinal ctDNA results for the 67 patient study cohort

Longitudinal representation of ctDNA results and clinical parameters. Circles represent ctDNA status (see color code in the right box). Treatment and imaging information is indicated for each patient. Patients are separated into two groups on the basis of clinical relapse status. Metastatic relapse (Patient 1-19); Non Relapse (20-67).

Figure 6. Pathological downstaging vs. ctDNA status at diagnosis, pre-CX and post CX

Association between pathological downstaging and ctDNA status before chemotherapy, before cystectomy, and any time after cystectomy.

Figure 7. Prognostic value of circulating tumor DNA (ctDNA) detection - dichotomized analysis

Association between disease recurrence and ctDNA status before chemotherapy, before cystectomy, and any time after cystectomy.

Figure 8. Monitoring tumor fraction during patient disease courses

Figure 9. ctDNA dynamic during NAC as predictive markers of chemotherapy response

(A) Association between ctDNA dynamic during NAC and pathological downstaging for ctDNA-negative patients (before and after NAC), patients where ctDNA was cleared during NAC, and patients in whom ctDNA remained
(B) Association between recurrence and pathological downstaging (left) and ctDNA dynamics during NAC (right) for patients ctDNA-positive before NAC.

Figure 10. Lead time inferred from ctDNA-based recurrence detection

Lead time in days shown as the differences between first molecular relapse (ctDNA positive) and clinical recurrence (radiographic imaging positive). CT Scan corrected Lead time is calculated as the difference between the first CT scan after molecular relapse and clinical recurrence (see box in figure). The CT Scan corrected Lead time is more restrictive and included to provide a fair comparison to radiographic imaging.

Table 1. Patient Characteristics and Demographics (n=67)

Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within two years post-CX. The effectiveness of current chemotherapy and immune checkpoint inhibitors (ICI) remains limited, highlighting an urgent need for reliable biomarker tests to track therapeutic responses. Additionally, there’s a growing necessity for biomarkers capable of detecting minimal residual disease (MRD) post-CX to commence timely treatment. Recent studies have revealed that analyzing mutations in cell-free DNA (cfDNA) from blood samples offers a promising avenue for monitoring MRD, yet challenges persist due to the low tumor fraction post-surgery and the minimal sample volume typically obtained from plasma.

Study Design: In our groundbreaking study, we enrolled 140 patients battling MIBC who underwent NAC and CX, divided into an initial test group of 19 patients and a subsequent validation group of 121. We collected and analyzed cfDNA from approximately 1mL of plasma, gathered across various stages: during NAC (to measure response), before cystectomy (to measure response), after surgery (for relapse monitoring), and throughout immunotherapy (during ICI treatment). Our approach utilized whole-genome sequencing (WGS) on tumor/germline pairings and plasma cfDNA, enabling comprehensive genomic alteration detection and precise ctDNA quantification via the MRDetect method.

Findings: Our innovative, personalized WGS model, which merges genome-wide mutation data and copy number variations with sophisticated signal processing and AI-driven error minimization, has set a new standard in precision medicine. By identifying patient-specific somatic variants, we achieved remarkable sensitivity in ctDNA detection from low-input blood samples through WGS. This method successfully identified tumor fractions as low as 8*10^-5. Impressively, in our test cohort, we observed ctDNA post-CX in 7 out of 8 patients who later showed clinical relapse (demonstrating 88% sensitivity) and found no ctDNA in 11 out of 11 patients without clinical relapse (showing 100% specificity). Our method also predicted MRD-based recurrence with a significant lead-time advantage of 9 months over traditional CT imaging. These promising results will be further elaborated at the upcoming AACR 2022 conference.

Conclusion: The evolution of precision oncology necessitates the development of quantitative, non-invasive techniques to customize treatment plans and monitor patient progress closely. Our findings underscore the clinical value of integrating personalized genomic mutations for ultra-sensitive, non-invasive MRD detection and treatment response monitoring, offering a new direction in the clinical management of bladder cancer patients. 

 us to find out more about our services

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Press Release
OncoDNA signs collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness projectSep 24th

In the current context of economic and social inequalities in cancer care that exist in many European countries, the need to find the best possible solutions for cancer patients is critical. Technological developments have now...Read more →

 Press Release
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncologyDec 16th

The Appolo study will assess the impact of biomarker testing on access to precision medicines and on posttreatment surveillance for cancer patients across the sounth of France. OncoDNA, a genomic and theranostic company specializing in...Read more →

 Press Release
New molecular diagnostic innovation partnership to facilitate patient access to personalised cancer care across the UKNov 24th

OncoDNA, the healthcare technology company making precision medicine in oncology a reality, has announced the launch of the Molecular Diagnostic Innovation Partnership (MDIP) during a virtual panel discussion co-organised with Rutherford Diagnostics hosting experts from Macmillan Cancer Support, Aviva and...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Contact

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129266



12_ONCODNA-COM-CERTIFICATIONS-ACCREDITATION

Certifications&Accreditations|OncoDNA

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDNA: Quality environment for testing 

Testing activities from our subcontractor lab (and shareholder), IPG, are performed under ISO 15189:2012 (accredited lab since 06/2009). ISO 15189 is an international standard that specifies the quality and competence management system requirements particular to medical laboratories.​ 

OncoDNA’s laboratory in Evry is CLIA certified (Clinical Laboratory Improvement Act) and CAP accredited (College of American Pathologists) to reinforce its global clinical trial testing services.​ 

GCP – Good Clinical Practice ​

OncoDNA is compliant with the Guideline for Good Clinical Practices of the International Conference on Harmonization (ICH GCP E6 R2) for the services provided to its customers. OncoDNA has been audited several times over the years to demonstrate its compliance. 

OncoDNA has a certified Quality Management System in place based on the standard ISO 13485:2016 Quality Management Systems – Requirements for regulatory purposes, covering the design, the development and the servicing of our in vitro diagnostic products. 

GDPR - General Data Protection Regulation

Compliance to GDPR is a central preoccupation for OncoDNA and is supervized by our internal DPO. This compliance ensures greater patient and oncologist confidence in privacy, keeping data subjects’ personally identifiable information secure, improved data security and increased alignment with evolving technologies. 

OncoDNA is implementing ISO/IEC 27001:2022, after having successfully implemented the 2013 version of the norm in 2017. It will cover requirements for Information Security of our applications and Medical Device Software (MDSW). 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712114957



13_ONCODNA-COM-COOKIE-POLICY-EU

CookiePolicy(EU)|OncoDNA

GoogleAnalyticssnippetaddedbySiteKit

EndsnippetaddedbySiteKit

Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

 Legal document generated by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

This Cookie Policy was last updated on March 4, 2024 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland.

Our website, https://oncodna.com (hereinafter: "the website") uses cookies and other related technologies (for convenience all technologies are referred to as "cookies"). Cookies are also placed by third parties we have engaged. In the document below we inform you about the use of cookies on our website.
2. What are cookies?

A cookie is a small simple file that is sent along with pages of this website and stored by your browser on the hard drive of your computer or another device. The information stored therein may be returned to our servers or to the servers of the relevant third parties during a subsequent visit.
3. What are scripts?

A script is a piece of program code that is used to make our website function properly and interactively. This code is executed on our server or on your device.
4. What is a web beacon?

A web beacon (or a pixel tag) is a small, invisible piece of text or image on a website that is used to monitor traffic on a website. In order to do this, various data about you is stored using web beacons.

5.1 Technical or functional cookies

Some cookies ensure that certain parts of the website work properly and that your user preferences remain known. By placing functional cookies, we make it easier for you to visit our website. This way, you do not need to repeatedly enter the same information when visiting our website and, for example, the items remain in your shopping cart until you have paid. We may place these cookies without your consent.

We use statistics cookies to optimize the website experience for our users. With these statistics cookies we get insights in the usage of our website. We ask your permission to place statistics cookies.

/Tracking cookies are cookies or any other form of local storage, used to create user profiles to display advertising or to track the user on this website or across several websites for similar marketing purposes.

Consent to service 

This data is not shared with third parties.

 (anonymous)

elementor

Store performed actions on the website

Consent to service wordpress

This data is not shared with third parties.

al

Store logged in users

Google Analytics

Statistics
Consent to service google-analytics

This data is not shared with third parties.

Statistics

Store and count pageviews

Store and count pageviews

Consent to service google-adsense

This data is not shared with third parties.

Store and track conversions

Consent to service hubspot

This data is not shared with third parties.

Marketing

Store and track a visitor's identity

Marketing
Consent to service mailpoet

This data is not shared with third parties.

Marketing

Marketing
Consent to service google-ads

This data is not shared with third parties.

Marketing

Provide ad delivery or retargeting

Consent to service php

This data is not shared with third parties.

al

Provide functions across pages

Consent to service miscellaneous

Sharing of data is pending investigation

Purpose pending investigation

Function

Function

When you visit our website for the first time, we will show you a pop-up with an explanation about cookies. As soon as you click on "Save preferences", you consent to us using the categories of cookies and plug-ins you selected in the pop-up, as described in this Cookie Policy. You can disable the use of cookies via your browser, but please note that our website may no longer work properly.

7.1 Manage your consent settingsYou have loaded the Cookie Policy without javascript support. On AMP, you can use the manage consent button on the bottom of the page.
8. Enabling/disabling and deleting cookies

You can use your internet browser to automatically or manually delete cookies. You can also specify that certain cookies may not be placed. Another option is to change the settings of your internet browser so that you receive a message each time a cookie is placed. For more information about these options, please refer to the instructions in the Help section of your browser.

Please note that our website may not work properly if all cookies are disabled. If you do delete the cookies in your browser, they will be placed again after your consent when you visit our website again.
9. Your rights with respect to personal data

You have the following rights with respect to your personal data:
You have the right to know why your personal data is needed, what will happen to it, and how long it will be retained for.
Right of access: You have the right to access your personal data that is known to us.
Right to rectification: you have the right to supplement, correct, have deleted or blocked your personal data whenever you wish.
If you give us your consent to process your data, you have the right to revoke that consent and to have your personal data deleted.
Right to transfer your data: you have the right to request all your personal data from the controller and transfer it in its entirety to another controller.
Right to object: you may object to the processing of your data. We comply with this, unless there are justified grounds for processing.

To exercise these rights, please contact us. Please refer to the contact details at the bottom of this Cookie Policy. If you have a complaint about how we handle your data, we would like to hear from you, but you also have the right to submit a complaint to the supervisory authority (the Data Protection Authority).

For questions and/or comments about our Cookie Policy and this statement, please contact us by using the following contact details:

OncoDNA sa
Rue Louis Breguet 1, 6041 Charleroi

 Email: marcom@oncodna.com
Phone number: +32 71 18 35 00

This Cookie Policy was synchronized with cookiedatabase.org on March 4, 2024.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129304



14_ONCODNA-COM-ABOUT-ONCODNA-GROU

OncoDNAGroupMissionstatementandpersuitforbettercare.

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

We are a genomic and theranosticcompany specializing in precision medicine for the treatment of patients with cancer and genetic diseases. 

Our mission : Improving patients' health through precision care 

OncoDNA’s ultimate mission is to improve patients’ outcomes by empowering physicians, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement. 

Based on years of experience and Research and Development, we have been able to develop cutting-edge solutions. Our unique portfolio combines 3 pillars: cancer biomarker tests, genomic services in oncology and data interpretation tools.

OncoDNA, was born in from the idea of making precision medicine a reality in oncology. Combined with other technologies, Next-Generation Sequencing had the power to revolutionize the diagnosis and treatment of cancers and rare diseases and bring the right treatment for the right patient at the right time. 

In just a decade, we have grown into a renown company that drives innovation in research, accelerates drug development and has helped thousands of patients globally. Today, OncoDNA comprises two entities – BioSequence and IntegraGen – and employs more than 120 employees in 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories. 

« When I founded OncoDNA, I wished to bring the best of care to cancer patients and give them new hope. Today OncoDNA is the European champion in precision oncology. I am proud to be working with passionate teams who strive to foster innovation and advance patient care. »

Jean-Pol DETIFFE, Founder of OncoDNA 

Driving innovation in molecular profiling

Better understanding the behavior and molecular characteristics of a disease is key to improve patient journey and clinical outcome. At OncoDNA, we are specializing in the genomics and theranostics of cancer and genetic diseases. This enables us not only to bring the molecular insights that researchers, biopharma companies and clinicians need, but also to facilitate the analysis and clinical interpretation of those complex data. 

We strongly believe that empowering our employees and partners is key to stay ahead of the science. The field of genomics is advancing fast. Thanks to our flexibility, entrepreneurial mindset and highly competent teams, we have been able to develop a complete portfolio of genomic services, biomarker tests and bioinformatics solutions to support the translation of precision medicine from bench to bedside. Over the years, our solutions have helped deliver breakthrough, accelerate drug development, and bring therapeutic innovation into routine care. 

« OncoDNA has the unique potential to address the needs of the entire value chain, from translational research and drug development to patient treatment and monitoring. Our integrated portfolio and our highly experienced teams is what makes us different. We not only provide the best of genomic services and software solutions, we also deliver administrative, logistics and scientific support from A to Z »

Bernard Courtieu, CEO of OncoDNA	

2012

Foundation of OncoDNA by Jean-Pol Detiffe, with the idea of making precision medicine a reality in oncology. The OncoDNA startup sets ground in Gosselies, Belgium, and counts a small team of just 5 employees.

OncoDNA took its first steps in molecular profiling of advanced solid cancer with OncoDEEP®, the pioneering biomarker test. It screens tumor tissue and assists oncologists in matching molecular tumor characteristics with the most suitable treatment options for patients.

Launch of OncoSHARE, a secured online platform that provides access to the clinical recommendations resulting from OncoDNA biomarker tests from all over the world.

Specialization in liquid biopsy by introducing the groundbreaking OncoSELECT®, the first personalized liquid biopsy test available on the market. This test screens the circulating tumor DNA in blood samples to predict sensitivity or resistance to targeted therapies. Additionally, OncoFOLLOW, another product, monitors disease progression and detects early relapse.

Fusion with BioSequence, a Spanish company specializing in cancer genomics). This collaboration resulted in the global commercialization of OncoKDM®, a Software as a Service (SaaS) platform for NGS data interpretation. Clinical laboratories, pathologists, and biologists conducting genetic tests can now benefit from our knowledge database and clinical interpretation for enhanced insights.

OncoDNA completed a friendly takeover of IntegraGen, a leading French genomic services company. This collaboration combines their expertise to offer a wide range of services in laboratory testing, bioinformatics, and data interpretation for oncology and genetic diseases.

OncoDNA introduces the OncoDEEP® Kit, enabling in-house tumor profiling of solid tumors. This innovative test quickly and accurately analyzes numerous complex biomarkers (SNV/Indels, CNV, Translocations, MSI, TMB, and HRD) in a single assay. With robust data analysis and clinical interpretation software, this solution identifies a wider range of treatment options for patients, while reducing costs and reliance on outsourcing.

Our solutions have an impact on patients’ cancer journey the world over. We are proud to say that our biomarker tests and clinical decision support have contributed to the treatment of over 100,000 patients. It is motivating to see how they have improved their quality of life and clinical outcomes. 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Case of the Month
March: 42-year-old male with a metastatic colorectal cancer2 min readingMar 18th

Here we will describe the case of a man of 42 years old diagnosed in 2021 with metastatic colorectal cancer. Read more → Press Release
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.Feb 28th

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.   Gosselies, Belgium and Paris,...Read more → Article
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing servicesFeb 23rd

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129187



15_ONCODNA-COM-CONTENT-UPLOADS-2024-02-LINKEDIN_POST_CLIA-CAP_ACCREDITATION-PNG

  
          	Hs        Ax^ۖ9	
1Ԣ<Ў	YA) ˀއs

olDe(	Og:
W 4k 6_ڢۅŖ¶W֢Fh2/fѱgDf)l<^:XUڤ  

GSm۱Og/ 儒DUfǗW//4/|̉(խψ1G)m-_fgG٭

IaY㦿}#F	4%PAҮD"ښ29\r"2jׂD9Dm PQpmz -؅v/pGr%K#ÔgLv_j1pXЎ\TV

IhP Ү5 }9{Kd/@hc0þI7.UoɯeWWsIImW%rcg^h

b

z
/j2V\P-SǺ9rºsKNa5wbJ)5) T	GG	ݪuю["˚

W6Or"/Q[B{kSg2{ez;fIhkNwJ [Wj96[u)SgA-s 䨧Dї_T>>s wօ6w

|
bDA;HABdsm- þQ F3Ō%

)\XuShsRb  x;Q-m@h+ w>{rkF-&[[h/pqUorLu9;fp ]1f pݴ܉Fy6[@hF}DlϿ)ȱ{J;]Ͽ+Ӓ2Zevδ"ȥ	m)Ulץ).@Ν&ٚ)uAjFIIƅ7\ B-�	m/��gT�ֿ 

�

�

�

K�

�

HVF�c&�&�-3�]�k�9U-fFd/@L <�.(��&6&�gB9Nz �c �!�΀B{}|6@!coI	mK�!�pv�/wN\�z�d\ȍ�z�_l�F�UsC�풂o@�[3;]�&*uj��Uf/ �&�3މ{'*MXr$��ֈ�@h�k></N/p1OrB�K6Md6ѱ�&Jt!��\셽�-i�Y�RTUeśz��ڏo(�]R�d�>�n6CLN�iʬ�@�(q<d"0�@4�

��)��>�"&Q�̖7ct	�W�J��to"��R�p�D�p��~���y�<ܡ�ܧ9�c&9�D~�]ڥOĳ�6s�mG4>Ռ�ҡ��#�,!Al"=ω�Jɸn~�~-

�l�|�
BB{���˫ж�b~�@hmI���M�	m�ߟ��=J��K�+�sQ��ض�^Q���vI� ��𝅙��{���4�{-�Ͷ̖�2�ZNhP4�(ȝN�]#�@+�\�	���q�l ����x<��͜D�Q�R����

��

���

�约$�k̏��
���7�}��D����)��Q	�B�F���Sf���

M

���

���F�f�I�CL;�	�z֨��'�����R�>Ho����[�;L$d���ض�I|G,Z?��
�AD�����]	d�9��Y "ʓT ���K3�&�#��,q;g��-�$=���ˈ ;/rY��cOYHDl���v+�f���s�_a%��}p2������  ��8Gk7'�<m}��Ł�T�C�%�8OhK����yz`����#

B뚍��Q��-�9��RQ��R�A�e�ԾfK{�B���@h���о'^1Hd�v�&��ȑ��-�U�읾��Qd�����ؖ�@-�N<��b"[���lǞ �`������(�S;&7939:��9.-�{��]h$��l�K�S�Q��K �� ��ȯ&�}�K&�S���H��vJ;�ύk\�Ch�ڱ����z��o��եvŶV�(�=�>�\l�c�j��A8k ��$

���
��

-��3�}&Æ�Ah?R����|��׬9��k�S�� �
�r?i�7I�*]5c35��j��3�͍�Sڜ}��5�Ӭ��l	��'�}_�r�7:�{�	_b[33�<o�y

p
�

t#���T�F���J:�n(�\c9B���B;��&���	�__��GJ��&I�;�D	'�C�}]┶M�D�R?V˩U�j��-GJ߷Z�v�)����z4ޔNrZ���

�

�

�����''M�lxk��f<�h"�-�%����\�=�@l��'�`e��� ����_�s

V�-���}qy�����NO�}![m� ���A휭����f�{���.��k�"ڼq\y��jxkxlz\(l\٫=���.)�����?��-���_�^.{�=#��������c!#D�N=�vx'���m.f����6�S�kG3�X�A���8p��B[;I��-�3

q

�

����Uo    IDATO�R�6�y�s�W�"l�M)�Ԛ	�`�(h�G)`u/�~��EF�v�����֢sM�(�8�H�H���~Ă��/A;x,�+t<��8+ӥ�w�w�����Ux�v���;	D��~V� ��9TA;Fh��<�X=ų��-�e..��5M��C�w��{0;+���{�_͋�I��B�p�;��/�ٌ���7�J��y�DA�

����S��

Y��1�Ft�PZ�v6����0Y☸�CY�r@/C<j�6v�v���Tt��K�	.fb��}�����)fl�(l����Y�kL�Ui�6`2ӽ���ǯ������ޝ

��?��V%��DAۂn������#P �&Fz��iHJ؎�%81 ��a[w�p�m��$.��D���m��e#h��B���Ŧ�Jخ+Oj[.&h�ʽ.��������#A���ȞW�)6�[�(���u�����Y͈����\����	�y\�nii[�*�+�

��

�'

�
@��cU�L؞3�yv~}��Ȃ�	�	��7��嶇S�eʚo�7/��S��$A �sk3*A(;f��1�[�ka[%	� V�R�S�^�1��d�	��-�ё1�G9�j/e�8 ��VD�tA�ΰ�#n	UЖ�TA�*J;TA�h��Q

�

����

)�

��,
��

�u�

�

�

��

�)G��Q |L�Q�r7�5�}�=Tj_H��'�H�B���#"���Ҕ]��$dA;�(� ^7v\z��żHA[�(h;Ʊ����/i�U�A@��!h����F���v1��r��o;�j)^nO��C��?W��p�4mΓ���IiQj���h��<3P�m�mE�`�		���_���8}�F���d�N8p���{=�$�k�"B�}Gr��M�K�q�돚�����⋗��w��hm�,�����?�D�eVw�}+���y��������.#;w���k����oځ�^u3����

=

�9�

=
�lW,Ge��k�	=�&
��z	���_���cb�����3W߂��m�|÷����g`��U�vV$l�_��8is���$��v�A�3y����|��kpz��ߍ���B�=�oǌ�?J�E�fP��.6Ɋ�<jk��¤�҄a�h ����

�

�
��{��q��_�n�I�+�:R��$��N���/{9C��;~�$��0�"��;�e��_�H.�4־(&���8,"��aI�%�L	a1�ESG�)Q�K�Fi�.h�$W�_��	�@�y�C��.HG�l �1V��u�M���mK�q�sh�e��0�G�%c�ݒ��]oW�is6�\
7�

�

]�#

!
M�IB��o;�Aۆ��6 ����:$e��u�J�V	��m���	������e{6Q�eK%l� B�6�_���@��v��rm���	ٺc& 
lX�

�!Q�����19?ɋ�mB��]>k�ɯ����g��\m�W�y.�}�`��j�=����$������58k��Y���j�s !�>>j�˚~�G��H

A�t|ԅc�ܞ���)�$��#�\�э�6�$J�ߊ�����X)6�n���Wo�^&���o��Gr�����p�羊�?Y��,���Wጣ����m��j��=8�C���m����'�.�T �9R�7�}������c7�ϩ�1�dѻ]8{�l:	.��.�!��(��d��G���U��a�-\WEis���y�>ۆ���(<o��h�	���-a�ӂ�e��,hg�b���^Zd����6�=*�ʙ68iu�QM�G�*k�

a�g�������B��

���
&

���6��A�v
ډYw�z�	� 0`x���6��_Y��s����fS�*5v>���=LS,0Dj��g��}�vW2KX:���q��3ƾ�m�N<������ h?g�~���ӏ:|0.��|����Wo�Y[�[���������c����7xx��'n�ƿ�{�|�s��@�9K�

�K�

�s�8
��

� �



�6��N�6���#RU�Θ���z���n�F����#,�[���s\�4���vOm���ç�灶���5�nC���p��p�S�������aM:n�T�6 ��Ǿ�f�q�5��h

��uQЖ��(� ��g3����q�1������v\)��Q��ӏ�'n�
�o���f����	�􂷟����%������Ŏ���iá8�̓��е�מ���J̾�↻��Q����Ahݝ���$�N��T������ϥ|g�KQ�m��Hu�.i?��9�gM۝���1M�h
��᥸�������L$��iW	�m��6%�3������q��ؑHSB]o�%$L����h�F�JO}��C�� �5P�����n5

.
�Vu9C�Ro����@!�hܧ�0}�0rB�����|Gl�*�ׂ���<�����jy����{/��/mG�V�*ZfTy�m��^�ߊ ���	!��tY��3�0��`�����\���mYr

��|�

+��

=���

&��i
�

Y�

����MsB��mY�ۯIО����}��[�U
A{b.lw{�ן�����?��������咛��޼��l	�9]�6�(�KM�Gm�� 

M��
k��

p

H�

�

=
�

K���
h��

@

�

}�

�
���

��

|�

g�����

n

w�$;
|�&

�

�t��Ǝ�;�΍���C�(s䞷8䘛Y�� �k4\=��m?��vƵ�g{sً2H+ ��Rb��H�z����W҉wRa;c�iR�f�)���"��{�W�hZ���k�d���������c"c��%˹Z_q4�]KQ�m�
�0TL�����GO�0�n�B=� K����ļ�i��k�r<�{��Q�{�!)�w�?�j�_Pc������]?� �-	�	�M�"�S����=AX

����4�͏����j\��u V����f����/�a�T�b�!*���{��1�5
� -ry�A+��R֢��\�@�	N�X�Yd��r�=J;����vH�W��3�;�J�
ǘ�^؎Xh6!{������	;��bO��	m*�j�dB��m�R-�Cm�� b� �P!j

;n��i7)!hK=�9J�zaj�� �K����RN���_:=��	���&��O�ɠ[�{	a�{x��~�C���
RN�M���	l�6�΍e��;���^�Ҟ#��x��Ϫ�����ڧ�I�S>{�	���C�	���|%��6��V!@T5�`yl�iz�Փ&Cu�8@�X�01�k�(i//���%���

����

���hi���p

F�>t���mB�8�b ��P���qM�6w�v��M�-��<����	ڽ�J�"�qk3�C�hh����ab}ͅaK�v�F�D	a{�{��PFgPY�y���1�L,硾l��=��Y<�n���s��' ��]�C^����,�-Gڣ��T�����O\�G��|ܽ�{J�

V�M

*�

�

��~���
ڑh�cDA-lո
1 ��ˏ3�	>����m�ܧ{4A�<&׋w�,�_��a�{�Q�e�y

d

��+�
.

h��p�)lo����/�������1dz���>�(^_�(D]	����h����m	ʺ��l�"ʓR\�Hv���3��0s�6j�k֑� �>mI ��N���Ȼ
�

��o�
��8��

t

�

���mP.;�FQ������w��_�4Q;��AP$QZ�sՊ���q#`wL´(�rhtSix�9n�)��h�Ç햖�XS��M�]T�3G\�2�c��K6���	�1��ʹ>ȫ��7?������,�v+����h��B6[���`U��\k�����12��*j�r#�&h��ř^��K��4��� �� F�>�p���U�A�8E�0���

}�Gۈ}���q%�C#4�(m>0�vK��`/���9R�F��0x����z��l�Lyl��f�fa�&�e�}I8cf�9|�<����(h�B�%�wWn^�e�X�-A[�hW��m�� ƺ��%n����g�`q�

�

�#���
A�
�[���\��r�ʫ��A��։α���	�[4��3����#M^v�~\-�s�xuq�q8 𰬓��x�mI�f}%7l��0N�W�7�h=����v	�u੄h(Iq�ha ��<�hQ��}�(��X��%��E�r�$0��$�(N���c�Ƞ�c�á�m-ܼ���z�E�I�t�Reȝ����]T��Z,���

�s2�Oj*WD>���g�1�Q����m �uS��mϷb%�?�� ��	����(m_^�q� ���E�1<f����D5 �C{�v�m������
��

�

��>�

���{

�

���

�

1

�4�� ���I$y��.��Ld���;�eP]���L�ikKq�!*��OѶ���͞� ���1�	*�Tئ���з��b�I��90������&�x�I�d�$l���R��f�� 	!�B���u��M�8	�@�m��

V���

Q

tE�mt �*]m)N���_�
�)D	ۂ�,7M�YJ�<%b�6-o��6ϋZ<[��,/�� ����W6Eqa�O�����k� �u�f6�]��v��p�V�_Xa�G�&�H����0FK�1ǣ
i����

���
����W�
�6��

��	

�C�!

��	���a=��N���v�mFT���6v����2v8�iH�[�a f$�B�� ]�J	�Aڊ�/�sv�C�:)����+� d��^n`�n��Y,:�eУ��

d����

_�

��

�
�#�

y
��4

*El-���`��vH����I{���P@��ȳ�&���k0^�
"j�\S�X:���*FKC�a��4c:��I	�,�54T�	��0q$���H�s�(��h��5~J�Nm)�I[։��

D

�n�
l�?��
N��

�^9��RbR��i����s���Y�Y����3PF�<\��$�r�Y^�RsϯF`�����iR�%
���0���}�⷗������KPvr	|0�N����vfHb���Mp�ŃQv2y��[^��&~�ۮ�l;��h ��b)����v���q�i'Y.������	�<\ݧ+n�B\;I��m���Kݖ<�,AO��᷃O�5��

���1����<j�pMh�&~L�Qa�D�� ��,��+�x�-���"l��,�x	���ƴ������{�]��uk�S�B�r������	g��?Nxo:D VU��6 

]

�o�w�l' ?Ӗ�v����{�t5&~:W.s��9�m�oA{��Ux��x�f��W���ݵX��~:�4��~';nc~n�ӿz�M���0"����n�<��4L[�l��\YY�w���
���

�

M

��O�

~

�

�
H�
�+��
g�
���
�����
��
�

��

��B��5

Z���

��

� 

���

������
/M&�ϗi���7�ea-���hS�t�F�D�F�ǳ��	Q{��@���r���",6J����.��2�Q�A��)C{i���e����Nm�1�]���`x��Ciq%,�л��O�����q�P����d�l���TjL�o[5�v�Q�mT�q�-A̪����އ��c��l�Yp�`�����j�{�_���dGcH|�¸]	A[�)�m��N��-�1[��6 ��!

��TZh�*�nb�%/�#�G�ٝ���-���S[+h��d�m��?3'��;�'Q��J[Y��I�F���󼰠����>���L�6�-�c���؇O��%����S|5v���+��Cy��t����Y<3�p�Ø~~F�6��j��zZ9'�$�X��s�{J"f3���% V���	!l4���r������BskӶ�b���F+���O���xZ.����$n���Jn�`|:�KˑXT��MDl��CjN	gQ�թ-��7��N����age������J�x�y	���ڭ��d�؟	����y�����(HԖ��sF��	;�NrXi|�

 q&�&�j|5;�C�	�������+A��E�ZT?�Eq�=W���gﺔ�wwG�C[ts����_/��谬q�|e�s��U��s�|�W�`�����X�J�Þ8�ɿ����u���\t�J�Ż������: ����܍Y��'�-+

y

�xG��O_bۆ�D���2L#
�#�����/����	���س�������W�[A�x�I_���ُ��	}��P����6���~����؎���M�A�%f����6��x�GI+��1�B���)9�GXw/�����G��iy\9W�3�n-EоR�Ц욢����rj��F����c�6u$�ަ��l{�ʡ�"�/*��^�vWG

�:��-��8m"%��xw�d����M�\t�k����9y�� �*�Rt��@tj"���^!�/���~9�1��5k�`��u�n�F�gI�4JP����c��A�������ܝ����_��X�EIb�	�|���3���>�1ԁ=��(�b���'�Mx�tX���F�2�-���	���1�/�o�g'��(�x[�`u����n��Z}�c{jzn	=D�9ޕl�yE�ؚ�N�m>��k����R5�ݱ

�

&�

�

��

v
���]I�RHMHZ�)�:���j@WOj�T<����pc��$ �>"c�i��� t.�����"��ֈ�8f��=����J,�6�������K�&3;{�Ǔ��޾�Y��cn���d�Y��B��e��~��x���G�mZQ���x �@$%V����4��� _�~7��x��k������8��M�{�Pr�1�7�z<>�*%����sZ

q��

W��

@��
�(��

�7ou[��)�8^·��>�J	��}}�+]�p4��6X1;�-��QT}~�L>s�1���Gf�] u^���}K��

 霬�U��sRn��`V� ������S�ށR�+�ﻚ㜘Tg��r�Q�LJTz?˷�fBzOuؘG�n,4�Gd��3�p-]�+_��c1��=c��th��3�b�J�J\���"��	=���*���ST7�@��-�+r�&6���P�=���z�;P�A��h���Q��x:a��9�jh�&�`�v&���߈D	-�

�

8

��;

J���

���
h�L�

��h����L?'�(mR����i"�y	�5�Q�*kz}��mX�ẉ��Xc��A��!��� 	��$46�x��ܥ]����

�F
�
I

��

������j*�_ʩ�m/l��b����¶X;h��M.X�G�ha=��|P%�s�BZԧ�#b�bԶ �BNI��H��j¶-e'���^�ww"f*>v�%�ۚ=O���' ��tJQ[�uv�x+W�xQa��4)+�EP��#F�H��#�	����8W���{Vѱ�*`Oޞ��� �� �������$o'��⩹�]	�)�'*��$

������n=N; q�D j'c7�.G�ѹ	H�%\2g��O� �N

��
f��CXjY���<�������@��[�v<��Q��n%h@Ӑ����	u�cm��&;�E �Va�߾x;��Y.���

�
�|��k�\7���J��0�!h�	�����!B��4�s�i��[��ƹ�!;�I��	�|V��T��ø�{5����AL��ք��?�$�۬�MĈ�jU>�(�1�/���v�\�`�� ��ѵ��yC��} h�ᵠM�Y��pj<���p�)9�ay$�&��0ǻ򂠠|��y��7I@��i���\)�|������"h���Fi��

�

=�"���
�

�*��

�l

�G
���



$���

�!
�:�
�B�

�Uz�x����欚����6�O�~�܄�_� �����}C�n

�u

��eK3O ���!��v�my� �ۊ�F�r�O*l=�ɑA۞����y�$D6�W8ƽ@E��/x%��³����6����Dp�'�����8�Tc*����'�w�=7�"%3�w�|���񡹠M(�]xi�������ئ5��]�A��H� �	� 0i� Rj��ۍ��XFn@3�:VU���l����NJǘK�bPVK�lR%rD:*#����&����s
n�

�

e��)

;_PU�����	�ѳ�qZJ
4�2���w��H� ���7_1��P��s�5W�5W���Ex��٦���n����ۯ'G��0a�PL3w�ڂ��o�pq��k;��_u�#q3���i�]>�M�����	�c����e~^~�Pq��=�`����U����m

�抪	wna�����6516c#�t�2V�;�-9�%����baXٌ�)m@\�m�uUm�ؖ^Ц�vR`���)�lr�� ��d��s[|Q����� �(q���;����X�� |ݰ��W16�<��c+��x!��jm�׻����7��ݹ-�;��X�� ���1x�K'|5g<ɬ�S����^&��%�P�E�QsH&zi���c�b�D�ƶ|ݰp�$�=u_�؎�

��s

�

��s�

��

�BrA[���m\!��3WS$����bs%7�nbA&���$���� 킈�� _A�s|�y��� V�k

`

q�

�M������}�")�d*�o�׭�HȻ��?�? ��o��f��][ Il)���x�KՔGy�Wg�����6 XZȐ~�>�\��_�so�]��� |s ���&�~

��d

�O

��^��

 �����t9�i�C���r0�dX̀�6X�&j�W1$���/ ��}8*���!� �6��Ql���!��1(�lom�#�c���BG���K�ɡ-�:K�%1	��~�D�WmK,h�yo`11wN���:�����h|Q�?�

���

��

��



#��i����B��
 �=��X�S����⧷�Hf�H�+��fᙕ�+��K�/Ăȇ�j��MxUQ<�Y��#jjG��q����\Ra	��v=�"�~�)��J er[�����zZ�!�����ܧz�pc��	����uT�)�mVa[��]ǩM���Q�T�jj��6�m	�z�"ҳ����k��][0�^Uݯ�

W

��

�

�

A������غ7�d��;c�	#U���O��߽���؞x>�.~�6aA�$*�9� �P��|p@$�#w�9���kL!���]���X���a�_��	Qamx�u�ʽ����9� e�quX�mV/mBE
K
 X�M�׷еO|��7 ȇdbR�e24��@KK4��DcKK4��1G�0�D�|��>��O; 3�v�;������/���eo����F�^���|�>ve�����h��,7o�Ŭ	���܉�7 #��i������A�
b

���

�
�v

���

��
u

�� 

�

���
T

��;

���

��o_�ot=u�u뜁�(�q��O��M�;?9�}�~<��d�m�yy{��۫3n��ıB:�y?�4\2�'0ge���f����� ���9%�d엋���b��4\ܿ^���)�p*�5x担Ӭ<��tU��w#p|�T�:i�w�5�￰^��:��x:6m��fM��<�v,JYZWQ�G_��><:!]��m������������[/� �ej*.��	O�{��a�7i	��R`�w:��S2`:�O�A��k��Ϗn�vMP��uvga+u5�3G~��H������m{��vU���GU�g?@�p�y��	Kոd��������Ͻ1O�K��ߘ��B�m�E�ڧ�0a��QS�U�#c� �e�_

ڢi��6 ,�i�i�;����9�[�l��;f����ǌ���ݗ�o����y%x��oL��cw]�)�^��N�v����Ң�o���˻w�k?�(h���&˿�!��B`W�1 �F^�Q�6��'Y��-ǭh0�F�V�p�.��:�X]�jC���á�:�

�

m�`

�����N�?w���I��ֽ��f�OwA̎��l�}�;<�˫L�.�Ņ��x�d�9�;���,��t	1g���%��l�SRj����ܱ�q�i�p��q�@����~X���;%�GWA;�	ۊ����qU�.����[�

�
C��
?�QE� դ��l���̶hִ1�v3�F�@�a��؅���g?6+�;��gp�V8�K{4o�}��lk~	���ҽؼ�%� B4� ���nL �K<�05�};��h��MOJ���� {�.T
 

�l+z6k���?t�^�%U��K1��y?E��I�E=�6�)͛ +��������$-�~��]�dS��^���mrnHDm3d�A��V��)-�5��[�#�VT�����t/*	��h[�m�ޢYB������6�%�G<2Z�kFk4k��:���9X}ۊ��Б�X_�E�>����9\W� 74�5�g�F��'�ws����l+.GՑcX�k�b�Hm�r�#����Jo��MY�����-*���*��;@%z:�l�=YM������4���.����{*QVq����0AȮ�Bv����FK�m����X���ѵ]˘��T���0�+�?@
�-

Ȣ3̙`����6i?G���H�� ���I��,m������q��hHU`{��Hʶ6?Q"� ��x	7���m^�"�肘3�e "�:���¼^�h'�:

�P�$¶lD�$h;�����%�>W=�\ˎ�W�[}����C#AcN�b�*>>N��ymQh`��B�;�Ŧ4��$Hb�����P�:�K�Y���N�v�A����	�Nb6 _�V�"_��Л1"_%����u!@���%<�~C1ߣ�)�Z�

�Z��

��kY�yo_*��$�GD܃�s�E�q;D
�h�m��^� �B���)l֒�/�n�O��ڐ���R����z�Z��}�p���j����Hr	�'�

��^�ӖA��YRB� j�	�n
�D	��c]��O{dw�2�

�1

ꕾک/���U��Nd>�|�i�M�\�¶���BЖ����F�=�1��nDiGs�8�iĶ��vڮ I�fGM�zM��l-�Ϋyz�`@��� �r9���-B#�m'jC��@$J�&2�#���sE�2h���!۩-�6�IJtW��}p����A��	�����ʭ!`���yڼ��z�

���1i
��

����7����"	�����C�Gu0�΁|�p��t�ǃE	m��VZbi��|Y�����j )�1�&H�	l8\�a�����N��Y�����h�c$~�󾲣��KX�%�

ۼ���

�h�

�

�

��

8�

��

���[�@�y��ȎҖ���������$-�}r�p���@;�pk�q�(mO�1dV5�7[�w����%ߖ���,lK�	u�f�˅�\lZ���� �	�����

���A����tD�v���Nm�͛$\SYU������ V�*WV&����'�֡�A,�_���1�}�p�j��ۛ����%�:|kw��2Am����̶��l��mZXڼrs����2l:t�4�hj��Gk�D�+�)J�o�&�ݶڷ:���j�.�`�Ś�R,'�9	���%�m���=�d���'��E��P�� ��Ɗ��&wh8
s�X
S9��#�܎��}��?���m�ڜl�&�d/���y�>�������V�j��6>�:����`��}�N��L���ѣusd�h��&�H���8t$����b}%�Z�s	��/fǢ����!r,���W��/����������W�阖�k�fa�Y	׏�0K>�nq�	���G�O��0����+��i�h�����?u�r�^�

?��
�

���

���

�

�

B,y������z��?����l��mm�	����,!P*fxSu����F�0{pO�f�F��I^���	;�������O� �( l�g}�=����L����f�(�Ͽ�u��

0��mm��

q��

�6��[�

�
[�

���


��
�

h�k)ǥ�M��{&73��q�>�����\�$��t����7Rbi؊�� "��Ro��_3�&h�&�a ���s��r � ��%`�eg��kO�����_�w �x\����+}��3�-��k��32

��3��������}W���+H��|�)Y8�c��v����O 0���M�e��ǙH��¯�c��3��	�5	..��͇�Ӝ	�����{���{�aY\&vE'��>7!��%A��3�՞(h�y8~�c��q|̩z�oφ#6-?��7T���IԖ�y�>��x�`�?�|	1�ٸ�S�K9E�I�Û4��Gv��	Y�Enc���B�V�=�P1[���X�[ �~e$����Kƽ�O��=�ȁT�6 <���

�

�?��Z�

cVokt+.���{X��q��� ���z��mrԵ��y�,r�_����q:T���մ���+^�83�b�s�Ѷ
�J��5�.ǹ�!��}�;n�c��m�t&�Z.5#o~�������=a�;f��.�i����3Ǫ�QWe�?�_��Ի's�¢��_����s!Z��b�\u���܉����
ua

����|�	�JA�.v6��ב��c����'��}��wL��$U�����U����⿳��$���±Egc5k���x��?ZFp}��q��=u2������Nq�h�J��j|��?�XtB&\9-3=zb����>����6	��

�J���

&

��

Y�

��;��$��J>���*��[gLo���G�{6���� j�����KQ�H��$�& A�)��&x�\Ft��k�����w�q����Jyj_{b��5BRZR��������c����}�	H#��a���5�c������s$����*}�g��ztX��eT���G`a	�|�
���^

 �

��

�

� 

�g���

����
C���Z�

�*��
���H�&�8"1t��R���-^ʘ�l�ٞ�1$�B v� ��v��.%���1�T�*'+�E,�^���2a��Xі��s�n: 8|F�݈���T�]���7�}8�l�-���[��W !V����j�^4��S��Zi+�!�w��&Qs���

H

�

��**����p��]M��u��6����������=	���\4�Y����{X���fc��~�3�����PD2�1��̯���Hŗ[��
���

~����

��O��
F��

�t9��w�ZZ�%�O�A�׭�	c$+��	���V~M�/���ق��f\+7��,[(�g����c���1.Ll�ui#-l�C�언���2,9p'sy��F��;����s}#[ ��m��QA#՜ī��w<�w�Kao�V޵x{q�J���\�l�+ao�&��Gh.A��*�XE "	��a�*�d*��k������ �ЎDG�����zgsP�G�������2Z���c3�Ǉu��[[�$8 �lTO�{Aж���K� �W[����1�

�
�
��

*P�z?�D��~�cC��I����o�FN�-޵��GBr x�o;M2˹o9>�1s����!ȃ�äv!��	X���c�Ʒ�.��ǆѥ))�l!ԯ��A-6�M%zk��p:z���X�
�
!�

�q����

w���L

��ߛN���ָ����|��� Lڅw��'p���Ϋ�[T��	|o�1�WF��ג��c��t��GB6�E��~����	��vM�s��EtyQ�'ӈ��Yv.�	:�

CX��Y��b +�^��&^��7�]�l?9�p�6�*��.%|��(��
�B�ȝ�J/O�;��y����w[�,<��E<��ľ����� '�l���(�﬜���	dA�uV����4$��"q��&JѪ�
�

&�

P��Z6���&Ⓟ�"��K7��}*�N�p:.u�zti���<�/�I-�� �h^�>��7��^����6>\�ߝa-�O�����C���-`	= -k݇��F`�O9�
i0��2Ny��1�B�G�D�1�D>{���A]��٘98�x���Q=�<��h���Fk�"CP�x�g;���C!�w:�_��#�f`�0&!�µ�����xkR_AѰ�wm�	"�]��K^�2cdw�3:J�

���g�z��^��P��v'�Ǟ��\�z��<9xu	^�5�	����<���s��ڿp )/�?�C͚�

�

��ޙ��~�
�����u�	�.�� 8�>v:��+

�

���x

 �
�3

���

<��w��L��6l��,��g`�y��ŷ�A{~9r�z����h�K��o�ڇE��Ȳ�FߎaԢ6 $\����o����X8Cx�M�u���wbթT�=��H-����b��$<9�;"�ŷ���M|Q.ۍ�c�-~�wۏO�F���%�C3��]1n�X�;�

��

�


�t���5

?� 8�}g/�o��	�B��������]�w���u�]a��;i �<��7  ���MF�m{�� ����X���ȿQ�D�6���9 Ծ��o�0�zh�[A�>��׊o!)��\�т�ȿS

�t�
��

�Ov[�:�����3�����\Z&�c��Ցx|�������c[-�	=�~�Q	�X��`�8�U�Fĕ�i+j��l3�=��"M�O�'��	,�h?mǅ/�y9�,�U��;���i�P�T$�ڢ����}�A�/6 �{*�Z[d4�=��b� ��޵1oX$�F�@�N�p�

�e��
�"_��҅ ���n��	8z��\�&�j *�	�<Џ�
X������+׈�Ykrq�u>j$�U�o�bOm��8	R{�R/m�wV�T��]&�l1��M�m���M�T��f��t*��R�5�= �MZ�#�AmƦ��������U�W&���z+ԃ�t��UF�O��h��NW %$�L�X�\b6�̢�>�_

���j

�^�>�\�L�T��U�;m�m
�:C���/W�	�'g�����X�:qchKA?�5���G�?�+���s]SM�f��,¶r/m���0��h½(hl��

���1�W

��핫>��2��.5����@��b���&I\"hREM�$,��^V�8��8����j�=	v������*A�#��0b����mC]a��� cz�Ѳ{p�v̓��m�2�G�#zV���50�S挏����}ǒ��h2���	^#�̊�m��� &lW	��A�m����T�vFo���ق�QA�2<F��}��@�1��[c��3ϥ�sDm��P��ԃ{V��Dm�������Em��T

 �

1�Mʐ���,�D}M�%�i��b�z��`�3kc	6Y��bչmW��6LPG��8�����q�W���if��Az�\1��?C�&a���h�5�M�*K� ��2���	#xi-��k����Xqq�w;jy� ����efva�Y�֊`U7$f��?�^�&

�
��?�����,�=+���k������ő6��ƛY�w��G�u�5�ɺ�-�D�'j7�@;��ڎhUl�s�2��C)�m=�����-fh�"hK0�~Q׳����ڪԶ�ި�aI�1mU�޶�rK� ���I��j�8DW	� �Y�^�)�)�&����=�fž@� [���i'x/�ϜnC�G��Q�y
�0�
�:�m�˺�4�um)f�l��g�ѓ�ƌ=���93Ԑ���R�{�,���9[����~���<��k�i*7y˅&e�]��":D    IDAT~\.����s�-8[����-���༊%Yڜ1#�B�م_2u)�jkeR��y.���9�F���>|�ɾ@o~�%h��/��Y�L�������^�����Y�

�a�s�k��|ei�1D
�~up�\a;%h��s���r�u-h?��][�e���|.j�zM-<�W ��m��e=��g���g���+4�L���=	��<j-j,�l��y=5���|�4	�6

<

h���

�

96j��z��b�~�Jn��Q���쯮Ͷ��-GCY�FUuFA�L�ڧ�	�r�,mj)�����>ִ��͇SK6P'RUXT�ȿ*p$l�,��L*K;W�!�6\�v���.l�E�Y���f<��ǒ	n�� ��2`�!�~

�%�:�B�y�^��~���|f;�k�=!D�"�`�&�ͨ3|}���|���.���9�����(�m�ôߘ�\¶�PB�ފ�glף%A۫���/J��M��h/�	}[��J�N}	�Wʑ���N�ts�̮��,�L��(���2¶R���x�9-	ڞ���*�{wr0�~���i[q�֘Z

�

�J����9���
-

�m
*a�n\�R��6�_1�3F�#0�Z�^h��x��_��Yz�x[X��r,h�/( �����҂X�C��Y�>��

x��
�x
�7�ba����^����0쟋-Ax����a���).!�?!<2 U���H��x�z�~��H퇼'�����jY�!o(�Ί^��Y�1�Mp���s���gf�:�M[��s��N�+W=��
l	ۜX���3����[�V3�9�ʙ�pA�5Lk���47 �kۺeZh��+������

M8Ƙ��$h/�Ŷ�gRy^��#�/�b�0�{^��ʟ�PX��+�B]�:���H�ٺhm=��J^�u�v�@uM�
؝��%�pk���H	�fi{ 51ݣF�6p�,mɶ�Z�֜53�M�	�ֵ��W ̦��v�]:��[�NE�

�
�!

���c��w�@�?���	�zFX���@]3��/Aۗ� �Q!^t��Ӆ��U�l;U�x�!7K�,��F5x��x?O;�2)+A�%��v �L
a�

�z�����;�Ϧ"������gn! 
�6EОI	�j"���C �rE�����T��S���u=m���f	&1{��O��Z���)��5�5J3�v#fZQR@�|���۩m����i�����	��7%��ց�X2���%��i�/h���c4�Ҿ"�}�"$E}J�v3�i

�

iA��]K��m ��(��9�W\Ô�}]9I[U#��2.U"߀Y��e�!�'���� �k����j�)!{���T,��Kd]��`��z<���I�6��x���r�ܭ�%��5��=di����������.o�*�v3!��=d�8gM	�[u:���m
���Z

j-�7u3u2�pR��0����}d�r�
�Z	-��3�Ӫ|jy���<mY���10���e��k���:5��?�ƺY�,�q�Yںsy՛)�g���Q��6���m	{ƻ���p

���t�#>c�G�l1.x�� �6��l�}�� w,�n[Krm-�KS	�)�v��A��?8� ��*� JγJ=���-.��ԞR[�N�ϮT����0���F��'��S�B�\�R�Ht

��

��

���1`��ԩ&�1�4W0�kkM2�%�-WSs�ܹ�Lj~�7�W��;��H�
�i'C��])q+���C),v	� ��Wa:hb�� a�/���F��9���    IDAT�PB�Ν_�����=�E̞��;���(x�8�|�{,�C��V�

&���YE祽	^��ϸ���GIyn�^��_�H|�`!�pmm-K;waiM�y�7�%�6K썓
��,�%�¶\��d�#�S;��5��/OS���m+a�+���Si�l�H(��-���� ��A��*��8|��h>�ş}�~��M-	� ��9Q�

��_�6MmR��i��X�Ğ߬�炜��j��,Lv����(��Μ��t)q�?����'�.�A�G��DǏMs��Z�}P} hrq*e �D��C�C��xb�G�1�1~P��{����>7�����گSV}��NQ�~(G���>�y�^l�e���s0К���������_�f�Z�g�� 	�󯘰

6�"�}q.6��U[ж��)�w� ���}��Z� ��v�*U	�\�vK�vǒ���ێ���rm�|; 	�w����Йx���Y�u�)��i�	A ��6K�e

a�Yڒ�$�#�C��،�,����P��ѵ�6Lgz�M$�$�Y��.f]�~E���߫mz�1�S����{�{i�l���+X�(��(��-�ςKJ��zƤ����V ��H��.��x�뚧z3�m�g�l[�g���oC �����}��q.v	�fi���7|?�;���)M��](��v��y�������Q6�C

����m�*�-޷��	44m ]�VB�-���	����#0,�߉���㥳��F��cюm��
��m+Gj�\C���mka{>�#FD|H����E�pǻe��՜�&��B�%�_Rmm�u���u��cяK�¶�,^�Rkc�[���؉�͹)��B�9���)E[�V�t#f6��]�d��@��fj����^�@����av�]4�F�h �v�_�u��E�����qD��~^��h7�,�$,��#��sJҶh��_�hm婵��7��u��N����
�����Xdjߔ��U�d;��)s�B���=�)c����s�� �q�G�������%<4� �i[ހk nap7G�0 �?���v}ڨ�Z�hT��5kA�D���7��F{y#ܢ����

�
7a-h�x��'K�Ifa�P���B)�4�皓��OL���	�%-���Ex�����h�	/c`��L�ۧ������l�4Ah�.f?�-��������j:>i1Ľ^�q;���͂L����64��9z�[���|5X�>j}��<�6�Q6{��~�� K;�0p8G�j��ޝ�Q4��
;

8��

 ~\���Vg޲DS{�b����ξRؐ��,�F9Q;
Aסv�c%�Hia��ң���]��yU��A5K��Qp��Q����Gp�%����W��5E���Es���?�m������$u��9ݞU�n��u��,픠m��-�٬�1��-���מ\A���j��ho,{�ƾ@��ֱ��6���q�s5>k��,3��4a=	/#�{s��ֶ+E�i��m�b6�U'ˌ�/a�9	PB2O���v�׷�ϝN�A��KHf��di��1�]�fҲ#_o�v!;' �K���6ޒQkl=~X�嚅�[!��b��?�pX�`�h�di{ �=�po�b�]���{�4�	۞�/��s�[����*7    IDAT����y��

\��

��x

�*<��~�C�m��?�1-l[Bv܎}�z��ik���v:gF�٫ei+�:�P�u�hE�.IN;z�!_Lo�l�/�8�J��	%��>#^�ޖ����WmLx¶y�f�rh��s��� K �G#,���'�H

o
�}�

�q
�

�+
���

��

�c
�v.

�
a7
Cr���!�KL���'ˌ!<��T��*m[�؁��[���Nt=��8��{�
�i�t��o�c<Js�yO����o���E	�3e\�,	�aǵ���TU1B�A��:>�#~���8:jX�cg8��&�n��a������珴R{���U��I撝ț�`���}�\ �z����ɡJuW�P�B�]Ww�E��

�

2�
i

�|��

=

x�խJ;K��8ڐ�*��0��a��[����wi=����s ����?����ŅB!�B!�V^ �ԣ�-�UÑe��s@YX�B�{�G��&������9�Iӆ�h�C���c%l��bTC�6�vV���Dߔ��[���XU�#�w^J��F��>���ǻJ�o���ͯ��7�¥����O~����G���B!�B!R2��Ti���?$)Kr�R#���$Ui-���ʦAH;��iX��O{��S�
��

��=>
m��

W&�J��6q$�[�=>��O�3�_f��b;�QF��U�=��LT�� ��환zb�#��8�Q�iOұ�K������N��'��@[!�B!�b�ҷ����*��z<B�hVB�����$�Ie�$}�JK� �_��m��~ړ	=l']�=��I�����#��̧=�hF%�Z�0�l�T�	��B!�B!&͠}�O9�

��}����Y
�a�

�=]
����

z

��
�E
����i��Q�~��+W�*��GP��m0�꫄�<y	����B��A@����&�!Zk;�gz�0D��+s���i��i�(���,,3j���h4��O���QJS*M�\ ���jOP� �ԻOR$Ȅ��wWdK�iO��������7��J���1L�A����MH�*;��Vi�t��D����p�lϥ�K
E
�C

�{
�


�

�?�

��!
� 

��2�vV���~�O;����q��ޯ�`;���� �>&�l���W��_�t�E��8����G��!����SozlV�ԛ>��i�}ju���:��v���=-Ca

��

�B��B��[�����ZS�׹y��+�8�õkWY\Z��Ky����ɓ'���Xv�\�q�5Ԟ�La�&}#��{�J%߸�U�h�J�Iz|�� 8���>�-	��}��������n�]4���"�!�1��Ѵ�x�N%�^�-�'؎#�w�M���3�����.?�����K�b섺3u�Cj� �

e����3�M�QA��j�j5�ܾÝ;w������|����g/<�w��q��r��j7lon���oq��m�.�{�SU�aR٪p��Mn�zӰ��`w��Z�������"��asB�K��]����n�au8?�u�]�ݻϵ+Wyp�.KKKؖ���Ӝ晱��]�g�4��Ӊ6�U��Ǔ�խXH��9��g�F-�f��0��~-	�{�p��p\�hj��l#�Gm�BL��ؽ^��?{�1�}{��

�

B�G3"v���S4��9^;m!��<0A�X�<����jQ(�0L����Μ��m	��X� �9��Y
��L���

���

B
�Ķ

S��(�2e�΃t�4|����ۜQ��pr*�VVV�|�V�E��]�+�;�llnr��l��g/`;��� Bdف9�E"���0�fH#��p2�M�v�f�2ІNp$z豋Fq��m��aۑ���`����	�C��
p

����X�

"�
��y��

�

�?�

���=�-,����K�X�P��J�,�����#�ܾM�$A�d�*����͛��|����#ⷶ�U���2�K�~C\�2?2��2a���g~a���iV����n�n5񿾿O�VZ�>�kk<}��b!����!�i���,#� �T��&���[��89��!/

�(

r��ٗ�������s�����=�8B��ak�0-�0�z�
SSSx��s�4��� �c��%�0�^� �Ĳ,���V���Z-��|J,˦T�61A���0�G�:�	����

��2

��g��ܩ	���Et�]~��/���O������@��Ak����v}˲��"���KM

�患i/����
.�4k���h�#�W�>�,6�l	۞�D�N�p�O�վ���� 7���e�ϩ�G

��s��6

�J

�� 



�

��

g��l.D�Jo�Sr�$#��5#c�����9�1�˺�~08jR?�r�	�/`��\�g� I��-�|]����B�s���K{'[�v(��^{a�U���k����O�/�����22�����7}���y�ܣ�QJ(hT�<�+9�����S-�8�~A{0�	"E���Y���ϳ�

*�
�

���
 ��

�� 

R

_����
��

��n�h�4&/��yJ.��X�N������_�5�++���/�-�q����}�ff�����1��`@��B��S��-t�#7?�{e�����<v�y���g���k~����������[o�x}�o}�[L���z1�OV:��r��~�κ�(�H�������X�?�5��X�ɜEn���X)��>�V��g��������f%�Kki߸u���&�&�]���i-�?���w�����tA�G�I��:.�c���}���E��*֞$�Ø���P���w���¡�h��v�Jcn�_'$���>���	�u��rX�ڱ�#@������<��N�E�$X����O��4�

!Q���C"���+W�(��8��4��A?ִ���~HÏ؈��� �	� ��K6�K
b���t:<y��U�<~�cY؎Ã�����UD.�)%I�Z�Ϟ�{����B�>�4�*&n4�F�����*Ϟ>�޽�i5��A���0-�ٹ9*�m�'	� b�P"�aL/I +�u?�l[���"և�J��$E��� �JoG�o!��0

gd�յ�60��@���a�z�ϯ�n����!Zi�$����H�$	�f�Ǧ��Z������xv6�����U�0�������eY��m�h�s?�	Z'�j3�#�DkJ)����P*!��&�~�V�M����$$���tB� P	*I�$8� C	��

�"J

�

�j

�N�mӲY�v�ZmӲ��@� -�T����{��Q�G����4f���l>�D:�-�J������g}m����͛�_[�Z)��6R�j�͛�<˝>c��� F�T8x��gq,Ǹk�s̗Z8�2�D�h��9�Si�X��a���>1*�$uί�����Jc����Lk�i�i���	r�|Z���q�R���k�q����v:��.���#�ޠG���z}�"����5�;�:m

j�

:��L��%����`�]�0l���_�@�P�"!�4,�\6ᛑq�ĉL�gXv�.|�|��(S��N�28R3�T,N��`��!xw�ȕ��;�� �	=�XL�mj9��eb��N�0�V*�B��X)͛��|����=B s�e����Vi!pii䆹_ܵL�|����qC��i�+|�w�lǈ�����v+H�:�o�sm�1��1�=� H(����h}�;�L]�V��!7�O৵����޴I�,K�{�^�c�=�R�tU�R�=b���M&�����I

��z��猣�Ҍ(�x��!�Ng_�A�6(��7���3��@�8SȘ)���ԛ
��*qa�~�8Ɣ=*��n���������x{V�j�d���tx��	�>���G���/ٸ��S��!KKK�Z-���T��'�[��#ǟ��8�7>���,탼��=��g�33J�
�

�

����Q

���

��

���{

L�

q
���.yo�ɋY��h���u��4��Y�Iӌ$�P�4�h�V�y��d!(��I��(��0&�U�L��N��!�ɘ���8����d}}���-a	vwv	�ʤ�>�2 �Uf�ZB�L	�yQ����զ�ֺ��;;��=ƣ!B>�-o iKj�*�K�T�a�r�RJ��P�ש�j4
\סP*{��i����pĠ?��룊�a�,Em��s�`�'I�4�/^���5L�_� ��� �b�,C�K�6<����|�0`m�k/q���Z-�J�D��'���3> >����yo�Y�oh��u

��+

���,F��
����\d>�ǘ��e�l��T��t\�(��u�R�S�1XB���l�ƶ ��rťg4�r�ShC͑���\��:��c��G�^��l��t�t��xbY�k5��*��aK��>U������:emscJ�Κ��P���$qJE��lƛS��V������i�����xF�-X]Yaqy���y\��wg9	��A@��dey�V�IQ����m,@+M��t�]\ϣ�n�lo����

�Z�f����

?w��@�Ĵxa{����=��0��y����>�LS�������s�a��8+Ŵc`�g��R�%��|?YZ`FcE��͏�c,�:�)u�wX\��ٍ&��!����kS�����qA�ܺ�ã�x�1 ˊ����6�f�q�Q� ���_^ \�3�5j�e�J�0�6IAkE�ediF����5ZkT����:8"M�<�R���g�/������	�wbWjY��ׯ277����q���6Q4BS��}���n1���{wﲳ�����,-/q��e~��!aP�^��xf�jB�8��,�h�X�pa�7�iJ�&$iF���F#F�!RFH)ɲ

��ޭ�x����9;��v��cv���>�x����=M�K��qm���W�Qd��	=[G	����>Ȼ��

�e��J���c�{��D洓�)B��B���l6�p��V��7��0?����Zof9�ѣM)hF�XiR]f������g�X�����D��8���6��O�z� ɤ�:	a{��p�l��g<Ǜ��ceic��q�y��=�����(a��x;a{:���.���

���;

��p

�
~����=z�2=�2���;�q0�R��7�_X����Ƚ���μ�,�y�I�k�Q�ש�!�ˋ�~@��������1FSM7���8'�%�mQw�r�|���<1{�_�t�飙Y��9�K�iei&pMC�� n�K�� u
`�>
�q���

����

R

�8��

���J��
ݹ

��

�u
9��

2����F6�
V!B������̲�$e m+W$}� E�v��<ʶ��� RJ

''�>+��V��DqB��l��cy�/ʸ;a�ؖ"��MS���R! ��h`�)2��B�$K69�D����|>O��\�L�P��"��1>6�m���c�V#_ȣ�"���x~�u���ʪ�,

�att�ɉ	&''��0���f�V�����s!H���eb;頰�vL,��0M�� J���I!I��98Rҍ�@L�+��y6�!��1�ضM���ʕ+*�*333��F�d )�B �����)��33�~��Z�0=9���$ξqUY*�#71	QB�ϲ�صQ�c�4N�J{?�0�,�b�@�R�\.�p�E�N4q

�
��

����*����L�iP|���8f��r��{q�U����`��,a�����'����n=�޽K����۷��B�P@�p��>�N�/����ݧ�h`&����J��1L�4���0~���^l�|�0��j�p���[*E��&I���s��Ǖ��0L�L�fC����$M��c���?�6����A��l����x��tѡb[�r|?�hoU���W�b萃<m�U�٧��<���3��R�f�~��O�>�P\���$�i�97Np޿H�!�¾��!瓗	��� ��8��4=�8�����;�-�׏h��/6h����xTR`e�M�S�~�e������Z�#g|6WƵ
�$!�S�X�/��a�l�|s{���٨����3�o���4�I���4ޚ@�s�Q�8I��1:I	���2�^�TV� ���U���8��R

�

�

�$���

��&B۾P�!C�,�D�	a��(�b���Ґ��("��&nw�=~�N4IcW+�n.�#-��}�ǽ?��� �R�� _,fm�7N&	a�

���

����

�0^*jGQH��g�^��i!���M2�]�Y�E������y:��EJ�i�x9��Rƶm� $"��.M�����i4l�w�>0����r^�iV$�S���n��v�ǭ>�m� Iq�d"o3Qp�,<Ca�7WІ���k��^$��\}�b�1�jȐ�`4<��}���?�}��4�ĊS�T��O�C�������	�H�W�H���y�mx߶�=)�

�D
���y��u�D���~��{?;��8�5�~���a���,�y��� ��H��+U*�^?fa�M��cg��eѿ��-��{�$��0LŕKU&j9>�Yaj"O�x���� ��j���[�}���=���WXӽ�=[m���i���1
�a

���4�

�0l�azz�P�������x�1�N��}��B�������o~���$�^�����Ged$+M��U�̱&s)	�}:�.�v����U���?���ǋ,���&�F�� ��j������

��c\8<��"�c'=���X��#�'/lr���� Դ�=?�a>Yb�1�t�1?������g���WG)�t{1I��:w:I�I��p�J�z�mp�R�K�.�߬Q,�zh�aB��x����&�=�H8��cޮ���)����6�!бfz�D>�}"ԙ��T�q�2�v�e<^n�� J��
����

CEa��y{���!o�D��Ӑ�	A�	��8I�DLE��L�̪ybz�d	5�N��(���>�v���RI:�6��'ɞ誓�0�	I6 ��=�R*� �B��>Z�l�

ʕ

?
x�����

k� �lL�@��i�Ӕ��� �6�21�a*���\���H)0
��h� H�����G��	�F� L�����d����#9�"��V=

"
V=�

��R)%�("M�]B�Ai��y��Ef�fi��(W+O���F�(N�t��޾�������OGl�����������\�t	��I��	�r�_~�K�p���2��]�b�ƒ�033˹s�8a����t׉�$K��HU�6_J

�����

�
��
�|��v�F���˗���!(��������J����6�J�$Mp]��T�����;��l�(�CFQH{c��0d��2��a����	Ð�q�i��� 36h��N������Rfn�xq��M~���������K���u�ٖ��w��]�ܽ�����v���|�8IP�0=3���<�Z�ݩ��8.�F����֬?~�%%�n�`��"A���;����VW�i5��uf�O�����<�Ǝ���v��,1� ˌ����i�r����t��n��	�$A`(���Kյ)��uO�����J�"��V[���R����TlˢZoP�T��V����?������_q��}��O��_��v?�q�˒�f�R������w����e2[�D�5�֢jk/��L8G ,���Ű%����[�C�j\HF0�����

P

Q

0

>���

iY��G�X$�"�h����i��R�ߺy�n�K�\�T*Q*�v�=.� wj�J���Q�T���X,bI���M>xȠ�g}�1��P��i5�؝�s���$�����{�����׌��pȇ���,Z,P.�����Ao�� ����{!��C�z���z�~�r�^d���~����^YyDw���;w�� �q���}9̷�%	�6�h�o��9J&�s��%���sh�6M��1�"8�G����|B��dc}����ll��}�&�^�8�

��9���

��
��p

Nc���pi�?P��VB�@v��ݜC�uS���3�g����A�h\k,9@�	 -L.l�e@i���m��$.���w���
B

^]�W\��ə �6(
*ըWX���A%�T,e�_g�3q�	+��<Z��6�"�@#!��.2;U��}��˚ʙPR�HӔ������o�F!I���viNM���s��%fff^�\NN�k��L��S�������

bW

��B�

q
�����O>�\�p��Q�g�֪X��;�l6�v�*�v�u	����q=�$N]�0t�C��KE�;�m�;"���r��yVWVh��X��F��>�����iR�TPU��śt�}._����7 ��r

�}�VV�� �wy�~�.�-&�?���84UE�4j��b�B��ӿq���t�<�׮�ܖrG����,%E`y��G�u
�{� �v��Y^^&ھ��O��YJ**��c96��SCQ�{2�<UJLEe����x�1���f?M���!��Kf�A3Y08Ys(�ƧF܎3HR�!7:.K}�_,�Ys���$���x���t��J�M��\��T�
\��
9r���	N}�%R!�z�>���~�3��g8����h>Q��ow;!P�4q��I�B�p�Ï�r�c��1}ץ�ϯ7۶��W��T$iZA�A$1 �c�(�O��ln�j�^>��iTk5���G(/�Hӄ$M��z��}>�t�N{���UZ�-?��<�TP�J%�ggf�=t���	���LO�m��1�N��K�l�6�p��벹��w=�$�)�`;��"g㈱�	tMC7�G��$!�B��6�N�t�
�hH�T:�.�n����X_[��lr��YN�8���I��VWָv�*��~���i�����MMQQ4���U~����;�����7o011�¿��,,,�����������X�z

����W��

����

G������
E

�r����

�

�

\

�jn���Q��4
�(���&�C��5L� I3�6;�������|��?	Eebb���^~�{��n'��4�a�jm0�X_[	��*��x>_�B�P��j155EjYy�����4Ir�z�̉�'�l�R�tG��^Ȳ�r��mY8��}�[& ��}�����3;;���,G���z�"�'X,�R�(b��Da�r��V��P�uA@��"�c�0�R��._x�

;

G��H)�
�ֱ-����͸���T�&��1�D��jylny��?;���$�H���O	��4��Xs�VL��$��~�o$�.PK��	_��

����q

�

'

?���
�
���R)��m(��Ȳ����PH�EQIE�@��aY�J�,˘?|�b�@�T�U��"�J�y�S��卄dR�jZ.0f ����1&UUj�Ap����~��n�$I�=�V���V�j�Kcb辶�ȅK�<�ܢ(r�|�y��T��m)ܳ��D�㐥)�a��S*1>>�iZ���k�\�A��}|�cmu�ťe�]�N�ZEJy�:̏��H�L����c)��5���R d^�D�ϛ ��W�<�JQT�4}�� �۴���	��P��@�,���.%di�U�T,�eQs��1

7
[ò�0�\T��"Z[>k�}|?���I����U侽ݪ8����J�<I� �O�J3�׬y}���Ƶ�8I۶Qw	��� �Ȳ:�.t;
��

b�H

E

�0

E��f���LOwW/���U�KeeFfDd���n�t0��-"#23���P(d����3�g���}�?������:i]@?��E)w�!��	w�	�,'�Ş��)D�]@U	�`�b3_u����J�P�����\��/����0i�c�4��?������{��o�����u��3'�OsD8�K��

�5��

�$�

�fsc�4����qq]���Y|ߧ��`X&���+�|��K�R�ca�QLCQ��q\�q	����DqDF�i���z���{x�����mc��O�I��p��E�g�)
�UZ�S���Q�R@�R��W���eiu�0��{DQH�$x^˲�V|�gg�}Ӵ�-B����)s�����S}C�VC	ɷ�1

�,�

���

b���

R3qiO�y�3/��?���?�Ǉm���������$^�4�%z����~�}<UA�_u�\ڧ�ȷ�a_5a�Iq����e�z�E!^Z�6�Y�8a�~)J�9[��~��t�JR�e�x��qL,k�	�,/HӜQ�0�G�	a��e���x� Ir� %Nmr]�d��ћA#� 3��	R

pR


�#
�%

��

o6<+.���K5�Ś����	g���	��j��_�������7�t���3~�����qq�=�yvJ�5��K�8U��+�YE�����!�1�b�]��3������E��

X

�8��
��b

��g�

�T{

�



�

�#��Ad�MA�j"]H�(�g�\Cr���!�
�B�eη����L[ɉ�}�95Q��]�gɱG���}xA����?>l�3��91<�b�}9	��Y�:���D�>��|^ř	��8V�u�pBm����~·����,x�%

\��0-\���+�C���^�,K�Ҝ4K)�f}c��~]h�,% �("M�  `zv�`4$	�RX3M���c��^]�8I�{�X

����

�

��

'E�2�Y^��`}įnlF)yS
�N��w���(�_�� �i�(e�A�$�x�1�ٰ�4���͵���q��->��o��{�CǥV�r��e�R$i����������%��\�s}�ggh6�ԪU�4ess���1?��#�dna

�������
��

��q%%a����p8$ý�熱�(��Q�1�ns���2�E�	$�����m|��0MZ�a!q�'	I� `��'o�B�cW$����U� Y���W���f&�v���Ty���cA�X�~�(�R�

=X�M�O	=H�
� 	e2���9%�-���l����L��VU�][�d�q���UY�YY�]KVw���2nDܸ��s�=����˟{�b����,��I�J�n��׾�5Φ	����W>���< ��C���o����p0 KS�4���+ܸv�r��Dm����Q�M��{8�c�$�ëWimos��

�q

��

��
%



E�

�g���Fk���4�G�����uK�K6����臌��3��^�13�37�Q*9�Ĉ7[#�������F�fkH���~���*S�>EϤZ1��)�:����)X8�ͱ��wuff|�$�u��`�P��X�0�'�X��	�a|[丣��'=�&=�,Up\�8���h$����m�����ۛl��

�=�

�$w



��*

TU;t�J����!q����v��|���?fs�΋/�ș�g����
�^���*����,?��� %_�N�$|���$i���� �R)������y�P��N,|8����u�\��2��m�\��뺸�˗��eJ�2

�w���

w

n

._~�0
�}E%���    IDAT��ћ���Z����h�h�Z<���S*�w��NxX2	�p���W�����/���IӔB���e^|�^z�q�O~�Y��,Y^^�ڵk���;?|�0������Z�mΜ=�;}�.fE�1�gϞea~�,͸y���	��Vh5��ٟ~�R�Ȼ��ŋ���&x��KخK�T²LTUCѴ��H3�0$Ib�c�ysc��~�{4M>��A�z�`;6�b�4Nȴ

�v:	��TU`���E$hm�$͞��-D��1�m�ڄM�d��:�����^wI*I�v;wѶ�!�AD&Ob�;w�g�$���^/ I%D�
Q5
z�

�

����
3

%l���

���(

�v�]����o��6�n���<��U�s��-TE��0�j.0I��?I2�����A���ҙ3TJ%^z�%O�fnv���94}��RE((���d� %�s�#$=(��2Kg���/�4��Mڭ6I�����[��/��2��Ǖ����S"/]!E4U��0y�o#P�.2~�~N �dF*%�k�8�����Y\��D$(�]1��(��#Y�ǉp�2���/��{A�0`\�9E�)*��1=9I�V�u<�]\fzz��.rji	��=���C��JU��)�{��v��/�J�\V5�x� %?Vz��!PT}\�$�2�!W�\E׮�jG{ҖR�Q*qm�/��*Y�199E&��slg�5u�7��'�R�]�M�����*��o/�r
��:��t\�G��-��a�ܝ��?���_���6=2�~�2��7ﻍ.� C�]��/-����������㟿����'��2q��K������8Ϳ��_������W������Ua�I��i9N����*!}�x�3�O��r=��2	ڟE����y�����~��
cX��� ۱�dzǭZ`I��u��EUq=]7�5�/�&	����»"@���L�A���zh��P�<!X(��)M��:�cQ=���E ��D��d�q�' Mb�8N5MŶ,&���MԘ�V�

w�_��oyb>�v�7���8�8|(�l�k����厮{mo����H�1���K{kp.�U��9H���

��O��M[[�<)�0Lv��M6�c`p ���4���������h�N��8�.!C!�4)�v�sd�B���I��Y����8 ͩT�4�� �I�J�پ}��;�t��0ы���}}}$�I,�b��ݔJe�?F�Z%?3�S�Ήښ�c�&��%�
8��
]

�

�ٗ

���t[�^�mb�iR���l`:���ҹ����'&f�`��mC)���LMV���0v�Ж�p�l�B�J&k��c��gaۍ�,]/`l���L�G�dz�L���^���_� �Pr8q�H���	,k�)(�ԑ��8���2��
��
�����܀j�cj����eJ���B
(W<\�gf���L�B�B����K�215<ϧPp�T�q�M	��ؖ�45t]!������ C$�}	����|犉�����������<��7�g�&{��v�?<���	ڏ
:��Ѽފ,��BP�zLL�O�I%��4C��YLN�I&Mfg+@�X�P����;i�}{������m���cbbbbbbbbbbbb֋���lb��u�xӫ��2k�O~�V��s��w�$*���wm[�����o]��ǊE>p�������e��\�U�X��s����5V*"n�|ڱ���C�s#����O��l���%*�1�����Тu"^�cbH&L�����S�O�p���6A��x�=S�Tp�4�eKLMq�t��2SӥZ�h�ȁ� B����2�e�N��49��\	�dM��TJG(	��{�A0�"��

�۸�f���a�Q��r��:@��¾�������ɸ�۶3� *^{mVm[Q�N�|���Jڡ>��ڢ�~nw./�QeB{���kwnt�~�A���;������z�p-��6�d���5.��������5m9�������4�7���&c�{ikB���~����D������]͝-"m�K��2i�7�<e�����;�G�����?���'nwY�����
��Ca(�ڮ���RX��4�.�g+C
�ME6c2<��N�ȭ��s���~(� q��E� � ϗb�M?��1#�4��OP{���G-m�ya)�l7�3D�@�\��' _�l����>���,�.z�Ϙ	|��M������m��io�w��҅mV��r�A�	?�˶o]0�}�|;�6

�+

���

%

�pl�ƨUϣ�y�*Qv\ʎK�P�&�Q��	�w<N̖yr�D��3��L�΍�r�g���0�M � m*�h�7��}r�D��R�<�)C�\$TW��%f+iS��|L]`jڒ���R����y�&)C�3mâ��x����2�O��zH

{Q���

�����

$

�"��3�UΔ*���YҺ��6�K��R�^0�]/`��<σ���}F3	�f� T�� \f�����

����R
$

'<���3�4H�
�dq75���1�IPv�]���5�k�cHIR�؝�ɛ�F���;�ד0|y�e�4ۓ6��dM�A����1�2xJo�R"�kؚXr�RB�K�}ٰ/,��jFMt��:� �"m(��rI�&9KG�b�Hӥ$gilK��X��F�N�Rn-Aj�v,h�f����y��D���S/��k�e�,����?77�l͹�)���w,�4�&ӎ�Gp_��ϻ`7�y�!���@�eKx�h��h����t�|��DXwN'�v��k!h_�~^��C\}ŅQ���.p���|���h�W㥽Y�X7A/�5+�����¹ƕ�q��}�!��o����G�E]���½�M�k��ڟ���B�iGluݲ�[�

󻯹n���V�~���7���N�Z�ތ��[�x7#[%��J<�W*j���0V�S�/_u톆o�;�y��}��z���v����G�,�o>z3����M_WB���^��M~���

�
�9�

��
���V��/�U(�5��[�!>���l�L�P_)D � )����#D�ۮygKAS!�;0f 4ЄZ�ŷ%dM�
=r[�5�m&15m.��ruP"4RB��Fs[o�~࡚�u�}a��G���FBomE�h-�:JH� Y˕�II@Xf3av1V������f��}�!����~��KL-�S��&@�~�Ѻ���ёH�#�`i��yt	
[

�
�.

4

ӳ

�
w��

��
��a�#ϖ[S�Qw�����%Y=>�?u�����w�p�X6{�Y+�

���

�B�

�
��

�t���IV45�A4}��7��r�4�|���$�mR�E��k:�X�P0����;��`�6㣣8���j�!�@`�}i�f�@2��*�خM<ވ$I��N}��`[&�dj�}cUM�EЩe�w�vl,Ӝ�LA ��kѪ�3^���y�$5���AB�nsE��qlƆ�)�EL��s�W���� I�HMS	G"X�I:�)m���<�]��4�i��d0t���"��c��3��ˈx �h����D��0
���
>�ǿ~�a>xϭ�Bg��խ�p��ra�w�����殃�B�_ ������'z�Gy�h? �<�ޢvks�u6�Piٳ�G��H����ٜ� hI�?y�|�"�W��	d��PH��&@�`r������x����8�Dc���lD�H2�<

��O�L%����?MQ	E"�hjbӦM���\�q�,O�g���	�z{9v��2	�\�e

���

���

��ᛏ<�;oy���ۋ]=��־�5�Y��9�XQxa�������:˅����/����_<ĝ�/�5��V���s$7*2{õ�����Wv�|��s l�~E���]�R�=�l^�w6���y�O>�4�g��C���~[��e�C����vå|��G�Ѿ�O�=[$-�O~�!���(z�o\��h���S����v��O���y�m���
b�

444�������ti4%�C��^^¡���9��Kd9<��.�T���
�]��Ʀ&��ut;�����Ɗ�M:�bhh���>��m--X�	����n_�.�\�d"A__�`pښ�q�B�m�


�

�B�

�>

�Ҟ�����
��-��<yz!\w����7^���qە���x��a�<�����?>8K�ܼ��Kʅ���D�rTL� ,��t6�GA9�~�:T��DDQ@�EtC!���Q_�>

��O������<Z[Z�dE�O(Yv�6��"K"�$ K"�Z��'_o��|�[DQ����Ҿ()�wBpl�l.GwOG��8|�0�{�{iZ���5kPu���v��6�~������@�5bU��o½e�$���224DcS#


�v

�S\��	�m��ct�\�YGX䍡��������dݲ �xXZA�s?`�������vZpo�[���� j/��"s�"���}�S

��

�

#�u
�

x��

��AR�dUiڀo.D���{z��d2�_��_��/r��>�?�~000�C���ﾛ�F7̎�$I � ��!UQl�[��299��|�I��'���?���f`��w��q�����8��k��7��}�mؤ�a�oEM���u

�'恈D̹!b�[�_�V��
���?��|g��-��'���.0�Rf������ʧ�3X�;���w?v/�?r��9v�S(��~�{��%>��7y��E�W֘-�)��;

?~

�J�L�Vgjz�z�A"�"�N182z�[����3@o_��s�[`~~���EdIbe�ĉ�i4���޵���oDn��}Sw�_t���i�5:�)�*��p��+�W;�^\����β�\��_�6_|�戲	M���� ����ShG�����,߼1�TwdA~�h?�:�څ��*

.

�

{�c

�x

���v���� �q����ٹ9�;r�������I&����E����EEA�8;/��
�j122B�y�''������ѣ,�|�s��e��ar�,�iuE�ۍ[Y��a5�6V�G���/����[�����R��ڴIh*���]����:��������Q����'�q|ۢ������|�S��l�6�?��r_�ʱN!��O�~�=�v

#�1� lV���c������ODԽ��'Qq���'6�#b1ǹ�^TU$4Uf��,٬M����,��$YB�������QU�⵬HX�֬���	Y������װ.]�t�r[ �2�m�N��'H��k��F� �\]7���j����[���v

�z��N
���+�

��/���

���v����*x�����J�T�_6� ;�����]��YQ		M�	È0R���CWÈ(�S�����8�IQ�2Q!a*���~E�I�5��BdIFVDb���0�$�"��k���$���H����M���`��ҥK�.o:TMB���!�b���
s󬮔���(A@�k�hx������`��x�Бe������J��q��n���n )⻚ר�!A෯�$��	;�T*�����Y��d��б^��$	۶�m���!L��0u

4M'�N���̱�_h��.�D�\.�m;�	2�$�iP��Y^Ya��F�&��%h;ި��f��*�Nc���,*�S)a���㲴�@Oo/�cc,��p��qf��H$��z�o�,��@?�=��cG����/��/x���p������rI�#���199ٞ��x���	N�:E��aY6���ئ����D}	�4�Yj�: /^����u����}	�����@Ȳ��8��݇a[Qq��ϲ��FD���0v��5�6dYAX�����R,�lϭ�����=�ŋc,�,��f9�� CC�*�*��`jr���9��EN�>M__�{M�tR�,�D�]�F�t���qfgfD��l�eZWT�"�3��H�^�TZ#�N7��)�ǈT*ɧ>�IfX^YU�a��53��^����F��&4�X<��i����(��01>���(�J,��0m�R��-�,�N�iDm��g/�,���x<8��J�'�r���W��n���d��c�!v� ��f��|�u�[����G�i�=RH󵉙Na�����v��-JR)W�Bn	W	��䏾���Dmk{�5~���7_[|�SO]����Oύs�SO1ؓ��GN��s�<�R��k����N!��O?u݂v�ϼ6Ρ?��l�?�=��v����_��/�gC9�v��������i>��s�Bo,;H�۟p��]���
�|
�����
�
�
���
�+������ɿ�.AD��#/����zFz��NQ����m�>;���-���ſ|�SȖ��vT}~a|����������� #���x��n�H�8u����@������_���W�'�B7��?�NN\���&:��v��l�G�g��B�����˯�>�.j�������gY�	j���������؊������ [I���?����ݾ�]��b���]�t���vG�5dUcd�.dE��Kq�&�x��WH�R$S)�5


���=Kiu���%�%��%}ED�Xc��6�%GQHDDj��#������I4�d��]#�Ʌ/<�73M�"l�s�,}Ȉ5a�X�\.��ѣ�./���̝�p�d2ٞ��HFC�Jk,//359��i����Q��l�u�f3���b�N�bii���9�("�L122��i��Jqi��R�WΞevf���e�8@��@oo����D�F���Z�����e�?.D���Dճ,So�ix

��

����


/������ B��j�|>�����[��V���%S�RQI�J1??ϙ3�y���3� ��eZO6�$���<��{�#�$R���%�vll���"�����D�0���K$x�����"	@U�mUE�rl��pc1���(��y��_E�$	���x��r�����Ӄ�(h��9�:6�emj��Ar��y��.2;3�{�����
���Z�`Q���T:��8�� R��@�V#�s]�1G�ڲ������"I2���#��008@>�#O K`���ǉ�=��F�F��n��͞����T�U��]���։�a�J��������w�)� �

]�0

�0

�

���

�2

���

��;�

3

�g����G��/�4A���O�?��<.����kwYTY+D�D�����R<S��#5�H�uXf�Y�Ҭ���4o4E��[oT9R�4�\����3�ٙ�]|?�;�ٝ������y�?���]%� >�'�i��J���Y��ح��$�-m�o� �WX!�������������Y���r d��Bnr�'��'/A!��PX�I>y��S!��13ɸG��ފ����f�|�!�f�O��B=q�8�$E�i=ޯ���"�E|�E��5��V������Ya&i���B�\q(c�iKdVT�׷.Ν=�

�
��5�a�ح>�C��1D���y&����	�i����r�Q[~݄��n�B	!�B!�B�

���

���L�O��PV��/aѻ��+�`w�y9��^�<s	~��ѿ���_ݪVMV��	7���+LK&�^{��X�`��	n]��\f� �J�#M�ٝT

�

�

�����8�

n�TVKiΊ}f�|7T������g.�ϳ:�wd�J��g
��� �r+D2qY�5����H��Ɵ7�] @-qB &2����ҮҶf�q�4�7Z�Ŧ��ѳG^�)�7!�B!�B)l��.G2����{���"�N����*��5�

���

��鏻0~�^$攽ϭ�6_LĆ�'Xa���捄�Q
 ;��K,[c��9�jZ7��w[] }�6�?X��嶮���l_i}��]�[���˖��{����B!�B!�H���g�+k	m p仈'Q���q�

}

*�

�_��
������Im	�X��q�J+�nX���MVO�/8w#M��|�2�A&�c�?��+��6LPo�/+�s�!��e�����gm��[��Ҩ�.(,J�K�ض��e�	�JhKI�^�4�Ҍ�#�l�T�e����𽗆S�E��h�_�B!�B!�
������,�

n�

������

� �

'D

j�����u



����
Tf?�<g�!$�
)Ubל�S��K��mJ�g ���}{� �sg�>��>B!�B!��!<K�P�,o?n���N����}'1�oޘK���]ƥ�KUQ�����g��}�7b7�Ǌ��Ӫ���a�b�����(��R������x�8��I�&c
`��؛�a��O����/ڂ�q�P`�O�����_K�d��@�؃ѭ�Ug'�f���B�߸�΃R&�к^�x����,JZ��5 �N' ݠ=q�f��%�n-쾖Ĺ�P`Ӻ�ѳ���+T��^���)i��dY8.e��lu
�\���

�

 ��b��SX���x����4������^��G/�=nb���~�#c�����~���� �ލ|�*��m>�y'��2 �!.�Ư���=%�	��5B���`���8y���׬�pS���XqRﾖ>���n�QҾ���+��Z����]�v��3	�`q3�����
~

�

������

�

�O

N�

�

n
���&

ZX�

J���

���

��!�����5u2y�����O0x֏�z�`�x%��� _�ڋ��1�QI�jJZ&gB �ܺ�wPӺ�=|暹n����m? ��31��X��8�}a�� lP�u>Y�9�vp���$z����fXs�<��n���i#�qt����D���o��\>`�Rę�X�%�:�_N�&M��
-�P��
���{9	?D��]�1�1 �&���]1�]�AOGO_��3����G�Ź��5P���SL���DI�	����Pg�׬0����T�je4�i�q�2��p������x��ķg���$��M��������Ǽ��0�-�Pl?�	Kw!;��::;/��Ɯ�Y�X��0�7�R ;?����9�5��f?�����{�hߎ���[�w���%$imyQ

�x�
�}
�u�Zk���0u`}���ۑڦ�)$-W�R�Qj�����"R�7oi�r��-_{�]X�������� ����a<���3��-rD� � � � �氐��`%h
袷w�t<����3�ǻ��.� x�?�n<�O��D<��ߊ�}���+� � � ���E�z�V��v���ͳ������<?��כ
4�����z���&��0a�8�5�>8N\�
{WA;W����m�d�V(`[�+5a�Q�۴�Uع�x�_����������g�y�s��o��:|�5��S��d\}�U�-� � � �p����޵Ҏ���pɘ��࿗�Ev�?>��ǁ|9�q����m��CG�+��u�(r�oeq9�=�ъ��F��N����Q{���1~�.�V^}���C�H�~9����#�"V����3w��=uxTy�?�����.�7\�h �S�rt�?z�wBAAAa	�GjϐU�V~�8�\s�#M�mpݕ��Sg��]���[nÍ=��x-��;�N���

���>

��

�

��8���m�

S���5�

4����s�
�

s�


9�|�J+�-<La}���+`���C1 �s�`�f�*��G(��t��lV�������fMB'l?�k;ڦ/�^5&l�~7�is�3q�    IDAT(���ؾ"�6��an\\��4���9�yG�8

E
���=���
�=	

���
���������H�^_��ߋ����,;�T v��nU���m�S��J��5g�f��BX^�~�D�z�s<3%	ڶ�G%
�@��ǹ­���w}�SL��rӟ~��o߄O����袡��/)�X�i� (_�	CH����'J���� lw�&,Pc^�Ei�
�

A����
���

��m�

=�M

a��

�

��Q�Q

M

'

��G0��-�b:�{)\�(j�L�(��w��b��D��;J�Ga�k�aĈ��u�#G)��%xE8b�
��1^�� @qB�PJ��/�	�/)�ӌ	�\M��[ ȗ.=�����

p

�

;;=>�

�����r��

8�

�
h�

�jLن[�vao�d�w�5f�A��}J�ͽ�>p�e�iL�[b	�\�����KpB�p��>%	�ہD"h�a%jSN��"¶ ��3�iMcTmGjO

���Tc�6��������}�s͔x,wi�c>¶"p8��a���i�V�����؈;�u��d�M�˪��]&u_^
%u�Z�sv�F�t�v� -U��n>O��_�>��Z����    IDATG#�T=��^l8Di3�Bq�|%>P	ۍʩ!M7�ơ�<���>�f�����PP��ݯw.�6`��

���

���
ދ

j

�

��������

۔

�

i
1�

�

�'��

��

Z����
��
�����
'�l�
����+
����

.�.e��H���jO\[��#řm�Me�S�b���
� ��-���|	�ە:|F���}�Ct��e;���0�d?s12�w~�M��"��B�"U�(�yQ3�1;[7���D�Ts�K3U[6N�*4u���ӥ�����-�1�������ݖ�]�C���n���]������-���}�u��Y7��tl��б�@[7�ݗ)�ڝ�׺�9fO	��c[�

��/��,h�djY�����T���l*���B{/�
�l[2\p�M�K�.E�Ema��	ۜrN��G�b_<���#��v��6C¶��p8D��S����	�f���	�:�J	�

U�
�
}

֍�9�����"H�L���Co�ۍ���x����ʎ��\�="܄�K�$���Q�M��J%Jy��:c
_�Fp�ݢdQ�� Q���l�!��	�=5u=^��;���B'^{` b'��m���C����W�G��^�v�:,h4p_����

B

��a

��1��g�v���,��1R�K���H���}E��j?F����9�����8�fA�gduO�����vUuF���re(�xÍ$�Y��TzH� >���p9�9�fiπ��G����JH2Z��OL0��S �ؾ./��=R衵9b�E�~�e�No���¶d{I��oP�̕ı������ ���3����F�lJQ0E���>M�`�H��)(�����vc�pp�C�_p�geg"?t2�6� ZcF[n������m����lQ������8���}ؿB�G��B�������.!l+���0c��B�6�

q�

���
��  .�
�Y?>���s��¶d;DX�f�#6i&@�@`��:T��4�>�K`prs��&��L�Νc�Dm����/(SL�������{R�;�-	��iq%l���c�=Z��G���\o�r帩p���{��^И���Ŷ���ߥʄ��.���E�T�CO6W���f�����<�^�R4��X������3�#aJ���@
��"��>�ܠ=
���SB�s#Y-R�j�ܒ9��e(x�	�v���Ph�k�	�ъ�{��8X��?�	��u�ᔬ�݊ښ@�l�m�ߋ=���Q�Ӯ9z|E�v�Y�� �3GZi�O��
L�
ۜ

!�x�*�����-�îNs(�p݌�O2� &hg�5V�'U�^y�& �b�v��"߃��,P=x ��:�0��.ѷt��V�C��}��f?�C���5R�f+g)���n�q�)ј��e�l��o�3	q}�͆���$�Wa���>�?	v4^�
����x��



j�Y��a�.A{�D���ݚįS���(�iQX� A���,�ad�w�~(��S�/q�~�е#�s�
 �	۱#�5c�k���� �~gd�w�o��;�;8�M~���G�Q@�ڌm����oiA{Px8?%k�H����6t�Q��L��

�����

����
�w

ۢYڃ�i��ܸ]*�0���ڝ(��,m,�����pzZ#��P�eiwC����#a;���t��m�Mtu�z���}�'�Y��� �ܸ�6�3"��93����K@�>�->��N�QGM��z��."q��ej
�i˗��\�e�������$��%9;z|O��3�ǉ���^l�G끰On�L�9��Լ �"lg�'	?M�

�5J�

�����W���m�
=.�

�i��
�
I

=����

������(La;F���{��4E5�c��G�� `RvBb�pV��*< �Mq'�O�	/��2�Wm�!l�djlǜ�0;�P�|	ڤ�,�y���OR�8#���fM��>���,J�=nlm6�`��x�Y�����������T�ݧ�j18�7 ��$*lc���M&�V��}���ք�^���.��#��ʆ�ׇ������w�b

y4

��

y�ߟ\r�vYf��tDQ����j�Ѹ������?r�Jd5A;	�.5���	��Q�ڄm�q0�!y������J�R�<Hgi��*l�D���O$y��� �{���%hH��

�c��z/���E"6��	>�	�gw �Gdi��5P�[i��S�H6�

i

�P

�

'���

�

c�� C�A������W#l��Y���J�]D���} ɜ��7�>���곴e����,$��ʲ��h�;�b(�'�1բ�a�H�G�[��>Va��BÁ�  ���ã�}�	�����RDǒ�J�H�[5�(tpڂ�i�Q�L3]�sX'~�3��B�6��_ZBc`qL��Yj`��R��R�U���{��]N̮�d��a����6K�ծ	�Ca5�N�O�#j����V�����y�8��0z�/�����_DcO�c/?��;�W�'����N�0�޸"���1��"0�u�w��
�����i;��$֮[z_�Z��B�]vF0��E,��O�}�������ǉ�M!<k�G�p?�(��h,'s��؜�����l31���][�ɕ�&h'�C�vޯ�ˇ��q�a s��=*��fiK�)��Y���ML��{��SX���8��c	�$#�x

߳

��?�Q}����^U���odɅ�}+R�5r���F�J������V*s�b��b�fX��6�s����k�|�u05��������/�WZ�� �,	 7�z6A;	���
k4P�O�&��֌ҷf    IEND�B`�



16_ONCODNA-COM-CAREER

OncoDNA:CareersinGeneticCancerCare

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDNA is growing and in constant search for talents ready to contribute to the fight against cancer. 

Interested in a position at OncoDNA?

We are constantly looking for new talents. Feel free to send us your resume and cover letter at jobs@oncodna.com.

At OncoDNA (rue Louis Breguet 1, BE-6041 Charleroi, 0501.631.837), we care about your privacy (). We will process your personal data exclusively for the purposes of completing the application process on the legal basis of your consent. During the processing, your personal data will not be transferred outside EEA. You have the right to request access to, rectification or erasure of your personal data as well as restriction or portability of the processing of your personal data. You can withdraw your consent at any time through our contact form. You can lodge a complaint with the Belgian Authority of Data Protection at rue de la Presse 35, BE-1000 Bruxelles. 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Privacy Policy

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712105356



17_ONCODNA-COM-FOR-CLINICAL-RESEARCH-DNA-SEQUENCING

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDNA offers a broard variety of DNA-based sequencing solutions for oncology and rare disease research. 

OncoDNA provides first-in-class exome sequencing service for researchers with the latest high-throughput sequencing technologies and proprietary analytical tools for analyzing data. We help our customers to identify mutations in rare and complex diseases and in oncology.

Exome sequencing enables researchers to target the protein coding regions of the genome reducing both the cost of sequencing as well as data storage and analysis costs. This enables researchers to increase sample numbers better enabling the study of larger populations. 

Experience working with world renowned researchers across a large variety of fields of genomic research including:

Experienced with the operation of clinical grade sequencing platforms for oncology exome and RNA sequencing projects.
Numerous customer publications based on results from research projects.

We have a robust quality control (QC) system incorporated into each critical step of the sequencing process and a continuous quality improvement (CQI) program for our laboratory protocols and analysis of sequencing data.	

How we add value

Ability to process DNA from samples with low DNA quantities or degraded samples (FFPE).
Decreased turnaround time as a result of access to newer technologies including:

The latest sequencing platforms from Illumina;
Automation via advanced lab robotics.

Expertise in the design of genomic research projects.
Expert insight and assistance with results handling and data interpretation.

Custom gene panel sequencing 

IntegraGen offers commercial and customized gene panels for your specific gene targeting needs, enabling deep sequencing and the identification of low frequency genetic variants. We can help you to design the ideal targeted gene panel sequencing approach for your project helping you to save both time and money.
How we add valueExperts at gene panel design.Availability of either commercial or customized panels.Customized panels via capture or multiplex PCR.Available throughput from 10’s to 100’s of samples as a result of automation via advanced laboratory robotics.Expert insight and assistance with results handling and data interpretation. 

IntegraGen is highly experienced with whole genome sequencing of any species combining a full range of library preparation methods, Illumina’s sequencing technology, and custom bioinformatics analysis.
Why choose OncoDNA for your whole genome sequencing needs?

We have the expertise to work with a full panel of library prep methods:Paired-end libraries;Mate-pair libraries;PCR-free libraries;Small quantity;Fragmentation or tagmentation protocols.

We have high-throughput capacity with the latest sequencing platform from Illumina.
Technical guaranteesRobust quality control process for samples.QC at each critical steps of library preparation.Guaranteed sequence quantity and quality.
Explore ctDNA from liquid biopsies for oncology applications 

Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. 

OncoKDM: A powerful tool for personalized cancer care 

OncoKDM is a clinical decision support platform that helps laboratories interpret NGS data to provide personalized cancer care.

The platform uses a comprehensive database of genetic variants to identify actionable variants that can be targeted by therapy. OncoKDM also provides recommendations for clinical trials and supportive care.

OncoKDM is a valuable resource for laboratories that want to improve the care of their cancer patients. 

Learn more about OncoKDM and how it can help you improve patient care.

	“Despite the substantial sample quantity, OncoDNA (ex-Integragen) successfully conducted its part of the project in a timely manner. We were impressed with the professionalism of the teams, their services, and the performance of their processes, including the quality data process that includes identito-vigilance controls”	

Dr Marie-Christine Etienne-GrimaldiHead of the Oncopharmacology Laboratory at the Antoine Lacassagne Center Center, Nice, France. 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712102370



18_ONCODNA-COM-CONTENT-UPLOADS-2024-02-GLIOMA-STAGE-IV-PERSONALIZED-TREATMENT-JPG

 Exif  II*                V       ^   (              i    f       `      `            010          0100                       http://ns.dobe.com/xap/1.0/ xpacket begin='﻿' id='5M0MpehiHzreSzNTczkc9d'?

2

Templates Pts Website - glioma-stage-IV-personalized-treatment

%# , #&')*)-0-(0%() C



LP85IՈJ1KE &(-LQ�Z(� ԜP%Q\�HQ  Q QE� R  ��( ��( ��(�P)h ��)�RR�H�(�)hRQE� -S ��( ��( ���6�-��Q@(���QJ( �M�i��AEP�� QE QE�R�EP 4��T�0��) b�R�@Q@RK�)h �aE� �Rъ J(� Q�Z(�OQ�2j�2�R�LQ@	K�(4 QK� R�@	�1KE QK�%�F*R

� ~�]k_�U��� ��Qǥ� ���s	Ԍ��l�|�|^.�S� �~~T?S����B.L	�_���ڝ�&���� T�k�~;}~�맘�<��zc�\��� �����V�A�sa



�c������ �����J�J��9,��%��I�Nu�Ӳ%�P�J���~�e-π�Qi�<c-m!P� ��<�޼�Q���o����K{�[d�H0�jMT�ѵo���-��;�H����Px5����������p$zƞ|�A#� �ܬ=\Q�*RJN鋖���<�᷆��w�,�k����u��F�-��*O�>

�g}Z5��؍������m��� $����y��\��QQ�'+lx���R�Z9V�u�'����<7yow-�j�4����X�?�?�p��k���W�� ^r�W��Xy9B��
��b�s���0�SIR1E-%- b�K@	�)h���P ��( ��Z Q@-%(�aF)h��/,))�I���$�@����.h���b��	�QE QE.(�Rъ( ��� (��

� פ���b�/���Uo��� �׌�<u�/��H�I�sl��>T{��ooJ���������� ����G�pE�Nn�*d|� �� �o� �h���7� C�� ~�� �׏�V�;|L��W�Q����&��u{Ao0���&�v�Ӝb�2����� �_���yI� �A^+F�h1�� ��Z�9��( ��--

��n�

(�.( ���P!1KE�/E��dn ���    )i(�AJ))E -QL�J(h���EPES ��( ��QHAES ��( �QK@QL�)q@�R�E ���
(�P�EP�E QE )h���)	KK���+�J))il1ii- ��EP ��Z @)K@	���QE �Q@R�IJi*X

1KE
�Q�=( ���7WC��8&�G&���4�R�P1�	�\QE ��b�	E.(� r�QEdnQE QE QE QE QV��>�U�m�4�Z{����b�ZM�V	6슽�k�~,�>��Qhq���n�"v��]v�/||ǯ�q^�u��6�|-=�È�z��֔f�

8�

0����Au�jo�f8T��E��'��y�h�V�s��K���=��[���4�I��ws��RI=�h��l��W��Ar�Ƒb]�[q${�F���7� ȟ����#� E�S�ͳ�uy�}���w)���

�

a�

�
]�

-��@�R�@R�� sKғ4��q���Qp
P9��֒E-V���Ӏ� R�E� b�(���J(b��\Pb��( ��( ��R�@ ��(�֊)EgԡGJZ(�R�E QJ()h����� JZQF( �R�@�Q@�� J��.(�R��%	�ZxL�4��ҋ䈀��'ڥ�)i�\�b?Zp@;S���݀R�S�R▀K�Z(�0jMOHˑ�&���h�e �F)	E.(���� J\QE rtQEdtQ@Q@��(����(�tό���zf�w�m6�

�%�#�;+[C9���Aۇ�Ҹ�����^"�T�� M�( NDQ��s��I>��⹺(�;;�v�ud��gxO�/���/�K�k�|~Tw�t�x��z�$

�
E

	�m�W��D�% �&t�ʖ6v��c�|K�M>;�w� �8�� �>Rq�5��z��L��������m��2�G�x�~\5��7�kul:� �~�O��2�N<��Έ�a.x���uh�E���o�i0�g����'�@
����eS���MS�S�|[�o_�n����2Kk`��$.w0Q�P�;ךW��D�_�-K�����<1
�� O:�cpS�r\�H�z���)J-͙ba�( ����ǋ��e���n�W�lA���FEg���z��6�oJ��F8:e	�

�

�

Ǥ
6��ݬ̥��Q��:`��֔c(պVFU�	Q��vym}�%t�G��� �Z�⾇���x�����o��9�?�G�G�Q�� �� �5��� �����w���y>Nѷ�B����� ��y� \!� �k+ை������#���o�O�� }�m?�g(s�F����/ԋ��� �

��a����ZG�� I�|oi� P� ��ξ��?��ؾ��N+O������u���~��ǟ�$����� ��0���i���&աY�	|�8�eC������?����]s���rU�����G��h��f.[�2�@H$w�\w W�~����t

{��+�C�0�)�����y�E�O����+��s���)2�@���_j���� ��� �x��f)8�]ʵ��¯��`�5H�	-��{s �%���(뎤g�$�B���9#־������
���
����
���O�

�

os
�
��

+��
QE

Z�

^):2��dZ�֣�{<>"�I�2�� |M�t�[����q� �N���b�9Q�E8ea����k^�Ώ�G�U��8�r�q�a��릞a%���[)�֛>A���ğ����OQ�#�p?�?Z�xcX���uk	�\�K�ѷч�Z�)�i�ٞUl%Z_1�h��9��

Z)h �m-滸�X��yjG�f>����	�+��6�dR<�߈���9��<�

W�

QE-ɻ�Q�=#���I��"p��
-IbҊAKT ��K@zw�o�W�!jϙe��W�q�������<7��ӟľ#��+o1� ��ƌ 9l������������,<%����|��7�sS��y�

X��4�V��ʯӟ�y]�ks5��|Ȝ�m`� �����c�i�;�8uO	H�d	S��sןA�J�t)P\���X����

G��
(��

(��

�/
Q?���bE���ᑑ�^��*�RQV[N�&����k�z��|+��!Đ[;!� ko�ٮ#�L�?���S�/�*E5y��-6���[�.��>�t�o��W�bv�ƾ���u��\�.��+t���?�%{�t�ez��q尵.n�H�Ib 

�	

(��
(��
(��

�(� 

 �

"��vs��

k� �'� B�6�Z����5�Y��%��`������+��ŪZ8;A�'��O��j���.��//'��J�=#�1�ϝuk�Ō���;c����nrk��,��x�B�u'�$�p�/�`pA��^�w�CM;0��S$1E������	KF)h(�-��\Q@	K�)q@	��K�(�QE`u�Q@Q@(�� QE�(�� (��P �Q@��)

Z(��
E

�

�Q�Y � Y!����z����%Mnx�*O]�kCv�(���>?�+�N�D'ˎ�K�ӕ`����~j��~7��Ct�g�{0n��`׭|s���/��ƈ=��E5�?mZ��:,q��p�~	��W��I�s��7

(��

(��

�#���
��

���

 QE

)E �������Gt.�h�JDb>�X����k�g]q$ӯ�Y\	a�Dtl�@� ���jw]K+��VϩO�����ѬT�$��bx���:��񞏪Oix�_Z���q�>A<���^~��ߴ~�$�N��Ĥ���2�|`�l�?�B����K*t��#�A� xq�2x�	��}_�{�j�?Z��̥���>�V� .Kk�v�4�D��

(���+�����Z��0��$�u�}3��#֌���Ŧ��T������^xó�N#
���C �P �Пƻ�L�^o�;�5��o.��J�j�6�2���V���:Zu��ǚ����|Z���,o�igR�q,��)� ُ��Ҽ�>

�

�
�

J�

�{

(��

����

�9�*����L�>��"��][�x�~���
V��'oc+�����}7W�'��I@� yH� �+�~)�پ9��W���=����{uv� ��0�]?ÈG�����MKJ�Q̱�,� ���U�B\����UH��.ǒb�)q^�〢�Q@���- QF)h1KE QK�(b�)hͨ����
(��

(��
(��



|�����

��

�

@��

���w�

���

(��
(��


(��


����L����8ɫ�cj�U��*x ��נ��k-��)�|����Ěso�]��3���l��� ��V=v�e^�kc����1^���>�ޭ	t�`����yL�
��

�A�

���	تQ�q���f�!�/ �����؆ǜGR��u�p��� S�,���8���Er��]s-����GQ��@Py� h�*��Q��X*1�s������a� �4|5��@��:7 g�>��|B�w�

CM�_ai����+h���Gq�|�L�f����>���?�7��K&��e�q����	��:t���J�U���S��>��/���i��*�}:)\(� F	�p��τ� �����/� ]%����� `u� �B�6�L=ջ�ߊ�ʊ��c�It�|NОh��+�F�&������_0�@�׃|G6�twǍ�K�D=ױ����>����$"��4&N�J�z��B}kҿj->)4

���3���>��h������NWP�w��2k��9|;o
jM��Q�{�����C������ϲ�8�g��_�֗������g�\+5�壜�9��8�?�V
R�

YP�	�prΜ�+nz�FQ�ؽ4Q��2+��+�PEy�>�/y�#uk6<�	��<{����>���0��e�7O�

(��
(��

W

�

(��
���
�

y

�<
�����T�0��)��~������_�at�W������kZ��Si"�5�! 4/�$�˞�ڝ�x�Kנ�t�����&p��SȮ������R���G�uu

(��

(��

��)��U����R�]J�H��xW�;�t�4��uw �6��}Y{@1�]��O�3�-��)�.T�y��^����Ҿu�i'��F�W%���=I5ف�&��dyٞ"�i]���-��-���ʺ1R>�Wc�|J�&��6�K���[���A?��)NE-zs�	�H��Z�7�z��

(��

�)

��(

���

�u

�M%/Z QKH)i�R�R� )E%(��Q@�@�-Q@E� u��P�(�P iE%�C֖�t��D�h��bQE(�4Ph R�w����֝@���R�N�Ө #"�O�#4�	���gN���a�rZZ���+D�CN���� ��@�o���֋��M£��>Q����=鴽zR����	�l�4X.���T�@�Le���a^�@���ť���)E� 

(

-1

(��(���M D�-IE�G���K@��(�AE.(���



19_ONCODNA-COM-CONTAC

Needassistance?OncoDNAinBelgium,FranceorSpain

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedby Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

IntegraGen S.A.Genopole Campus 1 – Bât. 85, Rue de Henri DesbruèresFR-91000 Evry

+33 (0) 1 60 91 09 00 

BioSequence S.L.Avenida Amado Granell Mesado nº75, oficina 8BES-46013 Valencia

+34 (0)96 071 91 34 

Drop Us a Message 

If you have questions or need assistance, please contact us. Our teams are available from Monday to Friday, 9 AM to 5 PM CET. 

"*" indicates required fields

First name :* Last name :* Email :*

Message :I am a*Healthcare providerNGS labBiopharmaResearcher / academicOtherCountry* Newsletter

I would like to receive regular updates about OncoDNA products, services, activities and educational material.
Consent* I confirm that I have read the and I agree the personal data that I have provided will be used by OncoDNA according to the .NameThis field is for validation purposes and should be left unchanged.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Privacy Policy

Contact
Privacy Policy

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712125896



20_ONCODNA-COM-FOR-LABORATORIES-SOLID-BIOPSY-ONCODEE

ExploreOncoDNA'sSolidBiopsyKit|+10yearsofknowledge

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogleTagManagersnippetaddedbySiteKit

GoogleTagManager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Initiated for patients by oncology experts

Clinically-relevant oncology targets and biomarkers

Clinical interpretation of genomic data

Initiated for patients by oncology experts 

	Initiated for patient testing, the OncoDEEP® Kit is built on the OncoDEEP® molecular diagnostic test, which is the result of more than a decade of strong collaboration with oncology experts.	

10 years of knowledge that matters 

Since 2013, OncoDNA has performed more than 100,000 tests, enabling us to build a comprehensive database (OncoKDO®) comprising 4,6 million variants across 22,000 genes, along with information on 1,600 drugs and 10,000 clinical trials. This vast repository of information allows OncoDNA to provide our clients with the most accurate and up-to-date molecular profiling for personalized cancer treatment. 

An all-in-one solution with the largest panel in the market 

OncoDEEP® Kit DNA & RNA panel is the largest and the most complete of the market. This panel is composed of probes targeting 63 genes for a final content of 1.8 Mb. It supports identification of all relevant variants involved in various solid tumor types with genes carefully selected based on their biological and therapeutical relevance.

In addition, specific sequences have been added to cover key regions associated with phenotypes of interest such as Tumor Mutational Burden (), Microsatellite Instability (), Loss Of Heterozygosity (LOH) in Tumor Suppressor Genes (TSGs), introns tilling for genes ALK/RO/RET and MET-ex14, sub-telomeric Single Nucleotide Polymorphisms (SNPs) for Homologous Recombination Deficiency () calculation and promoter of TERT. 

A unique capture method for high quality data with less sequencing 

OncoDEEP® Kit uses a unique Twist Biosciences’ capture method allowing high coverage and uniformity with less DNA/RNA input and less sequencing needed. 

An easy process automatization 

Thanks to the compatibility with Illumina’s technology, the easy automation process simplifies tasks by continuing using the current tools without disturbing the automate routine activities and losing time in extra training and manipulations. 

Read our white paper

Compatible with Illumina Technology 

OncoDEEP® Kit has been meticulously designed to seamlessly integrate Illumina’s cutting-edge sequencing platforms, ensuring a streamlined and efficient workflow. This singular compatibility empowers researchers to concentrate on their scientific goals, free from the burden of technical obstacles. By optimizing the compatibility ofOncoDEEP® Kit, we strike the perfect balance between cost efficiency and constand precision, guaranteeing reliable results without compromising accuracy. 

NextSeq 500/550 2x75 cycles

NextSeq 2000 2x100 cycles

S1

8

Achieving high-performance sequencing is now more accessible than ever, thanks to the OncoDEEP® Kit and Illumina sequencers. By utilizing these cutting-edge technologies, laboratories can process multiple samples per flow cell, as outlined in the Table above. This streamlined process allows faster and more efficient sequencing, resulting in more accurate data and better outcomes. 

From sample preparation to clinical insights in just 5 days 

OncoDEEP® Kit revolutionizes the diagnostic process by significantly reducing the timeline from DNA extraction to clinical and biological interpretation to just 5 days. This accelerated timeframe enables healthcare professionals to make faster decisions, resulting in enhanced patient care and improved outcomes. 

Extracted DNA and/or RNA from FFPE tumor tissue or unstained slides

: Library preparation

DNA fragmentation, end repair & dA tailing
Ligation Twist universal adapters and purification
PCR amplification using Twist UDI Primers, purification and QC

: Target Enrichment

Libraries preparation for hybridization
Binding hybridized targets to streptavidin beads
Post-capture PCR amplification, purification and QC

DNA concentration adjustment according to sequencer specifications

: Analyse and interpretation

Upload FASTQ files
Secondary and tertiary analysis via OncoDEEP pipeline
Clinical and biological interpretation through OncoKDM
QC visualization via Mercury

Day 2

Day 3

Day 5

Clinically-relevant oncology targets and biomarkers 

Designed by oncology experts, the OncoDEEP® panel contains the most relevant and complete cancer gene panel. Over the time this panel was optimized to include all clinically-relevant oncology targets. The panel is composed of 638 genes, reporting genomic alterations (SNV, insertion, deletion, CNV) and complex genetic signature (, and ). 

Insertion / Deletion / CNV / SNV 

ALK / ROS1 / RET / translocation / MET-Exon 14 

ALK / ROS1 / RET / FGFR1 / FGFR2 / FGFR3 / NTRK1 / NTRK2 / NTRK3 / BRAF / NRG1 

BRCA1 / BRCA2 / PTEN / AR / EGFR / ERBB2 / MET / PALB2 / RB1 

TMB

TMB

Tumor Mutational Burden (TMB) is a biomarker that can predict how responsive solid tumors may be to immunotherapy. The higher the TMB score, the greater the likelihood of a positive response to immunotherapy. 

MSI

MSI

Microsatellite instability (MSI) is a hypermutable phenotype caused by the loss of DNA mismatch repair (MMR) activity, which is associated with inactivation, loss or epigenetic silencing of MMR genes (MSH2, MLH1, MSH6 and PMS2). 

HRD

HRD

The determination of HRD status can provide crucial information, which can be used to personalize the treatment of patients with ovarian, breast, pancreatic and prostate cancer. 

Clear data insight and clinical interpretation 

Easy sequencing files upload

After the sequencing, output files (FASTQ + Medata files) are uploaded 

Easy sequencing files upload

After the sequencing, output files (Fastq + medata files) are uploaded on a secured storage to automatically launch a batch of samples. 

Variants identification & annotation

Our BioIT pipeline performs the secondary analysis of genomic data 

Variants identification & annotation

Our BioIT pipeline performs the secondary analysis of genomic data by aligning the data, identifying, annotating and classifying the variants, and cleaning the bias. 

Data cross-referencing with our proprietary knowledge base

We use our proprietary knowledge base 

Data cross-referencing with our proprietary knowledge base

We use our proprietary knowledge base OncoKDO to perform tertiary analysis by cross-referencing molecular data, resulting in the clinical interpretation of the data. 

Clinical validation by scientific team

Our team of oncology experts reviews each report 

Clinical validation by scientific team

Our team of oncology experts reviews each report before making it available on OncoKDM 

OncoKDM® ’s comprehensive interpretation reports provide labs with eight essential assets to enhance the understanding of NGS data, including detailed annotations, a list of actionable variants, a list of therapies recommendation and a summary of relevant clinical trials. 

We considered multiple in-house comprehensive genomic profiling NGS options, but during the validation phase, our results demonstrated that OncoDNA’s OncoDEEP single multiplex assay provides a consistent, time-efficient, and simple sample-to-clinical report solution for accurate comprehensive genomic profiling in FFPE samples.

Marcel Trautmann
Head of the molecular diagnostics and translational cancer research lab

Which types of cancer is the OncoDEEP® Kit recommended for?

The OncoDEEP® Kit is recommended for a wide range of cancer types. Its comprehensive gene panel and ability to detect various genomic alterations make it applicable to solid tumors across different cancer types. It can help in identifying relevant variants and genetic signatures in cancers such as lung cancer, breast cancer, colorectal cancer, ovarian cancer, melanoma, and many others.

How long does it take to get my reports available in Mercury and OncoKDM®? 

The turnaround time for OncoDEEP® Kit is determined from the receipt of sequencing data to their validation by OncoDNA®, and subsequently, the release of reports on both platforms. The typical TAT is within 48 hours or two business days.

How often do we update our annotation database / information?

We regularly update our annotation database and information to ensure that it reflects the most relevant and accurate information for clinical interpretation and decision-making. The frequency of updates may vary, but it is done on a regular basis to incorporate new scientific discoveries, clinical findings, and emerging genomic data.

Can I edit the analysis report after it has been published in OncoKDM®?

Depending on your workspace configuration, you can edit almost every part of the report until you validate it. Every change is recorded and can be reviewed in the report’s history of changes.

How many genes are covered by OncoDEEP® Kit panel? 

The OncoDEEP® Kit panel covers 638 genes. These genes have been carefully selected based on their biological and therapeutic relevance in various solid tumor types. The comprehensive coverage of these genes allows for the detection of genomic alterations and complex genetic signatures associated with cancer.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712128769



22_ONCODNA-COM-CONTENT-UPLOADS-2024-02-STUDY-BRAIN-CANCER-CTDNA-PNG

HD     3   sR    sBT  pHYs     TXMd.mp     xpackt begn﻿ id='5MMpehiHzeSzNTczkcd'

Templates Posts Website stdy-brain-cancer-ctDN

!D8qCD 0Űąqg Y&!d!ɽgOWWWwW?oRujSSDycWcq= zNkHJ += Tچq!L?Puc@p[3՟{Ɂѫ

㣉vm cn'RĶveVA6݋8= P'J"$/{wS҂۬Ф^PCbC'{; miX@ukشcb蒸3a	n{AIޓĽ jk ޖ4^=JM\M! %4>	J *nL9b+@v+#J{!بر:įa=cVX@_UZSﰩ>d3Azp8	'NS 'ֶshqόͷx(H0mb{.KM9#QRbCH J3%MПe=+VWِ>bk٦6P!ϙm7;#M J^M.m+(	RǓQ"j>	'Nhv堉"ah"yI(!$hDx"vN%wˢVZ9{(*KJ>aez%

+

j$7e"%ش&#P mj	{A$rΧȎ
"yZ/o
TaѯD`̅'TS^hțBS RbAذZ Fyb m}uϡN^O׳U vϙK!

Ɵ8�%3cٲV9V�W*�˴f�E�"B��BDV�E	K>�	}�i�#L�KJ�$5��ΊU�9Ly}

���

�McPۗ�m�bM�vZҀ9��L�6�8qb%�"K�ZO�͓�ɵ�Љ���.
��Xԭ\?ƌ��K�E"�@yC�VW��!՟��\C�nCҪƹ!�EN��0:|�a�	�&ʝړ�



�
v.2�Ŗ�C_1�hto1V�˭y��|P�{	b-`ɨs4���">���	i& v69_%��l��0��

P7�fn7B!�j{�z|���`Z2yʋmqLW��}ќr*$�iy���0��6U�}g�	�T�>	\����ŁohY8�&b�|�l�4�p@l�ipD��Drٶ�0ȅ���Q^u4_�

��~
�

���%^ƊDI�%��	"�ϪC7N4J��Ue�-���pA�_a�Wa�:cx�͛��ۍ�F ;FzcԄ~D�M���#�jl�,Wr���'����|

�	

ѷ�n�!�к9Xg��}�8�N��.Z�p;q�LP�R��$m1�˦+	�q�lW�Xs��m��,��7͑q�W�vmN��/�fK�I�>��e�$~���$L���wJ(�j�	5���?"b2��S��	|c]�fE_I&�

�
��

�L�.zbդ�l�b��.Mk!?��*niQQ�/��b3̤�Pz�M�L���~2�mi����#���3e���#}�W̮4S��B_Fl[�p=�?��@'�`���JvA?2$6
�IRfY�T��\y������־#	#o�ewW w�8{ ��*պ�

�

��

�D�yKMM>˚+ �3)��X����a��3ڑ� E{�|�İM�����v#|���a�d��A�D���#l^RwQ>��C�^]aM&L�Ϗ�/D䄥,hK[�RK�4	,��!�BoSf�9�Ω�c+(?/E��?F+b{"�;%aEB�s53��I�87�ȶ�2뾜�'��h=��GMv8́ m�4�Vxj���0b�W�Q.`�ŵ���5N�Z�q[!BG ��g�ŁܞV*]%��8[KN��!d?b�7�D3�c�&?k���0|�5,m��,+�9o��uJKN�/��B�}�8ɫ'N�ũ?6@`p"5�!�N�6LY�#(5F2H

C��rQu\�_Fᘻ�v!���AF�1�}���_    IDAT-LmR#��־��ǭ�a�ۯ��uop��`��ا�e���	���j���u����`~�Di�v0��0h�ѩ�8qOa��p��נ�;1

_
��
�

����ؒ�|[�2勹�OZ&J���|����4����5���-P�f�[��D�+�e��8q@0 tk6ٍ�6�Հ�7R F�6�����=6�!e��v�u�{�)4An.��N&ce03N�JGO����!`&�΍u��U�gE��̎i�␓�a�m'�MK[����O״+|g��gA7�\gڢL _	��akD)�&c�(u�v`��[���_Hv`�&0�ʆ�u�Ż6�1��	�lH?�9g:ց*߹�3�zX�x��"��W���vXʉ1��ܹ�:i�	��vp�ت8�&t�3��̏S

���W�}+3a#��_/���j?�O�X�M�gc0g"u��-��; W�}k/~/3�j�MXa-r�l�S�e�W!欁'�FȐ����y �F�^�"Ҏ�e�ˬ��D�%Z�rWǱu�c�#y�^�R��]0L�Ր|��L�� f��W{���vX��l�

J�

~

�o�


,

z
=3p���R�"��_?v�Q��g���˘����̸�	�6�����-��|}h/�Z�7y$KRm�>Hq�m�r��%~\Uƪ�� �Yd������^�#�ZTw=�����

�

�z�

q>�iOŧ>��x�K�?|�7�]��W=��V>�YO�W��ߋ'?���|��Ώ���{~��Ad���<���K��L����[q\�z��;�M_�|��8����

r�ӯ�쀞UY�\��2,���#�/�S����|FVK\���і�?L^Zp�A���9��tf/��m�uް�e�%��1�b�t��rp��#��i�1�X<Q��(���G�7���x�S?/��������������������ۿ�ٳ�+�G�w�����?�K?�2�/�5��>	?��/Ƿ}��W>������

?������x�[�|�?��5���4����ݟ�w�c�k?�˿�z(���qo��y��[�_^�F7�b���W?0�P/yūq�:�:�#»=�1x�w������w�O|��'ŷ�ő�[��!�����~}XΪ�XCuq��� lֳ����v�r��J�vp �A?P����2�ٻ�

��O>�7�	��˿?�K�lz?�C? ����xD o~�%/�����xы��=84��$�w.��z?|��|8>�����ހg~���W�ר\�!�3��S��g>_�i�p�}�s���_�~1gr��
d��

|�χ�`��b�Ĥ���Ś-�#g�' n�Jld�W5`k�a� �P�p�c�`3'�+A� K|�
S��.�����A?��/���?���y!

I
�

�a��
�a|1�h�����g^�������]������0�Q���vGLy��ހo~�?w1��s~�3���=�!���������ɟ�!b��e�ĳ���x��%�YO{*>�W���觎����������ހ���$��p��l|�w� ���
�-

��y
����5����{�������i}��#��]q�u�
s���*|_����"Z������7���_~�uﴓ�0�4C`tLƪ�2a';����"���,;mP��ݶrj�Ђ�Ԙ���z���enE �>-�<5мԶa���Co�X��/=̆�[����E�I�,�i�g�o����Kc���*c ��Z�z����-$�P�e�QF��	X�6��~�!n'k�"L��T�H ��VT���a�L��.���Uʖ�'��p1�+ط�>��^��-��r\��@��(��|g��9VR��y�n:k.��VD�c�

�_�

m

�
�
�]

�

�

�

��WZ�_���_� 5iR��<�l��f�ET�k>fo�%LO �+�xǻű��M�	i9Y��QF�6˪�[��	��(��1'��Ϣ�<2>,#� ȼ�w�

�

|

�����.8�w�ݾ�Ya���������ُ�o�K�|�vG<&������w�=�C�R�L�;��Ye�S2WH$;� �p�[�!�<?���N���{�+�Ə<�/q��7�yQ�̷N��8�����F���~�˚(���� P@�
a�j)�<H�=�fq�7��Ctg�\�q ���}i:biέu �/bIH�;[Kj]c���I��ù?e�ŭ�S���;�iM���G_P	F^	?����Kr��F�"�21Qc��Z�ŉYNud���e�[��4�8�xxV�J��b�?^�x���V

���

��߼�?q��G��>�ǭߎ>�0�y��x�{>:�p%&�s.�o]�K�����f 61zſ��yн����C�;������_�g�d,}�wU��he���8V >��M
c���i	���I/���ml�ʥ-��y/An��>b��%��8��\�	N�g��yf�����MQ*��*�5ڞ_v��ڊu�kn��!>Y1&>�:�=g�E��xw-G�~�]�> L

0h�S ��׈rl���m�W�*��/l�YNOhϢ�m�@�2�Fc�'���.�3w!Q�,\�R��%�$�uuZ���ۻL}�m=�'Ejg��%���e���+*��G��C��5��EI�Ecy^U ���nre ��� '�qm�zv��+y�� �/.�d���wYŻ ��ʭ��f��.�~K�u��%�`�ٛ���{�ϝ9�����]ؿ��d��ÿ�|�+�3�

�<

�4�
�

Z�
�If����| ���������]�Y�d��g�Ж��$kd��u��8���yֽ#=/����y����I[y8���8o�lU����8yn��sɘ���IN?���8b�
���0�

'������s��(:�B�ҋ�._�%�]G/�=�x�)wjn�L`}��Kq�U׎vn�8��W_����S�#;D������;�>x�{>�+�y0�_u�n	=qI�@o�sd��'���~e�V!b{�f'��Z�1yv1�\�5P���>.`O��<����d��he9�Y�8�[�?U �v�p;�cVqȏ�- C����@�%��97���V�xR
�m��<URB�k�%PX9q�z�u卑�nqy�����{�[k� ~����������� qs���Ɠ}���u�A��!\~�����xͻ?<Xޗ�}�����

�;

�F��-y��qڧ�c&���U�Yl355�Ӑ>��HP�ŎR���9iI�ڮ��Pɾ�۪��J�	Wu���:˱m�p�)�i{�u��Rp�&nG�[$q�������p������F��x3^q��p�_z.��¿ťW^SP�<��x���'=����W�|���������{N������

�`��

�

�

��?

�<
�'T74��P9�p
�X��`�J�Z.�~Č	��u�t�.�z�	�&��X���C`ZYaj"@�(tE\�+�8Uk�� ��@{�XVXA���.�5��D�%qV��I��r��Q6��Y�ypH�:W¶�̿f�U�6�RmM5b��R#��^�i�����,[m"T5�Zha�k�H�1P�J�RM�E)C�eH�~Ē@��uOVQD5��

/��,y�{�l�
��$�B5`�S*9��k���r=�o#�yB�    IDATr���ٖZ(N�V��&>��"�7	�2�����5�dHT�W"ia����h[����+�e�1K�G�t�	��V�B�b�XƤ���ߙ[މ��HR�`i����BC@��l�B�� r� R��|X�Y�H]�Q��~�x�w�e����&-�w�>�Rw\rcRwI���XC��n��w��G]�
>�v
��

2

�t
�����P;H�N��$���ŶB&�;c���#X<�p��@M�F���Y�cϕ��TD�&��:�u'z�V*#M~��-�Ȓ��� �����2B�)F=��S�5�g�ų	{�}Ccac�I����$��4QC�*\?�.�W��Es+ m����
�|��

��D

I��*�kHB�D8
q�a�I�I����f�����/Ւ�\&F|���	5� ��wEⳝ^s�g���

l�oN^���d�h}��&<�WN�i�����=�{�M�Q��8x/;~�
"�����J~[�H�[�S��z!@��DC(�V�Wk�R9?8��E0�0ru�"�Ł�l�vДo�v�m�,A9�f�X���ƕ���ɩU���\��	P�b��J����j�^�xEiY���_Mp�b���,Ȕ���v��� �;D�._IpB4)�ӧ�eo�O����č��g��+��=uBmZ��}��hx&A΄_�

�
"��U�QX�A8 �bZ"�.Ro����'�
2��,0����+T` �`�Q�|���	R����$1* ;·QUhk_(�)�[_��Cc�y1�����a	{�h�cXU[�OSC��	7�M�. �N��3Md5wS}i���..�6-�T��ϯ��T&A�g�

�,

`

�`��

K

��

X
Ur�����9dnR�h�07���ڛ��J�k������Dj� ��������g����b�S�K�W�rN�3��x�nvn	�����"�N{_3��]c��	�R�m�C$����P&��t

Y^

�A�U,��9�SwV5PP{�0 �9|�ů�w���	>5V��������ǅJ�[FP}�im�$cl�,e w�5Y�P+(�u�{Z��'1&@����"F�;�C!���]L�e�F"����2�������^2O��z��G�7�A+��u����2w1��?yyu(�'^Б?������U �/[���U����[ת'
/Y����K��������l�C�ڰ�ȑ hv��\
��b�5��L�Z�2��⥞�5� C�jm�7C����*֯�zܧs��=��Mw]��������C�u�G���ne�G�зɋ��)kSnp�@S�Ǚ4^R-媦�<j��y�$���Xjy�3��Ŝ۟w�sZpd�N�\��l.�E���d�i�c} g�<��/�ˀ��C�좝K�{m==LH���=�1
'���tjmި�	^��Ȼi�&o�W�؆h}����|�ϼ�	������0�M�ba��|��G���Z��� ֏�t�8��E�����%���k�[���n���:SOI�����1D!����Z�`�PC�浂N�Jڠ�2��]�?�):�Mv

�

�`�

�

�"
�
��`0����~�V��6�o�a'���a<���錗���5�w�Z���G��=x%��5HJUJ�����k���x�ıbB|�0[XZ�����Do/�m�Pc�IC���&,̥���QB.�v��8��O �e��i]��ƭW�C�|3���f�8u��F�j8�� �)��X��<�[�jOk� fƦ���I���~�e���.���
Yt-9�^z*�B��q|S&\�w"!F��L@/b��� z�`se��ʞMzw܌���	@�4��`�l b�}#n�	�P�V)A�<�

x��lL�
S�m?�w�����ϩ���	�S+ĢL^.�m4�E�or|���.?<�i*�!J6��#U�'1#9˗��p�� d|��pjqY�q�s�� �z�R�w���lӇ{'�F��G��+6TR���<_c>������n�
�
�
�
k�

�6

	`�����k����NႬ�ex��w|��H�m��K���t��۟L��ݢ8���]�v�^ENN�م��"0�dZ
�,��?�w�

��

����K��j��7�w�� c�ǅ�c��6C_c���w������ �mh$=��F^�]#�yj��R8�jo����ԯ�����_
 �+��8X.xPA�� ��u}�r��G]>2���h�t%U�Iv��F?	#���Z0����f�Q}4쯻i7=Y�?�G�D�s]�w�)�9�`����(
�=�����7

=j 
:��

`]�j�V�'P��res�h���ε]3W�i����P2���x��h泞	��PO���/ ��9�6e��jϧ��T�k����@����԰ʉ�^J�J���{f�`��%�'&fY̦Q|��d�d�

L

����������
��

��Zs̎�W
a�p��jJ��S� �.������G�,�� 5��v9��,�w��$���Y�-�7�3����c���g��L��]9f�e:�r^$y��C����"�Y7Ыp^j^#	�^�K�MtH	 M�#�? ���� J9M��mJܷ�*��l�4j}�

}
���

�x�

1L���1�x���-$������9�����: X�3��d ����X�>��%* ;yF���1�8-Z9���Qn<p�г@6 (�y_`

�/[chx�2 C�� '?��XE�c�mP(҂ق�@8�c�,�����ԊM�d� �`/3j}��U �|evT��u6�`x�t��J�qp	��/������͂t����� �M�ƕ$��(��

�)��?��j��p_m�l9`t��`6C�#�y�v\�-�m9���H���M��
�������j\���H�	ׅMS�H}s;kT�V��Z�bb��x,�殼j-k���x�F)���~rx

f

��

��
`�

<���E?Sv��ϧe��
���	�qO���*������q��{O�)�}Fq�|:�/�Ր#p�556��Ү߳`�qL�J�X���걸�����}�匧�@�  Q�k r	 �i�N<6f��W���19�^��MS��g��k �H��$Fd �&K#��v]���'�

�@�p�_���3�ɣp�����X �1E,k�������`�vA�I����f ������Ȳ�u�j���A�r�nɑIU�mq�.�b�S����2�G�4��>K�ԩ98Σ;�u�^ %x���;���/���ηVe���3������UE
u

W[��ɯr�0l\j}c ���&{lp'-� w����qs_%v ��e㉌U�mA��1C�������v��>���sw����c@f4�65
��r�

��

��ʬ��h�u�k
ռAs+�L��9b��V�,�˪�IyX�Ū��7Ώ���zz�t%T�G��yu\@&q 'ߕ9��,�����f���T��8� %{F������A��%�& �=?�8PF���}{Y����p��/�|C�

�

�
`���

��=��

��
ZMm�{)��l�X|��q!�	p��yo�R��S�#8w	��I�������kE�b�1���1Hq!�_^S�����i6|��T��u����� ����ڨ�Ƭ�o��8�?��8Û���>X1� z�����9�=�Q.OK`J��jٛ����un�� �	�#*Ȍ3l;S�I;�#�����c*I� ]����OS8>��iȹt�~$2����*�

�������
��V�"4��vJԣ3ܖI�z�آ �x%7�f�"��Oe��!�T�U5��B���SG�.@F�v������x)�mV�ϰ X�$d�����%;J�o	����kݧ�H�Jo�ap��H�fSc܅��`ކ�y �V����~ V�N[���"����������m��d�,�N�g�ٴ�A�䥼�R�]�p"�����u1)Y��_��s��
f�[�������8>rK^��]Y9P�p]��s�ezT'�H�Ut��Mm̮�u�6%fX?��'��+���P���0�T�@���������M	��znl�]q�J��X�o�s56ä�)��/���`� �����H�7I�$�hGh��5Q݇c�5֋$��&�J+�T2�yZEϦ:	�Tdt��	�C+L��
��

�
��,�

�h

Pmp&�|�ޝ�BۑG��ϫo#� �xx)Sm;��V.�4�/����G֏������>r�*j�F9�)�+�^���j�i��jJ-�� �^�#�շƺ�Rd�cu��]�з�R�V��DA3"�c���1`��L;����T�j�f�bnE ��h�

x

,g#��7�ў��>�#���=�BM�,�ÈW�>��It�I8��C�����c��\ʶ���5l���_\`%m�)��_�M���K�  ��*^��3��-�O��mm���~_�'�F��edx����s����e�1<�R�d0~�ϭ7
���
�\�R�4��)�Ä�-kx�m�A�U�]�N�P����_�� /��F{v�#K�@ ����:
79_��=uS\,%��������Ô�������[�])�qYNm\U��<쥝Fr��x���Ig�[�|y�zD�y�H��)Wгz+��Se��$7-��ފ�4\&�9,�G�on&�|K)� XX;㤞��0�u�t&�� ���

@
�� 

���W

�

��~*
���	

�"��I�/ǠS����=��1��kM]�S �0#� jZk�>�Zu������ "#)V�ȫ
%��I%Jb^K�����E���Eyp�i_%Kq�xx5-8\���{)�~�U2�",�t���+Fb��rk%!���# 1�L͘�(9[a����3��&k"y��Q/	�>�n<V�FLR�x�<� ��/�Ŭot>K��⤗;~%`$hm�Y� #�8Y��U����1��v�5��	[$2��;oRM�lX�¢E�۲R��V�в��^!S��v��Ԕ���
TN^��+��*dג �o��JE�U�trD ��75�aN������R�L��UG���Z����ӄ
� MK�Y�;ӼmE[z��}��
@����/ZX���j����[ )��/�(�<f��VܿK�E���J�0���,)j���V�ADBa��J-�r���B+�֪��@�5#(�K�D �

�&

�|E�L�mPׇ������|���\"�/t�)<YSE��q�m�)�R H�Q��5�+Nޥ^}TU��	�bCa����� ��5�J�<^�$oÉ��ȑ:�\V������cyȏ'ow7\r_ N���(����t�X^>�����tD�â�$6Ŧ*����+�fQ�JH�4*��&.m=�

����

���_4�jTR����a|<o��j.�o�&=O՚E���0"5λ໴T�g3�O�韪��*Z&�x%1� 5�J:�{�ʏ�s�&�	� -�p6�%�K,
�]

j��&E��������W&�CI`m۳uο���@3v��d!� H]�U!�����C����'Qm"�#�=i�.��~9ED���U	�\j)����

�
����

����

��

��
0

��
��yDZH�hP��k�� P�](��	Yn�����%V�� �-W�PFy�ރ8^w�

��TF��L�O������Wc���������_�hW��V)�2��@)���ǰa�>,�݂�~^�M���bv&.��F��l�|���� jW*��Z�k�T)������Kr�&w�"��u�~݂��~�i�Je�CjW*�1�Z��YK �VB���ˇ��& w�
����

[������VA5�x�����^�}��̟�ⴻX/���/���������W>��_��jD�1�������;��x3�����*���ӭ5��m��������͸��防�k2�	���ԩIs�g�0�W[�=�?�בI�ވ{���W��>G�F9�T

�b.M��������<�̢M
b�YdYj@�;A#$�`f�1PYN?aypGU8S@_��$Tq-5����$ъ~ڇ�#�9�<mf</�$������1\l"��0��x!"M"��g�IML�����6m����Ѫ����]}	�7��X�i1�|��0Ԝ>h;oO���ۨ�x蒳`�0�޳=jV*�>7?io�
�e

�

:�

����
��

��D�ǽ&U�@ٳQ�5�?���}�p�D`�0�
�Z�1F!|&B�����C혊Z�gc�C���0�*�$y���i	�1p���s�){�T�d	�bK�V)e���/���� ��A�޸�LZ ���F@���)3G%~��Aڲ�21\V%��섖|��m

u�

�a�N�y�ҙZ�|�%�	"�^�#�	(�`��=����
�,7�� �x/��~�ǰ�ʒ����᧻���u�m96Ye]��SaoCI�M	��%���T��J����O[;���_�Lq	1���vϦ&��X���_

�&(���c�2@Q�:b4�E��Ȫ���0��z��*��b�4��Y�"�b�ð���Hg�	(�_,�B�Td�(���,ľC�Qvf��f:�I��A=Cu�+�R��Ӷ	�(|��y;G��-�� �~E��Qv���NFzz�Q;<�x�,���3'�

?���

��

L��
�\���k k-���ԯ!�_W1b nRɡ7!@�50s��f�*<�}�@���W %�i3 f����а���๗��I{x����A�s���݊[qɭr����S��7Q��7��ڭ{�jݷ
�

f�f�%�p�g��
X5�H��`�s�U�)�W�;���w@C��:$@�x�o�  D3\������`��1B�0 &@M�s�:>�rd�� �i�~�tSmB��b��#�ܧ���%�`��_�b(F�[��R	O�F�＝���=v

�-���

���

AU

[�
z�

��

�

��O|�
� � *J�A �&$@�H��{��?ffO�3{�.��sC��w�=g�)k�Z߬YC[�f��!BJR� 5H͑��wgYC������	a�Є�h�g�~��:lWg�Ͽ7[8��U>��y3?*`���%	��R�M h� m	����.��i��ȏ�[Y��X"8x��������<�uB��

�zo��]��x�~��0Ũ
�D�р*(��h�	���p@[ �	!�J��Vtځ�q�����}�������G�_����#�!��xRe�^�>�����|�J���S3����=�Sn�����s�

�������[�;�i�D)p�_���Ђ���#`m�Dm������[��+�%�6q��m��p�	3E��M-x�M��q�o��;��1~��㘕+�ڀV��� O������)�]����#+W�K+�T	�W����	��k����Y�j�^Z}=,�ܤ���}���U�c�M�͓�T�ʣ�m���

6�u4Щ};��/��㙵N����}v������^��q����M*w=7���}a
��^��e���`�Ru��}�    IDAT��<� L����Pkܖj���W&^L*g

�����

�Ȃ�"�U�
� aAX�� ��^�!"r��@	3����p�>w]�e<��s0������>
Y���v�N������
���JH[a���hTǃ��� �m�,%0�ջ�r3��w3�A}~4��&Y[��)h�H�2	��)�v � ;��

����$v�e�,]����s�퀙�~W{���%Q:Iq���C�?'���R���5�	�i2~���Sp�>#�e�ў1#���뾉�^z�N��ًW�}S���©cF���F��eά��;����_����/Y��I�]��^���&~�ًW�]S������S��љ��w<�^t�w	%�" z�$�y	��nյ����b�w�̕sڳ�|�~Ѿ�ԫKG�sѩX���֬G�e��p9��X~���z�&���kN>u" ��YMQ�6Rr�

s�o;� �Itպ
8�����k�{�M�^�����'g���5���݂5���Bt�#Y3�Th�58�Ww��������o����rSs

"

��5
q�

�l���vm��� /�Hts�duL��u�=Vf�Y�,5�D�l�˒��J ��P	�:���O"��,��͚��Z_���R7�	�]��!�z�_�n�޹#��^�E+Vc�'

��

�O�

��
�
���4�Ԓ.��<Jh�F;�W��o���2� 3M>@��GЀ hj(w�Q$�7���r�_��5�J~ ||6W�O�RC����Qϱ<�CR�	/� 	)f dk��E"

�w

�� ��

iI�U��x��.D�vq_:�0�=��0sTR���3��
*��M�Ȗ�]�<�^�,�I��k" �=Gjʑ�x�	9��V�6ySq8s��k;�1œ nY���ʨ�X?༚
���f

��

����4�|���Y�DI?�նH:���Pr�efQ�����,&Q򄖤Vվ��\���|S�о	#��v��G�N�Ю	�76c��u��`	��[��jY`C�Z�yML
��9����"戛��Z����iM vSʴHU��%X�e�*|�Z7xrA|��|�dX���H4����	A�e��	�����h���f@CJ�U�g;O���h�. !M ��rk�cm(�Q}a�FT2'j!���f��	N���!j|CB��b�4-@$_��0 G� Dc߈�

U���

�Ezf{����Ι�w� gH�����e���S��ޒ��l����]"�0��`��B�j�:,1�fQ�[ ��e}��Xs�� :�o  T�.�"��8��!?Ӥ#���͔��w��~;��Y�� O=qhkvR߈;�m ��w�y�23�q��;��J�w��d��E���X���sI�<�V��BW	�L�|M%�*٤t�d�w�"n��K1kj��_�A	�&��*��A�����Y�{')Oݶ5n
�BH���

T

���,��TX�R��j .0�!#�~U���=�}b`��{1�)턳����m�D|�67�	!ޙm!��p�O�$�:�*j̩��2}<E�S�G�����7="6�}Ҡ�?�� ����S��)�B�Z噤��"�|^N�y&z���?����)AD����hMJ� �{z�����

��b��

�
�`����� ��4Q��(l��W2aQ^��'�v��<��� �<p��k�3%�!T�M����^_��zS�_��CndI:j7�� b)�$��L�

x�W븖�R�qY6�p
$����	�J8��E+�Q�bz��3��ɼ���-��c\��r��$Ӱ2',���]�
�F��X����Ǿ��Yu9��q	N-�`k{ ��PXN$�
��3a�h��>��YM�!l�I�u�3Z�Q�w�� ��q��#U �M+���	�e��O��C�|͑�C��N�V�/��NK1� ��ڗ�����yQ��W�~Qx^��?�()��U��xY2� S�RI!��I�MR+���W��^�$����¿l�e�OϫuI��(�S�Q+�lU���)��e�]������4Е�"o��Y`��Z��&&��tvbk��Mj�#��g��ǩ �r�X"4"i���\҄)i�O^��}(����H@���ʷ��)���I�԰�=96�=����R:��D��L!����-N�Uj�u�>Ԡ�d��6[�b�A��Qwj3��MCڊ|n �[6"M�����W����i��#

��E��-�a��q&H�j¬(ኝ��H9r��l20��[o���#��P�Ӡ�P�ʜ���I����R^�O�j ���ҭײPV ��؊LC 84��X��*,�ژ,^� V���++{>

ϭ�`��f�G>r�E�o�9�h[¢����"�oѽ��^:�z!$�~V�+	ş%�0��(������p��ҁ[��[H)@C_�!g!��Kb��@H.Xm�� � &n" ��E���$��I�C��� UGL�~Ynn�͞L!L�4R��T~�<o��E�+�XB���V�iuf�1�G�W��L�k�_�4�����"`�� :�m�H$�Wʰ

�

����v�P�R��o��dm�싢N�n7q��NI�e4�
4� z�I�R���r�#��(,�Z���-Sc\@a�"s-������	�P{�	V��Ut|�� ���BZ�#疭�2��

�>��[��}%]��Kɻ�EȖbTK���4P{_M�*0�j֫'�����\+�9�|�X�Q����!�    IDAT� P6^��})Y� K$��E�q�ʥ!�_"��Ve0��r����j�	̣�Er�@C>��AG���@XAԜ�*���6

�q���p���?���
�S�|��Q�s�o�ZR�fyޖ�RY箤����bQ�[��5�N�;R�C�	���i<��U�e-e��~F$#�ð���Cr����v���'9|�	)�o ���b�U*�X�W���j��yB�ǥ1`I���R
(

�)

C�Z���2&EZ|������ �7W*<�"�2W@���R��#e^�b���Eh(�ɨb*�B�C�&tl���M-U��Tj��ʣE�5CdQV�����Ն������e��0�`���K�� ��R�ٰ�_K��)	G�9�he 2���,|	�/q

{�f

 �M��ܜ�"��1.S\Y4 ��m=�1j$^�U:	�ol�v���m��j6�|�'�TE*�Dc~7��|�n�}t���[La��7�(�9U}C�+���j/�V��F�����	\I��$�˿-#�s����8i����`����	J�

�)

�i-\���{
͆M���sb �a]`R�3t��$1�82/4�k�4��̛�u�ɋ�P�:�Ǝ�o�>��L�ET~

�

����9@���! ���`�yT ~�����
SJA�Ֆ*H � ��"*�ɜm|S �����J�����c�S���x^��?��dz}+�jRB�Ɗ�RM�.���+E��ϻl�<[�!�

��
�

=

2j(�����v��
���x���֬��>`�6�٥# `����6_�]���s�m������f�:;�ѹ�q��~ �u���:a�f,Y��f.������s�"�_�.8|���m����;w��u�d�:L���N���	�O�V];a��  �Z�x�ݙ���G

��
��z
B�

��

Q��s�

�x

-�

������L�[ef�`��$�:��?6���!:�0�6	��uG�1���`$�G�Z��/����pְ��Ң='�h�	�+_?=߅B;��{�����Lۘ�	������7Y���@��9�����?�Z���"�t����x��E�kbvO�ɼ�9ۏ`ޮcۧ����M���v­��Xs�
�}BxO%�|�e��]��B����*���~�<�K"�AAs��X���ưvӻr�]����ұ؅M������H�E!_L}�i�$	?.ڈn���D^��v�xf�HJ��7�oUmj�ad��HIKG��	N䕈u	'���E�{��04T4���_��Ⱥ�Q?���>����d�

�t�a���a��5����]���l�ާ�QW)[ܛ,{���� ��k�G���&I-jx����h_�2�Tմ��.�����(�A_M�-E�	��k�۸� �B6v��0wX. ��Rɢ ����G��[s�$���]I"hQ�^AA7�
�	��Zi;4��݊>���/�]�\�/̩�T�`�	;O]��ӗZ<�B��$	�L��ę�t�&�������t�� ���"I��e��vm�\
���l

>�

-�



�

����':�n���cǠ��1�u}�����ǰt�Q��{)��Mϛ�/�i{�FrԽfzA.w}�32��Q� Q��T�� �Α�e�o��A�	������٠Vu�x�h^5�%�����sW�l�	��s5!Zi���q�������w�/���\�f�k��ԍ�ܽ�

�

��0�

��

�p�4�8�J��+��ِ�*J�6ު�wI� �$I�ue� r�[�|��Zu*�J�� �m6P�/ ��R($"q�@�da�	)���rr@�

,
*���bF�+�伱H����\�������R)q�n�����½�@����:�^��n��u�i2u8�6�,+�%�z���� ����3     IDAT}.I5B

�c
U

_��

�

���

�p

�s
�
���

hWQ����ޛr�+�B
	%�*E" `AT�(X }>{}v}|�>ATDy���K�-B	%$!$R!�߳��ǔ=3{v=��{nȂ�s�޳gfϬY��g֬;<xN�6

 ��ɋ _E�^��;���7~�Ø<���'���O1	w?��\�V�݈�Þ���I{��Ѧg�O������u�o�22K�� �Zk��4v�"F�@(�<��"����G���:�[+

�{�

�����3�:�OO�~���X7=�,f>�*����N5S��Z'L�  ,��͚�s��O������{v��<�C���R���8O��_~=���D��ѯ�����ă&�X7=23���c����;�X[
~���

�

�ĵ���Uw=�=��/����//���:	�:Uy�����Q�Ͽ�+�|7>��d�;�8��W��/���}{!�:� ��o�3O��?�Q�7p��Y����1(A �k���op�����	����ƣ͡�0�0����������1�U��	u�ǟ������3��
2�4Zmtѳ�-��~���qtTk�)�m�	ï��n|�Y|�ԣp�{�ǰ�ѓ��-]�?�|
����k�޲����`,0�J�J�z�)��/_s+n�|���ਉ{)�B7�6lن�z���	�^�cyz�R|�o��:�L_ѩN��_�ӏ��3��Sc��h�{�9��x�����	��[��~���!�1<�����'q��/���;��إ��

���t

C����Ά�X��*ޔ<��*>��{������g[+�oن��Y����k7�g�D��p�bf�N����D�n�X�y+�-]���S	���8�X���>�/��߮��V=��Č4�$`����yj5�����>���n�}`�U*x{�f���j<�h�,

�

�,

 
��G�q�!�I�i��s�yE�ѕ1������QB8�A�W�0�S��-�A�����v���߯~$�T5�׌a��H�cB ݏ�t=�ZTjT��f��>(��:k��y3*[�o@�*��c�%��������Pc�=�xH ��ɏ5fϻ	)ΠM�7u������jב!C��̋~Y��ϖ�Tƪ�-H���"�+{��

:
��}�

E

��{

UI�+�����m���u�N#
�����;X�v Z�K2N��o8ڎ����e���W��؊��!��ټ`ϼR�K�L����

����M�GV

�ɲ
7J�6d	 �ND��m;������9I�t�)���&bu�b���vd*ɑG}�Fv�q�2�:p �k��6DD�	P�6�$�c+�r劃(�����n�Q<ߙz�W@�롑��P Pز���l�A�;�T�jAJ4�VA PE�K�רN��]��>���k$c{J���Q�O�z�#0~��S�,�k@�m�g� �X �c�C�����vf���=Ĉf$N�&��@�M�" �z}V��`�S�FVla�Kͬ�H�y��f������$͢�ԠbKK΀�ag4n\��

�
�1;9�P���T�Bo�@ڸ��%V� ��R	C�"V:	_$O�&a��<�H=��It�J��¦:�FW�� N`f� ΍h��@�, �< �tyc��E�s	���U��|( @���A�rM

k��4�u�e�eޗ����'��5`�G��R�H�^�৖5,�����*vN�bh�4��e�oɩ���Ǎ�\�	�`�R�->�`A$�oƎ�'��Q ��7�@�1�r��    IDAT
�

G�7�Ib������ߎ�s�8���<ף��G³ꊅ2(�	q�4cUx��v���[BY�I�p-��:�S�Q�. �QT��s�`Iɓ�O@3[��G�" ����i!ed=ÿG

|


��:���

k�����

)�K�BX��)FL�:ˮKg��.��wkC��{����Ѹ`��ORyb�o ��ZQ�Q^�vi�,�q�Xf#��H5��!H�I�ǎ�!��Ā�=�~�V���J<��kX�i[�r���U�=A��o��g ����%��w�6'4�q�vT���1	�[[�Z��b�^�b���Ҁ�f�tJ�c��m�`�`Ӷ��VHF��FK>}*�j5��`	���C��c��

#��y��

@

"�.�X��zb)�-ҦeWܭ0w�N��Y:)+��c�#M��BQ�>��{;ɭ��.&�2���T񴭃d&4s��&RL'��{;1�B!~�ӻ�]�谉��͏�  �m��t �Y��A�\�qhl*�/k���l�U��-���)�j{G���q���شu;F�����+�|��z�$��x�Ƽ��%aS�-LK��!�"Ցw��N�6���ё���zi V�ږHWl�Jgz���:��0 Z��\�)å� ���eWy�J7X�P�I����HxU��#

�����

���

��YIW#��"�[	/P�<�Lb�N�2�Sُ�U�ƫ����`L�C��ԪiL+�JTЍw`0ƙ)�*�+�"=-(.5x n	��� ��X�
?�
�O

1�



 
�

G��0

�
��{���	/,^������o��\���Z| 0q�Pu}x�>8e��0�����K�|M�7�L>�ڻ�c��ny�E,\
�5
@��_��=� O��ĝ�Њ �, �#��#"�1��������^=@DX�v#�,Z�[f���f?d�S����V� }{�����F��m-������	#�ǀ޸�����ͷg[

��+�
��ز���<�@�G��� V�ߌ+��� �n������q��1���i�wѥ�5������>{鍕8�+����Ϙ��q,�j�}�csq��oP�_��+�'��g��F��x���=m�����G��}Gg|�5�����<��p�V2�3��e��#�o%$L�����

�d
}9	���~��?o��{�	�ño�#�BY�,�]g�c��W��"��C�0�KKt�_����]Ǎ�q��&��<	e�=�kw�����gp��=<ON�����ˢk��ӵ%�xi��[7D�� t��"<Oɐ^Z�h�>�Q
�n�
4��
�

�*�Ø��y2\�
�5�-��nU�����g����E6��:��(��f2�X�賄Zq`������0z�,�5���(y���-�G�Za���y�J���	���j�x��s| �� �?o�ex���Yg��F�fU�<\��jJ0�w`g4Y����뮋���3��������hX
H��4

_��

�D��2��I�Z!e1,*R3��4�M�OW*m������N�Qb:��ĢMMs)l��Ƨ >-Y���pC�� � *�">
l:}3�F��M�ĳ��d����5*�R YR:���&�E�/�Z��χt���P�B :ԩ��n>2��l��aX<���$* �nWI��X��o~����2��&y����	i�/*F� Ԭ@�_W���=�݈��X�ps6`ٸ
O���
`鞓���gdotl�.
k";� c�_�-�-�̫���[�^�RL�� p��]���J"�" �y�.قM�	 ��rG��ձ�<��<EQX��HQ���01-6��b�

�e���w

���9

$ed����2��|�l��ۤ�:U�V��ٛO #7� ��z��	=ѹ.������K�<֕N����B����+����}D?����t)7�'�<Ù�XT�����b�%�1I�P����=܌MƉO�Px� W'�������<hI

�C

����+

�$�

���c���iK�T��n=���Yѽ�e��;���'����x� =�"nn(ۤ��h�e^��>aW6��?-���B�j���a���Jf Q�&x����'����D�iU��N��$���v�v�Ђb#�Fk��L�K�

W

r

�

�U

�

�
i���&�

��

��

ov���m;���r@�%^QOq�U�ω�>�	�T6S�0�u�	$'eդ�ğg��Ib ��L���?>!������ļѽ�{�N]A|���'� �kI�A-l�@��(}���	}�V����z���p|�lR�x��؈u�/+�Yv���J��8�|<ܠ,9y>�X\���n�\��.�V���w�bX�(��.�
 �

��G�P�O�-s~`͖��8�L��g�s��7�V,yNhW+�Gu19 ��+�Lm]���=Z���#p���;�#�ש�;됰��Eb:ͫcd�:0��5o}WǺ�}pk��y0f�h�F��@�խ(񠽽���2Ha�~�M]�����`����_�p)R����	���"�a��bB~9�^lX��ھ�c�K5�h� ��g�&4���A�I�J ��D��Ay�~�*աZ��'�,�4�r�p�4�3,w�a

��;�

4~�

�

���;

�M

:�����]H�)���O7b�޺����nĥa��rhf~����ϒ����Ɗ�������
��inN^�8hDը����]���)�PHF��F��ֺ)�SZ����{�����Rb̶�Y&���%Q��V�Y�5�bXQ[��T�E��r�"d[mR^�eDrjy FAz��ܱJ^���^��� ^�R�\��RB`)�9��6{������$8�g���{/�ę[��	g�U�ˢk�Zh^��"�

�
�

ڽ
�׷-�h�����_�N��]���u� >5mf,�ܱ�1�Gkhn.�� ��ސ  #'��ۃ�

�	

��
��E

�

0�	�`ۇ�\YO4�^A�^(,*F|z6'��q��k��m)�T{�Hy�	�WrU ��*���r4�4T���z�����yH����GqH��#�

�

��h

��

�������
��7"�Y,���tS��r�$��	�+���.=�B{y��y,iq��rĭ��@�A��2��bK�5 >����9��޲'ܿ��//�qc�x�����{����a�XCX��y�X���6`	�18�eL�=�׌�M1��?>��N��#wk(_3�6�zhWux�_��d�oճ��Xx�,c~

��(V��A{<�-ɾC.�s�F�9���@�[�G��	�╥b�����68?���i��n^� �4��h�5����
��Kn�S+��y�r�-�U�=�x[~%�X��`M�1B���/Ԓ9�D�G~���:���{<�����/����_��c�<���~����ÿ�/|�������������?��+J%�I�����=��^o�Ϳ�(�����<O��Je�Ze����H�멲����u�`v����25�e$���������x��'q,:ue�\9 f�U���

�

\�<�
Im
��
�

�7���

�

�9�$j�;S��t61�%������t�2�4}f��T+��'��R�˾z��lH��Qkf�+���Jr~z�1������@.;y`]�|�:��/��Z7�xu�i���n�P-��`    IDAT������bU�$�MX�]�>�	�G70�,����1�h lU��<�R �/�

�
�)

j��

x=

��"��

���
�*
f
�

<�
�
��pݏ*J�n�����	���� �W�}�U�>���=/B��ګ�1�J�P��^���&W��

���

��
��k��c��G�Ve^}��ofS�N����'p���yJ4��G��N���J�&�f������N���A�����D��W ���m��]��Hb@C�m�^���D*S<�3�EpT��ޓ���:'Yh���� //��9� F�n�fv���`,�B�9���+��ւ�

��=MRv���7��]).z^}8!�%�>+O��=��N�4�X����7��o3�-�3Ȝ���ʄYH"�Z�"�L�9"��1��cٍ���/�}�@�d!�C��G�������&b����5�V�K���o-|߃ʶ)J��K8	���km�4/��4j!����.;��	�zL䏪�'��+���T@��z#�i$T�i��* V,�x|����  ���

�

�� �



�

�'

Y_o��.	^��Q7\S{��	.>�5.�!d��S"�z鱔�d>�̤ɽ�.���E���nؠ/+f�I���i��Dm!�q�(���$w�r�*����8��D.� r��sG��`U��3� X>�� �����1����7�T���"
���

.

o
�k

�
X�
��g}Cl�P,7Jwim
ݚ�{	Z��3=~ �����oa�o�5�;�iJ]ܹ��C�N���-���;ZC4;6[�jk�S)s�i5�TF�^D�� k-eq�����v�z�����s���0ݵ�_Gl������m����1n���	t��vFVm
�
���(

�
��

�

	_1֐ۤ�8��+@�x��*Ƙ�\��j$��9;����#������#��0�t�V3����^��	@ޅ;:�΋lǝ�	�C��>���ʎy��K̴7;C�Y�Q�%;���,`-��p�

G
���

+�

�
�~u�M�D���	'o���Y-� (��;r��y/C�k+�lx�E�}��JG-��v�֓(�6��G��:4����s� �L�����yE�nD�o괕�	y3�1=�����?w�ixp�tY�W+&Jb���(,Z�0B4z��`��^����n�

1�

�0Y
���

��k

��

�o��

�

�

_

u��l5�ɧoe�lk7�P��U߸h�� Z-���T"id�Ts��jاҿ��=ֆ�e��h��[^�"��?��������<�ե�M�{�����#x �|���_>�)��_�$>���-�/�틗4;��p+$[�
A
���
`Nòg�ڳ��d�ta�U<��[]�Qk�Ͽ\�	�@�w�x��6�� �ʖ�=��kt(�{^�3��{b���u��w��M����/�����w�y{�Z����6>����/��_�g��
~㷾�W�Ϯ(������w�KxӋ��g��?�?�ίۅ�_������?��_�o|���� �?�K���� �e�	 �����Bw�]�*�S�a�

��=

�

��Dք�#i���#&L�V��
Rw�]�� �D���L�s|�<! �|��}G3�ܶE
��

��
����ecr�'
���	��=�G	ʞ�� ^Q e"��c吇zT���~E��F

Ď�����z��O��ғ��q
�*�-XIЗ�B�2R��;��#�r�"��P��T�W�\>�+N��H����!�֦��d�d2����c�;wF��鋼'��3�<	C9�=o��vy7V	�E
悚!��+�{X �Y����VW�N�F#4�'�oW}�Ȳ��d�2��~M��8%e(��SHY�
��S��}��B���[�Ԫy�    IDAT����e��jǋS�l�~z�P�T⍈�w�|���el��z����7%�c����5m�uH��(�h`l������F?���b��_Id�L�v+'
(!

s�

�����O

T)���

-�

����6lJ��uX����A��?b#C����.<7�z�xj~�l=k"x����<Pʭ�e�M��nR�	���~zȾ�\��B��Y�G���#��1M%eHlK�(����O��#�,�Uˍ}�����

I��D��9���#
���/9	���Աj;�G���}���5��K	��O��I#p�1xߩ�
�H��

q�
�z�
f�
B

:	׳.۲�ŵ���?.Ħ��!dB��N߄[矀��r�g��A�����:��bc@���U�T�j5߹tJ��ȫ�x�а�M;����_�؍`j�hT3,#@��'���v���T�~'L�̞�k{Vr�R@ʋWT����I�!'��}��c����

�]�w�p:.��8��	�q�xz�格;������x�|�z�t �2�o~�[b�G�Xz�)��ڲ�0^߰�-y�׻'�{�	��qK��S�e�*���Gơ�2��� �:;��ڭx~�V�w�D����;��س

,m�Q`��Ÿ���Z! ē�tm%���W�]LqR0K-��A`�2�RM�
��lI�VX��VL�����_� �,�.&�AÚ/��^]P�9W�$y���#���[o�V~[y\�EX�$����c�vLD�"���m��`�j��w��"4�r4�P8�sl1�aT��C��B`�*��ʞ �đ�r��	�`�Ŏቱ���/ |�f�c>ը�16N'�Z��E_gkK:���

�O

�

���L�_"�E�,eojˢMT���X���"+�e^������}��tX�P�RJ�<wn�II��A��+ ��b-���*�l��@h������ňenN��. �4�?.P�-��ؕ�b�.nn��	,6��@��R�N >(J�ۇ�o��*���w

&�
8�,��*������(���2�B���ʗ�ﳸ�.xR�\;*5B^��G�K���m}^$o�m���m�ȋ\���ē�4ɦPۼ@�������3�TM����x��};	Ď2'�^}=�W��M�O��lq9������f��MǛ�d=&~�9��I<�uFs&��y��Q��'��OM	��*�B���b,��Y' bc�@`��EY�f# J��}�;;JQ�<��&'��$"��%���ᓒ��ꒊ��`�� ���

�ň8wr>W���_")�	,[^"����ˏ�[����=p���!�$`7�E�9j�m��kc��@��QȠ �������We*9>

���a���Һ��
��/��}��֝+���υ���Z�34y�L�T��D�ד *٪���������V|��*���k��n_ke$�=Ko�nZK��!<o�����iV�tm_M�V��m�&OB+z��{�o	�X�EH�«󗾪I��m&���{ʻV�W�,������^+�=�n�`ׂ0R~	t��: !�H	N��	(�

� 6##��*/� K?	,,]Ń�(��E�HjS�|���i{���)Cl��o���Kqʸ&�9i^X�
͇ی!F���t.�����U���W}	�.{ pҘ��3zH�����ǥ3��9���Y��-�X��7�411쳫6����*�n;o�k*$o ��� ~��;�{�J|��7p�3���e�h�.l? �c�};���b���W �ه`ͮʳ�F�/?~	.�6=��������	�1b ��ڌCmG�S�ޖ��o�:����j=� �b�{�v�"�WE��T��j�YM+�=|.iT
qE	�K��S�2�W��q�cJ,]�e�Ba�%o��̸\5,#M]�q8^놀�����t��v��=��)��$���3��*i
L

��

�

���l

p�

}�
Vr�H�c~
��CY�PS^s���#���������d�(xMS)� B��V'��_|F��3��E�(�>@� �ߍ����x>|x��o$�ά�g�6r+&�	���~�Po�+�J�(6O�s"��|�U�`#�m�D$�3,e���bz

Z
=��

�� `
Ɔ

��q��p�

��dFa�$TS�'hmS�Y��z�t��Q���E�;�	,����ZR��g�؎Y�

�=�OT��a�$/��|K��=��ǊvV)ڞ��Q�ʪ+w"�|>�X}ԅ������>�	� 1�vA��D��	�Skv�x
Ƨ�{;� �r �t�#y%�G8�|�w��� ���S+7���Sӕ

�

0��
��h�

��|����*�$�,�y6�9b ��-�i	��O��'|=..b�2���ȝDq�r��!�&J�r�OB��Q��'��P�:6ي����n�ˊ�?��.Wy6���C�;�qޔ���o�V� 6�9�V>B8�_:kͮ��-� ��3

�
�
��
��
�r
Q➏L�	�R�Qg���V�Nƿ�����?,I``D�{�f�v�F\}��ܗ�Y	��d���'��e�gb�al�`W/v�®C��{��;:��`'�߹]�6�z�b|����ҸՙM���|�

�{�m���t�z�̃q��p�)�3?��[I$�����5F	�'��+Q��kD�H�����P��2�פ�"3Rʆ��/Бs�y�5e�@Ȥ��	GTa

o��]��
��������s�W 0}�L3��Ը'�$l�s���('��[s1m�|���Đ�|���4��K� ,�1��\�8�u�^؆��'�Vmk��~F_pƲ��ri�8 Ē�m��G��.{o�j͝6c<n8k.Ι3c����{q��k���;bBc$�q������aJ�(k(l�Ӑ���Ar^$���=V�#�ylӜi�

g���>s<�y�����KB�cVH��-?�G4,wb
>y����kF5TRBc��"M >3�+ LVa% Z*�ZPikEP� HOW�̟�j�RG|�|�n*ℰA��m�z�;w�����q01f6���ЕÔ�3#��D��M+�4XP�xKo��	t/ uUNZ��b8�B-`A��6

�

��(�'�MMf���Pi�S`+kx��|̖�g�vs�y��;��,�J��ۀ0J���{a�Y�0��y��f@��G�N�1�N�ay���)CH/��e�{|�Ԏ���Cu��-ȩR8^	T��9�m�{J��C�}�0KG�6Y3קAr˿xl�y\:~���1Mx�c@l�wj��v��Ҟ��-3��Oh"����( �+���5v��m+?_�b��zk��+q�w��a��Rݔ0���������좣�Ol�eF�c� ����ᕄo=��w��]:o>~��w�y扸t�T���܅��7F��B>�>�*��jn-�;�2ѧ����k"�

�

��
���

��

��

�
k�Ջ'�f����v|��	�c(�w�@]+[��''�ϟ�eo�M (�F�
m���

�

/�
 .chƜp�|Pi�(��J�m��97�����"F�3f�$�q�[������`����j;0㏯��� Y�J��d4\���������T@,�eF�&1��6�zcY�,Ն�	����P�v+�2X�ͺa�[
�i*TX�A�>)�F'�<��1�aq�E� v���^�B���3��n��lLr��"�3�wv�+#�|�>�q�f:e�qc� J�\���1	E�4I�6��tQƤ�G�\���2�[�b!�2��@PQ 

��t
�����=�

�K�x;�F9y�U���s ���\ܰ��\������q�I�d��=�`�Nd_KU�'�� �E �R2N^�

G&����)����v�g�ח�=����xe`���������L	�{�	3�[�
� �~�Am/�M�̤�*��BC�!�c���GD�#mh����ꠊ�^p��⿊�f)��ޮ�JgؠHޢ��K��d���.i!�Yؚ��@� vs�O^n���Տ��:B�{�G+* �����X ��'�Pb

��ގ

������u�uKҽ�]p�T���k�_�Ɨ�}�Gd�~9��M����݇������q"�Y2'5�,X<}<Fm���kJD�c�Fl�} +��������`'��CT��#/�R���m�ڥ'������Ջga��=� %��OǇ~� Vnߣ�!c���%�q��'ƾ{��ײ���s<o�|����K�U:۸�}t

��
J3��k��?��4���a-m
���o�	� `�!�\� �0���af��y~vwtc�}�o��V|��s  [�ƪ�������Ҟ�X�e/���=��%�q�y'a�c �������э��+3�

 vo87�� �����ȋ;�
5�D#Z�c������\�QC��;�݋[�_�?���Q�l�koN�*

����n�'B�l�"%�F� qP�S���K� ���%sl`��r]10Gs�M-�quy� �
!�{�I别ʬj��=��93"��A(�7�J�uT���$�R���¹�7��v�KE���H`��$�X'ܢ8ڽ6�N.Hҙ�ه�Ɔ�-��� ��&hp5��ݝ����^r�rGf�5DI�ں�+ ���^��
�G�^a]�.��{��$[]	Ė;�$̴eݨH	%�"G�F �0�Y hIo�A��v��sՓ�R0�:Li�E1y���->Vβ�,�YBN�5�8�

mG�3�K	[�^��
�:C�y�cb�;��x�"��J��}����	@�H�l��x?�����7�ˉ$�	/�!�G�+��Q2tOrdk��	�v��^�8b�����U�jg

�)
��o�JV�L��Nd{07�;�����6����;� X�c�w�`��u2s��j�޻��]�7����

��

��

��ֳϋ��c�Onٛ��Ԃ�#�~��?^(������U�~O�T|�A`b�*>aZr�s�3�$������	�2��Kb��8~���0vH��sT��w��i�����!@�X������K!�l��.��:$A�/��W0F82��焝��0n<�EYbj0(n�&����$oW�)���b���`$}�&�Ly��f�Sd�

@
P���` �y_՛l�n;*+~WS#��M_ �K������}�A|� @��Jiר�׻\�1p�R��a9�*-%v�P�

�0{�����?G��$�̲u�oUfm�4و{���E(�z�!��ٻx.+z�:�Ӵ8�����{�s�9biB�e�/��YL�3	ӧ�n %"�X� D

���:P��-�Q��kH}2nƼ�a�A��;��o|�28
 |��X��6<��+<'6�[�v	^���P�6l��P7^����^�7]��Դ�8؉��x���s�y��	��cbŖ=����A� K��T�ol��ba��xr�n<��

�w�Y`

o��%�
b�

 
o�

CpS�D¡h��(����2�FV�A ��m��H�Y�ew]�� ��ic���΃�x�-���=W'ػJÌ�#p����O�\����4�c�z󌣧V���{,��<6��	���Z҈��[ê�{q���1O����7E��y�f�>��}��:�u��������P����;�G
g�

���@Oǲ_�	M$�76`���@�!ɕII��
}ҦsK�e��	*��J\;m�2\&�C�UZ ���

���
��

�r�

��@���u[�U�q���8�;dK�/��&���2�l��h�ZN`س'��� 2�*ٝ}if�'C(�w�:�B@�7�7��*��2�?E�Q P��RE�1Z/�,6<ֹm$�k��x㍎j�&�NڼjؘK�3����,������^�͔��2{�(���/Ŝ	�y�{|�N<�q
�`
y
�

-��I4Ҿ����7�gA6n���~�#����9�>Fd�Հ�0��F�*��� F��Ђ���8͊,Hy�љ��h���6��Pm>���ÿ(�ѢP�7���>�*�{F���Ħ͐E|4\�Yɫ�~Rd�o�]{�̓wƤ�D���`%�q'����/�@�Qs/I�����mV�f��,� _d��6���Y8�)�t�S%��㍌	�%��kk��

�"
���y�i`i�pbPH�8��L�I����=� ��9d�ncuA�M�����m��_cF "a��� y%a�9_��i,�A 4�H�s�(@(���vM�LG�ź�7��\2B(�V � ���8

�|

	$�
���C��[����������ш��
�` ��,>�l:Z���W���1��hQ��	y�YV��ey�1!�'�� �w#}��xdW�4&�7f��F�ڱ�v���J������TL�Nǌ	y�N3��RB�;4�����B}{/z�F�<+���ļTd8+��L�A�����K�O*V�kЉ4�`�G��,GW����l'(�i$/���F�-����/X2]��'�*�6���9���-�p��iHO
MNA�o�C{� t!5���0i ���$_���$��؉�cM��M���i^hr���2.��.$E��ό�;@������<7	��j�j�X1�

r�

�e�P�1�~��8L!���=��sS�X6 ΢MZ7`�uǛs'���^}������"s	�G��&�;�f�B���މ\:!�)5�B�7�a�S�Q	�4A^��.^c^b���

I��

�

�

�� 

e

�@(Uj照�:p��'b'	�'+GmL���'��OZ�]�-�I�bX_E�s���M"�Wj���8�&�U�~	�X�\��zΛ���X��W^r�J���}�
I���
ܚ:

���h�

>�
E��
�
9(

%�4 ��b�#p�Xǚɂ�H��Ռ��AV0�`ϑ���0u��r~�2��jWO�✯��ho����S�wbȭŤ��ɳJ�jpE���N2���c;�I��KS8�&��R�#M�ǖ�s��X,��㕎���E~�x_��[�ߦ)>{%3T�=�bbq}Ix���9y���2 �j\�`�� ��:+�/��oX��|�u1��A �T�	�2���Cv١8��zY_R��H��r���תP3@�k��\���mj���v�H�:N�u�cW�FJ ~�&+-/m�=	G0�03K��14���|	

�3��Ě_#��9XPS�9Ue(��B@S���8r�,��~�^{YOV��L��)f���Jcl��"I�K�W9譨���Kb#غΏ�|lX�#1
ig��P�#Vt�2�`T��k��4�3G��)�bS��D^�	��Z�v�3��� +�� K<���������|c.�J�H� �	�!b^�%D�H�%���m��Ǻ�f�  ��V�T_�_a<P�0Ez���r��{XX�]2x��� e��%N ������Jh��Tg�#S�����mP Z  (�ȒΥ�|��]_��%v,s}#�u֝�d���n$�ҩ��o��Bz��	~��C��"ػ	4�bܩk�c�ȱ�a�w�����fSHRL�+f8t�J���śDԨ���

��M��GS� 4��??�
�/�I:�T���{�OC�H{Ϝ����{㒸���A�` K'�VLC���6�c���a<�	�ͬ@N(����<d����vX�@��ш���~�>ӉW�[�ؾ�j[=���)�k�F��0҃)(̌/��L�jK�v�94v(SaOs�Z8����7F��!�@�h��	1L��

�

S�
:�B����� �4
s���D�����[;�MA vi@Zjs����.���H	hH	hHMam2�`,

�z�

�]�
�q�#�xJ�X9��7���`��F�ʠ���@@(Of��,���>���+i�������'E�6ׁ(�	G�zv
>w�8�?�=�	/��g��P*fV���iUFSJQU���С�1z���`rI��^�(�:�8�?�P��eS+q����

���
k�D]s{X�ƃ�qr^��+	�����dx ����Cpu*�o{]gǒ�

�

������YTg���ߍd�cx^@���{�H��@&�6w6Јy3����y�#�sM�4`�[��솵��<�����0	�A"�H��+_V^��hwC^<�ৱ

t��
J�

|~

`$�

����

���񒃞i�jr�08�Bl���Y��| �~ �Ē;L�3��brJ�H2��ؾ	>�n�x+k�h��D���/(�4��D�w��''�<0�_�v �M�܊"�����5�e�	���������e���ճ�J�����w�w�
��J

��}'�Ծ��7���c_�GD���D���#cxj�)<���S��c�dܳt*�
�b� &�g�?n[���-�������}��]Ǳ��?�u�s3\�J	��X��?�	�C�Fݞ9t�G�ۖ#+��B7̌����%�\G~()e �����#2��S c�̮yp"�c������]i
�
ca���
G

\�

��S��5�p��rS ��&7!�!	�KB��������{�%KV��޻�{���9u��]ɂ�����ig�;�<��;Z  ��5���Q��[�����	'��/�|a�H�;���92�r�Z��/����֗���1Y��E �C�:�����t~3�/�

ܱ�ނ2_h�}lB�y�㞕�����Z� 8����h��IJ)�<EI]�k�  �ǍFrl4\��"

;�

�uKu����wD��⾴���C@�~�����5��S��-0˧݀I|�@ �B_�	�r ��z!��JJ�H�U���� �9�
{~]�r�o9���)�i�\9)�n��ۿ/����	�����+;����ƣ��ĝs̝��ꊙxp�x�ig>>)����r�[�� '1?]5

�
|��-.LH������gmfNrSQt�I+�W�K��jX���0,�h��C��*>�| ��R�{3��� �T�K�Ԛ��w�e�N��5���4�v�]w�d$�
�ל

�n�|l�.�y�g����<#��Π�jǂ"��#�.J(��b�a6}�!����N�h��� �/|����E%?z��� Yt6.�qS
���Қ!�}�!�<:���*���kq���H�6'����A��ݭ(�k����ԇ��(�kFus�j�����pp�����7�i�i�J䰿B��y��5|�.�����W�.�(��{R�$�c�#��Uu5 96)�Q2�!��7��;��k���s�V7��O`�����.	0!3i	�piډ��Ε�

���

E

Q

+�
�



[��

n��

^�

[�

���

8�!$���6�v)������Q<^�]��O8�n�]7��#����<�WΝ�Sa%r�� (�k�#ϼ��%�A�&u =1cF% 1Z�x���
����xy
�

,�
���6

��(�>⣩B^��$Rxm�Uֲ� ɫ/���Q�#"y��NV3��&�N׍e�E��eho�4�@ZB���'�ϻ.��oT�7(�/ �1;�k1!%�}�<�y~+�p<�9Q�)i��GWN�Փ2��ƣ8���X%xn_�>^�o/����7$�395��q9��S�g������z�*�G\x(.�
�����

�

o

7���

�

��
)�
w\:WG^I ���S��ۮª�d�*-8� &2\ �.nΚ�����va��\,����A)Š׋�;��xN�}��:/���J������
x��x��� �ء/�������x���~;_+�ᄑ�`����?"A����Z�L�>{(��26�g���+i�;�a�z�cO�;�y%���<�Z���˖Ǉ/Dey���X�p�`'e�a�6��C ���}������P��y

X8

�Y

�w�

�

��

k�

��

���3!�2��u�5�m6��)��Y�
�ⶾ�`(���ڌ��"?+߹�R4�ub�ͨomGUc+Ғ�� ��瓐����!HKN®���S/C">PJ��ԁy3G���Kf *˸��p���2������EX��0Ғ����]�������

������@Ef�*��q����Mx��=H	0w�P��k�=x���g��	?x�},��2�S�����Ԥ .�<

'���;Jq����� '�)ɘ1�{OV�R�d�9���U�Q^ۈev#� #%I~:����;�oށ{��/���̑�S��?���

w#ˬ`(@��W����lW�;��,r��g;�^��#�wL˝5�g�hK>z�ʘic$�2�}�g�zA��[i	+߸ \b��tZL���Xg�*56Y v	&Y���R
��

߿if��e� � ���yS�ގR�r5>7s<����tG�8^ӈ��vl=Z��#KPؿ"��9c������$�< ��i�oe�ʔ"%�Ǐn����o��_و��vr�OJ�R|{��ۗ����1����4��xk�uq_�U��-��E��p�LS
���/_���ڃ��u< 8�ԁ��� ��ヘ3$W�.�ⱅ8�ԁc�m	����I�`�L�_d�?!���&	 Il�p�R�;b�����S^-�����|
q����b�o�
�

F�q:����Ǹ��&zz;	���%�� �X��� ��	� �ݎ�2��F�$@�A`�h��w�ER��iD��|���]bX��l;�

��@�

�_�q;�Z�?Ɗ-�Q�Ԋ�`�4��=�rG���Ǫ�=�.IE��x��;�p�(��� ��'��t�&l9r�.�^!7�+IJ�s�� @ie-�8����mǜq���/]�˦���C�q�)U����5�mhj���o<���v$��q���������ᨌ�-[�~i)��� ����"���m���������w�"�v�����?�&�֋����
 !�]� �͛�I%:�R�/�ƈ�\\;s���誺q�E�����	�aX_u���f��� ����*��{���A^YT��=D��C�1�>0��r���:S[��]����J�L���� `~����

�N
r��

$ke^T��m��,�W$X8��˲d΢nԲSv��.^,y�I>��W�>HT"�hD�|��$Q��� Q���H.C8�h�- �$-ʫo/����h�>�c���0�'�gё^n���H�~a?��1�@G몑L�[�Ä�� �G)���X�c]"��Ҡ�xx�~���
�

��a79݂X�A�Q��1Չc{�m�x��u/�o�9۸hw_D����Z/r?V���7�6mb���`��۴Y� ,ZOar��h�h}��a\>��1?#]<| ں� Vyc;6���ʱEH���wg&0�$wL�KG
�|>��Ť��p4���$���@n�t�mw8�G+���I �	uMs>�W�-����ޅ��6�ge"=%Y����De�:^��Y��m���	��s�����ٓ18/��!�)E}k��ڄ߽�1�(�)�%

,

��

_�

!��mnÏ_|[�#�"��LÝg⚙��t�׿O�6�+7�k���՛Qv�!�%[	�� �]^�#�{ X��$+�Eu$>���J���H2ZPz���?t�Hx�)�Vs

r@�9�L??W�(�{��I�ַ�I� /+�3Q�Ҏ��6�{�O�ׯ���_7E�Y�<0��ĳ�7���X�PD�TBp��)��mWbB� ���dJ���I��u;������ѕ�:qG���҅R~����z���-vj��\�Cرbt��-=�u��G�
��x
8��Iט�U���?n�2�"�x��K �A�|�Ϡ��9B4�ާX�D	��~
����$�f��E�4!�� �=�	+���"+�h%�������2�-�2a	�@

c�

Kƀ�
�kZc��������	-9��1�0�s75��Rd.��9��Յ��q��	K&q��H)�_���4l9U�PT��t����^��Pc�Cz��&%`��|,�w�

�

i��^

���$�zCGF0B`A㱗 ,"�X���g�>7�' 3�& >� ���������O��`i�- ,�ף0>m��� `�y�~������(
�1�W���u=�$� �� � �ު2>~{3�m^,�z��9 ��o+ K/V��+g ��[� r8�,��Ţ �%

�

��b����HڱH��Rhs��Ē�QE�|��*��� T�J�[�nPQ�Z�?�����+c�w�٨�AL���;�|^b�PH��e ����z��Zq ꐶ�{"�_	���R{gs
��O

�


Q

�

]
��

`

d G

����



�7�
�}��	�D�@؅�Q�����g��#	��fNB���s�u|}_��x eVl��av1��c����
�����<z�

���T[�

��
`͸�0Z�I��a['��7Ot�g��	�fi�$��"�K�֜�׻���t6'y9Bf�|1�pl�@�x�B�@�H�	�2d��^�i�#Z/b��DZ��|Y��鎣｣������r����|��qҒ��0�h��ޡ�]�۹�`}Z��юL��c�v�\ӧ�u���izy2�L��,0[JeM��+�ұ��M㎘"�[��vC�>U^�t�X딟�D��-�.�:ߊ�MJ?�u}��I#&�\��v>�� ��q,�����IJ��3{���N��j�����Kn�%gME��܆�;C�����82��W�{�]E����vJ7I;o��炂k��m���2/��{p\��̈́Pr9�W�R��g�1��� ��s��������l���y�%\�M��
V�^�ܡ�v-����z|��T���K��K���3�6ͻ_��:�4k;jw ,�v�H �`����	��<o%Z�d���b���s ��֩w�z	 ,��e�+k0ﻕ�w��Jޅ_�������;�����/���#-��/��M�N����]���^�@~�����
t�"�)0;S~h�j���ƛD���I�r	�o�-��q b�X欄Ab�+2�IgQ	G� ��ٌ7<��T

�&�

��

�

�

�
�

C
]�ٹ]��uVX��X�Dnn� �=�Z��C `Ð��K��e�@n�R��	, ��|��F�9������h�� [:~躸	:�����Q��l���OXT�yL��\��9qԃx� �'E�����
��v�
� 

�����r?��_N^�޽6�T�*���1�M��u������m��@�����6h�`��*���l������!3C���1�rr�'�`�֨8o���c	��4 	��Ǣ�_~b?�w�����bPl�컴�>�5X�0����S��꡷*�pΎ���'Թ(���[�=O��!�/e]k���]^�I�t��RQIj��x�f(�|_Xf����*eZ��S��0���M��\�������?[���U�Ӷ���8�&�q8]L����n�h����ہ(���ep	�o�����~��9Fy�{�Q\���� �Myj9J��%�Y�Q�&0<���?�8ƚ��q_�-7

�

6�
��

F�
<

�0�

2"wv/�L3_� "��v~	��_I ��������N��+�`LG�-����:��

0��$�*n���H':��zk���Q]b�0a^�R���j��0���-��4Fhwv�_ZM�;_y�ݚ�}]���drȥ<'߶��	?W	K��Zj�>ɂio~��hL-�饸ķ�2�����ʆ2W	��I���-_ NF�F��������}���}�ӈ#d�i����r^�1-ů�-���6�$

��t���

�+

bO

���~��+s��{&��C����rj��t�~R�����5���zڷ ��1��)}�H=`8��`SX�)�r͈�2H�Ú� ����g�ZX�G��F��$��j��%sXXv��N�%O�'�8_�ŋ��

%%
#���

��
����:
�!
(������)�9'`&��U�2����ܶ	�1�$?i]~�w�꾭r���֋/œwۮ��$�^��X�rk��BR⸰��?�>�Y�QNJЋ�����m}��Bi!3\��%����ř��i����o����[��'I4�WȆ�!��N�x������ɂ�b�Ί�}�VQ6�r��� $�#n�����[x1�fM�[0�pu+ё��ú~�L���]��W��

oE�
����
w��
it�!:"��Y�g�-mnq8�#4q�f��<��厏�[�P ��؈��3���bKF�Y G��I�I՗$��mzv`x���Q_w��t��4�g�yi%]����K���.�_S�GK��u���A�#�#;ݣ~)�B�@��V	�ĺ����}�u����^8�j�������

�

<`
���>..%xJ����1�F+�#�jQ��20��g��pY�t��]c#�a�� ������=�7^j��(����bQ,E��)#(����YWNF��g�g��7�x�<��F;vf���H�gI)�P���<	!W��fs�>�<ˑ��y	���	2�q�w.�c���k	�e�U:Qj��7;�v����
/U�ێtӐ�<;�Uf��T1�#�F�� �`�_�_3�	��y��a�@ڐw,/c���,"���;>���K�oY3�2�

�a
9
���8��r�k��\�^�^�`����q�I�V�売<JG7'�O!��Z��GIwYI�, {�b��n��,������I�uV�)	Ƌ#��\�e����	]mlx�u�

�e�J;;ђ�ʛ��>2[rL�/h�{%.��S�L��E���,ՋO�nN%g�Q)�X1ݗc�|Y�F�,}�(�tR�V I�;�&)޲M�-�|�:���S�T�D���X�*Z֙�Z.����h�jՐ��]7�Z^���쪅�#���;5@�	�nY����uS��B��W!�!�[����يVU�	+rto$M}3F��l�B���rc�ۦ�^�.lb����"�H�J�����0pd��vjFٓށm*C�d�qH��42:4��:�x�|��Xu��a�ϊa���u���/���{a�Z����]xJ>�v^�������ꪱ��fd�;��E-�*yr�YR���"�#hZ��3����w��@��� [_����d��x��x��Q:��ke��t���\���D|��`��x8�+�Tc������9W�м�5n�3��Y��K�q�� ��ō��<I��x��.���	SU�K���vi���7��V9����v�l��i�&譵�أ��[�5p�i͕��c?y-�+�bz.ܙ��1��|:r,��T[�\9>��Vk��6�

�jr�?>zGIFG���^�,����=���7X��|�'�b<η�}�L�1K�6�u����h]����VK+�8���lkQa0�铙��[I,��M�z�{�%����RH�b�	���I�b��R��Q������[���մ$[z�wCk�	���V?<{��Eyr��c4	V�
H2 2��4M��� ��O���7�d0�.��Z�X��(#�C9W�����f_r�/�dݎ�>ދЦ��y�@��e�z�`x���o�ʖ,a�	�����5�@�dpio�S�U�V��N��rJr���������Y�W�?L���z�

:
�s�

N�    IEND�B`�



23_ONCODNA-COM-ARTICLE-CLIA-CERTICIFACTION

OncoDNA'sEvrylaboratoryatteinsCLIAcertificationandCAPaccreditationtoreinforceitsglobalclinicaltrialtestingservices|OncoDNA

GoogleAnalyticssnippetadded by Site Kit 

 End Google Analytics snippet added by Site Kit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services 

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and accurate diagnostics and follow-up becomes paramount. This article explores two critical facets shaping the landscape of clinical trials: the gold standards of CLIA/CAP certification and the transformative trend from solid to liquid biopsy.

CLIA Certification and CAP Accreditation: highest standards for precision testing

Today, clinical Laboratory Improvement Amendments (CLIA) certification and College of American Pathologists (CAP) accreditation stand as key requirements of precision in oncology clinical studies. The former ensures the highest standards of clinical laboratory testing, guaranteeing accuracy in molecular diagnostics. CAP accreditation, on the other hand, signifies a commitment to unparalleled quality, providing researchers with reliable and consistent results crucial for advancing our understanding of cancer.

Liquid Biopsy: a paradigm shift in clinical trials

Traditional tissue biopsies have limitations (invasive, tumor heterogeneity, tissueavailability, sampling bias, …) and the spotlight is now on liquid biopsy. The non-invasive approach analyzing circulating tumor DNA (ctDNA) and other biomarkers in the bloodstream offers real-time insights into tumor dynamics, treatment response, and the detection of minimal residual disease (MRD), enhancing the clinical trial’s approach. Reasons why OncoDNA has developed liquid biopsy solutions for precision oncology research for more several years.

OncoSELECT®: tailored biomarker profiling

By detecting potential sensitivity or resistance to targeted therapies and hormone treatments OncoSELECT®, empowers researchers with biomarker profiling, aiding in the identification of genetic alterations crucial for patient stratification and the development of personalized treatment plans in oncology clinical studies.

OncoFOLLOW®: real-time treatment monitoring

As demonstrated in two recent studies from Curie Institute (1), OncoFOLLO® allows detection of pathogenic variants that were missing from paired tissue-based NGS results, suggesting spatial heterogeneity but also facilitates real-time monitoring of treatment response. By tracking changes in ctDNA levels, it identifies emerging resistance mechanisms, allowing for adaptive trial design and optimized patient outcomes.

(1) Decoding link between ctDNA detection and cancer recurrence, AACR 2023 Abstract #3363 (Institue Curie / OncoDNA) & (ESMO 2023; FPN 864P)

MRD for Pharma: ultra-sensitive detection of residual disease

As depicted below Minimal Residual Disease (MRD) allows for early detection of recurrence and precise measurement of tumor burden (2) (3) (4) (5). This precision enhances the evaluation of treatment efficacy, guiding informed decision-making in clinical trials and ultimately improving patient outcomes in real-time.

Figure 1. Early detection of cancer recurrence comparing to CT approach.

Figure 2. Tumor fraction monitoring.

(2) Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (C2inform)

(3) Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer (C2inform)

(4) Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers (C2inform)

(5) AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test

In conclusion, OncoDNA, with its recently acquired CLIA certification and CAP Accreditation, stands as a great ally for biotech and pharmaceutical companies. It proves to be an invaluable partner, providing comprehensive support throughout the crucial stages of clinical studies, from transitional research to post-market surveillance. 

 us to find out more about our services

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Lab Case
Revolutionizing laboratory operations with OncoDEEP® Kit4 min readingJun 18th

Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...Read more →

 Press Release
OncoDNA has been nominated for the 2020 BVA Award Growth of the YearSep 8th

OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, is happy to announce its nomination for the 2020 BVA Award Growth Company of the Year. The third edition of the...Read more →

 Press Release
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncologyDec 16th

The Appolo study will assess the impact of biomarker testing on access to precision medicines and on posttreatment surveillance for cancer patients across the sounth of France. OncoDNA, a genomic and theranostic company specializing in...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

Company 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Contact

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712112277



24_ONCODNA-COM-FOR-PHARMA-COMPANIES-CLINICAL-TESTING

ClinicalTrialTestingforPharma

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetadded by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solutions

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Characterise patients in clinical trials with one single lab with two distinct technologies 

Exclusive molecular tools making the difference 

	Among other standard clinical testing tools, OncoDNA has developed two exclusive solutions to improve the characterisation of clinical trial’s patients and to ease treatment monitoring. These approaches are of course of interest in planned or up-and-running trials but also to have a comprehensive restrospectively analysis of patients’ samples collected during trial.	

Planned or up-and-running trials or a comprehensive retrospectively analysis of patients’ samplesOffering NGS and molecular pahtology as stand-alone or integrated assay.ISO 15189 lab processing.NGS sequencing – Ion torrent or Illumina based.Protein expression analysis through IHC / RNA-Seq.Pathologist team.Unique assesment of tumour microenvironment using immunogram and upgraded immunogram to support immonotherapy clinical trials.Liquid or solid biopsy. 

We have developed solutions especially designed for your clinical testings

We use a combination of the most relevant molecular technologies and bioinformatic approaches to offer you molecular integrated assays. 

What we do with Generation Sequencing?

OncoDNA uses next-generation sequencing for DNA and RNA analysis. Sequencing DNA allows us to address three classes of genomic alterations known to be relevant in solid tumours:Somatic point mutations;Indels (insertion or deletion of bases);Copy number variations (CNVs).

The 4th class of genomic alterations - translocations/fusions/rearrangements - is tested through RNA sequencing. RNA sequencing can also be used to perform expression profiling analyses.

What technology do we use?

Routinely, OncoDNA runs all 3 devices from Thermo Fisher Scientific using Ion Torrent™ sequencing technology: Ion PGM, Ion Proton and Ion S5 XL Systems.

For specific projects, we can also run Illumina devices.From single gene to complete panel.On demand target with validated panels or customised panel design.Using solid tumor (FFPE block or slides) and/or liquid biopsy (blood, urine, CSF, saliva…).From sample to biological and clinical interpretation.AND the most flexible and personalised ctDNA solution.

OncoDNA embraces the challenges and benefits of IHC. Our molecular pathology experts come from extensive clinical pathology and research-based backgrounds.

So the IHC assays available in our portfolio can serve cancer diagnostic and cancer theranostic, question the potential benefit of different treatment approaches (Chemo, targeted therapy, immunotherapy).Cancer diagnostic: ER, PR, CD117, CD10, CKs…Chemo potential benefit: TLE3, TOPO1, RRM1, TUBB3, TOP2A…Targeted therapies benefit: EGFR, VEGFR2, HER2, PTEN…Immunotherapies benefit: PD-L1, CD8…

Immunohistochemistry assays are also great tools to question activation of some cancer pathways in cancer cells: mTOR pathway, MAPK pathway, cell cycle pathway, … We have validated IHC and pIHC assays to question those pathways.Cancer pathways : p4EBP1, pERK1/2, cMET, pAKT, pRB, CDK4…

Beside the large portfolio of off-the-shelf IHCs assays, OncoDNA has developed a large expertise in IHC based biomarker assay development and validation services. Developed assays can be used from preclinical development through proof of concept to testing in clinical trials, ensuring transition of procedures and technology during the drug development process.

Specific biomarkers need specific assays

Biology is complex, so is the biomarker landscape. Beside molecular alterations that can easily be tested using NGS and/or IHS, a lot of biomarkers require specific technologies/assays to be evaluated. Being technology agnostic / biomarker believer, we have put in place and validated diffrent assays to answer those specific biomarkers

Splice variants: In cancer cells, various splicing alterations have been identified that e.g. eliminate protein domains or enzymatic activities required for efficacy of cancer therapies.

OncoDNA proposes RT-QPCR based assays to test those splice variants amongst which EGFR-VIII, AR-V7, MET Exon 14 Skipping…

Methylation analysis: In glioblastoma, promoter methylation of the gene encoding for MGMT is undoubtedly the genetic fingerprint with highest impact on clinical practice. We offer this biomarker testing through a combination of bisulfite treatment and pyrosequencing for accurate and cost-efficient assessment.

FISH or CISH: While FISH cannot be utilised as a screening test for chromosomal aberrations, FISH has been widely used to identify specific molecular targets with predictive, diagnostic and/or prognostic significance. As an example, HER2 FISH PharmDx Kit still is a companion diagnostic for some HER2 inhibitors.

PCR – QPCR – dPCR: OncoDNA has developed a large selection of validated PCR based methods and assays and PCR platforms to support your development and clinical needs.

A unique immunogram to properly predict response to immunotherapy 

	Our immunogram combines five different biomarkers for predicting clinical benefit of immune checkpoint inhibitors (ICIs): PD-L1 protein expression (FDA-approved marker), TMB, CD8+ T-cell infiltration, MSI (FDA-approved marker) and gene alterations leading to sensibility or resistance to ICIs. 	

Liquid biopsy to monitor treatment response

OncoDNA has developed a solution to monitor treatment response using a simple blood sample. It is the perfect tool to help pharma and biotech companies transition from tissue to blood based assays during drug development and/or for market positioning of already approved molecules.

This test is based on free circulating tumor DNA (ctDNA) in liquid biopsies, principally blood, while other matrixes are currently under validation (urine, saliva, vaginal swab, …).

In clinical trials, our personalised ctDNA assay can be used:To identify disease recurrence and potentially identify relapse drivers by monitoring the amount of ctDNA of treated patients and identifying escaping variants, allowing this way to change/initiate treatment earlier.To assess therapy response in the neoadjuvant setting to assess personalised therapies.To better characterise patients and optimise their selection or randomisation for clinical trials.

Customisation for each patient can be made by selecting a set of patient-specific variants, identified in the tumor by a previous genetic test.

Our assay can then be composed of one or two sets of markers:A first set of markers consisting in a core panel addressing variants (SNV, Indel and CNV) or translocation. We have standard panels ranging from 10 to 40 genes but this core panel can be designed according to your genes of interest.The second set of biomarkers consists in patients’ specific variants which allow to monitor the heterogeneity of the response. 

Your benefits with personalised ctDNA assay? 

The combination of clinically validated variants and patient-specific variants allows fast and robust treatment escape monitoring at a lower cost than large CDS gene panels. The panel can truly be used repeatedly on liquid biopsy samples. 

Relapses can be detected earlier than with routine imaging technologies. 

Identify new targets if the cancer grows resistant to the current therapy. 

They trust our expertise 

	Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions.	

M.D. PH.D ANTONIO GUALBERTOHead of Development and Chief Medical Officer, Kura Oncology - USA 

	The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)	

DR. ALAN L. HOOncologist, Memorial Sloan Kettering Cancer Center - USA 

 Next

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712105573



25_ONCODNA-COM-BIOLOGICAL-MERCURY

DNA&RNAsequencingresultsqualitycontrolinterface

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Extensive quality control checking and raw data vizualisation 

	MercuryTM  is an intuitive interface that enables users to check in detail the quality of their DNA and RNA sequencing results and extensively visualise raw data of cancer patient molecular profile.	

	MERCURYTM is RUO *

·RUO* Research use only , CNV; copynumber variant; LOH: loss of heterozygoty; INDEL: insertion / deletion; SNV: single nucleotide variant; TMB: tumor mutational burden; MSI: microsatelite instability; HRD : homologous recombination deficiency.	

Clear data insight and clinical interpretation 

	OncoKDM®’s comprehensive interpretation reports provide labs with eight essential assets to enhance the understanding of NGS data, including detailed annotations, a list of actionable variants, a list of therapies recommendation and a summary of relevant clinical trials.	

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712118514



26_ONCODNA-COM-OUR-BLOG-RESOURCE

ExploreOncoDNAKnowledgebase:avaluableoncologyresource

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Our Blog & 

Unlock a goldmine of cutting-edge knowledge and resources on our blog, where we delve into the forefront of precision medicine, offering expert perspectives, actionable insights, and game-changing discoveries to empower your journey in shaping the future of healthcare.  

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

Category
WebinarWhite paperArticleCase of the MonthLab CasePosterPress ReleaseScientific Application NoteScientific ReviewTestimonialVideo 

1 - 32 of 115 results 

 Case of the Month
March: 42-year-old male with a metastatic colorectal cancer2 min readingMar 18th

Here we will describe the case of a man of 42 years old diagnosed in 2021 with metastatic colorectal cancer. Read more → Press Release
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.Feb 28th

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.   Gosselies, Belgium and Paris,...Read more → Article
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing servicesFeb 23rd

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...Read more → Case of the Month
February: 40-year-old male with a stage IV glioma cancer2 min readingFeb 20th

OncoDEEP® identifies rare mutations & personalizes treatment for a 40-year-old male with a stage IV glioma cancerRead more → Webinar
Advancing personalized cancer treatment: Webinar ReplayFeb 19th

Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...Read more → Poster
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer5 min readingJan 22nd

Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...Read more →

 Webinar
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinarJan 22nd

Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...Read more →

 Press Release
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccineJan 17th

Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...Read more →

 Case of the Month
January: 45-year-old male with an intrahepatic cholangiocarcinoma2 min readingJan 16th

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...Read more → Poster
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers5 min readingJan 8th

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...Read more →

 Press Release
OncoDNA laboratory has received the CAP accreditationJan 4th

Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...Read more → Case of the Month
December: 52-year-old male with a stage IV gastric cancer2 min readingDec 19th

Case description: Gastric cancer is one of the leading causes of cancer-related mortality worldwide, with a 5-year survival rate ranging from 5% to 20% for advanced-stage cases (PMID: 30853093). We describe the case of a...Read more → Poster
Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer5 min readingDec 12th

Overview: The pivotal role of early detection of cancer recurrence and the precise monitoring of minimal residual disease (MRD) after surgery cannot be overstated, especially in the context of non-small cell lung cancer (NSCLC) where...Read more →

 Press Release
OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, GermanyDec 4th

OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment, today has announced the implementation of OncoDEEP® Kit in clinical routine by the Institute of Pathology at the Klinikum Region Hannover...Read more →

 Press Release
OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancerNov 23rd

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today has announced its support to the extension of the AURORA program, which aims to...Read more →

 Video
Decoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment

Join us in this video as Marcel Trautmann, Head of Molecular Diagnostics within the first German Department of Pathology and member of the German Network for Personalized Medicine (DNPM),  shares his firsthand experience with OncoDEEP®...20 minutesNov 15th

 Case of the Month
November: 68 year-old man with a Stage IV Prostate cancer2 min readingNov 14th

Case description: Prostate cancer is the fifth leading cause of cancer death in the world. When the cancer is localized, it is usually indolent, with a 5-year survival rate of nearly 100%. However, when the...Read more →

 Press Release
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, NetherlandsNov 7th

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...Read more →

 Poster
ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma5 min readingNov 2nd

Two recent studies, led by the Institute Curie in collaboration with OncoDNA, have assessed the potential of circulating tumor DNA (ctDNA) as a biomarker for early detection of Molecular Residual Disease (MRD) and predicting recurrence...Read more →

 Case of the Month
October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive2 min readingOct 31st

Case description: A 65 year-old woman was diagnosed with a metastatic breast cancer, hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Thanks to our OncoDEEP analysis, we notably detected a variant PIK3CA...Read more →

 Press Release
OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-houseOct 20th

OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house. Gosselies, Belgium, October 20th, 2023 – OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment,...Read more →

 Poster
Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)Oct 19th

Comprehensive genomic profiling (CGP) and reliable molecular characterization of solid tumors using NGS technology has become a key tool to facilitate biomarker-matched therapy selection. With a broad spectrum of therapies already approved or in clinical...Read more →

 Press Release
C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across EuropeOct 19th

OncoDNA’s lab in France is the first in the EU to enable access to the C2inform test for clinical decision-making Gosselies — (October 19, 2023) — OncoDNA, a genomic and theranostic company specializing in precision...Read more →

 Scientific Review
Scientific Review: Latest Discoveries in OncologyOct 3rd

In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked...Read more →

 Lab Case
Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies5 min readingSep 29th

What is HRD Genomic Scar? The HRD Genomic Scar (GS) is essentially a collection of genetic changes or signatures that indicate a cell’s inability to repair DNA damage effectively using this specific DNA repair pathway....Read more →

 Case of the Month
September: 53 year-old man with Metastatic Colorectal Cancer2 min readingSep 29th

Case description: A 53 year-old man was diagnosed with metastatic colorectal cancer. In 2023, the primary sample was tested using our OncoDEEP® Kit. The analysis revealed a FMN1-NTRK3 gene fusion for this patient and a...Read more →

 Video
Testimonial of OncoDNA’s Journey through its founder’s words

Dive Deep into OncoDNA’s journey tells by its founder Jean-Pol Detiffe !   In this video interview, you’ll discover the inspiration behind OncoDNA’s tests and its pioneering decentralized solution: OncoDEEP Kit. But that’s not all!...5 minutesAug 22nd

 Case of the Month
July: 53 year-old man with Non-Small Cell Lung Cancer2 min readingJul 24th

Case description: A 53 year-old man was diagnosed with a metastatic Non-Small Cell Lung Cancer (mNSCLC) in 2021. This patient was a non-smoker. In 2022, a biopsy from a bone metastasis was tested using our...Read more →

 Scientific Application Note
Cancer Management: Breast Cancer5 min readingJul 24th

What is Breast Cancer? With an estimated 2.26 million new cancer cases and 685 000 deaths in women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in 2020,...Read more →

 Testimonial
Revolutionizing precision medicine: OncoDNA’s data innovation story5 min readingJul 3rd

Once upon a time, in a world where personalized medicine was a luxury reserved for the few, a small but passionate group embarked on an audacious journey to change precision medicine. It was a crazy...Read more →

 Press Release
OncoDNA announces the closing of a round C financing of 6,5 M€Jul 3rd

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by...Read more → Lab Case
Revolutionizing laboratory operations with OncoDEEP® Kit4 min readingJun 18th

Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...Read more → 

Stay in the know 

	Get the latest resources, news and more.	

monthly
PhoneThis field is for validation purposes and should be left unchanged.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Resources

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712101530



27_ONCODNA-COM-TEAM

OncoDNA:MeettheTeam

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogleTagManagersnippetaddedby Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoDNA selects and hires people with very diverse but complementary profiles. Everyone represents a link in a chain, and this gives our enterprise a strong and unique fingerprint. 

	CHIEF STRATEGY & INNOVATION OFFICER	

EXECUTIVE CHAIRMAN OF THE BOARD 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129195



28_ONCODNA-COM-CONTENT-UPLOADS-2024-02-STUDY-BLADDER-CANCER-CTDNA-PNG

H     3   R       	pHY      tc.oe.p     pcketben﻿idW5M0MpCeiHreNckc9d'

Tempates osts Website - std-bladder-cancer-ctDNA

!0D8qCD 0QŰGąq Y&!d!ɽgOUWUWWwW?oRuUS@D\ycWcq= zN(@kHJ += Tچq!L?P6:uc@p3՟AɁѫ

㣉Um cn'RĶeA6݋8= P'J"/{wSB҂۬ФPCbC'{; mX@ukشcb蒸3a	n{AIޓ:qĽ k ޖ^=JM\M! q%c>	J *nL9f+@v+# J{!بر:įc>Xk@U7Sﰩ>d3zpf	'NS ֶsWό]ͷx(H,mb{.KMM9#QRbCH J3MП=+BWِGb$Uk٦6Pϙm7#M J^Mm+(z+	RǓQ"j>'Nv堉"ph"!$hDx"voN%wˢrXZ9q{(*K>aez

+

j|$7e%ش&#P m	{A$rΧȎCh
"Z/oI
T�]asѯD`̅o�'T�^	țBSL� RذZp��y�b muϡN^O�׳�U vϙ�K!

�ƟH3cٲJ�>9�0�VE�W�k*�˴E�E�"BDV�E	K>�s�k#L�K� J�$RDΊU�9Ly}

�



c&uۗ�m�bM�vZҀ9�`[�$�L�6�!�b%"K�ZO�͓�ɵ�Љ�-�.
ԭ�E\?ƌ��K�E"@y0VW�՟nCb��o�Ҫ�*kƹ!��EN��f�0:|�a�	�&ʝړ��Y



�
v.~2�Ŗ�C1�hto1V���]��˭y|P�P{	b-`ɨ���s������">	i& v69_%���0��

P7�fn7B!�j{�z|���`Z2y��ʋmqLr�W��}ќr*$�i��0��6U�}	�T�>	���ŁohY_&b�|�l��p@lp�D�Drٶ,��0#��^u_�

�

,

��%^ƊDI�%��	"�ϪC7N4J��Ue��pAa���	�Wa�:cx�͛�ۍ�F ;FzcԄ�G~D���jl�,Wr���'���|

�	

ѷ�n���)!�к9Xg��]��}�8�N��.p;q[���LP�R��$mG1&��˦+	�lWXsm��7͑q��;W�v�m-�N��/�fK�I�>��e$~k�$L��wJ(����j�	c�5���ގ��O"b�S�	|c]�fE_I&�

�
��

�L[��.zbդ�l�b��.Mk!*niQ5�/��b3�e��̤�Pz�M[��L2���W��mi����#���3e���#}�W̮4S��B_Fl[�p=�?��@'�)�`���JvA?2$6
�IRfT��\y�־�w#	#o�ewW w�8{�*պ�

��

�

��

�D�yKMM>˚+ �3)����a��3ڑ� E{|�İM��4�����v#|���a�A�#l^RwQ>��w��C�^]aM&L��<z���9Ϗ�/D䄥,hK[���RK�4	,��!�BoSfΩ�c+(?/E��?F+b{";%aEB�s53��I�87�ȶ�2뾜�'��h=��N�GMv8́ �Vxj���0b�W�Q.`�ŵ���=��5N�Z�n���&�q[!BGp� ��ŁܞF�V*]%��t��8[KN��!d?b�7�D3�c�&?k���0|�5,<m+���,+�9o�����l�OuJKN�/��B�}�8ɫ'N�ũ?6@`p"5�!�-�N�6LY�#(5F2H

C��rQu�z��\�_Fᘻ�!���AF�}���_    IDAT-LmR#��־��ǭ�a�ۯ��uop�@��`��ا�e�`~�Di�v0��0h�ѩ�8qOa��p��נ�;1

_
��
�

����ؒ�|[�2勹�O��OZ&J���|����4����5���-P�f�[��D�+�e��8q@0 tk6ٍ�6�Հ�7R F�6�����=6�!e��v�u�)4An.��N&ce03N�JGO����!`&�΍u�gE��̎i�␓�a�m'�MK[����O״��^+|g��gA�\gڢ��L _	��akD)�&c�(u�v`��[���_Hv`�&0�ʆ�u�Ż6�1��	�l�3�H?�9g:ց*߹� 3�zX�"��W���v:ʉ1��ܹ�:i�	��vp��z�ت8�&t�3��̏S

���W�}+3a#��_/���j?�O�X�M�gc0g"u��-��; W�}k/~/3�j�MXa�H��-r�l�S�e�W!欁'�FȐ����y �F�"Ҏ�e�ˬ��D�%Z�rWǱu�c�#y�7���^�R��]0L�Ր|� f��W{���v�z�X��l�

J�

~

�


,

z��{
=3p���R�"��_?v�Q��g���˘��̸�	�����-��|}h/�y$KRm�>Hq�m�r��%~\Uƪ�� �Yd���^�#�ZTw=�����

�

�z�

q>Oŧ>��x�K�?|�7�]��W=��V��t>�YO�W��ߋ'?������|������Ώ���{~��Ad����L��q\�z����;�M_�|��8����

r�ӯ�쀞UY�\��2#�/�S����|FVK\���і�?L^Zp�A���9��tf/��m�:�uް�e�%��1�b�t��rp��#��i�1�X<Q��(�7���x�S?/��������������������ۿ�ٳ�+�G�w�����??�2�/�5	?��/Ƿ}��W>������

?������x�[�|�?��54����ݟ�w�c�k?�˿�z(���q�_�o��y��[�_^�F7�b���W?0�P/yūq�:�:�#»=�1x�w������w�O|��'ŷ�ő�[��!��~}G��XΪ�XCuq��� lֳ����v�r��J�vp �A?P����2�ٻ�

��O>�7�	��˿?�K��s��lz?�C? ����xD o~�%/�����xы��=84��$�w.��z?|��|8>�����ހg~���W�ר\�!�3��S��g>_�i�p�}�s���_�~1gr��
d��

|�χ�`��b�Ĥ����Ś-�#g�' n�Jld�W5`k�a� �P�p�c�`3'�+A� K|�
S��.�����A?��/���?���y!

I
�

�a��
�a|1�h�����g�����]������0�Q���vGLy��ހo~�?w�=�1��s~�=�!���������ɟ�!b��e�ĳ���x��%�YO{*>�W觎����������ހ��p��l|�w� ���
�-

��y
����5����{�����}��#��]q�u�
s������*|_����"��_~�uﴓ�0�4C`tLƪ�2a';��"���,;mP��ݶrj�Ђ�Ԙ���z���enE �>-�<5мԶ@�a���Co�X��/=̆�[����E�I�,�i�g�o����Kc���*c ��Z�z����-$�P�e�QF��	X���q��6��~�!����n'k�"L��T�H ��VT���a�L��Uʖ�'��p1�+ط�>��^��-��r\��@�g��9VR��y�n:k.��VD�c�

�_�

m

�
�
�]

�

�

�

��WZ�_���_� 5iR��<�l��f�ET��}��k>fo�%LO ����+�xǻű��M�	i9Y��QF�6˪�[��	��(��1'��Ϣ�<2>,#� ȼ�w�

�

|

���w����.8�w�ݾ�Ya���������ُ4~�o�K�|�vG<&������w�=�C�R�L�;��Ye�S2WH$;� �p�[�!�<?���{�+�Ə<�/q��7�yQ�̷N��8�����F����~�˚(���� P@�
a�j)�<H�=�fq�7��Ctg�\�q ���}i:biέu �/bIH�;[Kj]c���I��ù?e�ŭ�S���;�iM���G_P	F^	?��Kr��F�"�21Qc��Z�ŉYNud���e�[��4�8�xxV�b�?^�x���V

���

��߼�?q��G��>�ǭߎ>�0�y��x�{>:�p%&�s.�o]�K�����f 61zſ��yн����C�;���_�g�d,�}�wU��he���8V >��M
c�	���I/���ml�ʥ-��y/An��>b��%��8��\�	��]�N�g��yf�����m���MQ*��*�5ڞ_v��ڊu�kn��!>Y1&>�:�=g�E��xw-G�~�]�> L

0h�S ��׈rl���m�W�*��/l�YNOhϢ�m�@�2�Fc�'���.�3w!Q�,\�R���$�uuZ���ۻL}�m=�'Ejg��%���e���+*��G��5��EI�GVEcy^U ���nre ��� '�qm�zv��+y�� �/.�d���wYŻ ��ʭ��f��.�~K�u��%�`�ٛ���{�ϝ9�����]ؿ��ÿ�|�+�3�

�<

�4�
�

Z�
�If����| ���������]�d��g�Ж��$kd��u��8���yֽ#=/����yI[y8���8o�lU����k��8yn��sɘ���IN?���8b�
���0�

'���)�����s��(:�B�ҋ�._�%�]G/�=�x�)wjn�L`}��Kq�U׎vn�8��W_����S�#;D������;�>x�{>�+�y0�_u�n	=qI�@o�sd��'���~e�V!b{�f'��Z�1yv1�\�5P���>.`O��<����d��he98�[�?U �v�p;�cVqȏ�- C�%��97���V�xR
�m��<URB�k�%PX9q�z�u卑�nqy�����{�[k� ����� qs���Ɠ}���3����u�A��!\~�����xͻ?<Xޗ�}�����

�;

�F��-y��qڧ�c&���U�Yl355�Ӑ>��HP�ŎR���9iI�ڮ��Pɾ�۪��J�	Wu���:˱m�p�)�i{�u��Rp�&nG�[$q�������p���������F��x3^q��p�_z.��¿ťW^SP�<��x���'=����W�|���������{N������

�`��

�

�

��?

�<
�'T74��P9�p
�X��`�J�Z.�~Č	��u�t�.�z�	�&��X���C`ZYaj"@�(tE\�+�8Uk�� ��@{�XVXA���.�5��D�%qV��I��r6��Y�ypH�:W¶�̿f�U�6�RmM5b��R#��^�i�����,[m"T5�Zha�k�H�1P�J�RM�E)C�eH�~Ē@��uOVQD5��

/��@�����,y�{�l�
��$�B5`�S*9��k=�o#�yB�    IDATr���ٖZ(N�V��&>��"�7	�2�����5�dHT�W"ia����h[����+�e�1K�G�t�	��V�B�b�XƤ���ߙ[މ��HR�`i����BC@��l�B�� r� R��|X�Y�H]�Q��~�x�w�e����&-�w�>�Rw\rcRwI���XC��n��w��G]�
>�v
��

2

�t
�����P;H�N��$���ŶB&�;c���#X<�p��@M�F���Y�cϕ��TD�&��:�u'zV*#M~��-�Ȓ��� ���2B�)F=��S�5�g�ų	{�}Ccac�I����$��4QC�*\?�.�W��Es+ m��
�|��

��D

I��*�kHB�D8
q�a�I�I����f�����/Ւ�\&�}tF|���	5� ��wEⳝ^s�g���

l�oN^���d�h}��&<�WN�i�����=�{�M�Q��8x/;~�
"�����J~[�H�[�S��z!@��DC(�V�Wk�R9?8��E0�0ru�"�Ł�l�vДo�v�m�,A9�f�X���ƕ���ɩU���\��b��J����j�^�xEiY���_Mp�b���,Ȕ���v��� �;D�._IpB4)�ӧ�eo�O����č��g��+��=uBmZ��}��hx&A΄_�

�
"��U�QX�A8 �bZ"�.Ro����'�
2��,0����+T` �`�Q�|���	R����$1* ;·QUhk_(�)�[_��Cc�y��a	{�h�cXU[�OSC��	7�M�. �N��3Md5wS}i���..�6-�T��ϯ��T&A�g�

�,

`

�`��

K

��

X
Ur�����9dnR�h�07���ڛ��J�k������Dj� ��������g����b�S�K�W�rN�3��x�nvn	�����"�N{_3��]c��	�R�m�C$����P&��t

Y^

�A�U,��9�SwV5PP{�0 �9|�ů�w���	>5V��������ǅJ�[FP}�im�$cl�,e w�5Y�P+(�u�{Z��'1&���&�@�������l"F�;�C!���]L�e�F"����2�������^2O��z��G�7�A+��u����2w1��?y�Һyu(�'^Б?������U �/[���U����[ת'
/Y����K������l�C�ڰ�ȑ hv��\
��b�5��L�Z�2��⥞�5� C�jm�7C����*֯�zܧs��=��Mw]��������C�u�G���ne�G�зɋ��)kSnp�@S����fǙ4^R-媦�<j��y�$���Xjy�3��Ŝ۟w�sZpd�N�\��l.�E���d�i�c} g�<��/�ˀ��C�좝K�{m==LH���=�1
'���tjmި�	^��Ȼi�&o�W�؆h}����|�ϼ�	������0�M�ba��|��G���Z��� ֏�t�8��E�����%���k�����[���n���:SOI�����1D!����Z�`�PC�9浂N�Jڠ�2��Q]�?�):�Mv

�

�`�

�

�"
�
��`0����~�V��6�o�a'���a<���錗���5�w�Z���G��=x%��5HJU��k���x�ıbB|�0[XZ�����Do/�m�Pc�IC���&,̥���QB.�v��8��O �e��i]��ƭW�C�|3���f�8u��F�j8�)��X��<�[�jOk� fƦ���I���~�e���.���
Yt-9�^z*�B��q|S&\�w"!F��L@/b��� z�`se��ʞMzw܌���	@�4��`�l b�}#n�	�P�V)A�<�

x��lL�
S�m?�w�����ϩ���	�S+ĢL^.�m4�E�or|���.?<�i*�!J6��#U�'1#9˗��p�� d|��pjqY�q�s�� �z�R�w���lӇ{'�F��G��+6TR���<_c>������n�
�
�
�
k�

�6

	`�����k����NႬ�ex��w|��H�m��K���t��۟L��ݢ8���w�Y�]�v�^ENN�م��"0�dZ
�,��?�w�

��

����;���K��j��7�w�� c�ǅ�c��6C_c���w������h$=��F^�]#��yj��R8�jo����ԯ�����_
 �+��8X.xPA�� ��u}�r��G]>2���h�t%U�Iv��F?	#���Z0����f�Q}4쯻i7=Y�?�G�D�s]�w�)�9�`����(
�=�����7

=j 
:��

`]�j�V�'P��res�h���ε]3W�i����P2���x��h泞	��PO���/ ��9�6e��jϧ��T�k����@����԰ʉ�^J�J���{f�`��%�'&fY̦Q|��d�d�

L

����������
��

��Zs̎�W
a�p��jJ��S� �.������G�,�� 5��v9��,�w��$���Y�-�Ɔ7�3����c���g��L��]9f�e:�r^$y��C����"�Y7Ыp^j^#	�^�K�MtH	 M�#�? ���� J9M��mJܷ�*��l�4j}�

}
���

�x�

1L���1�x���-$������9�����: X�3��d ����X�>��%* ;yF���1�8-Z9���Qn<p�г@6 (�y_`

�/[chx�2 C`�� '?��XE�c�mP(҂ق�@8�c�,�����ԊM�d� �`/3j}��U �|evT��u6�`x�t��J�qp	��/������͂t����� �M�ƕ$��(��

�)��?��j��p_m�l9`t��`6C�#�y�v\�-�m9���H���M��
�������j\���H�	ׅMS�H}s;kT�V��Z�bb��x,�殼j-k���x�F)���~rx

f

��

��
`�

<���E?Sv��ϧe��
���	�qO���*������q��{O�)�}Fq�:�/�Ր#p6��Ү߳`�qL�J�X���걸�����}�匧�@�  Q�k r	 �i�N<6f��W���19�^��MS��g��k �H��$Fd �&K#��v]���'�

�@�p�_���3�ɣ�X �1E,k��������(��`�vA�I����f ������Ȳ�u�A�r�nɑIU�mq�.�b�S����2�G�4��>K�ԩ98Σ;�u�^ %x��/���ηVe���3������UE
u

W[��ɯr�0l\j}c ���&p'-� w����qs_%v ��e㉌U�mA��1C�������v��>���sw����c@f4�65
��r�

��

��ʬ��h�u�k
ռAs+�L��9b��V�,�˪�IyX�Ū��7Ώ���zz�t%T�G��yu\@&q 'ߕ9��,�����f���T��8� %{F������A��%�& �=?�8PF���}{Y����p��/�|C�

�

�
`���

��=��

��
ZMm�{)��l�X|��q!�	p��yo�R��S�#8w	��I�������kE�b�1���1Hq!�_^S�����i6|��T��u����� ����ڨ�Ƭ�o��8�?��8Û���>X1� z�����9�=�Q.OK`J��jٛ����un�� �	�#*Ȍ3l;S�I;�#�����c*I� ]����OS8>��iȹt�~$2����*�

�������
��V�"4��vJԣ3ܖI�z�آ �x%7�f�"��Oe��!�T�U5��B���SG�.@F�v������x)�mV�ϰ X�$d�����%;J�o	����kݧ�H�Jo�ap��H�fSc܅��`ކ�y �V����~ V�N[����h���"��������d�,�N�g�ٴ�A�䥼�R�]�p"�����u1)Y-�����_��s��
f�[�������8>rK^��]Y9P�p]��s�ezT'�H�Ut��Mm̮�u�6%fX?��'��+���P���0�T�@���������M	��znl�]q�J��X�o�s56ä�)��/���`� �����H�7I�$�hGh��5Q݇c�5֋$��&�J+�T2�yZEϦ:	�Tdt��	�C+L��
��

�
��,�

�h

Pmp&�|�ޝ�BۑG��ϫo#� �xx)Sm;��V.�4�/����G֏������>r�*j�F9�)�+�^���j�i��jJ-�� �^�#�շƺ�Rd�cu��]�з�R�V��DA3"�c���1`��L;����T�j�f�bnE ��h�

x

,g#��7�ў��>�#���=�BM�,�ÈW�>��It�I8��C�����c��\ʶ���5l���_\`%m�)��_�M���K�  ��*^��3��-�O��mm��ܚ�~_�'�F��edx����s����e�1<�R�d0~�ϭ7
���
�\�R�4��)�Ä�-kx�m�A�U�]�N�P����_�� /��F{v�#K�@ ����:
79_��=uS\,%��������Ô�������[�])�qYNm\U��<쥝Fr��x���Ig�[�|;�y�zD�y�H��)Wгz+��Se��$7-Q����ފ�4\&�9,�G�on&�|K)� XX;㤞��0�u�t&�� ���

4�

�

�e@8;*�0PIQ}`�j$�e�|����-Y�Nc^���(�dU�h;��g�<:4O������o;tCF�$�������Hr�~��F]�=�U�xPCD��v�    IDAT�vӮ�8�1�vP�AQ�E��HW

�����:�P�ӗ���S�#9	e���Pn�̣"�S�8����$G��N����Yf:ʾ�'�Hp�~0�J�>U4`-��h�m�PG�1ւ�Kj/��\� ��M�QZ��B9��d�_�$�>�eEⴱ<

D���

�B����|\��1^>v�k����u��9�u���=)H[B�T,N����_�v3�N,�p��	�u��jF�q�b��p��\��r�m=��V��pF�D�����W�H4YDX��̲r� �(�82P�8�4	2���T

I���

M
yQEd�"gZ6 B3|#�%'��۔W��q�J..�[.9� ��d��iKV	В	�HJ�%~(�E��<�;4Oj����>�@��O�]���ͧ��P�L�pܞ�|Ն�w	ASy�gS��ä�}дZy˳����~^�~���z

)�
�l=����O�bbd7#���)@�EC�&�ߕ;��&ԛ���Pc��-Ѡ� ��a#	5�

��
�d���d
|

�

��J

��

 �

ŭ?��������-xo2�����I���P�a�ً�0��OB&�N��ƈ�? ��s��r^��,r�f�2̣�_3(���z�~FO�Ekq$��B�F���Rw��s8mw1�Sl7UvZ�[ݦ�F�v� G܄}���نhC�-����C| �h�K�-�$W}�̽ �q�7��$F(7jjy���҆�[�[aL��_yw�>��@�_m

j�s
Ѿ~u�VS�i�X?.�����ll;|��b����הs����4D���`��l>x�n�gy�>�k�-��e|�	_�J    IDAT�F�o��c1�S3toR�˗�/��������нImtkRMk� �T	�(���|�˾��GOa�ޣ��f�\�_ߖ�ѨJyӯ[��ς����Q}�x�����8q�"��zk�~��������C�jhV#eK$�lq�d�ܥ+������ǰ|�!�ܕn=�2�'�}ʦ�jrIa�����񁝡�U�=�4~ڲ���H(]<wwo)�c�u���g����0�[

��

��

z6���o����)�U"�bD�f|]CC����y&�����a���t�G���Ѥ���˷j�2�	�vLŰ��-��d3���*���u��}x��}Y� ��:2%���wK�5���ĹK !��q-�2�W-'��e��ٹ	V�9��|o�W-����7�jy�^�2�԰%�Y�
nS��� ���*L\�k�U+���u��V���ѿ]�3p���7=à�P��̢��@�$&d�B|Я	q�sb&����{fդ�4?E����+��6��X����i�`� ���#��|E3K�0n��h׿\v� ڀ�p4����`j���4���%1�K+��{s���;B]�

2����~����6
�W�LXilY�O���m��W^��J��{���|�jDG@$]��jz����C$�mk�W�.�2����9��0EQ��Թ/�Ҷ�T� 	��~�𩦩�9 ��We"N���.�N�UKS˵DZ�`�᷀����M52���<|���jׯZ��kgL����	��O�����;����X�i'��B
���
���;�

���

n�8~u��W+j�h���i>X$���e��^�  �T"f����Y��+�zU~�~Og!? �b�h_�2n�����U�a���9�����5�����G��h�Y���%�v���

�
�

��˜��p�,ش������`#��f���!��J,����=q�6ƪ�%q�B6�������X�ܝ��A"S�돮/NÑ3<��,}�Ү��@�%����{�������	,Q�4�7µ� ����ڰnn�k�O�u#�Y���x]��8�|2s

�.��d�*�C�,LX}�Z簻?�/=��#y�c�3��x��Y�fu�z�~�8!wR�>^���ݐ^�����M��/R�+?oُg��?T�Y��e5xb@G[��K���+_��1̕�|���2���A�
dGE�O�׻��v��(����$���N	 �	qՕV�=�^�n �(��u,LY�𦂹��ষfh~�؜���tL������l=Q50(�x��u�7>��c��3��`uL	 ��BN.��v)���W���~S���

�mP�7�0(X�8��\��s�A[�M|�z��� &D�\��9�v2�e��1	�?�YX��n�%��3W��Ep�ub'��/_ŨIsԸ셋��a���8�Y���H�ߴs�����^�O(�Q�����6q��M�%i���i���C�g�<�r�����m��y�OJ�8@��oxG+i �3�c�~2�{|Y$So¼

�%˲e���6>�׊�\��9q~���\�Y�
����Ь�V�V)'�s���8�%>8�~��6B�ޏ��!e|�4y$�X	���]%�C�īĭ�A��R�ٙK��vx��՚ߪ��ܦ~�7<3c	r��M�� l��g�PH�GepD �qC�����Q

�e�

�

�co��8-�M����{SYma
C8�4eJ Q	����W:uTj2r��6(��s�R&	 4�ۮ`��-p��U���cǁ�T��Q�|Bвn5Gg�K6�6f�e��C	q�FM��KS��Y�.

�g

�

���
���v�&=�ܩ���`��|T�<��^׳[P;;���٬�{bX���R6ޤ$��1��p?����}�[.��Q�l�پ��6�j�kM��j���e~	 	2(�A�S�c~m(��l���w0R�2�N)gr�a��Y���p��ω�Nvi8d���HmB7w��	ѕw�~�ooEq���=�����* b�"bG��c4�M�&1��&1j4�c�-vQb{� �w�����SvfvfwvϞs�U�|��-���|�g �1lsk��V���5�@�z�(N`źF�x��x���Ƕ��
�ڶi���sXߟ8����
?���I=�εu�h�1�ZԷ/V�w;h�Ծm�#]����A��#,��O���f�F���b��ܢ��xt�������>�+}�+V����#6[D���j W	\ë�
i�

��O���u���IA �O�ڏ��+	�q}�4��җ�Z�;�}�=`7���

�ѺL��j~�,v�L9�gW�Ta[��� k0�\������9{��%��9��PM]u!f#�)�>T@4�,\i7������Z�rm�9�U
������ �T�@�̹��Ds��x�B�ϋ���}�m��V�/�*[ZH��/����~���<L�%� @J% TW(��'R��8>��⪻#G�g����8+l�:!
���}�<����zv��6u�v2�P
�װ��8��ZL�"�YP�	щu!��@��e~j`3�(i�	m�<��"��N�>pc������64���[#�zfa���I����

���
4�

���%>?ثv_  �s���|>�s���z��]oGL<�?L	

���7(k74�Ww<*�yȞ8b�H˓���1z������p)�͎N�;簽Rì5�D~%::�[{�^]�O�1q��;I��aH��k�,O���i~���W���}H�j	@&+�qrЬ��ȧ��~� �+|��f})�]�ɬM{��A;E�Nw�	vۆ)�Ͽ7�ή�K��6]~���1����:Ɔ1" )γ�v�̰�gC�̓_�n���&}��#��DN��s�����(-������n����I�;�'�~u���q� $M�+�طI�ܼ��X����W�3�zg������qD��	i��ڮ���ʘ���!1Y �
�

���' ��^����w���J�����(���~L������������S?���G��5�fɫE�2.kL�z���2m��7�W7��ʎ�������'ߛ�;�D���$�5a�@@%	ȭ��S�,��{����(I Dd��u� ��$�ZĢp��dYA-�Z������S�O�2&�4�����簾�e�-��>��?�,
>E�#e S��+��gY]��h���v�[�e����m�w>��rK�	�*v�C��Tdܸ����ɠ��v�Ϗ�_��E����}�������޼

s

{l

��

Voh�W}ĕ�������p�C/���ٖ��l�r����ˣɔ��K�,��9�Z�ܠl���8Lr�o ��PT6�T>���LR[1H��m%�5_�B/�xWJ*����� ����&����O�]XcJ�5!~�N�	5)���jh�e3�Ӓ�b['��'_b�]�9�٪!�4�~9.;�`l�;-�l�=:w����\������z`�;8�B�c�Sś�s��O���	c��U�_�J7��Y�y��G_}��3���Ek��b�z��[�����fx�bW��)	{�W��	�ۜ��Ny�\u�S��B*��^�<öM��

�?

g

s



���U��w'��Ƣh߶
&������|oŚu���Gq��O%�8b���h9P�|k	(��dv>�J�ጣp�ؑ ��ȱ#q�X������ (~���q�=S�;oѭ�*�}6ϼ��V��N�F�����˅�j�>�s�^dõ
��

���������G
��c���������!��3����g�����&e��S��/��|����hl.c��F,]��[�i_,���f�Ys@)Ѷ"QMi��'2@X���1�>�=�.Fn�'�M>��O׎�K���Wg�&L��m��D���F`|k�a���Wc�Z7?��{�����8t�-��á��5���{�q����s[��A�n]RV�Q!�g�U��r��$l�!���W�b�^�$-�Fs���o5V��(Y{5�cœTQ^�d�@�z�����J ��O	��^��-]��D��Wnӹ��uAߞ�ѡ]�]߈/-�ޫ�^];a�!���FݰQ��X�f,[�7>�󗹝�J(+���� ��-b�>=ѷGW467c���9w�{�7S%�Uw��mN �`�������m�Ӗ1`�n�۳+�76cъU���||�����9��&�) '��\�t������c���a�F�Ц���+���O����ɾ�:�k��m�hぽ)�%��mx��ѷG�ojƢ�1��y��K�W

�Y

�55�\

T

�

���J�
�Μ����'V�oT���. |�_���T%,���d�՝�+J> P�)��&��Q�������=����P))r� f�j5��A�%� r�SOǓ��<��w���h컪|EocS̷�X]h[��d��Σ�D]	�`�b�MU'��$�	��_��E��ӝ�F��e\�銜���W���ִ�����"�-.m�ŰM�6

�S��K!���>�"E J[57�Iz��؄ܢ|5��|H},��D���Ш?A�D��.��`щcV�4���-����1�*��+��ʂ|aV��a�%��I�4�\��"�~Nn�v��<M�: �O {�ςH�i��f�G'�+"�m�)�4�H�ǊW�ٸ[�����ET�����m�Z7D
O�)`aXF.+@�!ۄ������S�$G�\�٫��"S��m�}�w�){��;o��7N,��+����⮩�0����F{�4r��������}H�B>y�g}/	~�`'�QP�Ai3S�h����\q:+�Ϸ'R��l0�?y�&���ƑX��?�ky�Bc}��[��?�2O��t������T���,�K��A�m���TnY����i˲P��� ����=C���GI�=�W�p(.���ɚ��S�C���.'H����4`�

@�i�d����oAR�KrB�&؂��P�Lj�c���'-��V�X*s"���4(��,;d^�
ᶼ��@�_����$��7K�<Y����=���#�o��cFO_�F��;�&�3��:�\�S9�Yfv�.Tu�-�V9s��@�W���4D��v�Ğ��G���d}'	�	���I�-	�fy��C��$7s�xd���ZN�U�����ŒxIO�y��jjAV

1N�i���7��@JS�Bs�Y�䝴ꃸ���U���3�2��@c��I3U�oG��x�۷�
UL�LR�U�	�2AO��V���j~^�_Y딲���X�w�bL~B:tMy�g4o_6�L�i@ �_�R����KQ<��韲�-TS��yS{�F��ح���=e��e��	$���Zt�E	O9)F�rK����TS"�B5�0����D����S��i`�yW���J	�j�(뫬y��6F��!4: !��U怀�X�U�ll$�e�A4&P˽�P��5

�7

���/

�

�

�w%�B�_N%�Va��+�Z�<*j��i�A�&U�v�&�2"�����It�.��wl��}�ۮTY�U��_�1�~zܡ�Ȗ��-Ȥ�:R�s�bmg�܊�G�x)0$��4�i��D��O� ���"�@Z�hI?aE�

�

T

����

�9�x+���4�!��li�N��D����K�y�Ǖ_M
I[��Z�I����UW���^$0��V� �15�N:F�	�DՑTT�+Il+��4��eN$ %o�<�H����I������������Ӊ뙸2��! T8�bAi��X>�ZQ�߆��a��ߔwmQW� �'��ԯP0(�&�j!�aDn�O�B�
)��

����7

_��

��P��
I

�������oU}{�	 }�D0�G�	�4�L������ر�1~� �����G_�p�$:��%^���Pժ,'�K�ڲ=�V����H74��YCD�y�_���*|��HY��p�%�.o��B8NF��"�

�����w�M�R m�9�U�y#�f�};�?��궫��sS��.���;��r�.p��`�^I�������=��Muu�1�1��t��)Pձc^oA�� (������bU��� �t<� ��6�!`�O&�����w�wLe��Eos(�r~1sd�Т�r���ʒW[��7��VQ�&T�.DQ>������

i�
(�ӎ�@�u�
�Z;|�L����<��,ED��i�z�^AP���+�7#Фt� ���A@��

��i

��h


 �

�

���n�1m߶�l��yz>����jP��_���
���ϧ�#48�����:6o��&ӡ�krM�.I�Y��,ش�I� ��G�[�
׫

ѕ�[�������q�������Qt���ThV'��/�ƀ�fpʍՊ X-��$7ukn�����,���	&H�Q����ڒ�����/k��r��;�� ��eڃcI�m$S.dp)� Q����ԭ@��(>�4�	}�q�W�9�%o2�shU����V�1��MF����)���&�Y��6gP��|���{�ߥ7��� �?�q=[yL

�M>Jjf.vD֪���-߿�b�ypDo���1��o��4N�f��/�ߟ������2�7 [���~uJ4�;mDp +�� =�7V�]��c�Ӝ��%���t���S
)
�w!���ȅ

����֕wn4�Yi���D*�f$�D�3��qRsM�6l �%����r0_��"�EI# �75B�Y)�W�6;߬��ԕ�I��>VՓ�zȫoV���W�qJ

Z���q���

�m#gW3�1��Q��s.3�ޯ���+w��Q
K+���ok�ѝM���CsOyoɟ*y��/j�ќ����ݟx��_9���G�;2$�լ*��9Θwf��+�H�+b�{�Y �c׊a�C�{�Ϭ��BЬ�����[�62��xq�/���Q�w~�����Z?ehg�ˬ#n�y�<;k9E6�,X��G��� ?J����N^����\'[������@�Ղ`5߫Iq��O���ȁ�鼿�O��=�W���Ŝ�v�v�zT���my�rwM_A�l��=^����c	^���҉�	�[�������=hߟ�Ɉ�s��v����;S;�}��+��<�� ��.>����ET���{��-�)A>EZP[P?H�?�.����

�

#

�����}�

A��
�V����1/ǜ�Kʈ��bhű�n�� ��:��a�Z,�XP�s�tuܸ��YuO��8Tb?)/o2�&���uqs�Jʸ�C"���4"�� �r

b���
��\�

����
?~�M�8���|)�E;B ��P��Y)͐n�qυ�Ⱦ|�S3����r���sW��ǫ��޷?���8=۴�<��T�~�Q����"�����z̗WZ.E��	�Bk_H�N���i��-�� ��f����;�y*%(�5��wU�ņm* ��>]�機����t�\Z�N�X�ܦ��.W�-�����o��T�X+����a���*g��ж���c��j�����C�*Q~*�q


����

�s
�

G
�H���

 

�

�|�

 -R��Q��K�~�����\�âlΆ`�]b��DD� +b�?���@R|7H���> O�+ɸ��U����
�>

��"�m

%}:�Ä�è}{<{s���	    IDAT.��Cu!~:"�N���-FM֓��?;}�:l�.[�&e�8`��hݬ	^��3L��i��w.�Q�݉�n��͛�qY	�z����������%+�e�n4kT�A=;���C�=���'������ ۻ�́ξ�!���ÙwJ�.�1��`��Mx���b�&lٹm[4�A���q�qh���t\��������F8}�R���z�:t8�.[��I߮��|�SgG�ęc�¡�����"���JK����K�>�}�1o)Vp����cT�
<�����

� �+�

z{
�x�

Z5C��-q�w&���L �U�Y4*
�)}��Z\p�d,�j�UrS�����	Q�!����zY�+"`=��|�y�R���a���ӬÉ��K K�C�	� ���(��̒�������@�1�z >&�b�
~

�I)���*��[s��g�9��t��r�7�}�T�u�$�u/c��yx�\<��g��q�Cc �M1���,�[��L� ���,�����45�xD��+�(8�Ph!�}�	<8�և�3��{�G���qC)���xt�\���>�����% er�]1~=*z[���LŖ��
���

B��

"

'

�

K��
?
�Z

N���
�L�!��R-�2O������i+y,#��4�����h��̯v7����� �Z�91�|5>�b����� �S��aK_�FT�?Ic^	��|4�ztr
24��-��Xrc��,p��`��� �5���q̈��:tP||�5?���v��ObiE���Ť�m�����M��R����#�0����y,��D��~�P���ҘM1�&    IDATL��ܿQ�;��^��(?	��S)��e���e�{�G�_�HȔ5�׌a���֎	<�~,�2�����(pi�c��y�C
3h�ڶ����-+d\��H� �z�E�����#r`)�UG[� f�籰l�	_��-�<�+
���@�

681���¸�Cy�߬�H�C�V�o-��b��=����ʻ�I�6n��m`S�7FmQ!$0p�QDB�Αe��qSƬI���hT�M�.)_�>�1O3�I�2�'n��(���k���1߉��;��@�j���މ�F	t��A)E6�e��.��hI

n��Z�44�A���<g�����6cԕ���K&ᢣF������S��m��U��oOb��ɒl�d_.K�x[�	ݯ�ƥ�7�'M
�˂��|�|� � ��BBtfݻC�����r ���)�

�P4�eֶV;Šu橁Z:�܅��\I̩��:��%��a��أ^p���A��aޞ�!
������C˭�d��r��n������[��~��@�*E�ڣ�w{e���㹷����#�c��ooٹ��Y�_���>�,4��h/��A�ެo��4�U�aR�+��ۚ2%&c.*W���)�B^@�%2��RXt�P��� "~W �#�_��+�(�m� �*� �����9��|�>�'�

V������ʥ]�d+IB!�ǈG�1���+Ԟ��&UԲ��ؖ�R訔l��rmO[���A�B�w��j���rW��
dh�F���I�O�R"ʏ�4]�0��ׁ���o��2	A|�������3@4�[.��"�b���!M�:��D^�@�D�o�J�sP����trD�U/�/� � �@�U ���<d�j�����s��l�

�

�
G
�Y�

�u�

�

��%

���r
�1l��_

o

�

a

�᱘w]͋2�Q�	6<�FT;i+�	��89����Ϡ1,���ƃ8���I�a̦~�8��<M<�� �B�	~P�/	xe���	��޷����B�-�6^�˕Rx��|@�1��
��

m�4
�����H
`���Q�D�T�_Š�5�ӳ���<V95_SO� Q���*B3�0 #�҂PJ��֞���;��K�Dn���kQ�	A�k��`��O2Ȩ0T@����/g9
��fγ	|6���ٸ�
����1�����E��.�ǅ~�G�GA&�߳�h�[ހS� 6�Pҳ�FQp�%�/u2 5܃�zy�%�z���	�Q��BU�"8��B"�Y����@�
�V

�4���m��B����N(HQ��[�a��~/
�%	�ױ�A[9ė�PV��uR��醮���+ah����1QF�c��P}[A����H^�1��"PMGBuq���5 ���(n��

J���

���
 �

��

���

�]j�'L��qr��H2��5�u~�-�zw[4$�D0fo�χ��j��q�V�|����@�T���'��A�K��k��fw���b���)- .;o�L��e���ۧ#Zt�`+�ܞܕ��`���>	2 9 P*k�,�3"	Q�e�禠�" )�H�lnX���c'�a��EM�h$�m��G�^W|��-q_8s<�P�~�b�W

e�'��:� n�9���s\���������H $vpE(�2$�t"�`-I��S%ɛ]c��0���[M��UF��? �D��h��:j�ե�ߖ�n���FBJْH���#�w�S<і�yq�u)�̉�F��(Ə��� ($P�Q�"PlXů�\� &��9j���G�p(Q��`�xV��T�F���@¯nc�D))�#�h����N���Q��iuF!�P�	��`7���>���8eu똕( �g��E^#���0�0�>@��#+̵*	�&���(GuS)DQ�؃Fy�>��]3���coJ߻�iiÚ��ze2���*�K]֕ � ���F%�_�%��@&2@%���+J5�B�sdPp�
�$�����Q�b؝�'ڶ�	U���  �$mNOU�	�Ck�C?�	�d�8tRVy�4�6�s\�s�I�F��3�jm؈�%��{ۿ(�*�08�kM��P;�c^h�IF�PRSrS_p�; ~��
�Y܄�oe*8��qȠ�ӈA ���"�B�9��ؙ�EW6�3�@Lj�sk�D,mHQ �)�8���h�KlX� t� sY�{�D	4uP��,�8"b�U�P,,�(�H�ϓF(:�C�v

X���hX��6��&�UP>=�q>��;�m���ۦ����F��W"�+�4־�_�����uh��r�i �yn���K��R	�ڴ:4�F�2i�H.�ç�`�����J�9|":/�M��`p����v5T)���8?��:�5;s���������h�HN�G�z5Ю~6�fWF��d�MM 
ԭ\N�MA@�x�����MkTD��5ѪvUT)����D�OaΟ�1s�Z�:�{�{�%	�����T�23R�����E8q�<6�?���r���-8z�\�-�W�*�3R����h�]	u*�EzR�|>�/@���X���ۅ�w����(�<�6�a����[���qõ�qE�zh\-�������w�c�fB$�	6g����rʕ�<�����M (U,<(���]�zT��eC�:��.��6�4"�Ep

y�3 ���X6��N�"�|��$M��fI�[�0�q��+��
��c6B�MMq�ߌhR�A��@| D2��?V1���x��> �Iӿ�����eW(��F�ÐK.B�� �>oYP�YNU�{���Ӻ|sQ�E�\������G"�6Ψ_�"n��+Ftm���xǰ�m܁����r��

��

�
��>��g>_�:]�>	���w��d�?��r�4�x]_��z�~q6����V�t*�yp�T��9-.՜ۼR�\ӭ%&�ꅔDg�GZR��	�tn����������Ixhp��~��|s�r�I�8��i��/|�

��m��

=��

�������r��
a�

^��



J��


��Y	���QP0X�w����$�b�gK��NP>GN�łu;�az5wO����-6)V���-T����1PM�d���"Ç�VE�����5K+aHm�(9�\{ 1�-������BY#B�7�K��(���9^K��M)1����r����L?+ej雭ypi�"�oy��`��B�ZH`݊EɊ�D�~L�d'� +��ɫH#R�vI�

��[

�/�

L$��uI	��Id���P���r#����4��I��h��T��*��_����b}a$�eP�BN�,
.��k~���}���G��*�,�NY�A��&�yQl    IDATK�B.�(M�U�D�7c\V�ܲ���<����AA	,e�eO|=��Fj슕-�� vu

�

� �����>����s��x�,��	}�ļ�pك��<a7u�!H-����U#�>��;���C�u�&����i�A�5g	��~5��ٮX�̣����h�X�YL����,AB����G�z�}qC4�a�v��q�]ѯu�}d*6�1n�:x��+��=���x�ӹ�2l���:vT�����\�`V�:��'#=

v

y(��F�.c���p���	��Ca&1��$u;��1S����g��X��-���:Uݝ.T\��]S��ӟ�-6����*���I�ڬ��{����f	[�Ɲo~�K|Ys֜]�,�\lt���i�zٶ[�x�,y���Ű�W�V�4J�$�?�}ST*�&�7�bm�8�`Sϝ�^�6w��A�ɮ���i�V�{���w��uܑ�,]��6o�ͬ/	`��ī��j�Ow�_�'�ul�m{�
T����UL�&�N���ؿ�;(d�H%��>	T��~h����q��8@�J>P�&	$@� �|��y�Q��Cs4,���J����z��R�ua$�CW�h�I�WԣF^y��
�r

��8$

����%

T�e��a����JI��c�T�8P<�O |	 R<�'?��  2s8��@���x]��|��Ϭ���� �GMoc��u����j� �n��Q�Q�������5b�LV��

�V

>����Q5�Ɖ;�YvE�=6�?
�$�VŲ�բ6�uhb vD޹u :O����N �MB��+7c��?1�ss���5+�ӻ��L)
D-��

�n%

��4OB �s����Vli^R�]�[��vJ *+ZY�o?��
<�����V-{�N(����R&��"E	������2Jŵ��� uᡮ�u���[{*B�	���_J+oU�������p��4

p�
?�~x�������mwl�ԟx��}O��?��X��O�x���_�W�;wíf�w^��x�mx��=cV��W��Cx��]�p��|��    IDAT� �3NK(�$�v`hshj��@�����!�Q�$�K�c�]m\�R�OS��)�� �
�
����3�����
�u�s���܄[n?�������?�,|գ��*����}������j����x�|�H��~��/�ۯ�(~�;��}��$ ������o��>������������
"�$=>�γ����vϥ>�R��#+ 6���y<�U/gD����A\=6���?~_��\����g��m�c� ��ɧ��׾����I<�I��w~͗��x��Y��(�������W���+p�mw4����K����<�I�	n-���c�������[/"

�
?��'������'��m�(~�_�_��	�}�x>���@����]��C�q���{>�����w��k.�l��<@�̸��k�{�~~�e���o�wL�'�t��8�c~��[��{	������_�������*����׿

b�

�
���

��

�

O��/'r=,�Ħ�,��g���y��d1����@�^���m7q���-�{�u%�`�d��6���p|�5�j&C�������t로vxh4>'�R�v�%�`߫��Y'}2�ފ~��ѥ������� H�o����ؚ?b�J�C��J����t��gU���='��g2��/�sw����^�Z%�P/]��}���kC	,Q~M>���r`

y��
5��
�

cj:��Ϙ�&Fu�n=�����b�<���p �Y?�NQ�V��$�Ǉ��֒ ��/ lA*��V���F^T�_w�r�r�lj^��d�j�O��

���K.�+?�y�r�-�T�%�xY~����3 V'�#�r{��JR������!��fv[j�]z<��#Q��z2Z�e	e����ң�����<{��5h���C�"=y2���"s����&;k�T�ET���'Kh�c>j�1W��ިԕ�r����d!;O

 �
�E

F1

Z
��㳭W�K���6�x�����Xd��D�l��g'l�&I<�%o��qLގ��z.k9yT�ᗯs{����[M>��+�o��2R�7�u��OG�
��w.�gW�V��	o7�'�3i~��Lr�{	*L�˛���q�w��ʒ47ߕwmF��H�n�=J� ���:�D���iBST�`e�*7s[�HsH�&��1רdp�����5yS�E

X

X��

�

��y

�;�

4�ذ1#�fcF��7ƚ�kű؏h��>���4�`�0�j��ΰs�	&��R�	�&%��,d�7�A�P:

�	���鐌�M	�{:�]�b�,�+�k��1�Q�o{��r;��%f�9����2����ɠZ���f����:L�d��a7'h��u8>v��������0��K�(j���j��w�

�

��
�gY�w�tԼxH��y�`�ڀZo���M:$}(ב0��ㆌ�f(��,-#a7�D���O���o,M�6d���8�s�͘;�[�57��"��v��{�w��������Gշn���ɱ�ڼ},56�LJ/"< �c�]��/0n�Rۺ���ޯ+���ey�\C;&F�f��&{L��rN�xw�[�[�VfnN��3�����{v9 k����	��v���DN�]�J�/>�^(ǆ>m�B/v� ,]ߚ±��n7�������sI�D��*u�yw�dv�;�	G�p0bO&c'Z���.+��� �$���*k%�:"29E@���-�3^g�h�����x�>9���i�T��w�s���pY�h	cđ5����-���8f?_� D����

�9�

�

l�
���A�Or���&k6�cO��8M�3�W�������������z���)X+���	H;PP�ògIP�����f�C�������
��Z��߂3��<�8��V%�t���ѩ�КȊ����V{/�Y�9ÀWD � �7{�]&��5x=�O5�g��� �h��e��d��YO��:��e��ZFi�n#;d���u����J�rn���¦k

���zf�aS"�҆��� ��͘Q�
��ߞlc�k�ñU�q��%��	.��ɲx��-Iv;G��ZdP$�y�3��l)c�1@��SG���2��� j�Gu��K�D�_��j>�q� V9m6w�_.8����"k�{V��c'ef欤�>h͠�*� s��1�LX	��)��Eh��(����s����y�r����c��~I[K�'6��(�~��\J�o��'c�־��P��9'����l�2n�����oZp�.���
�

iK�n�$T����H&�w_��F��"�!�wB+: �>�A�+��)��}����g �(��\!�4:��9H�_�J ��A�E��T�+F�;V�d�;0 �x���i|;�J�"�.�(�X�����A� l�H�#�9�rK�*\�'���xpoD������	o��\Y���Nu]���y�b����ܘ�Jn�3iBs� �b� �l�n�^�=�<���6��!|D�Ʊѭb

.�?۱[�*���
�9µҘqi����Ń��Md�!�|	�y6j+<E�9��N9��+Do�n��9k�`d�R�5��\Uʿ]x\����j��l+�4�^`S�i��

>r�a#��:YƔ�8O��[�D��`��+�"}K��xU�&��ٱ�2�r7�@<~CWk��ʰK(�wS&�҇���]4���U��L��.�	��	���Bm1ic�-@4� � {�X>�wa�r`4��#l"��=��������Q��Fa�,�ʰ��ō���v��3Γ�=��~.�R:�{aĩ�z�|�hV$�v����I�ԽFO ��)�Ԙ���f���}Z���S�|)���\] ` m��>l���A[B,���6� 2�;�ӍS[
� �

��jj

�����b�̧��#�OYo�*=Y�w�&ז���T2z"��Fo�m�A�[=��|��1�����l�����Ub� T+Hz/�|�{���i���-Z+��ol�Hc���5���WUDG>/"X� �p��G����1g�g3���ƶu����1F�5�T��!�M �yvSZ����ht#���>�����6����`H�:>V~��+    IDAT���y9�DZ�4>�1�}@wR>G���ך���	������^�
�

C�r���P]� X���*��	D���wh*���X42Ϥ��˗�>��W�B� �W�`	7�u���Zq��.���ύ�Y�',���(����N	�˹G �&*ҳՙH�*�׫�=Ǝ#�S�.-_���XsF�|�

��q�
ܜ�

��.�

�b�N53k��	[�;�E�| �bh��	%r/

�� ,A�v�pX��)|��Ƙ�x�P�~
��	2N�O���W�	^wղ��ҸɔE,nZ���i9��ͬ|��X�����7$����h!!h��b���I�\`�,�u�����F˦PN3�vE �z�i(yQ�w^O��(_�D`�C�1�˼�/�v���o�z4�s�sd	�͑�±�Fb"
��h="m�H�ife�f/��x"�Z��1V@4�KL]Â�"�Zk��X��Zh�'~/C��Hk��D���|������|	s�+�	'#혳�F�hk{����c����	��j�v��O)/��灲���e�ҝ��נ�S������2E���	�-�
)��A�
^�

�

B
���

�#��f ��t��XcgQ-��X>�ā�I]l����m�R)���t5��)�N����?�w��G������=C���� ��u� V���#���O����MKHSJ^�l{,f����3Z ��H*-4�_o~"%����TIօ`�h=2�̉��-|Tz�k~�	J�F������H�����?�#���cgE��%�SK�z����n����c��Q�[0�S.ل�>����X��wŸ��Q�+J�4Rwy@�JE ��d�;
��h�h~�nTzY5u�DB��ݔf�L3	��� �1�^TMv���5�o������I�� X	��X

����I(U�W��~w�n°Ӛ�����gf�	���%e'GAV�Y�ˀ�KϕҢ��u�Ui�JȚ4�zY}e%�\j�DH`}��'a��ldܑ��o�&�� �̔	l�<��D|���t/�~�#��D�8�"�d��bq���C��	Sa`�-�c���6���6G�8�����xXȨN��ۚ�� �+�XX�z�.e*-3�����V(U�\��

���

�`�+c��H�6�@�S�S#�?v�'l@P��	 ��/�[�ĺ���<	c�ǳ�`�I��!ڷ�Xi�:M-W°�[We��9���

-�`ݦf�����׼���?���=�i����������S?G��r��'�ɫ����S`~	 �e��љ�QˤX�LF�9I�ws� ��?�	���_��VK�����'�

�_

~*

��
�5�

0�


�R����������<
��C
 
Z�

[
�\����(s��	,5m?	�[��=D	�A�g �3\�R>@

4d�
+�d����=���[�<4�,{��/��G����d�AP[�4 �0��2�>�c���ΕRHЁ ���&3+ �d��q������t�P =�����u�Nmc�v.�

��

�|p����
�
<�

�

\���Sy���k�=���Y����y��e1�st�	G�5����|�����|�c}����*hJ>���'s'(KlJ����I^����J�!��מzy���99W

�
�

�

�i

'�

�

�

3�����Y,`�Ú����q(ǧ���b�ц�k	�Aа����,���&묑�6VNIm�x=�l�~�v}�Y+�<l}��
s%�>����	��գ�{�& �C_�	?�7n���,�8'�2��\��>J't�\�_���׾�x��7���F�j�z�Ur#���� $0�A,6k�5�MKq��އ��
��

?��
���

Ej��
�

�!1��<��̟1iC�d�k��w�}c�O>~�la��g�P7��d�c�\�"z�9�n��Ay`�x���w�U�u)<R�ޗGK:r����66 j�
N�K�@]��S��r����ՀW�>^D�^qc���H5�C�E6<f@�Z^��ra�VU�a^d�H���.���Y�"�aF�5%c��Sモ�Ŗ �&@���ž}<���]h�kֈ��d|=(�N�~1�5�V2���ˉ06�0=�zlK/ꙶ����ާ�҇��}wߡ9�������tc������H�I!��q̑G��?�l<�� �

���

^��h�p
��

������

`1�e�����1�#��9Qc���:,�� ˦s���Y�>K\�
��$�">:�������������:K�`�/R^(wy���d޲9�y�a:��2F�@��V�Z,*�{s�7f ���i���O$7y���:r� `9N� �e8FzQjm3D��1��T7c���T-��v!O�����n+�e?�|<�2`����6|�Zw*`�-�h[�Z���=;���}ޣ����vU+�+�r3~�ǧ���>�T<�g�Y;g����{��;���`��9�ݚc���o�q�9�o��p����

_��

;�z

��(�B��K)������Y�jz��
�= ,i�*��ʮ�1��-E^� ��K��m;-Tl&f��de} ��5�*�� �)� �	b��4YA7�

�QQZD80k����(��prA�ĭ�/��_�}�M�@�S"�l�[�U'I�,�2�i@�9�	`-k�o7�4e^�*�G�Em��Y�S`b��β���P�� ��n
���c*)&%��[Ld���:c�n �N���� `�
���	�	(�{,��@y���	�&N�"��ml�՟�����Ŗ��]�1�L�	$�=�(3f(��6�A wKQ���b�QI�\ef44&d���'�҇��O� ^e K��

�a��

�

�j��
�i�%



�
'

��{��Y

�L��

j

Q�

���Ľ�来����������݀�vs{��4�z���fxi��� JCc� ��㩮��zSJ~o]*J�@����C�hL@~o-N�$G	m2���9���GVe��o|/���� �of�,|+lr���^���Tq��


i

S

�@����>��� WA ��VE�1���k �+�Nk��Y��R�q��B��T�MH��Ա@�e��>����}"� |��_	e�&�Z�Q>j��֬���

�����

g�
��i�

 �m

��]v6�7���UYY*�y�RHT��(�P��6�Ss���H(���L3�6 l��	��l��HyU��L�fzu��=��t9+��¢��y,�@��@�G4�����m�O�1я�1�suZ	Z���kfm~��T�А�-2������3,���Ș�����)=�, 5��j��������^c� �G�F��f7��w*`o^-�)�����4x GUy��qu�`���w_}->yݭEΞy��Í
��+

���V�X:�}c7����V����%kF	�j�ۀ`��*I��,Al�_�M�f�xZ^I���6�lMy[0P�������dV�r�A����������d�~J�����U^�H����DA��G�J���?_L�����jL����	��U�Y��0VJ�B�: 	���� ��*� ��|֒l��X�:��e�����:-8�v��

4�

��

��O�



�

�

�

���
�T
�

��

�
��

�����

_



�
�y

a

����

��?NH{�CnN��?����8��ǻ�*ǃ���0����GgP�[.�{c�O����d��~�7��S�Ӳ������d�x�FeW�<e=�Fr��D vi���z~�͙�%9<�Ʃ<���I��������f��4_�?�턦 ��}��s�v��Q8V�Z��Fo�+�t5�R^Oc;��J�-��T�)6@5Lʊ���������X�5��b-/d�
}F�\�u�i��<"���쭲r}+�F�P*�Sl�2�}H��V�Y%uwlp��{�HOfJ=@��{���� (Kd�fe@pWxǺ/B Ӊ�n�7���L��8[TϚ2�Gw���1�C��B�ik2`�,�l|��B,�y��r{�3^�o	'YI���:m��2��z;��S�S�@�G6ɧ���;���1mxg�� ��On�5���Q2_�]��q�S���8RBpƐmZ���ϗ �?zP��ʴ

I�
�

��

�
h�������
L�ȅ`
�$i+�-�	 ��#'�t �XF	��ZY�[k�� 2����*�k�Yf�)�J��<+�^Rz���-X"XK�[O\�׾ɭ

�2������P��j}�P��n�
����v��i;��L�|f<Z��.o	�Q�9�s��ΨM�p:� �էw��`�Ý��^M��D��s��. �y�z,G��}���* �`�yՊG�

��~
�λ�
z

�q

�

�,

��y�

�MwT�
h
����
l
y��ubdm7Vɒ�[�J�*���/3ʛ�&K�8vk$��z����K]��ɘ�T�m�5�t	q�G�λ��y���1�1:�_����+�Q.
Q���
��

 ��[������K+�>�\CKH%�\ѹ4�*]��zjiO<�N'�΍�0�Q�Qch���ͤ���:�?&�]�
ONd^o{��h���xiݶˌ���P�>�,�����%㶔v@64Urnk���Q�Ӵ�� ;���Yx���f�����a�<�W�i;&�o.Ǘ���.&���ـ�7��^�P����]��<�|bj���s�>M :�3�_wtl���;)����K)��H}	`"���t �z�N�c/��zD���:[�a��XV�o%ϴ�

?����Ay��zyY:r=$(L
#ΦsvΒ `�xb�3�OT�����a�{�e��z��؁�<]*B�6�0�K�����1��PY��)�-��@햓D��Q�e�/��'�9�@'IOo���w���'���-��׍[�a@A��)��3D�\9�b�M�=MF���|

���

�

hW����K
Y c\0v_+���	2��~����w�3��M��$9��F�q� ��6�g�l* ���(���J����;� �4���5�s�p���3Y��8wt5=nޜ:NI������@�[j��oj ��G�[�O�_��=�샏��Ͻ�=��E������w?4)M�� 0d]���S�����X�+��]�Ө��� `���!�@YP����[����w�;��F�x�U0^)���>�G/\�1�)��d��7�~ѠH�GtR���+�ECJ�p{�_`#�4�~��"��b$�5��d� 

`
}{
ze
d�8��X+��cwEo�!�z�q�ٿ��^��%�Q�8]��}��$i���&���'*�wԀc���l2?�`J�����J�:,Ss7Qj|�A�5)�q�c���M6�X�!��:�%C�f�9���2��	dO�S�@����H�ui���;�f�M�ԝ̑����G� b�I2�2��%

�

��

}��

�

��

�Hcy��F����8OY�	m7��:;�>�� ����a_R�����k�/$�H��I�cP� Y7l���H���D

�R~��?������k��?Ё֦�~�>|��G�Ea�Wq��y W/���¡e����P�U��.4`_N��Xc]�<�N�iu  �� ���9��9��ͯx1���o{�+�3g�;̌�/�������ǽ<�

*�<V*��I�M��d��e�y��Սw `�'�����:��t�ؿ/,4�R�@5��1M�/ې���?S}�_��P�S���B��yY�<�A��C�^�"}��o_"r~l�3��@����1��@��=Iͺf�NS��Z�ڳm��W���uܩ��H�}9��`��c��W|�Zc�������(���������3������@+�?����m��H���(�{A;��۴��&�%��I��˻'/7F���)�k/�=�~������8�����v����7����7�k^�2�{����o}����c\ޤ���֛����x��

R�

�an����l �YD0��ioLb^?����r��t p�Ʒ�Ě6��zж�K����@D�

����

C�

�

��>�5��X��d:�D%X�+�9��.�9*� �&[S +ƫ���qf/~��9S�	 tm�i_�� ���hI��[Ò�Lm��z{�IPÐ�J���~�|#>2m$F*M�� 
P2�횝x�P E�(�4	.�O���S	T�N0'����M��ֵ�����՟���'	��;p�1��g?�����hF!��

����8�eL��T����W9<� �8��{n�f������GO9w�4.�ee~Xb��nj�����|�T�&���}*���><(/7�	;F�GR*s�+;tA "�Ѥ_N�L�u`C!b`1���7"E��;�L:=�|s(=,Pj�2@ �{��:�o92�����+�$t奒�9G�_ʌ/�W.I�LD:���C� T�Vb� ��˱��On�����)����A/m9�_��	w�V�D4@ ��Ս�wR?MD,*o���	�찡K�/�b�6D2rd���W~o��3|x�x�T (.������1�Nެ�*��q+6��������[ zbq4�ju=���E�4�q�Q{�teAAa�V��@^nΪ��.��	ê��F

8q

��

�t���
G�

��
�7��Ħ�󙸝�	ˌ3��4��L��.M�'y��_Ć���B��>E���
\��1a"�y/7W�˲@MV,�b �	bZ ���2��:7���8>����֝z����Ѷ.����h�����r`5�%(u

u

c���x���ƵR~&I[�l �"�t8x� X��"�=�����Y;��!{=�@B	9H�k�"/�j��CtL��A�Ɂ��$��V@SP��Z�i°L	��S�����z�����S��4K�׶lco�UZ�,��vQSs�)��m�Sњ6O�y#���Yj�V�	�H���$�ǁ���bQ$�9+GK�IB4��O�kI���Ձ,�|PסD�����c+��s�>���Ջ����ں������J��Ǡ��K�|0� ��]ߢ%	wV�|��*?�l�O�o�}]W��:�����6���_�)�5r)Uc`�j��-?�#75�=�J�P���� ��0�Q_��������|��g�y�y�yݠr�V�:>7MƯ��U?��j*A@�`�(̝P�|��v�J:S

�

��

�
�

V

x
W.���b�AM�g_ME	�;�,�~ٺ��Fq�{Pi��:���_���^z3F���#�:x�-�7e4�O��`"��>&����8��7� ;���p�9Sp��Ѱ,�҂<L���eQ��}^�̑ ��:�qgz{�B�M��H��

7Q����
�M

�

0�

��

�(�
d
�J

d

�

�28B�J=��/�݆����!�U+�Õ��"�q>f���o��5;���[|�w�G�	m	�[��O\8�7�1l�G%�/5��	x=s Q����y�1Y���

�S�

1�ؑ���AE&Z[��J�킔�m�����^�<�Q2�����2���8��Fق��t���~�t�4|qє����]O���G�_ �%��kr��Mq����k� d=��z��)ݡ�� A�*�hK�h�=3̈́	<�>��U%E�

9��TbǑF�� �x%e]=� �� ?������j���?%Jo)n�Pj ���

	�
��y����x|���x���APR��
5`Pi1�K�$�!������8�� �.9nZ�v�8~�t�m��}� �k�QSQꊉeQ�������C�y��։�Wo�ʭ�<�~��()�B4#�$bgF[Ո恤��㓥B;�����7�jA�cj�������ѵ�Yz��(.���#��ɔ�ZڱqN����T{�ڶ�Uǲ�<\5g�}4�M6�����rt���E�_A� $���!G�i��Ti�|��Y{���W��	��;�� j��,�H�h�l�X

��+J��a<[��@~Nեš�S�ۻ{\!c�Ey�	���1���WVAہRP��5�<�^�*���#�����RuY1����OA�һ�X�f���mL��*\i	~��r�ƃ]B�qV�<�����5p���PY\�� W��_N#Wz>7-
��f4

�

ϯۚ�R)��}�$���p�{Yzu��.w��(?7���F���̕�v�4��Q���"\|��������Wa���R�-��!bx "��7���#���IUO��ї:���+?�1xY�ܽT�Y���ᅕ�gV ��ɱ3��ӄš�8<����[32{H��D�e�Cл]��4Sr�?��`�uC�R� ?��Pw'�X�(X�Wy�oYq&w(��eY f

��

�
����

ӱ2Ǩ{���
�_�8S�����.p�~�O@�>�٥>�0d:�^6Y���ؓ cNN'��j�Y��k?p��6���A@�,�v�	kHl�Q��$2�<ʡ:bi�da4��a�Y�dH���:~���~\�m�e��-�ڙFQ����'~�*����8���aZ>h��@#.��+��{�7r3!#�a$c���}f�;V8�{ZI�0�

~������

{�=

P

�
�#

�
O)��)L�f��&i��m ����m&+T�R����4oU�yo,�T����T#�h�j1^QS|�x����ij}	E_J���BB�iI���N�^$`^��#	-"�Y�Li؂�>mL�^I��X��T�^?mQ�}>��|,����R±W��C�a��

:

�o

�8Tmb &d-\]኎̐!�FU�PR��K�y-}Hws)k~��!ʮ���Q�7��@l|���o��h�j�	J�b���&���+aZ�̟R�B� $�RP�駫��Z�o�Xt|��NZ��[������&�9	H!�=j쀍�G��0��������]�1�$;l]k�7 D2.�KG�S��?������.d%�qInz��_k7��� ��m��|����]�k a�H�pk��9$���E|��x�2�����+

Y�

y�

�d
�X��~�|,�=��_/��g�lE�� (�/DW��|	s.�������+7���7D�]V��D�����|WϨT�����>�G�z

���)���D��{�;���a�oFE'� ��Ƌw^j����7�}�ASو����+�%M��0�6b-N�_�P�v�1 !�Œ�=v��[Y�ar�O,��3-�r��MoI�:]*[�w�ࣟ�O	�}
��

Z�7

{

�

X��

!NZzr"n�7SF�dS��q-�J����4,�V�ieEh������l[7^>�#��>�(�S<�~nY0}�><�a��\N�Ǖ�i��#��}U�S�h:FnY0sǗb����GU�*�HN��cp�24w��=�p��
��

���4U��Ƿ]�������?��������<���GߠO�s�l��e����N¡�f���0&o$Z��d ��dc�Z;QY����/2$���k�L|�ϯb ݳd&ғ�]�R�,�h�9�:u�/����,�any)&�*���X<i,n]8�I	r���k��� ,��S� �����xq�^�Pd���s'���f���p��!�G�ˉ�3*��u���߿�#g[  �%y��5
�
�W��./���D���?���M��MOê|����'����|�2$��(�������6� �my��ʊh������B�\� ן�7͟�_��

:�

R
L
���

��y��O7����7�w�߈Ǝn�T��N��vb���!n��b����6�i���)�u����7>�r3��ۯ�=Kg��J�h��}�m�ԕ%��̺}�3��������/���x����v�6��k}LC]rzJ���[r�z�Á ����8,�\�����p�����o�w��	F�� �����&iU�������.�/�ן[�9���g�`TN;zt

!���"

�

�

����

�����

�~�~��&�A|��+�;���	򐔀�.����~PP��}J�eD! /oޏY�J������i�����F����%9��H$�]\3�E�r������g����|�/��G����\�����f��m��ބ����e���Q��%ߌ(QG��>�6^|�d	q	|~<�v�|&���}x{�Q�_�%����m����ø�\|����y�,�

�� �Fx���4�X�K��P ���7ZX�'����X��"��o9�~�c�*���w ��@)� ��蠐l_I�ElE�i%�����i�5��c��Vuuq�w�8�6�2

 '=�y���wv���rܢA _v%�� �N.�����<���-��;a�ￍS�mh��  ���@��Ic����t��+z �
�

�
j�{�b��I��(��\H_�8�5c̮LH4�)�&pH�p��zJ��-�h��0=�0O�ۉ�+���DcTu�J�TX|�����^c�n��,*�7�k��^V�%�z�K �4��$�-%�.(�d�8X�D
���,ݬ������H$̦k<ʵ�E����`��C���Ɣ�Y���(0������W��= {� �������HML@�[�q�g��?܍6�DKw2R�p�/߃�ӗ��G{��_^�X�����r:P���;/����r%]N

��	P�R���\1�x.v�ʒ�� =k�����#Ta�f�Nz}���̻�@?/[�:����C K�W� N#��Ih;YY������ڪF|m�Έ�ӞL�Dv�~��K��_\j�����<�A�'l=��u�Ī$	T"PE�8 k�I�S�T �j�d,Y�pp9ѕol{DGC`Iej5e�S;�V�

6



�x

��
_�����6

 ёL'y@H�34�X��t��w1zI�8���QefE��KF����-Y!/�`:n��);�E��Ve+��-�Ł.�'C���ʤv�m���Ru�4	��f�N�yF�&biJafT�FK�� X;δC��.�E*���=�����`ZI	;F�	�(r
g

	��
B1<�

�;�b}s�;�ʑ�)�'����y9���+s�`�\��Re�f�� ��x_�zNn\�Jǒ�(��͔x"e�HF&���+��	BIm	��wީԡ-����<��aX~0�G *��\�����d��m���#�u��&ߩ>�z��gS���g��Z7��X�(!'Vj��n������R�

�������?����Ɍ��������	��_�)|�u�����4���}��?�n��,�s��%�՟�<����

��
km"?!썯�1�p$p75�:�����x��6�!J瑼G��5aR{�/���pb.�9QJ�fQ�B=��Ͼ���� ��3�7#�juH�S6X<bW���4�_����7���ȥ��n(}ƪ>_c�܌��N6�̒uP@��0٬��$�ܷق,B�.��C�p�t7�b=}b�6�_� �	��~��g~�o���{~?R ��}<�����{��?�9�N[��'��L�8��ج`U�Z�'

,���
e��[����G㣏��y��o�;�x�`�63��	a:O*�qip�~dz)'��l����ra	���r�uٚ�	p�BY����/��n��My�8�	��&���Z��$�z�
h�(��|
���p�s�=���M�����73���`�o��)�Ϛ��HX��p�A� �Y;�} ����Pŏ��g�;�� &��������'������w��U�&;��Sٹ
^�
�7�aɱK�d;���ye����W0�̈́�������R�V��t��|>����F�3�F2�����g\�H��mWv����� ������=cX"*�j�����sw��;���'��,C�Z    IDATd�!9���f-����

�

C��
/�^�
�

��Ȅ[�`si(䡷Q�j:YGl�9G��=�<^�xy���i��۝q�h�m'`b�yI��/x��K�@Uc��pX{�1Cxy`���#�՟��~���F���ڒ\Ij�[�7C���G�~�"4[u��!B(�o6��HA�n�{k�&�d���C�@���%�*o����F��yt��=�FI8��H�T{]O$8�u;<���3@�c�`�L����h#����2�5ֻ+1�Y�è �1W������ �eW>��5���)�Z�l,dv;��7�pD���`�r��a@�Ƅ�?���'�wd-^��#��X;���V�YK�5C��c/�ПB4KK�#���{�j��y�Z�83�_�
�o

�

_�P!J�nr���(Q�GO^�Q;�gn�LW/r�6�O�0�(���R]�!S�dPf��@��ɤ�f0��r��r-m����M��l���fw��Ը�G��۾�ѵ`���GVA��Ef)��P>qV��Khc��Cͽ��;':��c�9�*s6���Pu�+?SϨ��D8�T���f��O~���Lv�� ˪^*T��H��[{��;��w/ ���쑼��Y��l�ޏ���~T)b���2���O������3��ͅs L6�tF���[

��;������.�����o	�� � ��,x`}��i&��O����u��<
��
9h�=�

�U���+G����ωB\97D�c��{]�$�Ve|/kM)��E�~��*� r�����&涪Ƭ�G璿A.���Iא�Z?�[o�>;�t��eL��jx�cB������d�)�狗�%S|^W�U���� ����?���������g~	��_��~3���4gw2ِ޾��܀����/�r

�?

��i" �

����

v�

��tB|�O��W!��|���G vb$�6X8���	��u^K�����){�ܿ?O��[��i�% ����a�����&���:*yg|ق'v��M~��Ν��o��:�0�AK�)����#��Q�@?\"�SrC����O�h���h~�h{"m�i���7�h��偵Oݖ�Uy#,1kɫ��{�����u4������@��yN]��yLo"�@ �is�K�^��

�

���

�Τ���G(�
D�e��z�$�˚k� akB��P���Y�}s ��m�������rI�.ޖj
Y�����Z�pa��ʲ}-�M^��A�?	?i�OP���	���X�M:���|��ͻ��	Y����<�`��O�����q�ffg��������n��C��^�Aߪ�+�����T�o��6Y��}*�x`!�%N�˾Yl�cG�v��^����䕧a�`RF'�����o��P

�



�

N:�c�<�݅Qn��k�c���� �=*ڑ����M��Y���Є$��� f0۰��b�.�/A�}�<����'���J^�0��u�+��{��X�w"�Έ#��~��"�����Ef]�**H ��	�Q{��&��s��'�b"A{}�"�D5�@��4%��6D;<�E9)���\�%sҎ��� �,G 5���X�J�	mמ����F�Z���2}A��9�Z�#M�K����_

x�6Y;���^�v�1�(�����C�yZ=#�_d������Ʌ]��u^X��X�ύ��n�u��~�C `Ð��K���~�IDs�/z�/�"� T'�C�9� �'˅����t|R��	:����I˽c���

y

�w �|�Hm���ĄA�%IU�j&���A���6���Z'�*����2N���%�5<�+�j�ϏBܔ��J;�b���F�s�����M37�#�(��֋��m��t��L^Bq��B�VR-a-��~�$I6 �/�$����g�6�	28��y��m�c�(��W�ޟ�w,nd�������� +�<tF�g����Y��]�͖�.���-ut3G����$k�v �b�x���هH�g��|�(�[
�

�V�'/;
����	������

��

�u��
�c`��UA��4=B	��"HɧD�H�_�O�d�=��L��	��p0/!�*6��82~g�ĠW

�x#�ƻ��l(��o�� ���������� H<+�@0qt��_�3x}>|=9�q�wk��'�1�o.
?�    IDAT,��`�!O �`ȁ(ܬ$�Wռ� �2

b���Q3�b=���G��E`�!�O��+&������&�d�1ol�=,�ڹt��x�w����-�	K��\pa=��d�9*�'��-��� _9�;��.&�����-��&��>���`L�㼯�!��8m\�Ey7����{Or4��:�Dw�ǥuv��.��X��}����$��O����

b

����
z

��������h�?���Q���2�q����V*0��O~\�^8��', SY�ͻ0M�O��(9q�d��|In#��������po$J��Ơ�?z�I�k�ٶ���ܞ�	,��;��Wx�/�>$�{�R*.UgI��ġ^��q6��j�	�~E��j�q	�I�"I�:�֌K�F�+�]�W/�v��u��}�`�X��|=͠

�o
=�[��C����>��0��e�*�֔r�fD�	��aM�����`-,�#xQc��|�o|5�5��5,��˺S��)@�d��E`]�p�ap���Q5�׬��Uq"D'��/��u��F�.Q,�n�~��h���VN���o4�������j�Ɛ��?z9V��K��1������4��(B=�	*���}o�

�+
��9!�[]}t�cIAq�r�gN��?-�c���| ��v�nȲ�Yf��m˘�.{/�`� ����c���C�Q����3�|?�%���R �Q0�E��㗤G|߳�~wDI�8�

%�{

]oH:��&1m�佼�M�c8�YNž��E�#�*�Ǯ̴YR����֪�,��3��*B���p�> �< �� ��E���.��C�w1�(*v�W׬X]�mb


1���
=i

�
� ��
��G�
v�

�

Dh�

g�

�8�

S�S��,�����X

�� �
��,
\�

�

�����[�ͽ� �批�pq�0HhKG��Ȯ��@R�xYE����&�N�v�;���e]p���{l�q{����3�j�$���e ���~4sG�&�3pM9S�ɳ�;�n��� %���1ጜ���	 xp2��2��t��>�	�4���-uSXY2��tc���p��s�,��'**���^+�F�8�
    IEND�B`�



29_ONCODNA-COM-FOR-HEALTHCARE-INSTITUTIONS-ONCOFOLLOW-PERSONALIZED-LIQUID-BIOPSY-FOR-PATIENT-MONITORING

CirculatingTumorDNA(ctDNA)Monitoring

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogleTagManager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

OncoFOLLOW : Personalized liquid biopsy for patient monitoring 

Liquid biopsy

2 blood samples 

First personalized liquid biopsy 

Monitor the progression and detect lack of response

OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.

This assay is customised for each patient, as it analyses up to 15 variants previously identified in the tumour of the patient. In addition, it sequences a fixed panel of 40 genes associated with response/resistance to targeted therapies and immunotherapy, and/or frequently mutated in cancer.

In 2013, OncoDNA became the first company to launch a personalized liquid biopsy test. 

SAMPLE TYPE: 

All stage IV solid tumours in adults that have been previously sequenced (with OncoDEEP or any other test sequencing more than 100 genes). 

40 genesUp to 15 variants previously identified in the tumour 

MATERIAL: 

2 blood samples (2x10ml Streck tubes) 

Unique Gene Panel For Each Patient 

The gene panel is customised for each patient by selecting a set of patient-specific variants, which were identified in the tumour by a previous sequencing test (with OncoDEEP, or with any other test sequencing more than 100 genes 

A minimally invasive technique
From a simple blood sample, this minimally invasive technique allows to follow the treatment response very closely and identify new targets if the cancer becomes resistant to the current therapy, and it may detect relapse earlier than routine imaging technologies.

	OncoDNA scientific team regularly publishes studies in peer-reviewed international journals. We have selected for you the key scientific publications that highlight the clinical impact of our OncoFOLLOW test.

	Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor	

	The clinical impact of using complex molecular profiling strategies in routine oncology practice	

	EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy	

	Translational Cancer Research 2019	

OncoDEEP® 

Comprehensive biomarker test to support clinical decisions

OncoDEEP® offers a unique combination of DNA, RNA and protein biomarker tests on solid biopsies. In less than two weeks, OncoDEEP is able to pinpoint the therapeutic vulnerabilities of an advanced, metastatic tumor and to recommend appropriate treatment options. The test screens for genomic alterations (DNA & RNA), genomic signatures (MSI, TMB, HRD) and protein biomarkers of response to targeted therapies, immunotherapies, hormone therapy and chemotherapy. 

Smart and cost-effective liquid biopsy panels with selected key genes per tumor type

OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted and hormonal therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression. 

How can I order an OncoFOLLOW test?

Ordering an OncoFOLLOW test is very simple: Just log in to OncoSHARE and select the diagnostic test(s) you are interested in. If you do not have a kit for sample collection, we will send you one.

How do I get the results of an OncoFOLLOW test?

After sample processing and interpretation by our expert team, a comprehensive report will be available for you on OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient’s tumour. Moreover, you will also be able to share the report with your colleagues.

 What is the price of an OncoFOLLOW test?

For information regarding the price of our OncoFOLLOW test in your respective country, please contact our sales team.

	Cannot find what you are looking for? ! Our Scientific Teams are available to answer all your questions from Monday to Friday.	

 us

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

Contact

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712110917



30_ONCODNA-COM-CASE-MONTH-MARCH-42-YEAR-OLD-MALE-WITH-A-METASTATIC-COLORECTAL-CANCER

HighTMB,MSI:ImmunotherapyforAdvancedColorectalCancer

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySite Kit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

March: 42-year-old male with a metastatic colorectal cancer 

The challenge of colorectal cancer: diagnosis and treatment options

Colorectal cancer is the third cancer with the highest incidence worldwide and remains the second most lethal cancer. It can be explained by the silent symptoms of the early stage of the disease. Indeed, early diagnosis of colorectal cancer remains a challenge. Prevention of colorectal cancer is thus crucial to avoid cancer development. The main clinical preventions are stool based tests and invasive endoscopic methods [PMID: 34243011]. Colorectal cancer can be classified depending on the site of the lesion in the large intestine: proximal colon, distal colon and rectum.

A better understanding of the pathophysiology of colorectal cancer paved the way for numerous treatments options. The main treatments strategies are based on surgery, chemotherapies, targeted therapies and immunotherapy. Surgery has been performed at first instance in early stage associated with neoadjuvant or adjuvant therapy. Standard chemotherapies relay the backbone of colorectal treatment. There are used alone or in multiple combination of regimens including oxaliplatin, irinotecan, capecitabine, fluoropyrimidine. Side effects and limitations of chemotherapies has led to the development of alternative treatment. Targeted therapy in the treatment of colorectal cancer remains a key since the various signalling pathways involved in this cancer. The study of those pathways leads the way to the approval and use of specific inhibitors [PMID: 32296018]. Immunotherapy is also meanly use in the treatment of colorectal cancer. This cancer is characterized by a dominant DNA mismatch repair (MMR) signature leading to a high sensitivity to immune check point inhibitors [PMID: 36828759]. 

Here we will describe the case of a man of 42 years old diagnosed in 2021 with metastatic colorectal cancer. Surgery has been performed with chemotherapies. The patient shows signs of resistance to the adjuvant therapy. Therefore, a genomic profile of the tumor has been performed using the OncoDEEP solution. 

Genetic fingerprint for targeted therapy : OncoDEEP Panel identifies actionable mutations

The OncoDEEP panel highlights a high number of variants. Indeed, a high tumor mutational burden (TMB) and a high microsatellite instability (MSI) have been observed for this patient. The TMB represents the number of mutations per mega bases. The MSI is an hypermutable phenotype due to alteration in the DNA mismatch repair activity. There is positive correlations between TMB high and MSI high [PMID: 31502149]. Both are associated with sensitivity to immune check points inhibitors [PMID: 28835386; PMID: 28877075]. Indeed, the accumulation of mutations results in the synthesis of many neoantigens that can be detected and triggers the immune system. A MSH2 (MutS homolog 2) variant leading to a stop codon has also been identified. MSH2 protein is a member of the DNA mismatch repair system (MMR) which is a mechanism involved in DNA base mismatches repair. Alteration in the MMR system can be followed by the analyse of the microsatellites, which are short tandem repeat sequences of the DNA. Modification of the length of those short-repeated sequences, due to DNA polymerase slippage, can leads to microsatellite instability. MSI is detected in about 15% of all colorectal cancer and can be associated with Lynch syndrome [PMID: 20420947 ; PMID: 16106253].
Lynch Syndrome: genetic risk for colorectal cancer

Lynch syndrome is characterized by a pathogenic variant in the MMR genes such as MSH2, MSH6 (MutS homolog 6), PSM2 (post meiotic segregation increased 2) and MLH1 (mutL homologue 1) or by a deletion in the EPCAM (Epithelial cell adhesion molecule) gene that regulates MSH2 expression. This syndrome increases the risk to develop cancer in the gastrointestinal and gynaecological tracts, notably, colorectal cancer and endometrial cancer. The prevalence of this inherited condition is about 1 in 125 individuals in the general population. Colorectal cancer related to Lynch syndrome appears at younger age and represent about 3 to 5% of all CRC [PMID: 35812033]. Guideline highly recommends using immunohistochemistry against MRR genes or microsatellite instability testing and more currently the use of next generation sequencing of a specific panel of gene, including MMR gene, on all colorectal cancer to guide the patient through the best treatment option but also to identify relatives without cancer that can benefit from a high surveillance [PMID: 36077639]. Depending on the MMR gene mutated, the contribution of Lynch syndrome is not the same. Indeed, the protein MSH6 and MSH2 form a heterodimer that recognize and binds to a DNA mismatch and trigger a conformational change of the DNA. Then, the heterodimer MLH1 and PMS2 recognises the mismatch sequence and induce degradation of the wrong DNA sequence through the recruitment of an exonuclease. Finally, the correct sequence is synthetised by polymerase. Therefore, loss of function of MLH1 or MSH2 protein are responsible of 60-70% of cancer related to Lynch syndrome. The germline variant in one of the fourth MMR genes induce a predisposition to MMR dysfunction, but a second hit is need on the wild type allele inducing a biallelic complete inactivation. Indeed, some patient with Lynch Syndrome will not develop any cancer. This complete inactivation induces a mutator phenotype, a microsatellite instability. In this case, the MSH2 variant has been associated with a high microsatellite instability leading to a sensitivity to immune checkpoints inhibitors. In MSI-high colorectal cancer, pembrolizumab and nivolumab with or without ipilimumab are FDA approved. Therefore, this patient can benefit from PD-1/PD-L1 inhibitors. The identification of this variant in this patient also highlights the need to screen the patient’s relatives for Lynch syndrome [PMID: 36077639].
OncoDEEP Panel identifies Lynch Syndrome risk: immunotherapy option and family screening recommended

Through the Oncodeep kit panel analysis, it highlights the potential sensitivity to immune checkpoints inhibitors for this patient based on the high TMB, MSI and the presence of the MSH2 variant, which highly recommend a screening of patient’s relatives for Lynch syndrome. 

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 White paper
Ensuring a Robust DNA Analysis and the Best Clinical Interpretation by Generating a High-Quality Data Set5 min readingJun 6th

OncoDEEP® Kit enables laboratories to achieve and consistently replicate high-quality sequencing data regarding coverage and sensitivity. Based on analytical performance this Whitepaper assesses the precision of OncoDEEP® Kit while measuring the repeatability and reproducibility. Combined...Read more →

 Scientific Application Note
RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure.Jun 22nd

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma IMPORTANCE Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the...Read more →

 Video
Decoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment5 min readingNov 15th

Join us in this video as Marcel Trautmann, Head of Molecular Diagnostics within the first German Department of Pathology and member of the German Network for Personalized Medicine (DNPM),  shares his firsthand experience with OncoDEEP®...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712101356



31_ONCODNA-COM-CLINICAL-ONCOKDM

OncoKDMturnsNGSdataintopersonalizedclinicalrecommendations

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Clinical and biological interpretation (OncoKDM) 

Clear data insight and clinical interpretation 

	OncoKDM®’s comprehensive interpretation reports provide labs with eight essential assets to enhance the understanding of NGS data, including detailed annotations, a list of actionable variants, a list of therapies recommendation and a summary of relevant clinical trials.	

Watch KDM full movie

Analysis details and quality control

Accurate and reliable clinical interpretation of genomic data is essential for labs. OncoKDM provides the necessary views to labs to ensure the quality of sequencing data by enabling them to control key values. However, if labs require a deeper insight into molecular data such as hotspots, they can utilize the advanced Mercury platform.

Our comprehensive variant analysis allows labs to discover all relevant variants detected through sequencing, which are categorized as SNV, INDEL, CNV, AMP. Additionally, we classify each variant based on its biological and therapeutic impact, using the TIER classification system that follows the established ACMG/AMP guidelines ensuring labs receive detailed and accurate information about each variant's potential clinical significance.

In addition to identifying individual alterations, the OncoDEEP kit also focuses on complex genomic signatures and rearrangements, such as HRD, MSI, and TM. Our process includes scoring and reporting the expression of these signatures into OncoKDM, enabling labs to access a comprehensive overview of their patients' molecular profile. By incorporating these signatures into the analysis, we provide a more complete picture of the tumor's biology ensuring the best clinical interpretation.

OncoKDM treatment recommendation provides a clear overview of the most effective treatment options based on official guidelines and clinical evidence, ensuring that non-responders are spared from unnecessary toxicities and ineffective therapies. We list each drug with its associated biomarkers and approval details, allowing oncologists to make informed decisions about the best treatment for the patients.

Easily find worldwide, relevant clinical trials that have reached at least Phase 2, based on your patient's specific condition and molecular profile. With our advanced search capabilities, you can quickly identify clinical trials that are most likely to benefit your patients and provide them with the latest treatment options available.

Our comprehensive reporting includes key findings, simplified pathway analysis, and treatment recommendations based on both molecular and clinical evidence. This allows labs to easily understand the implications of the molecular profiling results and make informed decisions about the best course of treatment for the patients.

The most advanced technologies coupled with our clinical expertise 

	Our BioIT team is dedicated to ongoing advancements in algorithm development, ensuring precise variant calling and accurate calculation of specific signatures. By integrating our proprietary knowledgebase, we harness the power of sequenced data to generate meaningful clinical recommendations. To ensure utmost reliability, our biologists meticulously validate these recommendations before they are published as comprehensive reports within OncoKDM®.	

	OncoKDM® is CE-IVD *, HIIPA * and GDPR * compliant / CE-IVD :European CE Marking for In Vitro Diagnostic medical Devices for safety, and environmental protection standards for products sold within the European Economic Area (EEA) / GDPR: European EU 2016/679 General Data Protection Regulation (GDPR) for personal data storage, management and security /HIPAA: Health Insurance Portability and Accountability ; American data privacy and security provisions for safeguarding medical information.	

"Every new feature we release is carefully designed to not only provide 
users with a solution but also provide them with a real value for their job."

No matter how comprehensive or focused, commercial or custom your panel is, OncoKDM® embeds a large library of BioIT pipelines enabling a seamless clinical interpretation of the NGS data. 

• AmpliSeq for Illumina BRCA Panel• AmpliSeq for Illumina Cancer Hotspot Panel V2• AmpliSeq for Illumina Focus Panel• AmpliSeq for Illumina Comprehensive Cancer Panel• TruSight Tumor 15• TruSight Tumor 170• TruSight Oncology 500

• OncoMINE Comprehensive Assay Plus
• OncoMINE Comprehensive Assay (V3)
• OncoMINE Focus Assay
• OncoMINE BRCA Assay

• Solid Tumor Solution

• Human Breast Cancer Panel• Human Colorectal Cancer Panel• Human Lung Cancer Panel• Human Actionable Solid Tumor Panel• Human BRCA 1 & 2 Plus Panel

ClearSeq Comprehensive Cancer Panel

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712124025



32_ONCODNA-COM-FOR-LABORATORIES-ONCOCDI

OndcoCDIanOncologyData-drivenDecisionvisualizationtool

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogleTagManagersnippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Clinical Data Intelligence (OncoCDI) 

Enabling clinical data-driven decision 

Over the past decade, there has been a rapid acceleration in the innovation of cancer diagnostics, treatments, and patient management. As a result of this acceleration, a tremendous amount of data is now generated. When this data is interconnected, it has the potential to provide oncology experts such as laboratory, Pharma company or academics with a comprehensive insight, enabling data-driven decision-making. 

Uncovering trends 
by using real-world data

Uncover patterns, correlations, and trends that were previously unseen thanks to your integrated data and by leveraging advanced data analytics techniques, such as machine learning and predictive modeling, oncology experts can extract meaningful information.

The best data visualization upon your needs

Whether you are a research centre, a laboratory or a pharma company the initial question is still the same: What would you like to get from your data ?

Because there are a variety of data sources, OncoCDI value proposition is providing you with the best visualization wherein all real-data are integrated, curated, validated and thus reliable. 

Define data and analytical needs
What data would be needed to answer the questions ?
Where does that data exist and is it accessible ?	

Clean, format and validate the reliability/accuracy of the data 

Clean, format and validate the reliability/accuracy of the data 

Leveraging from your internal data associated 
with OncoDNA’s extensive knowledgebase

One of the key advantages of OncoCDI is its ability to interconnect your sample-based molecular and clinical data with the extensive OncoDNA’s knowledge base allowing to unlock the full potential of your data.

This integration allows you to tap into a vast database of scientific and clinical information, enhancing your understanding of the molecular profiles of your patients and their associated implications. 

* From a global database of more than 120.000 samples 

Generating value from your data

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712110922



33_ONCODNA-COM-CASE-MONTH-FEBRUARY-40-YEAR-OLD-MALE-WITH-A-STAGE-IV-GLIOMA-CANCER

StageIVGlioma:PersonalizedTreatmentwithOncoDEEP®Kit

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

February: 40-year-old male with a stage IV glioma cancer 

We describe the case of a 40-year-old male diagnosed with stage IV glioma cancer in 2023. This patient presents peritoneal and liver metastases. Initial treatment involved Temozolomide chemotherapy.

Gliomas stand out as the prevalent form of malignant brain tumors in adults, originating in the glial tissue and developing throughout the central nervous system, with a predominant occurrence in the brain. While the incidence of glioma is relatively low in the population, they cause significant mortality and morbidity (PMID: 24842956). 

Clinical interpretation and analysis results

Adult diffuse gliomas refer to tumors originating in the central nervous system (CNS) with widespread infiltration of cells showing characteristics of glial differentiation. These tumors demonstrate variability in treatment respond and impact patient prognosis. Furthermore, even within the same histological subtype, tumor development can differ ((PMID: 32271284).

The genetic profile of the tumor plays a key role in its development and subsequently influences their behavior, response to therapies, and overall clinical outcomes for patients. For these reasons the World Health Organization (WHO) classification of glioma has evolved since the past decades to integrate molecular feature such as the mutational status of IDH1 (Isocitrate dehydrogenase 1) and ATRX (alpha thalassemia/mental retardation, X-linked) or the presence of 1p/19q codelation. Indeed, WHO classification of 2007 was almost only based on morphologic features but it’s in 2016 that these molecular markers were included (PMID: 27157931).

The most recent update to the WHO classification was performed in 2021. This update refines and expands upon the molecular and histological criteria introduced in 2016. Some of the significant modifications include the separation of Adult- and Pediatric-Type Gliomas and introduction of new biomarker such as FGFR (fibroblast growth factor receptors) alteration or H3K27M mutation. This relatively new classification is illustrated in the figure below (PMID: 37069792). 

Fig: Flowchart of 2021 WHO Classification for Gliomas 

The patient treatment is based on temozolomide regimen which stands as the only approved first-line therapy for this tumor type up to the present date. Temozolomide, an alkylating agent, exerts its action by delivering a methyl group to the purine bases of DNA. This mechanism effectively inhibits DNA and cellular replication (PMID: 22122467).

Using our OncoDEEP® panel, we identified the presence of an IDH1 R132H variant. No therapies directly targeting IDH1 alterations are currently approved, although therapies targeting mutant IDH1 are currently in clinical and preclinical development. Notably, it has been reported that variant in IDH1 could lead to a BRCAness phenotype and therefore, PPARP inhibitors might be associated with a clinical benefit (PMID: 17325041; PMID: 23558169; PMID: 23680144).

We also found a stop codon in the ATRX gene. This variant induces a truncated protein leading to a probable loss of the function of the protein. It has been reported that loss of function of ATRX triggers ATM phosphorylation and finally restrains the activation of downstream proteins of the ATM pathway and could affect the DNA homologous repair mechanism (PMID: 29378238).

Additionally, we found a deletion of two copies of RAD51B gene. RAD51B is a member of the RAD51 protein family involved in the homologous recombination repair (HRR) pathway. Loss of expression of this protein could induce a deficiency in the process of homologous recombination and could thus be associated with a clinical benefit to PARP inhibitors (PMID: 30551670).

These data together confirmed the diagnosis of adult diffuse glioma, grade 4, as the patient’s tumor exhibited mutations in both IDH1 and ATRX, and no 1p/19q codeletion was observed. (see figure).

Although Temozolomide is the only approved first-line therapy for glioma, the OncoDEEP® analysis revealed distinct mutations associated with ongoing clinical trials, particularly those involving PARP inhibitors. The inclusion of PARP inhibitors in these therapeutic approaches opens novel possibilities for glioma treatment. 

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Case of the Month
March: 42-year-old male with a metastatic colorectal cancer2 min readingMar 18th

Here we will describe the case of a man of 42 years old diagnosed in 2021 with metastatic colorectal cancer. Read more →

 Scientific Application Note
OncoDNA supports the AURORA study to identify molecular changes driving metastatic breast cancerJul 6th

AURORA, an international molecular screening program conducted by the Breast International Group, has uncovered genetic pattern specific to metastatic breast cancer (MBC). By performing multi-omics profiling on primary tumor and paired metastases, the research program succeeded...Read more →

 Press Release
C2i Genomics partners with OncoDNA to bring AI-powered liquid biopsy for cancer diagnostics across EuropeJan 10th

This partnership marks C2i’s launch into the EU and a first-of-its kind interventional clinical trial led by the Gustave Roussy Institute in France C2i Genomics, a cancer intelligence company, today announced expansion into Europe through...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129227



34_ONCODNA-COM-PROJECT-CARE

ReceiveCustomerOnboardingforOncoDNAservices&products

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

A commited team to providing you with assistance at every stage of your project 

Our support teams composed of s (FAS), Product Scientific and Customer support will be by your side to assist you and guide you throughout every step of the process, from sample preparation to data interpretation. They are dedicated to providing you with the necessary assistance and expertise to ensure a smooth and successful experience. 

As part of the implementation process, we will provide you with protocols tailored to your specific needs and offer advice on the most suitable equipment for running the OncoDEEP® Kit efficiently.

We optimize lab process by beta-testing the OncoDEEP® Kit using lab’s data that have been already processed. By comparing the results, we can improve the process and aim for the best balance between operational time and cost optimization.

Our Field Application Scientists (FAS) will arrange an onsite wet lab training session to assist you in achieving optimal sample and library preparation for sequencing.

After sequencing, our dedicated customer support team will guide you through the process of uploading your data to our cloud platform, providing any necessary reminders and outlining specific requirements to ensure your results are promptly and accurately analyzed.

Once your data is generated and analysis-ready on the platform, our expert customer and scientific support team will provide you with OncoKDM or Mercury software training, ensuring that you feel confident generating your final reports independently.

If your team have any scientific concerns regarding the analysis results, they will have the opportunity to bring them up during a dedicated meeting with our scientific support team.

Building strong customer relationships through training fosters long-term partnerships by establishing trust, collaboration, and customer confidence in leveraging our products to achieve their goals.

Field Application Specialist

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Lab Case
Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies5 min readingSep 29th

What is HRD Genomic Scar? The HRD Genomic Scar (GS) is essentially a collection of genetic changes or signatures that indicate a cell’s inability to repair DNA damage effectively using this specific DNA repair pathway....Read more → Lab Case
Revolutionizing laboratory operations with OncoDEEP® Kit4 min readingJun 18th

Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712118998



35_ONCODNA-COM-FOR-LABORATORIES-MOLECULAR-RESIDUAL-DISEASE

MRDpredictsthechancesofcancerrecurrenceorprogression

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySite Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Molecular Residual Disease (MRD) 

What MRD is? ​ 

	Molecular Residual Disease (MRD) testing is a powerful tool for predicting the likelihood of cancer recurrence or progression, surpassing traditional methods, and informing treatment decisions through the analysis of circulating tumor DNA (ctDNA).

Rapid generation of the patient-specific signature

Actionable
insights from a single blood sample

Real time cancer monitoring with a single blood test 

After effective medical treatment, such as tumor resection, a small quantity of residual cancer cells may remain in the body, undetectable to the resolution of standard-of-care imaging scans. MRD testing enables the identification of ultra-low levels of cancer cells present in the body. 

Uncovering trends 
by using real-world data 

Circulating Tumor DNA Allows for Early Detection of Recurrence And Precise Measurement of Tumor Burden.

Our ultra-sensitive test detects molecular traces of ctDNA through comprehensive tracking of the entire tumor mutation signature including aggregating complex features such as CNV and SNV. Therefore, an ultra-low number of cells can be detected compared to standard-of-care imaging. 

Our standardized workflow from the test shipment to providing MRD report has been designed to ensure consistency, accuracy, and efficiency at every stage of the process. 

After confirmation of the order, we dispatch the test kits 

After confirmation of the order, we dispatch the test kits, which include a solid biopsy block/slides holder and a barcoded blood collection tube, to the designated medical institution. 

Filter out noise and derive patient specific cancer mutational signature 

We identify the genetic pattern of a patient’s tumor using thousands of data points across the entire genome. 

MRD technology utilizes artificial intelligence that recognizes patient-specific cancer patterns 

AI & Advanced Signal Processing

MRD technology utilizes artificial intelligence that recognizes tumor specific genomic patterns to provide unprecedented acuity in cancer detection and monitoring. 

Our team of oncology experts reviews each report          

Clinical validation by scientific team

Our team of oncology experts reviews each report before making it available for the clinician 

A technology that enables a faster time to market for pharma companies 

Increase clinical trials efficiency 

Enhanced efficiency, reduced overall costs, and achieve a clearer demonstration of the long-term durability of treatment responses. 

Enable Pharma partners towards genomics-driven drug development, leading to quicker and more cost-effective drug development. 

AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer
Sensitive detection of circulating tumor DNA by whole genome sequencing (AACR )
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers (AACR)
Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC) (AACR)

What is MRD (powered by C2i Genomics) test and what does it test for?

C2inform is a personalized qualitative diagnostic tumor informed test for the circulating tumor DNA (ctDNA) – based Molecular Residual Disease (MRD) assessment by using whole-genome sequencing (WGS) data for patients previously diagnosed with solid cancer.

How accurate is C2i Genomics MRD test?

MRD test is designed to be highly sensitive and specific. It can detect extremely low levels of circulating tumor DNA (ctDNA) in a patient’s blood, allowing for the identification of residual cancer cells that might go undetected by conventional biomarker tests.

What information does the test report provide?

MRD test provides results in the form of a binary score (positive or negative).

What does a positive C2i Genomics MRD test result mean?

Test Positive: Estimated detection score is above or equal to a pre-defined threshold value – indicates MRD detection

What does a negative C2i Genomics MRD test result mean?

Test Negative: Estimated detection score is below a pre-defined threshold value – indicates MRD non-detection. A negative test result does not definitely indicate the absence of cancer. 

What type of samples are needed for MRD testing?

Data is generated from WGS analysis of the following specimen types from each patient: Tumor tissue sample (Formalin Fixed Paraffin Embedded (FFPE)), whole blood for both germline DNA from Peripheral Blood Mononuclear Cells (PBMCs), and plasma for circulating tumor DNA (ctDNA).

What is the turnaround time for my MRD test results?

The turnaround time is 14 Days.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129159



36_ONCODNA-COM-POSTER-WHOLE-GENOME-CELL-FREE-TUMOR-DNA-MUTATIONAL-SIGNATURES-FOR-NONINVASIVE-MONITORING-OF-PEDIATRIC-BRAIN-CANCER

WGSctDNAMonitoringforPediatricBrainCancer

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers 

Case Study : 6 y.o. M, Dx of medulloblastoma, Group 4, s/p gross total resection of the cerebral tumor, with spinal leptomeningeal disease. CSF: cytology and ctDNA negative on follow-up.

Case Study : 6 y.o. M, Dx of medulloblastoma, Group 4, s/p gross total resection of the cerebral tumor, with spinal leptomeningeal disease. CSF: cytology and ctDNA negative on follow-up.

Case Study : 6 y.o. M, Dx of medulloblastoma, Group 4, s/p gross total resection of the cerebral tumor, with spinal leptomeningeal disease. CSF: cytology and ctDNA negative on follow-up.

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer via blood samples has faced challenges, mainly due to the minimal tumor presence and scarce genetic mutations in the coding regions. Our research proposes using a whole genome sequencing (WGS)-based, unique mutational signature, derived from a tumor-normal WGS comparison, as a highly sensitive and specific method for identifying mutations in circulating tumor DNA (ctDNA). This approach aims to facilitate effective blood-based monitoring for pediatric brain tumor patients.

Study Approach: To categorize the tumors, we utilized whole genome DNA methylation profiling combined with a machine learning-based classification system. DNA from tumor samples and normal germline DNA from white blood cells were extracted, alongside ctDNA from 1-2 mL of plasma obtained post-operation or during follow-up. We applied WGS for detailed sequencing of DNA from the tumor-normal pairs and plasma samples, achieving 40x coverage for tumor-normal DNA and 20x for ctDNA. Employing the C2i assay, we generated a tailored mutational blueprint for each tumor, complemented by an AI-powered error reduction technique for ctDNA quantification and detection in plasma. This established a patient-centric catalog of somatic mutations, with ctDNA levels assessed during treatment or monitoring intervals, using AI to refine the accuracy by eliminating background noise from cfDNA and enhancing the detection of ctDNA based on the unique mutational signature.

Findings: Our analysis encompassed 7 pediatric brain tumors, including medulloblastomas (Group 3 and Group 4), pediatric glioblastomas (IDH wild-type), an ependymoma (PFA subtype), and a low-grade ganglioglioma. We successfully identified tumor-specific signatures in 5 patients exhibiting clinical disease, with tumor fractions ranging from 0.02 to 0.0005. Conversely, these markers were absent in patients without detectable tumors during blood sample analysis. Notably, in cases of medulloblastoma and glioblastoma, a progressive decline in ctDNA tumor fraction correlated with therapeutic response, as confirmed through imaging.

Implications: The application of a patient-specific WGS-derived tumor signature in ctDNA from blood samples presents a novel and effective method for the sensitive surveillance of pediatric brain tumor conditions. This technique underscores the potential of precision medicine in enhancing the monitoring and management of this vulnerable patient group. 

 us to find out more about our services

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Scientific Application Note
LYMPHOMA The FDA have approved the EZH2 inhibitor tazemetostat in folliciular lymphoma, third line for EZH2-mutant disease, or where there are no other treatment options for EZH2 wild-type diseaseJun 22nd

FDA granted accelerated approval to tazemetostat for follicular lymphoma On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or...Read more →

 Video
Decoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment5 min readingNov 15th

Join us in this video as Marcel Trautmann, Head of Molecular Diagnostics within the first German Department of Pathology and member of the German Network for Personalized Medicine (DNPM),  shares his firsthand experience with OncoDEEP®...Read more →

 Scientific Application Note
Endometrial Cancer Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002)Aug 11th

Abstract Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P),...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Contact

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712100891



37_ONCODNA-COM-WEBINAR-ADVANCING-PERSONALIZED-CANCER-TREATMENT-EXPLORE-THE-SYNERGY-OF-TWIST-BIOSCIENCE-AND-ONCODNA-IN-OUR-WEBINAR

Advancingpersonalizedcancertreatment:Webinar

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar 

Unlocking precision medicine through expert NGS panel design 

Tuesday, February 13, 20244:00 PM CEST 

By Dr. , , 

Join our webinar to discover revolutionary insights into personalised cancer treatment with OncoDEEP, learn more about advanced genomic signature identification, and see how leading German healthcare providers are implementing these innovations in clinical settings. Don’t miss this opportunity to transform your approach to cancer research and treatment!

!Please note that places are limited! 

5 reasons to attend this webinar 

A comprehensive overview of personalised cancer treatments: Gain valuable insights into how OncoDEEP can transform your approach to personalised cancer therapy.

Expert panel design for complex genomic signatures: Discover the methods used to identify complex genomic signatures such as HRD, TMB, MSI and LOH. Learn how these techniques are helping to advance cancer research and treatment.

Innovative technology in cancer research: Understand why Twist hybrid capture technology stands out in the field and how it improves test efficiency.

Validation and adoption in the real world: Learn about the practical application and validation of the test, and how it has been successfully adopted by one of Germany's largest healthcare providers. This real-world example will illustrate the impact and effectiveness of the test.

Maximising the value of NGS data in clinical settings: Explore strategies for fully exploiting your next-generation sequencing (NGS) data in clinical settings to improve both research and patient care.

Marcel Trautmann

Assistant Professor & Head Molecular Diagnostics and Research — Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster 

Koenraad Eycken

Chief Product Officer, OncoDNA 

Dr. James Flynn

Staff Product Manager, Twist Bioscience 

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Press Release
OncoDNA signs collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness projectSep 24th

In the current context of economic and social inequalities in cancer care that exist in many European countries, the need to find the best possible solutions for cancer patients is critical. Technological developments have now...Read more → Case of the Month
February: 40-year-old male with a stage IV glioma cancer2 min readingFeb 20th

OncoDEEP® identifies rare mutations & personalizes treatment for a 40-year-old male with a stage IV glioma cancerRead more →

 Scientific Application Note
When is the optimal time for biomarker testing in the patient pathway?Feb 26th

The two key questions addressed by biomarker testing are (1) is there an approved therapy available, and (2) is there a clinical trial option. Currently, a quarter of patients with advanced cancer will potentially benefit from...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712118775



38_ONCODNA-COM-SITEMA

NavigateandExploreourWebsite'sStructureandContent

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySite Kit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

PagesCertifications & AccreditationsWebinar: Advancing personalized cancer treatment: explore the synergy of Twist Bioscience & OncoDNAHomepage_DevelTwist WebinarAwardsFor Clinical ResearchSNP GenotypingEpigenomicsTranscriptomicsDNA/RNA SequencingFor Oncology ProfessionalsOncoFOLLOW : Personalized liquid biopsy for patient monitoringOncoDEEP® : Our comprehensive cancer biomarker testOncoSELECT® : Our biomarker test on liquid biopsyFor Biotechs and Pharma professionalsKnowledge-driven medicinePrecision enrollmentClinical TestingMolecular Residual Disease (MRD) for PharmaTeamFor Laboratory ProfessionalsLiquid Biopsy (OncoSELECT Kit)Molecular Residual Disease (MRD)Clinical Data Intelligence (OncoCDI)Solid Biopsy (OncoDEEP®)CareersDownload OncoDEEP reportRequest a DemoOrder KitAbout Biological (Mercury™)Clinical and biological interpretation (OncoKDM)Our Blog & Home
Posts
ArticleOncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services - 23 February 2024
Case of the MonthMarch: 42-year-old male with a metastatic colorectal cancer - 18 March 2024February: 40-year-old male with a stage IV glioma cancer - 20 February 2024January: 45-year-old male with an intrahepatic cholangiocarcinoma - 16 January 2024December: 52-year-old male with a stage IV gastric cancer - 19 December 2023November: 68 year-old man with a Stage IV Prostate cancer - 14 November 2023October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive - 31 October 2023September: 53 year-old man with Metastatic Colorectal Cancer - 29 September 2023July: 53 year-old man with Non-Small Cell Lung Cancer - 24 July 2023HRD in Ovarian Cancer Treatment: 60 year-old woman with Metastatic Ovarian Cancer - 16 May 2023
Lab CaseEnhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies - 29 September 2023Revolutionizing laboratory operations with OncoDEEP® Kit - 18 June 2023
PosterGenome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer - 22 January 2024Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers - 8 January 2024Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer - 12 December 2023ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma - 2 November 2023Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD) - 19 October 2023
Press ReleaseLeading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument. - 28 February 2024Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine - 17 January 2024OncoDNA laboratory has received the CAP accreditation - 4 January 2024OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany - 4 December 2023OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer - 23 November 2023OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands - 7 November 2023OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house - 20 October 2023C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe - 19 October 2023OncoDNA announces the closing of a round C financing of 6,5 M€ - 3 July 2023Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients - 24 November 2022Berkshire and Surrey Pathology Services & OncoDNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK - 18 October 2022OncoDNA announces the operational launch of its OncoDEEP® Kit for comprehensive genomic profiling of solid tumors - 12 September 2022OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany - 29 March 2022OncoDNA launches OncoDEEP® Kit for comprehensive biomarker testing of solid tumors - 10 February 2022C2i Genomics partners with OncoDNA to bring AI-powered liquid biopsy for cancer diagnostics across Europe - 10 January 2022OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology - 16 December 2021OncoDNA provides strategic support in Radiomics’ prospective clinical trial SALMON - 25 November 2021OncoDNA teams up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care - 30 September 2021New partnership to advance identification of best treatments for cancer patients - 9 August 2021Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia - 13 July 2021Institut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid - 17 June 2021OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers - 15 April 2021Fighting cancer with personalized vaccines: OncoDNA and myNEO join forces to unlock the power of mRNA therapeutics - 7 April 2021OncoDNA supports BSMO project to advance precision medicine for late stage cancer patients across Belgium - 4 February 2021OncoDNA appoints Dr Bernard Courtieu as Chief Executive Officer - 25 January 2021OncoDNA announces expansion of its services into the United States - 7 January 2021OncoDNA wins the Biotech Award of Deloitte’s 2020 Technology Fast50 competition - 27 November 2020New molecular diagnostic innovation partnership to facilitate patient access to personalised cancer care across the UK - 24 November 2020Successful friendly takeover bid initiated by OncoDNA on IntegraGen’shares - 17 November 2020OncoDNA has been nominated for the Deloitte’s 2020 Technology Fast 50 - 10 November 2020American Hospital of Paris and OncoDNA Partner to Advance Breast Cancer Patients Management - 13 October 2020OncoDNA signs collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness project - 24 September 2020OncoKDM® used as the support SaaS platform in a prospective pilot study of Veneto Institute of Oncology – IRCCS - 10 September 2020OncoDNA has been nominated for the 2020 BVA Award Growth of the Year - 8 September 2020ONCODNA provides an update about the friendly takeover bid on INTEGRAGEN - 12 August 2020Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share - 9 July 2020
Scientific Application NoteCancer Management: Breast Cancer - 24 July 2023Comprehensive Ovarian Cancer Treatment and Management - 9 June 2023Advanced lung cancer treatment and diagnostic solutions - 15 May 2023ctDNA as predictive biomarker of everolimus efficacy in advanced luminal breast cancer - 4 October 2021OncoDNA supports the AURORA study to identify molecular changes driving metastatic breast cancer - 6 July 2021Analysis of prognostic and predictive factors of response in squamous cell carcinoma using comprehensive biomarker testing - 21 May 2021BRCA1/2 mutation detection in breast cancer tumor tissue using NGS and OncoKDM - 12 May 2021Study assesses the clinical activity of tipifarnib for HNSCC patients with HRAS mutations using OncoKDM - 21 April 2021The economics of comprehensive biomarker testing in cancer - 24 March 2021When is the optimal time for biomarker testing in the patient pathway? - 26 February 2021ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report - 23 February 2021Something old, something new: when is a new biopsy preferable for biomarker analysis? - 31 January 2021Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) - 21 January 2021The evolution of BRCA testing: treatment & prevention opportunities - 20 December 2020Biomarker testing and horizon scanning help plan future treatments for patients - 19 November 2020What’s on the horizon for immunotherapy? - 15 October 2020The current landscape of biomarker directed therapy in oncology - 16 September 2020COVID-19 Pandemic : Determinants of COVID-19 disease severity in patients with cancer - 20 August 2020COVID-19 Pandemic : Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis - 20 August 2020Lung Cancer : Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis - 20 August 2020Brain Tumours : MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas - 20 August 2020Immunotherapy : Escape from nonsense-mediated decay associates with anti-tumor immunogenicity - 20 August 2020The fluid landscape of liquid biopsy - 13 August 2020Endometrial Cancer Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002) - 11 August 2020Biliary Tract Cancer Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial - 11 August 2020BREAST CANCER Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer - 11 August 2020Oncology in the time of COVID - 15 July 2020COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy. - 29 June 2020DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively) - 29 June 2020BLADDER CANCER: In a retrospective analysis, both ARID1A mutation and CXCL13 expression showed positive correlation with response to checkpoint inhibition, including overall survival. Combining the markers improved prediction. - 29 June 2020GASTROINTESTINAL CANCER: Promising results from a small phase Ib study of regorafenib + nivolumab in advanced gastric or colorectal cancer: ORR 44% & 36% respectively. - 29 June 2020CANCER PREVENTION The American Cancer Society (ACS) have updated their diet and physical exercise guidelines to advise avoidance of all alcohol, a change from previous guidance advising moderation. - 22 June 2020BREAST CANCER For newly diagnosed ER+ disease, neoadjuvant anti-oestrogen therapy may be an acceptable bridge to surgery in the face of COVID-19 related delays - 22 June 2020RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure. - 22 June 2020LYMPHOMA The FDA have approved the EZH2 inhibitor tazemetostat in folliciular lymphoma, third line for EZH2-mutant disease, or where there are no other treatment options for EZH2 wild-type disease - 22 June 2020LUNG CANCER Using genomic analysis to ascertain loss of heterozygosity at the HLA locus in combination with tumour mutational burden (TMB) provided better prediction of response to immunotherapy compared with TMB alone. - 22 June 2020IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric. - 22 June 2020COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%. - 22 June 2020CHOLANGIOCARCINOMA A small single arm study of PD-1 inhibition (nivolumab) for previously treated biliary tract cancers showed ORR 11% - 26 May 2020DRUG TARGETS: MET A phase I study of an anti-MET antibody (telisotuzumab) in advanced cancers reported partial responses in MET amplified tumours - 26 May 2020DRUG TARGETS: KRAS Disappointing results from ASCO of the KRAS G12C inhibitor (AMG-510), with a study in colorectal cancer and a basket study of non-NSCLC/CRC indications both delivering ORR 12%. - 26 May 2020PROSTATE CANCER: A PROTAC-based androgen receptor degrader has shown anti-tumour activity in first in human studies presented at ASCO. - 26 May 2020PROSTATE CANCER The FDA have granted accelerated approval to the PARP inhibitor rucaparib for BRCA-mutated (germline or somatic) metastatic castrate-resistant disease. - 26 May 2020MELANOMA: In a retrospective study of patients with advanced disease who achieved a complete response to immunotherapy, cessation of therapy was associated with a 27% risk of subsequent disease progression. - 26 May 2020HEPATOCELLULAR CANCER Combination PD-L1 and VEGFR inhibition (atezolizumab plus bevacizumab) delivered better overall and progression-free survival than standard of care sorafenib in a pivotal phase 3 study. - 26 May 2020LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively - 11 May 2020LUNG CANCER: Data from TRACERx presented at AACR provides further support for the use of personalised ctDNA assays in the assessment of minimal residual disease and impending progression following surgery for early stage disease - 11 May 2020GASTRIC/COLORECTAL CANCER: Promising early efficacy data for combined regorafenib plus nivolumab: ORR 44% and 36% for gastric and colorectal respectively, all bar one with microsatellite stable disease - 11 May 2020MELANOMA: The addition of PD-L1 blockade (atezolizumab) to combined BRAF/MEK inhibition (vemurafenib + cobimetinib) improved PFS as first line therapy in advanced BRAF V600 mutant melanoma. Survival data are awaited - 11 May 2020PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2 - 11 May 2020EARLY CANCER DETECTION: Data from GRAIL presented at AACR indicate continued progress in the development of a methylation-based ctDNA assay with high specificity for the early detection of cancer - 11 May 202047% of cancer overall positive response to treatment thanks to OncoDEEP combined tumour molecular profiling - 11 May 2020
Scientific ReviewScientific Review: Latest Discoveries in Oncology - 3 October 2023
TestimonialRevolutionizing precision medicine: OncoDNA’s data innovation story - 3 July 2023Comprehensive genomic profiling in oncology: A revolutionary approach by Marcel Trautmann - 11 May 2023
VideoDecoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment - 15 November 2023Testimonial of OncoDNA’s Journey through its founder’s words - 22 August 2023Precision oncology solutions: From molecular profiling to clinical decision with OncoKDM - 13 May 2023
WebinarAdvancing personalized cancer treatment: Webinar Replay - 19 February 2024Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar - 22 January 2024
White paperEnsuring a Robust DNA Analysis and the Best Clinical Interpretation by Generating a High-Quality Data Set - 6 June 2023White Paper: Homologous Recombination Deficiency (HRD) Assessment for Clinical Management using the OncoDEEP® Kit - 14 May 2023

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

Company 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Project Care
Resources
OncoDNA Group
Patients & Relatives
Cookie Policy (EU)

Contact

Submit complaint

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129318



39_ONCODNA-COM-CONTENT-UPLOADS-2024-02-GUSTAVE-ROUSSY-ROUTINE-ONCODEEP-KIT-PNG

IR         RGB    sB   pHYs    +  TXX:com.o.xmp     xpacetbegi﻿id='W5MMpCehiHreSTczkcd'

Tempates osts Website - Gstae-rouss-routine-oncodeep-kit

5IRUp
x- +?M U,k.,cb-U-KDҙuoB

]ߝ%Xߚ2beڠzݧs<nd 	׎ 
 P,	X?8ܻm5YQu{R$ un佥^LH"x2ION#WW`sȱt:Ay=i	=ˌ2I-6]T)޳U6r#	KyŽ^+<],|մSʒ~q~



垏HizIʟO?^
r DN 6#'I d[ioFN,HЅi?N^

q-ϴZڅ|	ZƜFz?o	p 

!2oǩp"6DӒuBB[I1nF&բ/IԞ~N$1^ieDqZ#T$"m/ʾDﻵ0zZKww
d$DM4moA gdvK1!exKm똤drOx~xY[Լ1`vOVh6Kﳄ!R#t{h|!mHIPV6C58E/WNhw	2X*bpF v݂K_Q&ʳd	h~_2lo

R

'

^˃9g7(h"
" mH_H)h3jK=ٙ8rʜK_&o&!

mv} x`|>4g/TܘD?L%D&*Ф&^" 1n; a"@B|řW%9EضBtf	s>hc:atI;,|m}5'흶B; we4�YqW-O�ŋ?߂>�"%m9}�qE�Mğ֗[0k

@�yǂ'_�ɄW-yD4oe    IDAT� �6O�'+mB~)ĸ'{�	aħ��	OfN{NǵY#�ȗ��|R�/��h�ݼ�2U݋��Q�/�tXGtr�n��o2&Vɇc�M4Z��t�1ve��[6m65�g�N4��"dcK���+���Ș��x��ݰ;�Y�9"-A 

�#�"F��ץ �ۅ� n�=c/��W�o�mc�S���K��{{qp�4 I3_C�a�
9�

��
x%Y>��a�	�&>GX�5Nő2�%���
�

}

�
I4��Xgמ�%B-u�� ���"O"��'(}H�ڭo��Ѷ(鳎�s�S2��a|/�xQ��g�� ���@���
��[�Փ<��##�c��a�]F�9�I�n=���{mh���ۈ�{����  ���l��

��<

�?w/8=[�QtҾ�DK��+��$�/��8��t�F�9c�m���6 ӣCr����|�쉏�^p'M���$݃�Ě.�HZ�EbD�XmXGgN/��&��ue�M�gׯ"�B���!�D�]a���aq�	@w�9���e<�%5Tib ��29����5��P�%9�?��㭃��-��ZiPܿ��#h�%�GMb{��y��[���K8��	D}A�gƲ����û�=�SQb[�poab�@��/Y���A-~�Їm؀�»�-l�'�B�b�
�uRlsj�ī�-��N8��@�n���Z��xI`�#o��9�Pv�p�M����ɧ����UXC�O'�T ��S�lK���'V�ڌG�v}'5(UT'�p4:���g�W}  ��?�ӕ,F�C�"��|&����"�(B����z'� m`\>XJ ��" ��X?�

�

��#�(�(.+� �ILƁ�lI�u[���ya!|�o#i*��K�k�+���W*��QQ,�_X`�o.p;g�4��	^��1� ·�)m��D9���n�68�q�nA��2�X~'r�K�"��Ɵ��Y/�4�ئ!" ��%�6 0�h��%[��.[����,|	�Gb
��/��<��X#��mÇ�;?`cm����
D�fQrCuY_h�?-<���\@�·b�Ԩ����(�|��Ӓ����H,��.ʐ�+�{*��>�^��/l�`�>��P� J~̡ՈIoH��$�R���x�K`�X

:��j[�'����z���,�   %b#�
sY��_���	;'�a߇�σ�|_��)˰�,;�h$�d��ǉb �?�՝��I0��	!�|(��uH�ƙch�ҭfd^�ix� ]���iB�.߼X�z���X�3�!�׋�d�&��W3���
�\w��e�B���N�)F�&�ܦM|ݶ�t�<<�Z��BN�S�xk�B�?ͪ���!A�z��BD�uץ�s��P��s x�<;�픾;�]�A�Z�x�t�	�mt�L�̈�$��)䂯o���K\��$��B���HL�.��u��f�>(�������@r^W�6�	�"�g�NC~�  ď�vK!9�nc��
��=y��(YogVd�H<�=���D��Do�8c��@A�QRȅ(�\jsi�����fo����a��� {�NV�y����=s�7{B� �F�"�X*���~-��h-UT-�jk��؉5�� !�D"!�{�|�eΜ9���%�?&�sg<ǳMc�-j�$��bL9eBDj#H���|ja�C|b��nJ���	LẵE�����L�y�_��O�w� N�����_�D����	�\&B����g�^������Y !]����W"S�/��5O/�q���; �좲�#��A�fF
b8�g->9H|htQ�ZBԨ33e-ԡ+A�QG>�-��:	#9����!R�%�XĪ�͐.t	bb�D.'���QB������&�sF�U���E	

r�

����

I�5��E��hޗV*ai�����z� ��+z5Acl�: �`��!V1UA��r�?�}�J�9Z�HpQI-����!�hY_Jy�1@�o����g�Ț63`;VY�9����Y ��s��կ�Sծ����q�mp*Z?Ib�����	�󇮓k�(O�����]��E\1�k0�B���Z�����!"*٠��B�h> 3��o1 �

��e�M��f>�*s�ݶtL�o�3��izB����~�gME`G%G�����++yU�R$#W�-@�Z �W�"�-ߺ"����OU�x-��MbqX��P���-��;o���b�� ςE�SV*ܛ��e�x

��q�1^=���<��{�l,i�x��W}X��j8��1��nۣ�^�ޙ�ѧ���p�����K��Ӧ����]�Gb�<�b����OI'(SW��IR����n������X��D�>�	A$]�2���-))�^a3L�y�	*�`)

�ћ���w��-�N��^2��(tj��g�q�೹�8e*ޘ>��-Y}{u�&�c�6C��z�6�^ݺ�·w������O��]O�<�|�п]�vht��>hM?��p>��,�5l��`%�o�O��-̭W5�s۬g��Wj��P��^Pb"�����2r�.�l��|���܂���4��5��oF!����ܲ��B��v�.�a�c�]<���嵱�aPrR��6!�s-�͝��H�XD�'�1-C�]���\�]~rN�I\�@�EQS�YhiX%��Of㌫oM��d���}\q�X��̹��}�\���+��騺8�w�}q�)G`�[ ��{�;#N� ��+��;cθ&}�iѽK'L�ݏ|��m'㬿߅���o"nmv¾;�}vF[�c��	/�����y5g�"��o������[�

�]�

�
��

�P��T�G�CU��D�^���;L��b|�F|+-Q�*pcN<����&YY�ak��~2���X!H��=���ݷ��0�p�_��	Ͻ��|�Xw�>�wy��-�W�.8囻��w<�2�x�C]}�����b�_]�_��H"��q��W�� ��Cϻ�&t����2����1����'^?�:�� ����!�^�� �zu�_}g?�c#���壀4�&��`��

\��
�

�Z

�

��

��Z���S��Ό�xc����V�?�<=�SAk��Qz"kU ��峀���ڮ��7[Ԩ�p��,l�1������d��ς�)w0|�->���	���T �m1�]jt�9�    IDAT��%

U
�N
�

<�Fn��Go�S�u�Ԏ?7�-��_O�["��PhfY�q$PlT�+�4�	��p�RG��p�P��J�v���>>QJ���S�<�M>����ojȾOd�1��y#X3�W�~�\u2�̋կ� ���-#��z"���X�M�K�'s�.'���.:��`�/X/W��w�Y��s���e%���k��

�y

/

�����{�m

# �~�kF`�p���G� �l4�XMy��XQ�
�Wr�P�!��cYO�	}%Y�I׀����bFB�.BU��{_*yu��^Y�f��	��	��M�6ƴ���J\?����\�J�

W��8�����Q(��;� �����x�M�}�8���~ʁ�a���c���e���r����8��W@&�
 n�̞�P}�舧�Gh�c�]͂:%���ʹ�i ��,mo���S\ҕm�O���,'��JىZ听2 `�	*B�

 p
��w�

��

���^�S���ѹ��)Ͱ°v�^8�1���3?��}�*���J� >J�$A��ˣ��f��D~"���K�b��De�)�F�p hX8���2����3�_c�}̓`�j�M��	%���+�q�ȭ�B�����9`�_@i�$6��Wө�)�� ����u*i]�j!�|¡�씉(2���d1�:,�� ��q�)b=_��U�,ό��¼�7���sm� �����bc��\mы��"$�U4X��l%Xv��h�U\��V#4�fē������@v�>;c/AZG̯
��N�m8k~���.m�H��a���}{uW�~{���°�����ɫڏ5����S }�/���4 	[�/�H��0ZNroYJ�/i�Q�PAF��

T

�����x
�

��1�

;

l
�

@�

�

b

Y�a`�I�	�r�����D-N��3ĕ������&�-�[�>m%#�ZX	X�n!��A���fּ�h��M��i��`(��k$4�L�&��B�(&܇Ȑ�T�6����DT�̔5l3q����SǺ���c��uM
4��厍asE���p��:�E���L&6�Ī����ȃ �	eˣx�x���W8 p!��H�)�?�!^܁;�ψ�#�G+��� ��`~q� ��"��b$+H�y-&

`���
�

�����)ۆ�.h�d�RƘ����x���\K:��	b&66�&&����	a9�I�pB�]|הd�;A��#��5ܫom�}R�BKb����I��)A�)�!��X)�Zh��2����VF�޴|�ө��f�R&��L2S"bQs%�f%fγ�i���n�	����P%P2V<F�-�R�"�d=�P�IZ2�Rt�A�R@`�2p��|pB�uA`�T

j

�

`��-FZe}�"�im�&/ϩ���_�鯵[�>�U"�k�^Û=�C��ǡ�l	��h$�ܚc{��G+�з�;�dQ�mc��#}�4�����~6��i�	�P���v��

�

	�fG��ՀMq-fX��I~�d�
)y,^���Y�� 2+��F�fȰq��b�Z��>�Lm��w�uq�>���v���y����I���C�&/.���M��@ M����

�c�
�

�

�

�u��

����m
�&�BS�	������jx�u��VZ� �W5�p�1tc�u`�����7'�����Wd� }}������=-Ei������.옢F�a=4GT6W��.�+���8�~�_�F,c���Lm�����Ĕ|5-��ՂU9D�>��ҾxW

7	$�{QN�)�n/��S�o)+�e�����{�IRN���r��ms��d:b�zQ��`2�� o�JC�c��x���� 2����fu�!�����3����%Pŷ�0���� ��

��d

�
d

 S

)��
\���

<�

����
��

�x�

��
�
)(wN�\`��;�:�D�C<{ y� �wt{}>Hr�q%�z�.%�#Ʊ��S^|-t�Wț|�li�6Y�"�C����	� �=��

����m�3 �  �Oe� ���/b0��s�j3$`��"���jT��,�Z�?^���fjң���$�Co?��k�����m����t6�	5�xZ� �έ�J}T�㗏sO�s{��~
�(���<oM�M]�y}Z1�z�6.���x3}�Z��o8�͎�>+���~C��c���i6�ͬ˕E�S��8it�T�I�{��X���'ȸ�ߒ.鞝�����tH�qq��=��I��Ѣ*�"�"�M��˴%���±���"�T ����T��|_-n!��������P�f������|zJܡ���D��)�4 �S#?���W1�u.3m��R-rWE#=~�5�b�68�>Ϗ�ECv=�"%y�FnRb��=�+j Vs�v����7��b���q�k�Q4e�Ī�3�e�u���b��UO��w��z�Y�/��GRaYT����%�Y	���A��a�

����

6����A�ܵ#��͙�ż:����q] � �ƤZ���/1��FyY�>5�����s�i�����8k͌M�L�T�4���Gi���v-�    IDAT��W"w��5"�

y�

�

q 
�
�(r^�5���4� �������&~L��@��k�T9��Y'��#��0������m�]�j�ž��D�� /@tV��Z6NY�w+;B\m�t,m%�D����5/�~�$�m��/d� c�1�۞���>�� ��b�*�γ�L���x݈���=�}�DE

����o

��r�NPb�[t7����a�1��6�v�qm8�g�N8qg��sN�[R�}Gy"|�ཀྵSl{ {����H��2{z� �(#�w�)z��VDϪ�������>_�a0Fi�@��՚g�

�.

��
"

���W�/5�sO�Re��&Qn�]I5�`+y�Ө�j#F���yZT<�! A��G	6,�hyn*M{&xCu5�	�-�Q#��,-{لG�ޮA	~�%R{��Hm���I�����Ll�d<�8꣯��E:(D� W�H��gN��#�=��n��z?�]!7fU\J�^�������^�lt��Vן��E��f��U�

6�l��P��8�҃:�r����L��p���m�����*�t��I@��̕`�3)ދ{3ق���M^ ��IS�bÅ7�q��jx�$�ގbr��-�����5�P-��S�7��Xy��?V����*c��5�%

�9���

5�?��8Û���?X1� �9�=�Q.OK`J��jٛ����un���	�#*Ȍ3l;S�I;�#�����c*I� ]����OS8>��iȹt�q$2����*�����D�튲����++ҙ fs˧��A��+4�dӇ�o$P8��⵵��:�1Y���]�@
��1�

8�c�Gf��5�/��x	hx0� �j�d�^ S;6خ�'������dRu�2C�΁��O? �nz�vؙ��v&G�~���h�^�@
>

��
*
����\	X��M��R~�-*|W��%�n=*^n*y�8�J���U�d+V�J�{�8J����H(�6�	}��������J.͘�C�hX�+E��k�gr �`�D`���r�?"��r�(x����1��Lǔ:-&�b�y�k �%D/���m}XXw�0�f���艦{�? �Nz"��K���]EU��\���{����w�6���T.�
�B

�

5A�?�h
�	 ֧P�`�ّ����Sn�}�j������M��J��3J��ILL^W>cC�\��0n. �� ����R

��/��"�v\�x��%o���(�F��v��2K0�1�e��#�z�+	9�Y�sO�@.Q"C�ef�aQ'����)�k�o'�O���O �J�T��͎��ˀ���� ��Y��	�-D�= ֏~���)_D�XT�Buۢ&��*@o�[��HC.�g��%+1����X#�K?)+V���͛�秌�>%Zڹ�B �GT�ܦ >�9m������C

z

0

�

�t

��

���
9bR�� �%&��5`�S��n	�,���[h_�ip��T�E}����a~����$���M~:?�!F�p� Y�)�S8�J�b0*�f氃�sB�>�'

F\u����?r�3X �:�����m�I&`��z��'_�n�d9t��̮uE0���.0We>��,:(D}6��<j�]��P	��5�B<@�	p�C�����䷌><8�	�H�`��2{%ؖ�&���8�nZٚʠ��^U�y<0w
^Y�%0jmY�ex��xn�f9�U|T(>���a����&xU��Ie�`�5.���;�Z���A��e�}�i�`t�	��Z�x��[$����~b�s�'P*` n� &7��P:h�ҟ����i>R��jU�N����:��ERi���Z���U�;
�B

�`�U�

6
Q?' z�F�_|S�j��y�̂"�J���'.���f�#��Gbl4�� �r�"Jt�oO�o���ш�� _od�̍[X��$ndI�XY ��@�TJ�� �q�㚢G�h�j� _o���\J�:{

�R��

��

����![��LV
��!2��7c��dp2;s�@�9��Wo�q	 &���6xut/ ���+�����	� ��^�����<:�0R�u�D�=���[3�&t���G  ^Jź#`x�d-K)tc�X_Ow<5�+��a>��J��S�Y��ae��A
��m���1�ڡ�a{@��ǚC�1c�_��a��36�5^��' ��6b�.岚@OL��uF���^��]	�x�2���9E�r�'�
���

��

���	

�

s`o��V^�ƘE5�,��e����U�~�/�~ )��?�;�;��`��a��}X�� >{|,���7�	�_����bl8tZ��WRPTZ?oO�?������R�(��x����

3�

��

��!���t\�j�jKU1*�����+��`=V�?��6������_@�����ሮ�20-Й�, �bC	���U��RQYΥe�Ih .��`ƚ=�x�2x޲&iyE�u�Y�8x���
��

3���V���F������O;!��/T{_N�Gh�Ŀ�I��&��Օ�����,�2�J3�g��S߮ �A/ދ� ���J<7-��h1����.x�������'�	�-!�L
�


n

'

�k��

�����ļ�D@��d������ĉ���l ��.C�x{ߤ~�мA(\Y߭���V�k����k��.*����,�r�v��NfEZ��ӧ�m����W�k�d�8�<�}���Y�VQ��:VM/�1�dqY9��g������[X��,�ނ�@ڞqM��;Ӝ�|��V��j�,4�e���<d��1���;�B�8�t�ɹ+p=�h���A<���7@�{{������y�ɋ�f�^&o����)93�}���}`�V��" �,��9A�fz��8!Z:I¾�i��N 0��5H�1M���#

��i����Rv�B0g�A�y��&�X��LAI9~ޭX(L��V�'�X[�D������[	�Jk�t%��_X�8�M4���=��'o-߉��

�
!��

V:�rMƑ��`����q}�ᚽ(c��*�R=`�D�������~����, f3��;��	^%����n;���oW[_A����)�5����Tf�`iC �Гx�q�"��O�Gc��%< �F�Ϭ�_��ն=.�:��Kn|�E��	h�d@A+� �O#2��{V�O��k7�%�]�k�S�.�����6�i/]���#.��=�U�

�+��

k�!~��)*1���^!ޘ\R^��z�:t9�f�Q	� B���x��r��^�x��Չ���Gk����	�p ���
�

��b�0�@"K�ܬk_�z��]��A�A����2"����l.�f1� <81&���{�U�ɬ<9��c$�DE3��72d +�^ @L đ�`�C���-��,b�i5������!���� oO����w���u��5�lM\����U�M�B�F���	�

ѿM4
�~�Sz^��`ɧ��-}53���ޱ���f�����v�����;Z� ����a��09"�Ov���t��=�%��@8��>	���tS�k
��V0�K� @��"x�6���_���|��df\�  3��3rPTV77���A��xy�#�qbG�,/@cZ��Wh��t�� ̸��P��ںNaLf8v3�e*'��AV�+��2Fq+�P����

w

���+����gl�Hq�J:�<��#0q�b6��D    IDAT���1����Le�Дٚ�,Dc�b�=$YIy83��*���7k1 >���
=Z4�׀F��x�_<үJ+��%�*V<��'�شz�F���ւSz���w��ƃ�ڪ���+q53�� ����Q!���Dd����[���jM�X��z�

�b

�

^�;�>5��~E�r_˟A�\5L�|1��*�0)��o'~^��P_;A�)����P���,��^q<ٮAm��!I����sˠ�P�+�3����ϼ��=."�	�M���:6�I^�*����v�巤C�:R���"B�ح����狤��6��r�

<;��V��r��uy�˩�~��e(�L��A�f/�������Qʾ~MOK����鑓�����l%|���<Ӷ�Ӳ��u^o��n�B���?���	1�$�q2sq���OI ���-a�lj��	#)Q	��}>Jap�+j������`��%�D)�

�

O
:{Q�jx�b�NX( 75	����J���8n�6i�u��e][��rkk(��S�8��<Fg�_/^Â �no�	J��&-�M~��}c4P�Zɘ���C#`*o_-��_g k��I.�ɲ\� �c@g�f���X���

�7�C/�;^aS<B��YK�j�.�����A��,�nJK�b�_����QK�XP/Y�M~�����J��޻w4jV,����GHB��m>�i</�x1��@f�W���w��D޲� ޙ��gx'��(ԯZ�c$��T�jE�p�0�{��=��p�V�>6�{i�ձa-<~兡yS��1��ջ�m�rN3��u;��wϖ��jN��W��qW�Th�~RʋQ<��t�{D�ָ��,o	��2

���?��

���

;�I��� !�A��
ᮃ�������A^�~ Zש�9# � ���H��1^y�#ӻ���G`P��5A��k�9����b�cP=P������:�D��}�+L�����~D	�IL>�E$�
���

�!
:�

�����
�V

���
w��

�<�
��

��

�[��

��

��\�/

����

�[�

�]�$��~�K�E�%!hLT;��-y(��3�0�hF$���:_�����w�A�a�`٤����g��ppcジ�J:%b�Er@� L%!E ����AE�P��?U�t�f�b��tG����m�"R�&���� �ʂ�Qh�"皥@��L����(�[$�Ӹ���r�NGVEP�:yS,�}'��N_hgܵ�&��O

�
����B��Av�z��6���	�a7S#��R+��y����Hw��d��`�Pm9����M���>��5��ˆm�y�K8��
!��p1��خ����1e�J%�"l��$[�΋�"�x�0 �	�kW�A��v<H��9���=��=���)�*�	��$������jg��R�2���ix<���u��඗>��l�ն)j7��(��[�r9|z�ehQ�2b��O��"��Ʊ���Ԩ�[��#C�;�$�q��o��q3�"?��

�������Dz��6��H"{B�	�O� aJ-� �M�5\ʿ�-j��&�ϕj�7;v�|���6R�dr'j��R
�x��3H������w��%'�f"���U.�	� hנ���m��q�=z�@��k]1|��/�f���SRH�m�;)T�B�Ӿss�8H��ua�\kOR���*

#
F$

��(��is��Z�J��"�z �,���1�ɗ���9HŎRc7	R�� �x��/W��ǬTe��1�z|�� ��V�M�0VK:~�7����X

��

��
��
D
 �

�僘�Oz ��[��R�W�)�ᯫ�I��
�4���@ (1}����*�rRJ��������m�y޽-�Ԫ��T^>�܀�/����d^��XсGl�Q4y���v7� ;!��� SyυW!���9

@

�]�

�
��Q�OKbbN�U.҄�@�}W�\��>�?��S�kE��c1N^�a���>)�i.6� ���o!T��a �ݩ��a%�AY>�ȏ�uy��	��E�-gz��q�T�a����!����/q(��#PT^�

�X5�f9o��_'��QA�d�SQ�{A;�s�T�q�X��*h̋w><�(�'pS�J��
Z�x��>:�H9�7I��m��y; @(�|����o�6u�ϑ���<4 =�W���.'h��է*{0��t=���0-�(n�mOQ J�Skg��r)��;����x̋��Y��	J���ؙ��O09i�GD+gu9�~l�v|Fg�rNP�c�xv�����
��	��� �	�DP�턤�z�X�d�d6刈��dv���.��,�=�5$��ʀe1���õ��`X +�B/x�xL��#	֊}�9�q]�iL��"Ӡ�cw`���mM��Q�\���X
��

k

�P

����&�4��-15�1�ebq�1p}HH G�a�gvܙ�5��g)Kr	�� Ӟ�z{�(�j���A5��&��y���y�#�fL���� ��qdI�������S"�)�0a ��-�uq�����F'���c� 1"��i@	�T*�
��R,�|�'��a`*5`"&��3���)� f>���q4ٯ��THJ�F0؅ �9�W��rr�X�E�n���)    IDAT8e^�-/����k�+����ƢG� �0m�t�y�

�{�&���7W�4Ҁf�jر�������W��� �oʶ�[�������?O,�Mڰ����C����J�m�U���y%�%��L(�7�2zbo��HN$J ��n	�.y)	 &bQa�']dm ��`����5Øb*��F2sR�<r��@*;��I�D�,ܵ�GZ"�w6vBiǊ���{����h.�<l}XOl*����+��	c ���j�²,q��=C{&n��Z�t	Jˣ웵ee$���r<Zc�^�����G)���NtZ�r,�;h�F�aTD69~��A*�lO{t`[64�H�*��k!GA=Ém�;T1���@��

n��rw����
̕UU(*-s`JR��:'q��l���<-�`(����L��	:Q}�y�� ��I[�F�A��
������

�

�
�r�q��

������

�

>
wW�3F>���ɤ��Ʉ&Dצ� ������r١�2?�R�1�-�����+E�|e!G��������z����S] ���
���
��

z����

=I

�
�������
l���
��

�

<��

�
��Y

��
���

�9�^��q�g�l�G6�\��N'�����4c���c�ؖ��^��T�Ftl	/wW�1��f�������MWu�B����`|L�^*ѣ&h�vm�_�����T	OwW|��`4���� ������߯<�F!�%z�p1�����hV/>_*��+`��('c�B��%�k�!I�Nǣ_��H��m8�ҊJxjH4~2q �_����

��

���	

�

�
����E�6j�5 xeTO����n�f�H� �	��R0��2oP	��A�K�83~^��'���޼!��/��	���ZZ�Q�����*��#V�����<���G

���H:�}K{�kE���T7�����\������*���P�FdV    IDAT�X�� �viNA	^]�

O��G�����ab��� ����rwUH��2���#X����C:cT����������D�]���[8���mtď��Ȏ1���w)��}���&�SVY)�W�v �4>�z3#?Z��sa[J��1o14BXK�aH��u���OW�����$�i�����d���b����ä�+4�Y�)�;b�Q�Zj��

��w��͚�p�&P��V�c�E˽���TH�,�
-؋�B��OV���w�$��pd 08~�:^���M"T�Ҽ5>ܳ����g�[�	_�آ�J����p���,��UR'	��d
0s

�d�}����i��$w��7,y�X������;%����j�x"�Q=�4i��=��8G8�B�	[w[�}t� ti��i\W����oG���C�$����a�B ?/w�GI^U��x�͸t�� _ɻ�[_(R�~!��W!���<3�����[��yk����BY��8�J�j��>IyD��W��j�!e�uc�S�� 	o�A�uDu��dg�P�Gn�%o��}�y�VF����'b|��!&ip�)�!~"yV�/�w͔��fFl���PM�D6�O��I��omz�v�6&��g]�L=$vl�ӯɤ�TV�����#�����

�
���9��

�

�>�

���
F���q�?�@Ǧ�Х���/a����#�X�*��;�2�PG6��Ry�S��8�E,X�M��|'Ԡ� ̚�7��_���=g�έ#	c�����a_��T��畛��?ay~��x�I2�y�������pEŘ�l ;/)JWw���Q�n�M�-�*W���Ŋ;��%4j�Ʈ�M5
L�

=�In�Hڰ���[&;��%у 61��(�j܏���e�Tu#,�TX�R�"T�K�F���8i{�1N���R4l��<y���b�`I긅C��ƍX��sS�I�����׍�D��@	�}6m

����

�

�M

��(M�"	�&99#��*������m¯+Qȃ�[�ϵf)�c�����hӠ^�b ��e8P�`��s2}JAm��$H҆p_�Wb��Xp�S�FgT�Q��#��h����J�����B�F���;r����N�� J�?��P�Kl9�
�u

���
w�

E�

������d��,  �����?o=tk�#��x���c�{^�J{�,�v=���j�{��F�%J�����;������~�E�Sc�y�8�H������K��a��d�A�ڡ�lO�g����F�w)�6d *�&�k��I��ʁ�(

�s�

��/|9��<_�A/�֩�S:��^[�c/ۉMC���l��#�r�>@������0���X�}/��;���Фv5�Աyh���ī�f�̎����$37Lݍ (x{��9�w����N�Ỗ����ug��N���W3��-�����<�)�>�7x,�jVG5����9W��9��].����Oܳ�v���Zb�#���q30�g'�Q���p�)�p�cQ�p���m{��	5����;�Tͫ��u��}�:��u(,N↷��'U�ţ�s��
7�
���

�0

�

�U����P

�a��

�`�fl޽'�y(n<�'��SТ~��oŐ�m���T���/y}(�O�f$�kB�2ʧ?.��9K��p���b���M���yx�ï�y����K�&���|J�����a���w
ꃇ.�ǂ�����D�7�    IDATW⦡��agpL>}o<f�؀�/��u�����Ӳ��������ง�M�ۆ��M���8��d��s

�

|
?

	�����j��]��՝��cYX�ޓ2��u/}�ag�<�A��Q�f
qd�hR�&r6�܋�+�c�����6�'c(�۾+6m�`��E\'i)�Ҫ	�4��F�k 7��M��b��uX�QPUX��S�FhQ�6b喝X�m�"0��E���=�ժ�5�!7'�m{�u�~�_����i1����hP����˞{ç���\�f�ؼ!jT�CAQ1��؃����v��'�6��K�ƨS�2�

*W�EAq1v�?��;�F��c��/�73<bq
$N[���i�w��x�Z�йyԯ^��WFAQ1v�?��[w�5�a��ӕ[g�NA�*y�ڲ�`�'ml�w �v���QT�d��j2�� �M� 4�J4����t��4;g�G3w��S�=��綑Ӂj{�C�1�c��0qS��='����H%)

�b�
�

mԺ�.�9���ua�l�=e����7H���W���e�`� ؼ�67D��R�ڮ�7"5"�]eap7������M�yy��
K`���q�w	l./��0�3f�+�ʥ��/����k���uJlYD�%�-�����1�P˂p��6;��]��]$�|�$8�����cY�E�.a���K��p��TK{����x-���*�d�x9��

$��

�\��

Q
+F��s�[eb���cV�z��Q^�G)��0r	J{���NYMu��suNES~�P����.b7��y�w�.ud�UP	l����%�8%����%�1
,���1s <v����;#Ja<�t��u��tY�7��r�������I��P�P����BQ��	3J>�B��oF!��3�� �R���Е;K�щ��M $�RFo�&��l��O3=��%���Kb(�v"u0

������r�G���C�0�>���T��:�����H����k�⻣CP�@G�(�^ �A��<$-iS���ܼ�_���tK������X`��+9ksV�QHuK�Mh�� (sk����B@,N�RF�h��t�s�(o���L�DMG��)���	�W�u��<u0 �G $��m3�2js2*���    IDAT�h��J,D|b��� �Vn�[���$�NA૬ț�.�J�MNzn�*�555m��X��$���Z�{\ɐu2G���o9�����D�!�J��#� J,�XR��'

���
�
@��

�

t�j��a�<%�-�F���#\�4�x�O,�$��B,H�>am�$�u�:j��\KQ��4d���q`&�^�.`V�� ����E)z��M�ǹ�X	��.�k>�ϮS�%M��10������e��$ 	f�!��$��Ad"��~S2

���

U��و!�k�e�P!>Z��pU��N@ٽ��u�����ɩ(Ȯ�o��/A�9΍���3�ـ�,Nb�U�︪�$Ҟ�ՉK#����{ �G���F�F]l�䗢�$\�l��ԎO~��[�N���.�?�5���]�5p�9�"Z�:�RJ�%1`X?�(s�� R!Vyyœ��G���CKW5�̂��pN:�<Ak%���u"N<��� ��Ԋ�����d	M�0�H%������,(;@e,��/���D��T��i�%��1����N��	@��%4�3�R�M�>׼�l Rf1��wnwB��A�ʉ�$!��TҬP����ݽ9�:���2T,_�$;X�Q��	o�@���N�k���E�s�����Aܳ���N[��t�+W"��EE&�N�A>iH啐2�^�ʃ���m&ۮ�3�@���|7�����
@"�#\���:��:q>d�|^��1��9����فV�%�LՕ@S\ݘ�;Tl�1J��)�ϛ:;�������X��U�	S����B��R�~�s���&�5��SIY

~���

]�N)Z�{�4�}^*�b3���N�3P9�8L��t�K����j�K��u��	Q ^�y $�$ACQ*�9�bE���S����o#$Z��^��( v �X&��^��f����~K�l	%6@�bXV.P��8�Z͂�{H`C�f��
��

Y��kd��VW14�z�q!,*!%)���[���hAE����R|O)�G�exB������F�o�6i���]a�-��6=4�����;	[2�%��%��Dh�F�,�AiMQ�R�(� -op�Ne1�J��B9i��T�@	����]%T��L�l��&�6�J���&	"[��!p͉ek-����I�

��$

4���

	��(��N�SH,9<LJ�@�D���|{���x@@@�x��kTI��>���P5;5ϑ��S��4*}��$���G�+jsL(���yv��48-+�4�ʛ0�\���,����_Ba�Pr�� *c	'e ^7����	,kTVϲL�����Q8;�-�:�'�y������i���b����v�E%����{_2YZ1������̾�߭
�v!>_�@Y�*t�VLT�ΔM/f(���+�p���2����a�-D����w��S7��^��`4ƨ:�5[AJ�$z�Y�� ����T�Np��;�S%5y�Z4�YKB�I�9-g;�����c�Y[�u�Q�;e	!��D	W�-�#��=]���#xxTo<9� `��C���̃Z����V����7򎍕1P7

X��_�|S_��}�n�V�ϊP����"�V��R����{T�/3�����R����,��$	O��@��ջ���o�w�lJ����1��mL��W��R��6�D�b�0�~�w�u'�vy�s�\��2�]0���`N#zi��I1�]C�Y~
Wvk ��/�/��׶`��P�O��r�g��`��cޖ}�,�2 �L��|��t��b�����A�����ZR�&���	#��UTu��Mʩ���\�gSHҋZ5v}G��Ɠ{j��X���y���a���E�J.z��d��"�r% ���@�HeCI�/&�d%�JL�j࿼��n%VCkz-��Jx�������;&;%���=zuK��v� Xu0
�:���w�w|?�"��{Ds���75#� �7Y���ɗ�@UT��*�	;T�r?��x8�Y�TP�fz

�պ�gQN(�� �*��Ŀ����_��g�Hz���[ZDs�Y:j��+�A)�R��~Ϳ��Y��"��/�R�3u�H�V#K�Ve�;$�0�>������~���ٍa�U�C��F�y�E �]��:R(n��)���nDSN�Kv�K%��H�QH	��
�T]{Q���0&c'w��`�A�q������"���@@ @\�A��8���u2��M�y#�TD��2 �v�'R-˫�Jg̫_���V��^�[�,T˝~���bȄ P�ۼU��S	Q��W���

���/�q�KN���SY�z�G��[f���u3N������&mT�Mh5�	��h�Ș��7�:���ͅ�*�ѹ�0���Ө:�PP� PPJ&b��4!��}�����6nH�K1=���	%p�U��A����v��QH��H:"�7DQT��>]A
C�{�	��HY=J���9�W�$���.[��v���O���]E��_��<,�.��!!J�:�ke�� M�꾑����	�,���ZyiUSR�D&��p�X���ZW� ��x���-�OP����T+���T�CՔWդc��b	�����A��m�Ƈ�E�N���}��JY�B��Fe)��K	�?�His�ө�2H����>Cv(oBx�<�

��L�E@p�_U�)�	�#��	y�S����4�CEd��!��͌��r���R	E�ù^('$m.

`m#yU���p��r�}�Y~�Q>4���/WT�|Πy*��]�X"�%�@#	P�j�VH*��8[�UԟL�A�_�h�;�W���9��s@u��� Pz�M�l8��}*��w,m*3[�4�W/�X�t+֒�}�5�	`�7�4�FU��qj�c}U���/��'

v

�
 ��

J)�
�

l�

��o�)vn|�R�v__�t�}�_�JY��&��n 0� 7�	�ޭ�~

�
�
��� x�ǥ��!Yy���tŔ!]jǲ����K��_d��o��� ��l�)C���D�[���߭ك'I�?�4�$���1 �ٜ|t~f��Yߖ	x���ض�e���J����k�a.���������eXǦx��+�J"7͐W\�/����+����  .2�^�M	���*/��GS5��qo�'+�>4k5�*���i^�nM���X� ���]���Ѯ�uy ��ܔ��W�!��H�v 6�4z�ճ\Fz�ăC:�q�*��y��ې��Qax��ݩ)\zߗ��g�;
�EP�È(Y�I���OM@+N��;�/��#�A\�A���}�s��ơ1�5M�j�T�I��)���J��s�q�	;HF׶�23u��hV�FS^3�'�*oi4�I[	K�Sd�~���

�j��'ྑ�1�q��=�GP���%�?�Z<<f��4�o�M�E��?ԐX	�j`��w�ks{8$(�3��x�^ӛ����uM� �G�H)�T���xr�`���c_����������6��ُߌV�kkB�_����K��H�����vW�:����	�sXoL�6'MHA��

z

���B�

�v

���

��n��
���



�#�F$��z7�O�i>���B��c�����̵;�	Ava1~۸�m܋ޭb��Ih��kL��_���Rv �9y$���	ťxn�b|�h���G�.߉��X����}>��Z�2�-�Ԫ�%/MAש�H2�V��>����')�բ

��è�-���c�z1�������c�qu.�[���_V�*L���@��	h�i���i���yEZ�4#'�R3���m�<�3ޘ8A.�

���O���$Qy�j	'�Z����v��I��K�����Zb�B!�A	�

�n7�

��
��

��� ���U�+7Bp�������Ns����9���!^2�>t&w�7D�L����&��E�	��[��-�Ɠk��	B�K�3W�ǵ{���q�B.Ƽ�bR�i7�m3�-܂��<��/�ьl|�|�r}}o�~�Xv

�dMy�+�j�oS��z+�J�j�I�R��W�oQLB���e;�v�6�t���\F���^(*u�Ưv���𮈍`k/�R���2�[�kߟ6��o�K ��T%xk|?�Ќ��7���

���J ��ʑX�F5!� �Z�U�=�S+G���{_�� ���Z��m��߄��9��q�]Ѱ��sw�'s��egVJ)n~�{�:o��9�b�A����	Ab�^��'���F)W�'���|wR�z����j������s	��
��w�6̷%���U�����4�Ŷ@�� #W��`�M�����mn}J'�B���n�n�~c#BpCw��S��J�9m�߮ߏ��[� ��MЪ�ÖUP�g����==�]�Ŵel���\�1���2r�ƾ �3RU���mIҠ�G-�2�J�0
+�z ��1C�6�6�^�������ڧ�p1�DG���"S��'уU	�8,��o�Z�]�>�K�6="��*z �*a�j����V=x*���

��|Z�����WT���2�#�A)���wR����i�z��-SX7F�K���L��q\4������U�|&	�P�w����k�&~�1@��&���H$hT+�a���#����9�KF*I*� T��1�3}홻R�3�~�ڥL,�+&�=W�;���    IDAT֯����\^�e���b����M�3� ���L
�

�������X�

Vߥk$
�A%�Q�B!iQI�\tT&�,� �L�\���4�M���c�	g�zك���=�v������(ՆYM�m�N`IPʰz4��x�ݻ#��h���Eؒ��M�Y���we��8���Q��	gN�E�?y��	�����N-q�U�0�K[m*Q�8|�,�v o?���GQ��Hs��,o��hAiZ���P���b���u���T�^L���*��fub��Ⱦޥ�ױ7]=�u	��0���Ɗ�ǐ�~mj#&"7��V[�0�Ss�<h���8xچ�0+<͜O BT����V�/FR@�= �Hr����P�K;�X	�\}�4V�/��DG �맭��B}�|�i[���d���w�8'fXù�d�)$@��HKK .L���z�Bߖ	�oף����S���w�YQdo��w���



&
l

��'

��o=

n�:


\���h�����B��Z
�}�#��*-��V���_��VW=�����W����	�_w.t��h��;		 ��g=�Q�ۉ3��dޖ�A�	P2K�ph@�L

J�z�Yd)��Qj@?�Bه0Y��Xg���C�M#E�գR�R��
UU�Vt�̧�?��%����R㇯�1T�O�c(�>��S �4�=: C��Z�c������H������8d4�4�{X,x	�
'���x�o.Yk���x}���E��/�%0���Uc�����17����.���!�y�i��-Oi��L��ٲ�	�[�7פD�F���h�^����r�ک�)�a��� On�Ҙ��凌զ����bqfW�VU�ǳ���S֊�i�pJ츮r� Y
頢e�j��'�pP��OA4(�����A���@�B�)Ⱦ	L�\���65D�B�D�-9O�1���ը�\�Uԯj�� >�u��r%1vկ�B�4}& /��ڜ��e������gydaah�ȃ7��#Q����d�1�w�q��r ���

�������

����
b�S��P!��nF��=F��.Y;�� %!�Nܫ	�X�<�FZ0D�������fe��٣m�R��#�nN���/����@u��?qug�}�

��

����

w��

��

��*

�
��s�����N��"��.��k���Oo;��9[�5MO��W��������"\��W��]�]Ǯ�u�5�ò�*��İv��H�ݷC��	Ftn��w� �Ͱ��	��� a�uQ���i�T��8_�TV���\�+cc�浓�Y�����6�8q  (����¿L��c`�����}�e?ԁ�k"h-�K�s�]�
��{�	������S0�M���N.LI���+���rpx����{�xt�\�e�}��<3{$��5
!����(�6gQqE5����Z��_�4}Zp�Ʃ����g:���&��]�x�cN��zT ֚�&�Ή}�|B�R( ׽Fui�u!q�6�	���#k]Fc�EJ� ���J�)���	\*�!�zx����������

�y�

����

c�

��j
���

�vX�Xw��
pދ_��� +5	�iI�w�$,ܲ���

Y�

�
1����Z�g�Y�g�]��?(���o����H ,�D�kev�M�5�++��s�<��}�Xjǀ���tk�1��VH'���׏�c��� V��Ø����i�Y�	�+��PJ�����׶������wx�Qޑ�ɓ{���^m���v.����K6ᅥ�PY�ǯ�Ob��ܧecd�%G��@��r��ܗ�g� \tF'(��e���(3m�+������2��9w��G�1幯���1�{+L��

�����i������Ŵ!�m�K}���0�����1��cѻ�\�9t��O}�Ĥ@����Сy\2fP������W��m{��%���!���
밺Ə��v╅?����)��Ə�o��R4I|��݇���G����9{H��xa	>X�O|���c=5	z����#���UŔ��\|��8��rH)��݇0w�j���s|*

�A

h���]

��
�

���

A�

��u���

N��=�wf[�\��,�ӄ��I5�\��_�<#�[e�iF*bcb�_Z�_�Ė�'���=16�>:YqR� @�a1�I��Kv&�6NCӴ$f�TT�縻�GB�	118U�E�	���՚o�BоI:�Ӓ�#((�Ď�WTCF��:-3�Ǖo-��m��0 f���gN#4MMB������div=���

�R�

�
�

�



��)�l#P�z����;�Q>g�a~%y7�C�v����e��F$W��= V�o�h���;[65 ���Z���h�*��7���9]ZwB�Dz����Uvq�Z��u[��蔱b+��%��9 �>hy�Z-)L�0��  �BՁz�� X2�

��

W��

@0��)�u�����n1��?U^�V.���;4�G/)�ո�����`��=J5 �}�0��K��(z ks�h�+�{PV'R�11�� �t��!�@���

:�

�C~�(H +�<��GV���g��D��);�}^����}��`�vש �	B@-�T��xѡPmh�yG�o�(���(�V ��_ ��n>��X6(@��8�����"��|c߫�{��&R�N���+𦲦��K^u�k�����~4� ;�j3��j�����{�ƓK��ڀC��!���

�4�

��j�
�

�����QIrr �, ;Q2 �a2�;�S��7�m ��Z�?\߁m�	��`@��~��k�T�v!xi���S��RI��v�


d:��`�s~�Gk    IDAT�sQ�s6�՞q��Z`+|K	�"d�{�{(n�]y6v�5:ݕPcֱ�9)��	���UKvMT�


�~�
�

J�

�7�r��ϭ<�Ǔ�o��/��I#Go�~=��� �ZA� � a�ۨ�	!c+���-����Gy�-r������L�ϩ��ǎ��/(�ۺ��Y�lĚ���8�o�K�C�)���C	Ģ~7�t�*�$ �� ��d�oa��9�\�����[h*o V��t�#��}�o�2x٢N }@�

 Js

���/�

�+



�
>0O )���^f��#���C;QV�Ѱ2/����A��"՜��1�')	Ƒ9B ��n�
�˸$ �*�<�<x��Y��o� q;�����=�FL�8��! ��_ ���( %	 %�W-� �@)��-�1}���e2���ʝ���nn	sD��;�!�[��X��)�"� +U�ߦ� \$�WM��x�]h�1��8ve,R�,째�d'�M_�� ����8�R[����0R^�Y���;��c�����-��ѫ�1:-�j)(k ��:>ur��(5.d��R~J��է�"�ux�_��<

]���4����p��(<�E���B��{��̒	}�s4И��o��c��w'Eй쐢 #5	 s�=y��C� 
�J��
�&��M���]�(�)�� 2��,���J$לk �TXq&�ؠӋ�"ϖ�9X)֧u��Tf�Qʏs�KA�Lh�Ƽ5���#����|QnH;Lw'����J�㹼*^?���%cěj\_��J�,"�D{� �q�W�>�W�ll���X�Ì���F9~ L�:�q�I�u{�fr�櫚yf�PQ�	-���[�\p?Yl�@7��p�I�~t�$D��l�n3�)��2�y\���>�sy �y�́���Ƙjeg!1��L�YE)��𱘔U������̍C  �.\��_��L�����w�� ���+S~

@�0�-[|��d|�ֱr�eZ�j��I�k[�����V���"hb�X�^Z }̺�-�3'<�y��n�صst}�d���e�7����	���X��71ޣM�	�n6L�X���;�g�� =�e�U����3���(g�;�8�f?G

����
��.���ԡ"g*\��vV	�|L���Γ��&��^�(�x��"�:�̌p8�(B�̺��s�(1UM>*��62Tc#���[uT؏�����F�h
*6�x5�gN�	�ٜJ�usJ����K�6% `7�z�W�i3,��fF˶ke76�cΕ&��"������o���ZJ	O)�D;.e��X�!1�

�

J�

�

)

��m�

�l@"�m����;��Ц�Nq$s�Q�g�:"�בX�G�ĝ���-/T�r&�� ��a;f��cҒ5��l=v:��p��Tǈ��qaKÅ���c�M�+(��e53-?>�tka��/7�6n���ǐw2�#km����C�J��o��'3�`��M�}J¨���n��]�I<�fe`�w�W?×s����;��+� ���E��òu�~ !EA�F�q�%=ѦA-=�G܀��a��c�u!n� ��Go���; 



=�UE��pÅ�й�!�_> �7��	��9!'����W���ch/tj��Ө����r�Qx�tq��.c\����O�m@�忛W��A��[��g	�h#�p������g~��n1���@���I�tAʌ��/��暖j�E!����sq(IL��:y��i�5��ߍ��q���y#

�
�~+��F��ø�?_����#t˶���y+��5���� ���aᆗ?�vN�1K���	�zo�B<��[�sZ�m/�~�k��i)�?~+�W��n-`ғw`����#�������SEg�����I�m1��ߎ�\�iώą- z�l��-`�Ɲ��y��t�n�����qݮ�X�uOL��hH�p�#����f,��L 
;

ΫS
��

�.؋iz�,ȹ�_�N������ ����	EO�    IDAT'���'���ڡ�F((:�^�W�<F���|j�L<��Lty�=L^�c7괊U �0���0Z���Х"M������q �$ �J�4\�뀻���ivk_�����+ ��2R����W��UA�Y\��8�;��w�Sg���'���g����y����Km�@8Ӿ����

P���Đ.�#�kӰ�w%ը����wAIXŐ����%k=�������AVZ*̎�v" x�Ρ(<s��/�Y��7����|������������w��A��h�����/�77�L�������g��=���]o��?:

����7G\E!(	�����h�n�:�� �x� �)���}���#s~��}G�ʤE�����
*1?��M�U3�п�=������d�!�n��(7�J�6���c#f��:���k�(�\~!�Ԩ���DǴ"����+��$zA��f�R�8 D���Si�<���A.t�󑒘���v`�[l��mD�I+7c� ��8��=�''�AUv|��L1��9̎ XR'�x�Z��� {W���c';[թ���Cy������-����P'z_Ǝ.j��+U��u;����fΨ�N


��y
)lSN4x���*J��j C�Z�x%f�
����1bm��]��RUm��t�����|�� �蒬AE��[�)E�o ��߱C��1C���

A��

��
�

AA�Y<��L�3�ȅ�0Cf��x��z�ڕ+���r����d�SQq	�m؉K:�8��je�x7�K?|iW��k�/����H:�B_=5n��j��qe�fx��%�y$���b��K ^��?o�c+ω�7tOB���+a��Ö����_��)ƻ!.�1�*��e�;�RH2��u˹S)�@UuJ��#I�&�.

������U

�����
�4

��

�;�\���'O�J�T4�Y)��(*v�m���4��,!�4�S�BV��u�� E4�=f&K�iV�M���1�x��m>"�D�MXf�q~���ʋ(��:� x

���z���R��������Wkǽd|G+�#@Qnc����F����"cM���y$������TJq��)��y=4�V	�jU��A��%&�h�˛����;�w2��ΜŶ���M��

Pc�3� 	Gh��>�X_�������X6����̯v�+��(!C��ʄ����ˋl�Zt�h��X������������k��1����f�{Θ�\* ���H��RP�� C��� �_��!��mc�����'!����6|T�zݤ��t���d�A� ���0V;����P�I4�Ύ�����Hm%E�W3

Q7�

�

�Q���\
��V�F��!$HAY�������r����n@v���&+V?�g�s�yr��_�m��R)	.pU�'qv\�xd\o|$�)�Xٳv��*c��]�|:d��;�  2���.�*�M��߹�׸c� ��ߟ�2�i���K7_����h���?�����>X�� �;��֪LDC�Pح*N�˒i�� ��MxRU͕O�r�������M�"pF�� �xa���a%���V?�_��?}�a���Y��땷����{���������L���[o2	y+,p����^ �
@

��

�

�`��y���Y�9>����x#6�7���������n�����G�~���F���~)~v�[�wo[m�Y%o���y��!�ko�5w�;9��;'�>��]~��x��`���V����?=�y�G|cxݑ�W�|;��o���[��^�i�-l���p.��[��2{$�c��	.��6�鑒������%�0(����b�NUGY%(�/=�~���v�B|駿��*�P���������W��x͋�buDt�m�p�-��� P����~�? ��

<ow*޶o��o�ѵ�����R �A��K?�\v�8��{Vc�9�[�^��nx��{c3�Kk��p҇?��	�g:ȶI��F[��6����������/�;.]�KN�u��8��_��o��G ����xъ=�Ɨ����

�

��

�S^t0(������]}3���O��_^������c����~�Q���g����ǽ �<{_���Lݵ�|��+��� w?��2�I"�w=�����'O�-���^=���«�3�s|��kz)o����w��O��	8����A�X���ӕ�?��	�tn�8��~�w�yx�a�q��w���ď��bQ��zN�x]"T�<@�b0�_+������>��x��������(p�ݫ��oƗ~v]#�ٌ��#TpP� fy��:.�խ�u|��,��(\���~�h��_��K���zvONW�"�%@�W�����Y�j�,���v��>�m�����z{�&B9����u���am���"{473va

)���

�v E�s'�)y������[Ú�#㏤���ǁ�����N���f[e9cn��I�,4PDʼc�B`b���/;c,�.<��T���&����|��؀Hzb2	�$f������t�ε$ɤ�|4����	x��[R�8�h��|"=��	R

9

}

�

��

�<���
H��

'�
�X�

ǌ

���
8

�L�Od<�:� �m<�J��2Xs�% �n���Hې�\�V���Mn9��mm���N*wmt^��;\�N��'��V+��� � �B�����L�0Y	D�K�S�����P��E/�h$U�O��6r������F7:I�.N[����!S�^t���맕�ι���I�p�V��rAQ ��փuﺹ�bZET���n�M#~1�<	�UO�

��

���F�



��

����J�<�o�@F�:Dd�s>��]�3By�~ej*0���%�sN�����'�@f��j,�і�,�+��\u�	Z'���i�	?s�JӸ

������� �pԞ�U-y�J#b� V��Y2�k], �j��"4����b���߲�B�i|���m��

��繈�os��0A{����V�铼` �!4Ֆ�:(��J�=�%�$f4
�>g ���1�4�u���#c<�!E4JU��Z�e�ik�-�=��E��w)qA�Hm��E/ H��W��������U�r�eT8�c�EޘF��q�?�7���a�8���=^#��	r�h�T\�aW5��)�� ��_)��(�<L�x�Qy�t���(j�558#H���?�Ǯ v`�)��s��U��[6r*�O��8��Yˡ���X

�q�

�

F	���du{��kJ�7�
�w�al�'By�E��Bs�ɨ�v���Ƣ�^ԎC�g} �����p���Mmx7�Xӷ���J���N�mw����O��ϲUe:1�J�*�smo���	[�SV>M��'B]�q<�	1p��Cҷ�)c�i%�ҕ���.�o(+{�U���}М��q�&��y�����U�Z���@���?�<�Q ְ���	V7����s��	�2��+�̪{P�T��ꑫ�|��)Q�L�>-�����'�K#uB"8_��3�|��
�
䝽�.����w<����U��*���E:z���N��9�Z<8��.�$���}G�h�`f>���v`�[�τ�j��v�mp���;J�Μ�2,�/BI�J�8s���#x�7��8vd�LC�@��}Rhqh���F	5�����kr�":X�=� Ȭa945 V~��qTu��UOM�
!

���=�B��+J�OC�җ��W5������&H���bn�x>��!�xb��ׇL]^����*��L@"Y��5Tc��W�>ԺS���vc���( �� f�C�����Xwm�7�6�;?�'&�r�^[�i� �ӷ"�gD$�:��Kq0�i1I�B:X��`Xm1ֵ|p�G��w�\�~�T:���~pd#��w�����\�ܐ��� *}P��&�蹟��K	�q�Ӳ�6G�J}=��Oꂔ�{�̚�M ��-�����UH�s�#��EĔ�)��d4��͙Q���h:� �N"���j�O�k�4�"C�

@�M2$ͨ�Eǳ2s�,���?�%�J +�h� <���	���@� )So֦�-T4�N��Ě2��Ѧe�2�;��\)

ޢ:=lũ5��T����S�@��b���X�6GR9i�*�M��lO�\P%)���¬���)�ǲ�
�rM�۸[� kpԁ�֠�ND ��N�P|�!<��F�K�Ӏ��_Y~e=Eth�mnF-@��%���`	��eS��)���2Ky�@yXdzl�[45���s

v�=5�U6\�M}(�����M{�SX�e[G��&c�{,K��s�H�χ�����MPǱ �=TL�m.�p� 2�/�!��5�|//?�Kee;Ү���7�    IDATF���`	5c���Xf "Y��)bT4�Fғ�f�1Ӥ�1�nP.����Y�XB/R�2aW@ ( ���� ��R1�y�����U0��J#�r�D@�Ȗ��,_�@V����:��8Cp��cn�r�p1���+#�Ȯ���\�ߍ�$�!G�\��4v�xK8�s|�	祝�B{W������	Q�K�c��\8�{� 4_Q��O\�

��^��i
n�

�W

�

�

 
��V�

I?�J

�

����

s

��

v

�1�

C�
�

���
����

}

�}���&�GQ����\����� �G���5��(o��Y��Es�,���g����6K?/�>���ݼl3�Gv#��׏R\��O���w�����2.�F��!�Q���^�nX�Y

���j

\

����

�-�d�E�1g��r�m��t ��Ƥ���V��!�*�����*[�cl\#k����nz�lT��)�h'w��+e?�'Od�)l빛�,���5��o<��V�����rZ��l�C��x^9V#��I�K��W9��75�$����6D AP�JJ���	�Sy�r��WU�

�

��R�
�
���r

]��

��]���

ƻ
�

1霣|40O=rU�f0Z�M]s���g��٨�ҽ���F����.Qߋw��S���;�D���4ZY�����uy��G���T�Κ���N��2hv��/���û�t�G1�gG��*�L��s�t:1os����-M^���[�=G�L��T�@~I�/�a_�6�3\�� p�Ҩ�:-��:�Y��6��'֪luݒ��N���-��]k1�E�*�b�D��]�¡�US���jn~���W�^]�~��T��*-��~�noh5D}r�盽 �u�/�1��k�r� ���f�	g�]��5oF��K�տ	�/���Ұ��$��٦ŬA�X�����:/y

��
��
��]�W

�|����B���G&�9��8���_��	��iC}���@��9p�IN�\��t��ge\�R��u[X��LW�u
������

�͕Qz�[7�����!�w��nt��/� �h  G#H� ~G��AĿ�w�Պ�>јR^22�"���ݱ\���m���۩�I��%.G�-@&���SԎ;V�|,� q�X

�C�	�

���zΞ�o��[,w)��Ij��-d����^��5�! k/)�Y�O{[Ď.�G��u���U�o��v�R�K���Mt �	y��P�$�����A ��

#��

�u��
�
�k�Q��z?~K��m@z���. ����9	��8&[��<��Q1ó��>�>�cIy��R<	���S8:&�e` ��W���<���$0{���9�ӝ_�v���Ou��\Y�ם�^Z�+F��zƤ�����7���dD;��Q�A.�uϲ��h��7�

�Q��� "��a�[_/s��)W6.����帜�)���    IDAT�������A  �(�QX���7�|(�ȿ��O�צF_� x��`�l�I-*4Ie���#�
GU�凒n�]���SFRq��7j�	�%$�	�e�)�=��߷[i�*Vʾ��A&o�O�嵖���O�sgjS^��I��}zWL�w�7z5Y7����=u�6@.��Xκ`���u@�a�u�̣@F
�l�)%��Ʃ�]����K�J�N� �JՓ��K�h�=^���=Ex�9-mG2�Ca��R���,�CfJ֓����Q�8�'�5V��BNý(X����[�%1X�0�eh��2�$�6Y�֬�eXL�w�R�.�lOIWtSK��uŮo͉2���\zO�$����:�\V(���:)�)��O������d���Աr�.�lǑ�W���<�y-�, e�r��+��Y5�����ү�i0ըӤ�C[f5y$���K�lt�	�8�_�`

l
�$

 V�I����:��e����2Ԩ����^|�	�r��O�c��=�כ �^�w2�o���y�'�{��o��	�@��B�����8��.��&f��
Z

ߕ*Íu�ԫ��H�Q�|�a�%����i1�ۤ�o �o�]J�%LN��i��I;�{{jN�U4�.�_[뛨�wy�{��	1�isڟ�c���� �}�Yp�B;�yG�W�W�k��jX��:ӂ�6F�<Ժ`:�cP1�#��}�z:
��^��eVs�|�J�I�:�`�
A���<��ר��!� eo���;c���c}#��>W��(�h�V��x�$�Xz&*/��� �D@��ᒂ/�D��S �ݦ�rE�<'�&

^�(�W�`i+�Sƕ�����Z}�'�rUb
�w���9(/ z��j��1�Nї��f������׋g�_QP���?�����<ѷ�c���<�އA����o7�l��h��Z��Y�������D죳�m�K	�Ͱ�-4�R����|s�Ɏ6��Qk�w(`q�; ��x�

�

�V����
0m�Hr�������XV��EEy�>5�	8+�w��q�z�\v��m�'�fm�=����ȶ�-�5��TH{+�vf��_�g=^�⠀���LG�N��e�N}�Us��tҤ�������/���7M�G�d֪����R�}�l�e={����gا�9�w>���4��v�qf���u�2�e�����J]b�m?1S8~o �P���ӱ�,�e�L����i�s�����7�qW_ݲ��ʘ����<���8V};w�q%	t��i�K����{�Xˮ�<�[�����UիyfY��"�l��խ��b� �,�mX��8	`�v8	$H#q��@`!�

�

"�
�&����2�x$!�h0��Zy�3�LU�f�)��6��s-�L^����\��rU���{��%�#�P��^�����Dqc�� ��	fC0?� é9Q���p\�܌�ePjݎ�>#�a�̊������g��kkKT

���
��q��
KA�fWo���ǒ����T��+~����|>��z$�b��Q7%��/g�T��o��|m[)�'�}�|�N�>� �R� ��_|k)!�&�Bh ��
���H�Q�,Y�[� m�F���#0i���V�`��7y��Or�S�hT�}��"��5]�1���YB:����tWO��?��0��:�㏜|�-9��>1�)4�š?L��P �Y&}��1� �>ϩ�b�;=����V}{���:tIߣ

���*�)6�sJ�	�>k�U,G�mL�Pˏ>ۣn�7�O��*�S��K�r;t��dN_b��Q�*N�.�5�j�eSRYS2^Yf}b6w����6��*�V�$,.I&g��� P RZ�̕M	�Q����\I�1��
�y����

�

��f�ߥُb��� k��FM պ��f
���V��\�|�+M��p�<t�wӑ� ��6�ǔZ�7�ʠB�i �|�1�T%�	T�0�G*

m�

��
d�

?�i���T�z(~����S�fL�LB������j���g2m�w(	�J�$���l ,���)-��)�2_9��^=kr�o��G�c ���Ãk����L_P���Z���0{��i�%;;�{���;ͩ)�k�Ĥ�������L����_�Y{Q�u;����Qk<�2[/B��t@Hٟ� �8Ui�@�C����#3$@� ��*�^T�(ZsH��H�

H
_

�;

m�Zv

L�

�

I�

��
��?�
3

�

vÇ�b��ÉZ�E.�9���@� �q=V�sȵ˟F�3�~\��|�Ȃ���X�(�m3 �}��r9���	4�GR����Z K>��p,���	W`"�6�R����q��).�����w�b �8);&���b

%�

����

�����Z��_���LJ5&�FS�����PT�8\Z<@Fj��B��\����J�Y������
xr��*�N/�#V1�D1�|�f�xe�pt�6�ғ���<�}۶h�>3�U����앛��o������__BI\D�ן:�����s˼�߼��g�^r�#��D��;�W�w�ڹ`���7�=���l���=[7�g9����p��m�~Ӻ x��>��i|�G���װ�q���1<~hwg��x������oZ +�̓9��'

�@��q�֖HFͩ*ۏ}hH�%^�ǰ���P��Խ��>z�x��n_��>�2��ZIT��i�r�����^|o���d�#���"�6^ ��dHf01 "0k�洨o�[���(<fe�(l�����D�/aA�`�=�1��j�d�
�

��

��

����

.��PϞ��������;���H�ѝ���ѽ	 ���de�Y�2H�&�7���eKd ח���gN�W�v��q��M��ￆ/�|7W����>f�x���H�e����{�4��=�q���Ts ����]��".�(߬�ڥ������Gl�����������$  �

�w�"

�

J

>ٵ��O�?��ݥ61�n��w��"���35�+��ő�P��� �Ș���D4I𪞺���E�t�Ӭ��.��O��&;I(������	!�#�U�W��:g���x1�S�d��l}$�9�Gn�B�-�-Wk�[� U�nR�5�G�h� ��
��d�gf�IuLc�\�}�8�g�� ~��#{1_I������ʳ�b�;��[��+z��'��<1��A0.^_¿����_�

|

^���
���:�

ߏ

UO
N
��
 �.

b�
����

%���e�GX�`)���v�W_8��{��8�o����$��W��z	_x�5�X.+�1Տ�S��mD�d� oG9�d 

�^��A��f��[3���~>��ar�S&��¯�m�lb^�>�2?P����ݿ���9�����3p�Y}Η��NVn�t��D���^����//�;g.c �B` �6�O܍_|�n�޺ɦ{��n�ڲ����n<�̉�0_v�]���gN]��Ѝ��7n�
����

MI
 ��\@�Q,�)�^ �EhT�'�p��ԁOMTN;+�/0���.�v���Qp̚@�/�x��%��Dx��� ��d��6��R"2�<IV�*�t��2~�'�en���Խ�;h��&�^�� $�x�Cs���?v,x�i �{���}���k�Bp�qӠ�G�ُ�޼�7o�*�}��2���9��{��ڴw�f|�8wu)�:#|��;8w��O
�
���H������'�ⅳ���1��.Yx��.��?R.�(�u�<>��Q<}�<�m|�s��K��̏��՛�`f\�q�����/��m�����q����W��78�ɱi������.	k(C�1���GN��pû~U��y�m��L �	R�g���� ��hT���l��@-@	�:��,L;K�U��@���vyk�����p����<W`��f�

��!��00E�5�
$�ӳ�~B(�{$U�_%�\gm�����    IDAT+�Ѓ)K"BX���Ӫ���>]D�W7;����x훜�or����ڻ���S<wi��x� |

�

��*�)t>��kC%�>9+� �ܬ�w4�;9���Z�<���FsK˼|����t�S�#��F��wok��,��B*�?<��W_8ͱ�7ػ�����dgs
~�d� ZWc���ck�@�@ ��ķ$�	.]K�$�?���oL�Jh}Yד�l�
������

�

>�
l�

	��

s`S�
�Hb	`�,�������n����mT��5,�R������ybYX3}�	w�V���v����7.��r"��n����,ϝ�en)�`imA��)pH#���-����rah��v�����ڲ A�E@RB4�`tn���<sa���t���|�b�ru��CS<���;��)-!���

6�

��

�f�

�V�W|��dփ#�+��kkΫ�	z�8"D+H03��x��Uq��v�'7���{��#���	%��-]˭dN,��ʤ���F���� [?��s��.I?�3l������K���-����H}r�c��>j���ʄr!��Gw�s}��h
	�D�O����r޼���C�~o0"�&�*BP������?�هx�w�_{�塀}���WCE)[�+x��%�O�9Z�5V��j�$67pdK!��9�����{��T=�������r��Q���k��B#���G��u볠�|ww���?� �mou��Χ[��#t	O���v�|��f���G�#��	k����B�*��^�U��'}�3?h�߾��C�_�C3*X��>^Epwg3?��������y6ז�R����

��

[�V����]'Q�Nʚɍښ��V�h��L9�����"J�=�!U���$��ƞ�O��9*�֑�V�����?V�L���������F����� m�����N:t}��+s~�������=7۟����U֨��q�

��
�r��

7�

�_���v>��$�c������~�T�	##	�v��<��n	�s�5}��

����
�3

��8

�U�

�
�#

�V��

SK�Ec	�	�S���~e����|��3��s�z�gG+���!�H3�3@���_~�$��p:�%�66M��
��or�Ɗ�if$%<���/=������
Z[D��f���t����4 �Ͼ���$_��Y�lׅ�||�p'�=�Ü���]MU�l����Q�4��QA�y���ۮ�&�v���Y���3�� �H�J�{���

�



��

_��

cd�
���������

��s

�
C1���

}
�

�5�

�j

N����N��y�!q���Q(�,Ws���Y�P�<�g�L�l�4�%�o+�<��)8t��
���� ���1gL�*�L7��d��V�� 	m�$Xu2nꤑ�zH�&E�C�9%PI2�4���݅��X
�����

t���

����ŭ*|���|�ʵ���7&yeF"{b�Y�F�H�5[w	��fBA:�o�x ̓βvI97�_�GUg|(�	��������.�iچ'rNoh2ȁ�>nnnp$��bKc5�E�

�

vb����N������"��x�l/=�A�]M�#P
��fǎ�K�d�eN�4�@�����s�a�N��$�����"f �po/�ܟr����x�th^X�I��肔	��̌�[��6Œ����yc .�&e�v�׈[3��]$�"��I5{Jz6���Sxp{�fxx�
f�������6ӂ����?����;��9���N�(��2�~ p�W��t�^V�� �4)�yf/��*K���\�ǯYoܤ;���cS|�;/��|o֕�b���>ʋ(-H��1�c�Z��S�/�~~���|��x�M,� ������d(�߾p�WN�3� ��"�o\�'�i������I �L����ɑ���sFҠ

�

�
�
;M
�

�O

a
�ۢEB��<�_P������M�1�÷����$m�s�Kq1I�\�w|o�U�6|�V�%YK�㔐��[<�ܗr�	��K,�� ��a�7��P�*8�M..��Fּ�����'�J��oۊZ~��t��'�k2��-[��U�R�+��Fyj�

�

�

#������

�

��
�

����{�<ܴv)[�񨊣{����9�5����rk_)�{�Ͽ�q���3ݼ6	I(B�D�֡	F� 	3[�&��p��ӽ�H��h�k;Fb��b�����������ʊ:��1���=.�z��ï��ϡ�-}9��1G�4�=ҒB���1&�ӏ���NF|а��HL�#m<�ue����*n\SG��ٜ4u�'���]Iu�/av�s�2>��Iɠ?ğ�t��Z���-j��v�I�~a̳�� ��}�xL�����Gf��33}�:70��^8����b%e�����g����ZQ2��=�Ls��v}�t��{���)�&���bq���'��[6��2U��"3�-=A���a��2���0=�����8��_=���T�3G�\ܘ�:�b���2�"Up)�9:���#AX��K8C6.q����� �Ek�X�"���븑5o*s�9�i��ݺٳi.1����F������`�0�*-Gwy����QR3�6�D�L(�>Ƀ��'��� p�
���:��u�}�C�3~�D0���Ϣk�@"�g�c[���A�D�0'��CG��II�]�v����`�����a�1�n��6[J}���i{�>��ۜ��,���h ��g�m�Z��(R�trޖ�����h� Ǻ��>�|-p�k���3	+AM�w��O��0�~�d�NN>�6�|#���

�#%�(#��h�1os� ��.��n$��I��L������)�	G	�ꦄ�L̳�~ƽ��o�m�Fֲ��>�,ߧ�K�EQf{�_��Z�"��n��ځ�-'�N�M�V+�fi��%
�U�
K��a]���D�ډV��ҼiFO2�]&XA�P������&�þ�Iz�q	���<f���ό�o.�{� ٣��pI��Ś{�?��}ZE�� �r�/ӈ����]YrR$��7�o"�HӜ7BJd\C��FZ"���@���+���L\��P�������3����r^


l�

���

��
}��/

��

׭��

�y
�

���H



����*+k�ص��2��� ��hK�ٓS�$�<*�y�v�x�V9��kR����|�������V��d�3���J~��ʡH��>�6��EPZ������څ�1����u����ƒN�iH4����|��/>z�H�<����QY��w﹊���+�3�]�g��޿��v�!��"�G��4���qN�Mس����3�,G�v�ϊB_�}_�} �k��]L�}B&����pap����wq�

 ��7�4[R���C�h�|��k�O7nv�ivK\�����9�h �q>ٯ���Ir���(��qMr�c�ӽ#H��� �@$ʉ�!TC� n
�



���k

e
���4

�

&

�,�

~+{y�J���=9���'`��	e[��j�����)I��������P��%��P�����BONT���g�<P��[��3M���y�~�<ٌ�#�n�e+85:�W��c�`8����@�����Sv�b���$/]�K�\��G��RA�4ٹ��=���ĩ+|��3L.Þ'޺��śK

�0
�T

���

�����

��}����p�{�� QR)���<v�T�\?�s#�ܱ�άV���7R*�]㻯����+<w�S� ~��F��s���l�RI���	»�^��g�	9t@�֑��X�s�+'�v�mUN ����aaO���o�H�5ߛ"����&�Y'4%��Z�D���$����s����Z� �

��

#���

���

�{��
�

�

�
q�

(
�{7���~^�0�T���v��c��������+�*N�D��;���ݛ�ϳP�T�s�l�����7ϟ"�ܷs=�}'��~��h����៎�g�d1Н�߽�>z�v���7xd��O-���M.�0](�������ph� ?���99>��|>����`l��o?u�R�b�@7z;�x����8�)�OIǵ�����^L



t
�
�7���
���

�*	��4�D��u�!�&܅�m�:�o�Q=���Oh� �oM\T��8A�WT�Z\�X�9�Wp�աڮ�տ��3�f���3�K���97Zn���-k�>�˥�������}���mϞ�Ɨ^9hpk��~N��pjtF�쥷#K��2ƒ���z��x�!޽o��=Q-CO ����N�ڶ�Ŋd�3Õ�<�?s��i���-��Ϝ�P�822��v���1 �����n����z;�|��9.L/�ܥ�>u�`�p?k{:�7�Ǟ�~>��9�+Q�3�f)D
��3��
��

�
݆��`�˦�ɼ�{q���^����O�� h9pCZ}Ѷz-��e�ȋe�>Js��ߐ�?�s����'�0p�����41U
�

���� Ppu.�K�'y����zu�׮N� �B�=[���[����,�R�gd6ϩ�9�'�k(d)���X)�\��2e`�Rѓ��Qlc��� }"�ϝ�	�� Bٗ�H��=

W�
�

| ��}�o &C���r��1�JY/��n}�ON�7\�V"�[n��N��8v� V_�rj��?}�2��mb'����$F|�ɰ�t3B�@�T���kA�Y��yT7W�u��&�@������	�lb�0bJ��"�J

)�

�

��

��N�
lWZ�'K9�{
o$֗����7	J�q<�m�.�"7&̂R�v�d�t�3�pN�@*7��r]�u�GY�����i�Z���RW+�n+�܎]!�)t���k� XT�$�+D��6{.��	�`��D����IT�s�dU����h���$�L�#)�H�˖�w�w:��)���(5�h��~�

��>��.�R��/�C'�N�]���� 1��V�U��hU�X*Z�v^�{�i�;9M�(�m�c�����~#��IҬ�o��k�0��n"�cEhǲr G�N��h��l��j��!���C$��Y��i�� ��t9����o�h��ؖ����C��z7֦pܰz����������k��,��׷��z��?E�ƜS��Y��*�#" �y|�lI���|<hC������<N�Qds�f�Đt	�@�O��U�����n���	����	M������#�`�z̴���0�B�

��J
)A

�����#�O�

Z|k��m���v�|��¬|��f�$���gq8�o/+.c�؊����xQ��-9��:n����4<��Bo%m�#�a@JP9R�3�� ٲ��)��tY��t1�-%��rK��;�< ��[�z/�#�������`#�u ͩ�|[��G��ɽ�f�֔�,��'���VE����ʥ��ŋ

�l�

����
�����;�`�ն�	�Yb�S� ��a��	�]n����

�p��mG

��

�|r���؃�Ma��)x�x1XQ0X)nV���^~>��Sg��7�-E��2�+5��8��mF�#���~�C7cը�F�`p��vޯ!m�.B�
LTc�{������5`})�ŷx��.����eP��oZrSp�k^o""�1Ͼ`ĊN=;�/fA�щϩ���1[W7�Ű���/�/&�?	=.���5�P�k��g����

J

;

�
�X�

&�

�b
��u�

�%�

��1���

��G��

�

�
��G�

v���

��
���_

�Q��

d�

�	�
z�
;���

i���

@
�

W��#Z����{=���'�b��J��]�5;��gb��9D�� �9I�jϢ��~�$;��5�C�k�{�^U�ڋ����c����<R~�. �9�l�d5j	2��G�#9����� v���s�������K�9Y����
��a��-��#���x ����*2��5+uF�}���V�e��sF�}�}��M�S�ϞuV�&�Z�^>���Of�h��{�)gn�8yUf��m��$�~3&��s-� ���8��s
[L$�#� y�'-�[��������>�x��=#_<�ͯ�q�o��h܂�]��R����    IEND�B`�



40_ONCODNA-COM-PATIENTS-RELATIVE

OncoDNA:SupportforPatientsandCaregivers

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogleTagManagersnippetaddedby Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

There might be better treatment options for your cancer type 

How biomarker tests can help you get the best treatment 

How does cancer work? 

A collection of diseases

Cancer is the name given to a group of diseases characterized by the abnormal proliferation of cells that can invade different tissues of the body. While healthy cells grow and divide in a controlled manner, cancer cells multiply out of control. 

Tumors begin to develop when a cell acquires a series of mutations that allow it to divide uncontrollably. 

Multiplication of abnormal cells causes the volume of the tissue to increase, a phenomenon called hyperplasia. Further mutations may occur, which further affect the control of cell growth. 

In addition to showing uncontrolled proliferation, the cells are abnormally shaped. The tissue is now said to show dysplasia. After a while, new genetic changes may occur.

Mutated cells become even more abnormal in size and appearance, but for the moment they have not spread to other parts of the body. This is called carcinoma in situ, and it may remain confined indefinitely to the area from which it arose.

If genetic changes give the abnormal cells the potential for spreading to lymph nodes and nearby tissues, the cancer is said to be invasive. Cells are likely to give rise to new tumors (metastases) throughout the body. 

Why is your cancer unique? 

Each tumor is unique and treatment can be personalized for each patient 

Unique combination of mutations

Each cancer has a different combination of mutations in its DNA. This is what makes a tumor unique.

Biomarker testing helps to establish, what we could call, the fingerprinting of a cancer. 

Different types of mutations

There are several types of DNA mutations: single nucleotide variant (SNV), deletion or insertion of DNA nucleotides (indel), fusion of two DNA fragments to create an oncogene, and the amplification (copy/paste) of a same fragment of DNA (CNV). All these mutations can be detected by OncoDNA biomarker tests. 

In addition to DNA mutations, a tumor may also show many surface proteins that could help identify the best therapy. OncoDNA is a pioneer in analyzing not only the DNA of the tumor but also its proteins. OncoDNA is able to identify these proteins using a technique of tumor cell staining called “immunohistochemistry”.  

How can precision medicine help you?

	The past decades have seen significant progress in the understanding of cancer biology, and oncologists can now choose a treatment based on the presence of specific biomarkers. Biomarker testing and personalized treatment strategies can increase the chances of survival, as well as avoid unnecessary treatments and their adverse events.

Targeted therapies have become key in precision medicine. Many are currently under development. Their goal is to halt tumor progression by inhibiting the activity of specific targets related to tumor progression.Extracellular growth factors that promote the formation of new blood vessels (a process called angiogenesis). These blood vessels supply the cancer cells with oxygen and nutrients and are therefore crucial for tumor enlargement and invasion of new tissues.Transmembrane receptors. These receptors are located on the surface of tumor cells and bind to extracellular molecules (signals), such as growth factors. The receptors subsequently transmit the signal information to other molecules (proteins) inside of the cell.Intracellular proteins that receive the signal transmitted through the transmembrane receptors. They promote a variety of cellular processes, such as tumor growth, survival or invasion. 

Hormones are important molecules in our body which regulate many processes, such as growth, development and reproduction.

Hormonal therapies are drugs used to block the action or production of hormones, thereby slowing down or stopping the growth of certain cancers that are hormone-sensitive (meaning that they are dependent on a hormone for survival and/or growth). Hormone-sensitive tumors show hormone receptors on their surface, such as estrogen and progesterone receptors in breast cancer, or androgen receptor in prostate cancer. 

Stimulating our immune system

One of the main roles of our immune system is to defend the body against infecting and other foreign agents by distinguishing our body´s own cells from foreign elements. The principal immunologic cells are called leukocytes or white blood cells. Some examples include macrophages and lymphocytes (natural killer cells, T-cells and B-cells).

The immune system not only provides a line of defense against foreign agents, it can also protect us against tumor cells. Unfortunately, cancer cells have several strategies to become "invisible" to the immune system avoiding immune-mediated elimination.

The goal of immunotherapy is to mobilise the patient's own immune system against the disease. There are several kinds of immunotherapies, such as artificial monoclonal antibodies or immune checkpoint inhibitors. The latter ones bind to molecules that inhibit the immune system, blocking those immune-inhibitory molecules and reactivating the immune system. 

What biomarker testing does OncoDNA offer?

	Our innovative approach is to combine DNA and RNA sequencing (NGS) with protein analysis (immunohistochemistry-IHC) and additional techniques. This gives a comprehensive view of the tumor profile and helps identify more treatment options for patients.

OncoDEEP® 

Analysis of advanced tumors

OncoDEEP® analyzes a tissue sample from the primary tumor or metastasis through a series of tests on 638 genes and protein biomarkers. This comprehensive biomarker test helps to predict a patient’s response to approved or experimental targeted therapies, immunotherapies, hormonal therapies and chemotherapies. 

Blood analysis if no tumor tissue is available

OncoSELECT is a fast and minimally invasive analysis of a blood sample. It is the perfect solution to identify treatment options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can help to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as to monitor cancer progression. 

Personalized liquid biopsy as a monitoring tool

OncoFOLLOW is a test based on the analysis of circulating tumor DNA. It helps to monitor a patient’s response to a treatment and to detect a possible recurrence of the disease. The test is customized for each patient, as it targets specific mutations identified through previous biomarker testing. 

Discover patient stories on our YouTube Channel

What about reimbursement or financing of our tests?

Our tests are reimbursed in a growing number of countries. The reimbursement depends on your public or private health insurance scheme, and either some or all our tests may be covered. Our solutions may also be available through certain research projects in which your oncologist may be taking part in. In any case, talk to your oncologist and to your insurance provider for additional information.

What are the odds that OncoDNA will detect a better treatment for me?

A scientific paper showed that OncoDNA provided information on available treatments in 92% of patients with advanced solid cancer. However, each cancer is different and it may also be that no alternative is found. The effectiveness of the biomarker test will depend on your type of cancer, its severity, the treatments you have already received, and many other factors. Feel free to ask your oncologist to contact us to assess together the potential benefits regarding your case.

How to order an OncoDNA biomarker test?

Your oncologist can order the biomarker tests that best fit your clinical situation via OncoSHARE. OncoSHARE is a web platform on which it takes just a few minutes to create a secure account and place orders. Your oncologist will receive the invoice and the kit to be used in order to send us your sample (tumor tissue specimen or/and blood sample). Once we receive your payment and sample(s), we will perform the analyses in our certified laboratory. Your oncologist will be notified as soon as the report with all the test results and our clinical recommendations is available on OncoSHARE.

Is there a real chance that I will respond to treatment and live longer?

Our biomarker tests are designed to provide your oncologist with the most comprehensive information to make the best choice of treatment. However, cancer is a complex disease that evolves over time, and therefore it is very tricky to predict the efficiency of a treatment. What we do is to provide you with the best treatment options based on scientific knowledge.

How will your tumour tissue and/or blood samples be shipped to our labs?

After ordering the test that you need via the OncoSHARE web platform, your oncologist will receive a kit that he/she will use to send us your tumour tissue or/and blood sample. You will also be asked to settle your invoice. Once we receive your payment and sample(s), we will perform the analysis in our certified laboratory. Your oncologist will be notified as soon as the results are available (7 to 10 working days), so that he/she can check the report with our therapeutic recommendations.

For what types of cancer is biomarker testing recommended?

We do not advise to use our tests for early-stage cancers (stage 1 or 2), as well as for liquid tumors (i.e. leukemia, myeloma). We also do not analyse paediatric tumours (patients aged ≤ 18 years), except for glioblastoma cases. In summary, we recommend using our biomarker tests for stage 3 or 4 solid cancers in adults (except for glioblastoma patients).

If OncoDNA report suggests a new treatment, will it be available for me and covered by my health insurance?

We cannot guarantee that all suggested treatments will be available and/or reimbursed in your country. In some cases, if a treatment is not officially available or reimbursed, you could enroll in a clinical trial. Do not hesitate to ask your oncologist about the best options.

Would biomarker testing predict my response to immunotherapy?

Yes, our biomarker tests may provide your oncologist with insights on your response to immunotherapy. We test a wide range of markers of sensitivity to immunotherapy and provide an immunogram to better visualise the results. However, we may also recommend other treatment options such as hormonal therapy, chemotherapy and targeted therapy.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712125182



41_ONCODNA-COM-CONTENT-UPLOADS-2024-02-WEBINAR-REPLAY-PRECISION-MEDICINE-NGS-PANEL-2-PNG

Tlatesosts ebsite (Liken Post ebina-repla-precision-eicine-ngs-panel

Cn2);)$C﩯nxɺpQJiHo  s 	'   PrL 	kTr

 @y㨡!Zƞ͚ &; SpF	OZЁ;P ږn7P	ӝ2yt"eAk

% NAH^t"@-POItиOۘ
	F1H<ֶ2uiԽDwc 5	0~-D

B
xVW5P(.٤Inm	͖4k5I$nmggO	btsu:%%hVkA̫%Бѱt+PY4Y0퐓ò3c &

uL|Sw˗:L"T^֘v<WPk#proNyIEͺ`t#dX]1GBF7sEm#oA0B]թ\%)r|ޘ^u/X+"Kt/+Y I-WڥC^"|%Ы	v }b ] Y {p$발sv=!Oad`\|O+0b%N N X5Oo/2

v

W

yP8[ gyt	D' 	,֯飛{.`	u#&/QD@Q)b.,



r8NYee$4	T,[n	oUrI6U:H>8U   @|@IWmS{<ud-wqG7.	mJПb66nsUwp},Uۈb[vp̪u5ʌY+S,	]

%i;h懧sr de/t5u5b-R}"F0qs0(=.

s/G8aXX3|ccT-5$Mr-q\(s5x5
Fjɫ%돭R"G?IAuYJ[Y	�J:�s]��T�nD41GHhɿ	�XY:$�+Nf4t#']n�y�S c/ග �

gA%(72^I��CVN�u}TEVm,�:�٤�+1_8d
��	�$yE^�XNx�q�UFBMN��Q B��*�8��yA	B�^0��
5�@LUI My	�α�9�2ղ٦-!� p	�)�

�

CP�J!B�ٓ�Y�圵�]&4�Q�+۾y5�%߅�2od9+U6J#ʫtW�9��EU$1!�g�d�\&^ui�w�J7�%y�W�U ��3ݡĒ$���Ml	�

�

o0��/J�L*�o�qw�؂���gG}T�R�_@Zx	ܽ}34Mñs�W�aQ�e d��W�R���:�@�$*n�E0 �tB�]!ILF ,�>S\j'�9I�-�²

���CB8u ʏ�0��	pB�Ofdq�8�>\@�yR�$�,��~14 ��QqYf���Q���+I1�]I�d	A!�7��A�Cd2 ���.48�ώ�Ed�;�F�E��.V��5�s��s���-:s�U�� "X V:��\S�;�c�ZQV�o�d��X

��h�M.�$��Q9%}3��J+#x:�{:�,Su�'�Y�S�slU�usiZƹ���J$k��wd+؜���.���l[�mMp�B��U<9�"�mD�;j��!B��cDVM�Ӆ��	���,m`ΞkE�RxT"�0	�%� 8��oZ$U.x陼����/Y)Q]J]�I��5]혜[����������_���\>̽9a�uUsM�$�N�a.�F��+��9O�+��H,SV�m]��'%g]�-��b\x&��5���4���=Y�g��*9�bg�br 7c"V�@UG�A��!BuBUz�9�	I����U^E�Uՠ,�6�	FG}U[J�E���L�M]-������U]O^Fp��wu�ݚ��f[���߃Gv�CkS#^=}	�702�h(}ԧ)uw��3H�����b�o�V
���P
�<�(��EV�� c��]�Q�\P� �n�K���+䕽�R�Y�����S�\u��;>,����R��B%꽖	H��ͼ����߻IW�M�JM ex���!ݛ��ȝ���aUg+��ɗ�Jg*�-;��DA�sla� ��+ ��S}�` �Z�	.@$

�
�

w
�
�
����\%��

�r
j

�4
�呈iؿe-�
� ����<>^>}	����}3Ã;�cug�1�,�X���9�ދk@@F�C�t45���	}��hL�1�����s�9����,��5��_ꆠ�zۚ���

�q�

�?
�7��x�{
�M

�x
�r

q�-�* Ǿ�.� `!���o�CsC�܀DL����2؍kӳ��B G.^��uuzZ�qubo�I!f�Yι?=�*^ t}�
�

�m

�\

�

O

�

����

<�0ư����@2��s�s�7��;We�;]�ۗG5ܳe�w�G�3͸|sZ���������L&-Cill�Bv�s)�'E-.�W���T(QL�Q~KE%�U=𨸕@^��s_N�"�!Խ�� ��gr;�ʥ< <�WaB0��6hƜP��݆��G ۹���ٷ̕I `�!

�X

��o

�B����<
'�$�M�{So�4�&q��].�e˒�b�%�w, ��}{�9�3�;ۀ� $~�[fΜ;O�&�8�Q�{	KX��.��>+������)L="L��s/�K���^�>�4�P� (��袮�ۮ[���A�N;���:F���������6ڇ�����kV��
 9�7��fn��	�**Ǽl~�K�*N����U˛)w�P��p ������/�����@��3�`2/Ft0�

Bј���I�����Z��	��� cL̦>e�XK$��x^`d�I��P�e������J`�;���@b�	�,�BQ�Db1l6�嵕lh�eec--5�NGO����k�y|�y�,�o����

E���������~��ʹ��.���]� �6�M��ٱ��@�%�&�����5Z�"�k��{odòz!h��b��\G�SU�P��&���i����q��癜����q�(3zxz4�dN-w����kBk	KXB1#鱄�X����a��W�����G�bӊFU�}���/�뺩}�=!UQxǍ��Gne��f\vc*(̫���ѾS�9�l�NE�5���v��t2~�{�|j�}<�E0�	��}�X�T˝�V��h�*�����Uͼz�"Ԗ�����{�_���&��N�o(�s�ÙQ��tt�q�g���2\v+j+��{oDQ�

���
�o~�*�>GT�R�;!f��K`�⻯ce}%�}[�l�۸u�JV5T`�1�h����Gb�.\�w�C}y	BV�Wqc[

��
E�����

3�

��
�Q

����,j]��B��<&]0H�NH�|��S ��P	�|�s�箙���0.��eq�<�$�[��5�k���1�l�l���*�Ԥ�檥���D7�"TE�I���Sn<f�)�6����Ec�z��߸�j�* I��0#�B(����g��x�
ۈ��0/(��Q�ѝ>�X�����]*J�t��	��F-�K�B{�����d�g$	�Es-4S��L�p$Lע�����,X�5̖0��Vz�X"�R13�4BzX�iT�2E�b'�m(r/iS�L7�c<t˂�� �X%�9�&������r�9O��y	hsAJ[z��	��W7],�,��+Y����
{�@զ��7QY�B�|�D�>�C;ֳ���ڲ�;m_ǝWq�b%.Sk�h�HL�0{� ,�)�����xx�z*J� D�1�9r�s�#S8O�������TUA"	�4��
E��PG�)q���)Db1&�!J�vJ�vb�Θ/Ș/��K\�##4F��BU�M�q9lT�]a���#����6�1���@�$+�!���P]�&��	�)s9(q���v�	�o Q��%.B��P�r�#�/K�%�PMJ��0�H���DcC

j�IY6L_���1j1�Y̾o兩���	�!�,�IX�В��G�u.L���-��vب�D���	D2}��u���i�h�&�ݿm�BMY	B�MU��Ŧ[_$�e�Ué�'4�/tXq��.�BuY)

ޱ�M����ޢw�P���4#44�u���k�,��ZX�dҧ�Hw/P2ָ�VTr�I�+�Bp�q�+�x�z��W����E�h�ZĜ`�f	K�:Q��8�d<
��s�K��Dɚ�陑�p�M��C1��	/ɱ-Y��ɨi_$�:�1	se�+06��߿g�kߦ� A* ���Y���e�:|��M�����$6�[[�h�,5

���

?�

��9

��*

������v�

����X0�:�/��Ȍ�o���R3I�[d�B��ulAZ��Lt	�|����B?�"h�,�g��s��������O���{f�6sN��8
r�g0���n�-k��#����.A��[{�qn`4�]�������i�q���ӗ��g/q��`$��g-E�%R,�S���8�0L	��c/��L�%���s1��M��Z^�%��:~�-�T���*�Zp��j�Ʀ����)��sdګ��w��8��
#
�>

��m�

`�
�

�� ��v��5�%x�������I��R�����,uӴ��,l�	�!��s0A�oT*/�:��~5n����Qp���a���O��x���P�]��ĽJ����ҿ	�Xo�ɗ�.��#?�n<p�����ᅛ���1�ȫ䍺)�����#%8|���5��,  H"�j��!�ڬ�w?YR3�e�w1u�(%�8��PBN
X�n�v��t���8@m�$&+C6���JlV�$�RX�R���Zʱ�$33�e�iOK��* ���>f#� ǸZbpr��h/����5��z�?�t�a	P�4�W��6	,F�}�WM+J�u�p9�8����w��������]VR�e�\2�UdP�<	t"9vh�:Ɍ! vga�2f!�� �(Q}QGLz�u��:�z����K`��N��x�%�ͷ�w�M��3x��,��܅�bOh�]*/,��cu���

�

R



u��<�#�kS?�ݩx{�}��˕i�	�=�����'.�`�7�vhgky�]fXJ� ��Y�vM(%+�9��*�%�Ȓ����w��恵aÆ�c�J�Z���Wc���

�

B
O��

��kAZÆ��Z'���u���~J�z$.]�P��.��=1�͗w����_��>�S�^��Iy�h#2�ȓ��Q ��w+w�4����j�q�[�L$P��

��

�s����

�

��k;w=�[���y�Z�	�L�mq1J�\n�N��X�Tx�d[� ,����UA����EWm�ޘ9�W"C��t�Bx�#�x�L�>Yvb�k��[nl�4Y_�t�+Er��

Z

n�V?�yo.���Ca�� Br�K4�U�((��:�{���{��{�hiח�z=Q�<:�7���6YZU?^ 悞Ȗ;y-	^��v��$�Щ�PzZ�ʨ�Q?���}yc��K��8���W7�� � �

�S

�6$[����ח�eۦ�Z��+T'���6@.+���ݚ7��!���~�l^qc������3��R�wZ侰p}ӐZ�#�("�9"����(���N�ޙ��!.C��K��U3��	�g3�!D�\��28OK�V���+�ʯ��u�\�M������ha�_� �b�K\��!���t�m(�GU���G_�A^�
��p
�

x����F)���W�d
X���ư{�K����<�QT�����d�Gދ襑�F/T����(���U�Qu�P9e{5O�̕��t�I�	#1�%Կ%�DJ��#e/�H��Ah�صx{y_�X��g�����h@C����Sɫ�W�KH�s����B'�%��k�tj�NX�r�kD��LP�%O�e��!©��E��U5.i"����[{b���
���

,�

e

�

V�G�#�A�� Ɇ	�4}��,P��z�k�w���M���

��
��

�

�]�+T�N\��8�����:�&�%�� �.���,A!��{@L�><�ZLڎH �N`D2R�K@�Vπ˚�G���śwsV�M6��-�RP�. �-ԬT7���K�|�*���� ԜoqhPj�$�ԠO݂����!���hz&�o�^HȀ^���8�D��)�=��ǅ��:�_��$��Ns�h��Mae$D��إ�q�c��^��{PɐGp��D\�F����h��d^��:r�D`9����]$�i,7 C

���i���<�e�k��I�\A}P
Ȭ4�����ɡ���W^�^7����� u�ETd���y�����:g��^l"uXBs���ZpRI'���#|/{C1D��J"�!��/	6I���k@��ٿK�hP�2z�lhJ�+(��oN�(�
��ڴ����O���+�ڤE81_�֬���g[�����$9?(�~�57Ee�?�E-;	��J�jΒ����,BA����\��b4(P��H(@ÊF#�T�L�;��F��ڬ��5�͍��7�H7_�N���(�pc&1�QR����>f"\��Ld	��/]���E����.:�$T���-n&!�c��X�y7�ޠZe����]E��3�ri#{�Cfz)��}���\ں�0o����焻�j ���Q��r��?J� %�@�b��V̀""��}VjW.�����|�H

j9�Vv�9�gY"|�b	�4Nx �&D�oai��q?.Yh/ψj���A�M�#��ŏ�~�x�HX6W�H�	��lm!�	JD|0�7a�}����	sW�ȩ����eJ���]�G�^��˔��Of.���
�

+���ƚ�T�dCQ���	��'��;�x$ SE�����Yk ���� 	!)Ek3a-N=[`S#��0

|��

�
����
�M���?�$���d>C�,�z�ޭ��ŷKX����1p�>��Rx��f/�ة�u�V"�H"�D��H����{�Mꧭن��o�ҫ�+�;�ho��R�`�C"�)�)�<�%J"a�4�Z�ş�Qm�Bu��hZ)f�	13S�ĂR�C';�S@�, �L�j��)W�Pj�2s ����z�9���2�S��)#�a�p��9�F�K�c2�}�`Y?!��ha��i�%�� j1~7�ܵ���t�w�Q��:Z��#�(� u"��Q� �T�b���ؼ��ǲy�Dn�ۙK�XP���,�*��?�l�,�O3�ŏ�%�_�y'��E��;���XV����q�ӆ�ŶBp��,�i�+?.�=��h�Z6u�]!(��l"&��~��(�*��p�dd���T�U$"�h�E�*[��O	�k(��P�mDM�W֘L[�v���c��2�p^��Ca�]��ձBd�p��'� ���< zMۢ���A��$��V���g�Fs?9e��*yq���ݠJ��y�h@����'>�8B	3K"	{��$^�6��G9��e!

n�

����
�=��H��蓈с:�)"�"8��)+$:�ҕ,�����	a�k�$� ��騡�������\|�`5��Ô޴V�vn�����d�2thd�<�5�+�*��̽�

F��Z.��@��uѻe=����J{���)�ϲbˁc��~�3��ܾ	dU��#�o32$T,���:6��~�@�o��;�	��.s4	J�v��?e@��M�']`����XO������v�	b�ĕN��};kӝ@�F�H 1L	~m�䦘g���L�⇄s!M��n�?�#�<�nZ�F#	^��`S�h�)�����;�;��=��=�E����t�2�뎫L�F�֍�;�_�Y�9_�hߨ6z�h����jv
��

��

���5�
��

}
�

M

�S����{����D�

+�?�

�

�{bTyx���O�E�Y�U�Z�rٌ�?�+ޝ��~�h �"+�m�ǥ��BhV�jD���6��Ҝ|�q�]�),�x죟��$��ᕻ��Mu���ǋ�����5]Z�M=ޑ��Ng��/���{39RC;6��ޛ��l�E��$}�J)��+-�?�R�$��*B~x��¶}O�����c�V�X�i���бQ-p�Nj��;}9�����򚆑�e���֔���x�j�oQ�	)�-U��� ࿉�w�̝W~� ��	S�2Z6��w!$

[��w�( c���M�̠V�Q���e$�pE��1A��������	/Q�ݖC�7�ܾOd�/I`9���L"�$�P4�~�����Ȟ���\��1HK	���<9������[�n�\�@7,����u����D�T�覔
%���w��e��(����!���lJ�`d�6��{��	*�D��CX����	,޲SVnF���#�y������z�>��g���U;�o_�Ĭ���p��S��]�}���=^gg�l`����U��@

�

U��7

�

�

O�P(
$�\��~�k��'��/����W��x��x ����/P7g�k?{ lU&N=���S)V$����Y�

��qͪ\zѷmSک��H�Ue�3����U\����f3��M�8�	�Vz{����I�e�IC�T�ٯ��g�)U7�q�#���=�������_!���b2��@��v-���5�4��k߬�+6m-*8O��+-Zn�L@�=�w�B��B�я��Kҡ)n��k�xE^A!f��I�.Mj�U]�_:����0J�T�X��2)/���kUō=[9�G<���8��ÐnB��7��!w8P�*hR����

��
�

U�S�`ڮ���,A�߃B%(�	�Ad%�����*�Rc�o!I���F#���/y����	�Xv$&��g����mO��+�T��8b+Z��2c�UJ

��
�4�Jn�t] P��� ���`���㑔��C}��.���_o鎅�m�7IWO�z%ri���=nܹ'��$B!0l�PH���P��y٥J��������W
P'�S��"�H�h	-bIf'Ћ���F���ť	պ�=�vܑX��@_�tݔ6�KJLYB $¬�����Vv+) I[>���KQ���6"���G"�J^��e���C`��\�%�~

����8Yי#XJ��rН�f��E�q��<�V��S"��t뼯I�$PH�b�e,�/�k��(
q�68(�B�7o�z|S��	2si#�W�<��S��Ti�M0oկ[�xt�

���#T���CD�(�s�bpi��A��e�"��O7�N��6�:K�V�B�"[�(�BDbV.j{*
k�й�+��Ǿ灃�\0.�����.I�)�wp����IdB���Z!�\mM�-�Z����vfQA`U"�̀\��V � ��ᔰ8���J��8>�F����b�7A&y�;X)�_�r:G�\�y[X����O�e��!�d�Ǣ����7�K;�M���-	$J1q�W���(t��z/�;��^�j�|c

��

���

������=�hZ�&�����鮈w��r�C�_M�i��zիb��n	��Q��ퟱf��~<�4ۦ�A�Xo}����h��ӞŬ���и7��W�����.�4��Q�}Z���?	]%gg��� ��&� Ew�k�x��1[b�4

��P

��k���t�hm�ہ^�@�(�M^��\@�6�(&<$!@	��H��uή��kV�Zk�Z���kg�2N���{��YU�fU�j֬q~�ۄ�Qc+Aۛ�,���Q�Y���%;P�햀�;i���������>�I`}��W��\?^�

&�҅Ϯ��f����&0���	;~ir5�d�da��5U�䎵����Z�<�	,��-��LO�o��{��;���[��8�M 葋�6�	P������B^�ilJ`

&�

�n�

h

"

� 

���

�D��b

�

��

�]<�:\�Ԗ�Z�͈0��p�U�W
���	�]шs���;�ԓ�SOƷ���g>�,��+�/z��������u)[o�r��
�]�
�

�

��

�
���Iʟ.`&�w�S9�%�4����s�&_[gѳ�����>��q	1z�I�	еJ�}�� ��ַpH/����FV̔��	��1���^MI��'�[k5��M��
�J����:�`"@����L� cb��m�Ш1�J�y��-?5���y�뗧���Xc��)rٚJ���`���6]^�nǦ&A�,Z�*��t{�}�ɒ	���ݮ�8��t�K��g� �v��]Igo��AFw���`j���a� �
1�����+�� ��C�r�/v+� *Ɛ)ʺ�0V ��b �w���6�y�W��=qv6Jz��K�.
��

��w

@m�

�

��w����%(2�ܟZB^��R�9�8K<���~w6�,IRw�'=�<�gowU������*������'�7����&���$���D��o�I�4�4����o� ��V�
����v	����c�0t���u�=�ǒǝ��Rn��8�;CX΄6�+���BJZ�����غ���0�<5*�W5���p�t�0xy��7��iKG7�A�	�=U����p�E��"zo�m��蘦�K�F�� ���g%+,�f(��Q����gv��V ɱ�����7O���
��Rfs�������̈́X��5;o:�	#�"�b��a+��;���WVL(�}�x�p�	@�]*p�3�
���E

���
�

���

��
��

U�%�
�	�5�*�c7;�d�4�&�q��8�&; ;����ݍP�K�a�I���kW��G�j�	MI7�fO+A	y�$L}d��t��CS��}n,˶-�F���h�,{R3�	5�m�&�jm

��v�$�\�|��Ռ�g�q��jA6�(�B�N�� Y� i�)#0zܨm�Q��ƘX��c�����,��'�bIJ�Ĳ:���ʥ�L�t8oӲ�c��OU�Hu�L�2X94dLF��}F�?��Fض�\v��m��V +�R6��80�e��f�n��S��4��9﫺�.VX������K���)�ʶI�P�-s�*�zیT����-!�<��ul�~vǶ

d�%V��t��6� Č�ڌ��lYٍ�4�\�}�R9�=��X��Y$r����{����`ي�[�����h� �Z	udQ�%c�ۆ23Ӷ�n�qr����x*(Eq_��S��_�� �g�]�mCȇ�t���66�d�2��㙁6	+�w:�[��N��q�dycن�WՉ�(��&����yب<�o�rs�q��x�T�#����{�}���8Y��!7)u��=�n���h�*��Z�ʟ��}<� ƫu�4� �s�r�7

�
�

<���

��}�

�;

��D�dl���r�d��u�w��  ���]w|T���Φ�B(	$$$$t��� ��Pvņ�'�ςϧ{�TQD, � ��^�H������m涽��M6�/����{g�N9s�;眩#�j	�x
=

P�

�
�<�+Y���V��>��$�9;_����*�@�R��R,Y�[C���2yzx��V�HQ2��p�:b~����e���R��ܧ�L�{�����W�	�j]��W)�L�����U_��Տ�BQBP�ߪe�����'������{�

����LDq]��)���bf�kl"�w�=9Q��Ӫ��z�e�^��My]LU�&����:��R��S��
�q�S�p��N={QL2���[��UW�T)�����2.K^BA�| 6ȃJ��G�M��G�Y�7r�f�r˩T�?X�,���ҞF暨�]���Ƶ�W�X,!e)Ⱦc`�ޣQG�A�3�+uev���]5��@mD)�n�n����J��-˄�,�d�D	@�Nԩ��x��Pظ	Mʗ]�[)�;��ըM,��
��.

�v
�R
,v�ʛ
{L�ՒE�#�&���� EQi)�f�v��5��������:�r���uS^�C��~~q*��׭�����A�jZD	����g���W,?���[DBT$~��{��/�)��W�3^:�����`'f�	�Ƙ�X!�)��V���N)"���.(� ���D�h"�����i,�0���n򦊢��zv�S����|��!���� ��0n�

�J

}�%�ƔskM���R�m��a!��v+�F#t��vJ�X?Z�ź�B��	�a�0��p	��5 �b@g��Vo�'�mS���-per�*	�XO�eҦ |ĿE�KJR�٭r��ܗйR�eb�
��(

?�k;Sz齘�kz�Lo�c�M��N�8I�ԑ�č5�����v�ͦ�*y=�
Dv�ՖG}m`6�ޥ�"B� ��0ߟ\��R���'���f~� �!"�**�~���kё9f]��u�#�Hp�	SZ(���0

JLv����	Z�6A������$4C��XD5Cp�?��_Ʈ��f�Q��&���膈n&_��\������*�b� "$�>>�TT�c9��p �.\tK>z�	F�Vqh�

���"

��@*�|u���6@D�@��N��zT��F���{tN`�ZY�Qx/=����Z!��@�S��YΎ�֍�Peg��!�es��&�N�J�uṳ�G��zu�u�>a(  ���7<���}|S<4��un��I-�}�9�����p@��fp�x�v����Ù��4CXp ��

�
��

�

���

h��ح¸�vƵ�kp:�?��
���h�3e4n��	7�Z��y�ܩ=����k��,9rJ��r���A{Ƶc��]��$�	��%z��a��X�����g()������~��^Ld^�i n�َs�2Bxp �vm�Qiɘ��F�⪪親C+��S�;��ʂ�%HK+� ��

p��

�


���
?��GO�pN���w�Lh�轢��C	�d��ջ�l�\T-L�%5�C��q]�Vr	��Ơ��-o�*�V/����7;�v��D�����-�9����Tֹzߣ-ޟ2�s��9b�ڽ�� ��ߨ>&H�݃:!$����GǢ���ѝ��VPT��Y�K@��P��ɼ����)�`��7�_;ac��|�n7�߸[����AHg�*�ľ
6
��
Mk�۵���hɜ�#�Q��	����CXp *�v|��Z<��2�4����}'0��m�2T J�

����F
v

�

��
�����)'�_D�g>�;˘�)�mTE=Mi���-+���ڗ��ZUr�LC�R��������	����r���|�b�~�8�}���@p{k�:l<��g��N�S�$��?MV����ū�o�:����R�G��?wՉ��	���oW��

 �����

��

���(�gaIn{g��%������q)��ϓ|�K�y�6 ����ȗ˱p��9�� �������	)���}l���Y�6b��?,��1魸������O�z�S��-�Ox���b&�y��KE8zF��t�-�S��

]�
��Ƅ�M#|xX��y]=}���q�¼ ��ΌGa���d&�J�7"�#�b	�U�G��L��~v�4�!����?�[y#Q^߂��%�d��Œ*�vԏ�R+?�ү�+;S�0�X5�;�!.S��j��
�,�n��o���h��Z� {;-^��z����>������� � �k��tW'
 �]�;r�L�ȡ� ���J�2�0?a$&&�y%x}�A���4@�9
9�ICl5 5�R� ϱ-�a*�<�8&d�_?[1 �WH\�U �DGł%

*��
�

���R�;s�J���������z��[��c�4 ��;U�-&C�t��|����q�T�(9������F	}:=j��d�N���y	#)c���r�G��WmŔ������kV�@��ya���Pä����?U�Hah'�<�

 ���VT46��b,_�#I�@�8����R�-Rr��X�� �<��)��Sֆ��� 9��F��ΐ�B�^�w�}P?:x0~~r��y���df�vZ����J
*� ����%'�C����3��`D\7z�L<_X���l���d���UCT_��"A��׵v�����MA����D�a�*��2�Ύ�9^J�PR׌���,�h<�5����f��D��������	psv�Ϗ-2�-��X��6dY�`$� s�j��6���{�:ɶ�{�:Yב�m,���6}�B�tz=��z��ȖH����5��V=;�䑡��_�����#:���K!�� �G�� L$2W��c�)�̂hJ���u4��

H�

���z�

\�

���i6�C���_�	<�1�z����}ENꌓ+&a��~�9�����vv#���R_	J]/*�r�P9D�-�N��3�(�{aC;-��y�i�/(.����_z���
�G

��

^��

��

�h�����u�����UK�f'�z��g�jLe��f?�y��crRǚ�ZK�`o[�ȶ�f<$�U,�#Ǉ���t���$��r ���lwy_a�A�f�-�7]��lwM�lT��Ś׋��e;�	�M)�0�� ����ч^M�j�7�K7�)�Dfy�:#��pb~o��

Mf�4��TX"�<���©Vs�(�dI�&jK��5�J�vg-�1� �2�*U	ͦ6)$v��3�����҈q�E��z&��Y3~l� �!��=�z�I��@_�2I�ַv�ӽ���cL�͆u)<��z2&�Ie�z&n� �}	,�`�p���ү���P��;��ͧ����C�Cc�|�5��rF���

G
����i��Za�K�����}�{!��/<f4�Z1b��5�Җ8��U,"��)����N|sX�쬖��{Z�b�H$q��_�~����QT�,mKdٵ^n$�pF�_��lI��F��o�B���bz :�IG��{�"�����4.�� ���`꽪��

*�U��!C�́����
�/�f|��݃w��m��KR��Wa��P��c5���g/!����0^n�wh�	��l�vZ*�.�J���ޔϘ)-�4�zoQ�N��y�

�@
�^�z~z�G&A|8����đ����Z��,��u?�}
E5����X¿����_�F*�j@�	?>[0!2����l4p��������@:��	�%��0*Rk1!27���	�G�^Y�4

��������L��

�5

z��

6

�w�_o,O��d㩍T���L6�2]�8�J ȉ6�M� ��	H����9��>�.�vĘ�C��\��_O�	�^\t�MKh��<7�	c=;�;R�� �h@��8�2����{Y}��Y���uѰ.y�e���&����wJF0��r>{t)�-�p�`��}s&�ܧ�p�Ti �����Ǜ��a�Xv%LfB�Ҕ��-

f1dK�`��&��Z:�
J%	��bñt�[e�P_|����X.���t�\<}�D�g�K������2�H��ԋ��p ���D2^�C��<�w���|a�iy8�1;ɗe�3AD
��5
�x�6*k^KG���-��sB鐪��Pe_��x�\��pi_ݽ}H�)R�v�']Q�������0"h0��]����g`�Peü���@U�4���j��C�`��;��DvZ,�<������D���V��sEI	�}���n�`�ŷ�/��,E���#���������Kxb�tb ����w��?)˷���e����x�Pa�89���כ�>.�.����� �P�\P1���C�F�z�,����`_��96,��y+g%��8#y��`�Ec���U���*��Gvi5f��%��:{z)���q�����'.�_�

���eL�?�r?#MlN1_��Z`$���a���A�	cӖ�n<��Nj�h��;�|�]<U�:Z�q�:*�<��>~��GQ�Z�����<��&���f��

/�

{�t

m

���

���(��$j�}�~]�`�ssv�W�n���p0�
r+����W'��Bbx #���(�o��?.�?�^ G�X�TV��?�Ny1���{���7B鞾a"���7��b�p��HJ�b􍝧;��Ǆ�^��}�cq��q(khAec+8�C��<�e�

��z�?|+ !k���w~�m+�i�%��)��xFis���I�8�e>#% �6���>���+0��C�Ύ�cB� ��������	a�с�T���~(�ԐDd��H�X������X8APVi5�F

��

��

9
\�P\��HFQ�a�<R����,_��p&F� .< ���h�ECk��ې�_���Jh 衁^�������Nlѷ&˒Ex����T��;-&GaL�|�]`o�AC['j�ۑVX��$!�������y?��1"�>���Ճ��F�ߗ���`���^U��������� �����߷i ���g��)4D�T�������̿�H��0���`�@!�Y���]�*~��*j	M[�4�&-��}gǱ

��
��@�O;;7���� ����>���s���u���g��|r�� � �*�� �m�5�� �q����T����Avu�o:���\<��~����v�(�j��X�J��QB
�^�� ��0>`���l_�  ���}w�\E��w�ޛNi�W�H#�ZU��*�(������� ?��׆���H%� -�@H��r��g~L�3���=�r��l��<����3�({�q��"!)Ĥ

)

��

�YqTv=��}S�;Y'��l+���gB��T'����~Cr�j���|�Y$1�$a�k��R��@�����V
b�����!3��c�Px�����U��� �]��Ƽ��Ϋ D�Q�q��PyUɼ�Ο�@��:��MQ��>vp} �O˟`z�ǿ�)\2yli	�бmk�p�Z�ܽ�?h&mɾ�[�c�����*׺�š�

���4��N&��G^��u[��ޖ�^Wí���L��r�MM7-W^�tMqR^9�j/y��R�y%`�K	�ϒWlSL�m�&ݬ-��+	�>M%�� 8�xQ��)AX/e�A.u0Bp�iG��o\�6��go#>��{�nK���f��A�(��+�b�����)
�b��]�j�!�.�Y�����ɒ8���S��d�>��X<���|u�i~���}\>��D^U�����E���l�)J~� ܪ��� �l&���O]몤��ie0�E�/)W�l���W���� ��ҵ��+��ϏZ�W�_y?�I9�Y�Yݎ���<�	I��Y�a+ڴ��N��W>��mZ�

o�

Z��

o������u&�RR�6PN�����f\=(-5�;�ôÆ��0��չڷ��v7���m��x��^�O�]�7�����(|^<JAh�%ˣC�]���ٶx3���,1u�I�<�!���mi�z�������I�	�g��Aʑ��w�dc�$�(����@(��A�>�_?�^�,����	��X�"�r��;�B`eG`	�,�)/S(2�OF�&g 	"�B����j�VjM`eD ��Vx\�S'$Q�� �߇�T�|Wp��?�&K�$��+y@5&�D�����ŎS�[A"�<+K��)_|
V

[

�x'
��N

���7

��
��K�

����

�

a�?��}d}m,Շf�U-;�F��If1���Gle�:�'�����>'^C����e!�~�5��z➞ٖ&i2ǝ�<��4�I����	,�dʭvDl�&�ܧL\�"Wt��bޢL&}ۏ�gS� >�Pv2gs�­�.��K�SA�����"�D�@m���B�����,�R�+g�5nD��%�[�Ӟ�
��,
J�P
���t[���	���:#<h�5�����՘��s�3���l�fc���"�[��j<�DA���O�j��$�8�,�o�A}���-��"�I,6�$��#:X7B)F%�Wv�UN,�H�,�×2�.

'�|

B��,R�y,7}�M�S�D�Xځ�$Q� -�m�`o�w�i����ڒ��߷}�U�W2�@}�j��EA�Z��U�&j�1U	���G4+�$%�U�D�*A��Ђ�PyUV:�a��[�YD͙�r�2�l�?%��ge�S��sw���t��;�]Lۈt��?T�fC��f	�F���VRe�5��(3���gi��4����؞>^�ǷJ��	�t����"#��E	�� JJ��J#�l+���0 W��x+E^�q'�e���MXgV&v3�!�[l��0�������?��

�

�?��V�

��+�8

��

R��
��~�Dy�c�^�{�=��?3��d�w��jX���+༣}��Q�0u�y���u��ϕ-Gc��9��W�mB��+E��I�&���"nbȋ\��2^�N�I����˜���S=�TP�Vh��("�g�JlRu������w�^	}�!�{����	j2���sG�GJ	9�Mk� %��՛Bг8�	+e�E9)�_T��'�me���?����S���	Uu2o)���q�O��_���bX�d�egH��0�;�/�˕� ���9�f�=�/j�u��K��	�@(��=o�"4jֺ��>$��Nb��8d$L��J��X0����B����0��&sB5�ϑ�
�Ǒ0�0S��ΝR�������2K����������0���^���k�^r��~н��~sI���q�z����D�c�^þF|���a��wK�'��{�e ��}���#�����>�����۞~=39t8'f�/�'��=fI�&OT[��$qE+����B � �:����ԁ� u�� �:In�î����V�\�c���4yi+¶Ekz�

�]

��x탕�գ3BHR��T�>� ��+Q�����Ο>�|��1?��q���O)���?����`�$���|�9�5y��=����Eǎ��#�c�֡�ظ���.~���شM�^�Z�"$��l��>����q}��}E/-X�[�~�g-P�E��<g��V��J�m���s�`���	įI�HM�7��_>iN?

����
��

�f

B

�

���q���C~_�n3���Y8�K��׈+��$���^�[���@�Y,�����^3�,x=;G��t�~]��V;9L�4���!LQg<��#l� �� ��6�z�~��(r�h`��x�	! �� �w��-���H�3WKeX_e4�OL��P�T

 ����t5 ���¯~ٸ�թ�нc{�?�<��~�[��ڃ�!dٸA�1������y��yG�V�,�D�����a��Rw��Ax�����֫��/Mô�#ѶU����6i�1%)(�x-�۵�G}�������~� v6�S��hb�������1�<�@���E�����?x�s�d#�o��4�>ѩ
@����s���fDΡ�M�@3�[�,k���8O�X��U�n�0��(�߼�	\v�É�<l��a''��=���L	[v�����/s�ri��	%O�����|�
�
��������



'�

<x��'�����<8�]l���J���afYyc_n%/1�9�(c���Gg��FMr�GGU_�>

�Z����ԄN�mھ���9��9,w"փڷie�|���Mi�v |l����D�	J3i�i �P�R��Q�ƀ��h�"�#A��a��%tq�	�6҇-�Va�[Q�0�9���E�1FrZD�V�

wgљ�t��sTp�Mva���$dYȞ�����Q{uUo����^r��w�vWUW�:uί�9U���Z���@�ԟ����t�T�+oq��˒m�y4B��Xj�ϙ	�c�R���"��᝸��?��7�2g�>�[���Cp����2���K��mx,5�	9����ݏ��Â������B�R.
����

���^

Y

�
�

�J�

������ 
9�
 E���=x��3��˩8�	��و�����(	�=~�P+�&�s=��y��Ih s�Q��b��O�
	ܵw.[�Z;|1�Ʌ��8-QLF���1�OQY�1>';���F�r!�����>�i�����4��<2ˎ� 9�J�!Bk��H^�M��4?dkb��/114ȶ�"D D �u�-���`l��@1!��;HP,�����hb�(�}�L;

�
[�����s�1<�x����W���䉎��)���rf��	���^����D��R�8sa���a��n|��S�g�_Z���~Ƭ��	���į�	!Tu�\

'�

6�D��r���n�孷y���n��˦O�d z���c�8x�8�E����!b�c�Q"CY��� �����35�����w�|!�US�#�)[Il��yᥥm%���d�U��.�|e�{Ρ6C���V�p�y�u N�!/�Q�D_�Mߺ�<�
f�`ɘ��Od�W�"���2λ��:@���p�����:e!0���ɝP���I٪̰�1��x*� /1�{�=�$	�ђu�p��֛��Fᮿ�s|�gc`wZ�_-/<a~����7��)�9��Zyn���

_��

~��w`��a����~fe2�O�` <�R1�n���}w���5a`����pC|˫ �u<�;EB�TA܃���W�"<0���5D� k �<U<Y{�?yM

?����q

�`C)�}��:|��
�$��&6H��m��T�ek��\g�*v���n�	pϔ�q\[�Cd�^����E�� ��u�n ������z�(�`p�zP?ٯB�;�Q):i`A����]��I��#��A�OAJy]�

��
����
�J�

B�
�%�{�al�Q7"�<��.F���d�%�&�rUN�M��<�Q.��_�/��Q���ۗ?ǭo.��)��I�{b����W,	�����W�9W�m�1'䓼����Q����?��u�5��Y�9�V��̻����{P�2�8���+��l��0%_�u(�*H�� 9���� ���+&:�C)��f�Xd���|

8 ;����W����V��IcR��A @x30�	G-���>~��9{*3�vcˎ�X�f#�{~9�l�w��|����q���X�y�ʥV�[Ո�(�.��Z�ϥ:��i����b�0l�@lݵ��Ģ՛��V��M�K�G�]��<

�

c��QR'�� uUwmI�S��F��)�jO�{ט�rI5&d3 T+���ۜlSszz��#��r�	C����Q�3�	�S�O5!�-%i �n�u��4��wi+9�sn�2�<�'.y ����R��r�b	J��r�45'�?���Vw��Jo9�e�V�p�*�s�й�Vnڊ��^E�l��eIE��41�0�;��=oomV��mPxE`M�-��Tp�	"1�|i�ǿ`���"�

˺��~L�R�S;���c5��,�$ׂ�ZE.X���_�`-FTseV�̲�y�ʎe9`���,�'���	ڿne�c��y�Q�1�8!�q�t���D�rC��:���%��@��Bu'r94O�`�wUrU���,�S�?s.,3�>�r�L��D��+���

��UsZ��Gsa�O�%��s�����ʅf�+�U9�Q�Wh� ����S��Ą׈���I1�"��ZgL�D;�R�*���p��:9D� y�w0�W���������{76�#{�Cx!��S�Al��k�������
A

)�Z�XP�jo���iģ�&��E��Ӻe��"͢�f��Ara?@���P\�L2>���j��q�.LCV�����t@f��������GU*e�ӊ� P�>x3�=$�YS�v>�t�xo����Ko6�?��V͏���BD�������$�	�k�v�ӤqHxք�kM�j�d6� 1D|..��g���g �û{�a�����تM������]�FH���@�O�P2�fd)��� �xo���LU`��T!��.P��<C%��yؚ"C-�G3�r�}�B�F�մ��`M%T1&6 _�L00�g�2��	w8�r�W�}�1�%�,�D������1������������:lJ"�	Ȝ�:-%)���w���Q?|�~J�F' ����v	�p�}T�¸p������������ժDVM��Yu�[�ӊ(�w3�ݭ�Ҍ�z�*U�v�zO�>����K<���Ai@�TZT�

��������
�

�����-[ɩ�:�׋��&��5w%�*��)eT~��i4�nՓ�"�g%�冈4�;��|�!�e���̥ٜM����6��v��	p�1 S

eHi�I��{��x��'7��O��^qѬ���N�i~ 	?� g�ejJ�	T��.������� �l���2���3H�b��c!B�e8 ���6��Tm�
1�L���	Wd�S��J�W�� rB�I�)�do� �k��o��d��!'���~F|#6m�����
�6

�C����QTu��8���{e��SY'�AD�X�j��p��x��i�%����/�s^(�2�������p�4'����[�ڍ]���vR��K ��|����	��`?���d�жf4Eҋ��N�����:@���I�j~W��)QZ���Z��Δ
��&uf���=�Rq��ɜ%I��q�B��}s�jձa�չ(�:G����<�|�De Ԛ�@���u	�[ [���.T&%�@��ta�J}�eEd�	�5�=6`��.���

tK��o7�r8�	���%*�*���Em�0���9:�'����_
�	�)��	5O�'��#>>���"�V�"K��w�L�n彶tR!�,i�'K�����=�.��X2���c	q�rW)�ax_���ם��n�c�7s�q����+`m�_�Fr{��*(5L�mi��1B5

��'��

�n�@�g-	�"Y��N���$�]%��~�]g?��OcTRH�4�
�uL F�2�5���b�H� &� k���md�
�

*�



P=�yM��ƅ���˙}r�����y2��D�-�y�" "č^��!" f�Tɘ�֕Q�	�2Y5D_c�
�
�

o�m
��

O

T��Y

F��
,�
�

�V

��=
��@������� 9�١����W���$�$�uA�Jj	�
b�7�K�Wa[U�S���*_��]|Jű�>� �Lw���+xEKY�

�

9�¸��ߗu��k&of���KV�2��<�,k�݅u���J�֋wX^ J���1d�1�_=!�@��tkӅ�d�bR
�5��&��{7��X8m�;.�\�)lVU��Q��d��H�VS�~K`/�w�)Yk55+�xM�uǒN��	��L��c�\�o��kH�2����o�qL[�O�;vB"z��J�2czy������:�������`J&��*�]Ci�j�k��)��k�X�#^�.���u�ԕ����v=s�蘙�;t��d����iR�=�Gk!�,�K�vϫk������5"ڎ��ĥ�Zꠥݢ���� s�iƔ�|� #^�D�=N6���

qu!����~����O�u�L�{���c�{S�ò)�{�j��caq�=��R\�8�}�,a'�&��n��1�_����5IÑ����3��B�GN��=�:�0P�<7k. �{Zx4j��M�}���ć	i�_6�B�	�������'{�o��΂�*}r��9er�p<�ӾZ�>��m梜��*M�^?A� X��1����_�~n�}Ui�2�e��&��v;W�߰ y�&�X�˓ƌS��+ m�R�k.F���ӕ��0�.y�����n�gwX�h���]DKz���ZR8�@^-wO���XU�f����.��N�ٸ�3%���RIq^~�ȰU`jz7�����c�'�J@:"ͫ
����t

��c
Pv

���?

��
�I�

�

�



1�

���

�z�



�
�a

�
*

���
�t�

�

�

r

�z�

"�䲟
C�Mh���|�� <s�lNN��!W1?�� �'��o*�q�J��z0 &O���,$�9(���2@l�  ��@

~

���

��

�BC�,^�q)DyT>�E��	إ�r��xK�����tbZ9㊐�DH	�
��
���

�j!

���]�

��

�/���

�}����$��

���!

�

��
t��Yp1��t>�������X9ͣ�\:s��ݭ��$�]\EH��M�N��b��9���E9��1�5�mO�ΒB��p�����f�N^a���x+��1�=��	��/�k��{%D�G/�i F<!�� TN^U����tޗU�B�W[/[��w0��ޢ0Â����O�Ll~��5�j3�� &���W�ߙa���;��+�`�;�N`'�W{�C�};(�-7�!o)�GG�

�M������ʹ�/4�Wd��\��M ��~�Q�Q]���5B��V(�6��	V��6��Xgw��,��^�R�.U��j�ȫ��	

�

������h�(�D�CT]􆢅�M�����A�>y�b���ET:Gt\���D�*J�\���=�}f�uy�/I@i�|�%�}I��kf�߮��Xxf9�UQ	wE�Y{�&����%���R�m_1�t��+	�}�(��UT~�V��.$�-T^�ê������X����.=J�=��b��u��w2���Q�m�!�6�ʣt��8��P

q� 

�
�Y����c��V���a������q�;���]{�x�#��!Jb�m[�8����ˁ��+��!�6�O	����n������L^�� T���!�¸�^���W�ʥd;D*��m����@���a	��a���a]%�`��pW(B�t�ے��
���

��h

�v�
�

�ӳ�N�Ρ݉�F)�t�FJ��y�}+�J��4��v������v����qM������p�,���^����o��!���d-)L����t�'�@)�x	�Do^~O$j8w�<�J�E��V�s}�S�ަ�0L/x��A��W��۽�1j� ���p~̦ 	�t|��� �s�(�<u6��o�M3J���A���ǫ���N����]��:kg��M�8��ژ�)�	��o����]%i���d��X[x8�D����:��O��b�� ��8�}�p"��!B�X��"ۊ7�� OѤatz����hmi�g]�LO�

�

���

�����ѕ�T�Q������St�cmu���%,���i�\������)~��7Lϯ�][E� R�������/�R3p

�L 

��j

K

���

�

�

>

��q��`���

�

�

�
������|E�\-//S.���r�J%Rn`�i��J���R��w
�$���>C���!��A�G����? �r�� Ql��'@����}o��>z���/�x��^x���R V���R�{��� 1S��"�

ծ
�

�

X�

5�����&��b�e�V�J�7���ip��xS)p-䕑<I.>Z�	{v3��E�<]���@���	m��L�=m!q|iVg� ���$+U����w� $�

I

�V

���3�
���

�x

�
��

N

V{ӆ�C��C�A�I�Ć�cƚ�a���i_��>�|�[�+H�GJ��_;�|��2�/J����#(-���e��p?�ʍ�̎��xI�X�={�o�v*t�P��j�ť����醬�����UΝ���o�,��!��c����:d#Q �#���P���Z
��[
e�ÑVl�D (�X^[ciu�����Ԙ����ʴm2>�)2"G�k��V<~�����'w��]n�]��]�ҷ�H��ե�\z�>�==Gj:� "'�x�C�sb,j�n?�D����R�q�\L	m��\OJ�Q�@jh�wXZm��t�續��21VÉ�d[�����8n�z�����~��:L���
Z�

���

��
n
\lT_�����XOH�� �'�͝�2��䉷���W��!�_-�Fk��r�n'$n����9�.!��l�������;"�I]�6sVG֚��I�ct���byum����#�uH7d#Fmꉕ����p?H�	@H���(a���;��Z}�,�pbv���5qL�W��*q2'�Kn�[������h�J>#�=s�Z��݅E��v�n�ᝏ.�+������5

	��,k�R�� ���5��,v2�Vl;s�T���I�y�I^��g����dI⛀�&��%3ig�¡�+S���@Sʮ`ƕ���R��ijnw�,.��zH��X&;ߤ��E�rO	޾��	�cU�c

�Ji�}�A����+(��J)�Hǵ�����07YG�} ĝ�� ���5Z]��:̎W)ɸ��T	� ��O�by�����g��O��	�z��o�+����"���^湧O�܉Ɍ�>�O�\ր�ҷ���:TxZ����}���U

���;�

�*��
�
$x4J����eu�ثZY&��Ĳ��:�k���/�xW�xq�x7���D��s����%R�x45����@^�v!n��+�^O�d�L2�ꐿ�zZ�F0�� ]g7���Ik��1������7j�B�*�'81�
l�z�Z �?>~�A�F���= �|�6kk-|/bE

�

!���

�jo��X��
������Sǹt�&�k-����hw�<w��j	!�N�;���x�&�8���ZV-��К��U��~oY�Z����g��`a���:8>���q&�^V�O�M�KCU��a�ӰL���+��0R�
�������ST�X[i���}���el���f����
�N�%QZ1>1��{��q�BK.|y���\C��ƪ�}8hB/�;��#!D�g�_��.�-2!���"vb�"�$h'�c�0��"���xN�V����7n� %���H��zc'O�MA@kʾ��^y��7W	:}n�Z����C�={�r����

m

M��

���&�r�:�fV���&��&���|J�3��� Rk�`�R��yԱs���䀤�Q�n�݋��ƣt���ĶҖzc+���^b�diNʶ�`���f��MH���!��J)��>�~�؆P`�0�zB3�b 7[�P��\��p0�GČ��u��<�3�;ѡ_��9a�E�`�(�YU$78��r��x5�m�^��:��Y�C�q���^��f7��=S�I��~�:W>��	ys�6��$�4mK�bc	\

�

{

n��
v��

9��A


#mQ���4�$ԍ��}����e�U%��`�xZ&��Blg\�<`&�FxxljM |6�mZJ�{���.��Rj�!��&��=�K,��B['i�F!�*�2�G%��5�RyZ�N�/����J*�yѤ����*�L����P%�a��ߌKgʮ=�b�+�� ��B�����N�,\+u�/��:���=ʙ={HG	��:x��Y�S��ԛ9����

���

õ

.'�R�X,�V4nX�Ыeh��4͆Ը>���b(ܞ�}�T��w�~!G[�O���_��n"t�[��T�S|��*���߸E���G_�I�D�����4����7��L273I�������W⍥[�EA� ���

�{8

L�

����
S�w	� )D�N�����<wg��5��+*"�W��4�v���d$�*��i!X�B؇g��:vJ�j1]obu��

y
�

y�

���
ɕ��s��v����L�.)��T�R�Ե���L?��<�ټ��6O����u�tU��TZRR�r'���� Hb�]"�}|	���� � ��������/�|���聵�S�!S\N"vp^��1�Y��T��xQ�%QC� {悡uZ�d�n����e~y�������m�Y[]��MiwRz	h%�n��KvR�Y��-�Y���Ԋ%�F���#�&�f�ɱO�pd|���#�:�Z�P

����6

����1��bjl���&u��C��.0�����&���1��*lv�=����/��O(�N��t:���p��!�fN Tx��^p@���X ����Ν	���'�kW�Z�9R�Qk|�X���Osxj�{�fQY�{߻�D���CF�1�Ͽ����BE��KdC֮b����)�eXc��0*+��r���Vz�vW""�9=�}�5Mi���͈�9��y��

�w�

.

P�

�1�

���
�T��

��C��z

���l�

�"/��(�YX��ۯnqgn�����:{��x�֢|ۦx�6�P���c� ][[��� �>}����ݭZ���$��g�I8Ґ<Y�i�#��z^&��7�13m����h#����>\� M��:$

�

�_

-

eo+�~yy����������%O�-g�RjhiIUA. 忇�Ya<����Gf���[���^cZk��ܻw�۷o��������upG�;]^U�!��N���t�?7��٧�?]`e�M�ۡ�KHRe�/sF-�i4j���phj�S�Gx��$��#�j�p`�	h,<Y�L!.J�<����

�:)Y��UI �v��=M����Nx��ʝO�Z���x�s�����83}�F-"��*�� �,���`�&�h^kfF$�����u�9	Y$��	�|�ՙjD^��

Eil�S$IF���OfYF�f�YJ�fdY�V�^�,SދJ[O*��R(�P��쫔'[5��]OnI�w�w2��]̬V�E�^�k!KKK|��gL�ftl��ots\��w�mM����ǟ_cyy�iK(J���b�f1o/�D��s�e�.p��#�:��z�2G�G�D�

��?I��]	B�޽Ǘ_~�wo!�,cii� ��c*8 �W�?�W���"��tf'5��[�I\]F@���l��Z��ޣ��������N�j�A+@Z�

G���

�TxU��r�D��θ`%U<��n�-�;v�6��5�it��Ƹ�̘��6���z �����4��9 �A�����%͓N ���ڲ�� 4B+���7�kf�O���UI\�Pa�a�m��(5�
ŧ<³+JN��K���~ȟ�����D3���	��~�K�{���!�IU�C�-~������9�Z�<��:ghJ�/k�ן�t�1�jr��1R4���|�t���c�Vg|����QFGF���`t�E��曜[���޸���Y^Y3^X�g����|D�;�#�c||�

L`�{�t:�iJ�V�r{�IXE4�����]������Vd$=���@x��Xؠ ���P�
J �ig)]�C�1�_~�"qd�O.�8��9�+l�9�ZjZs��Y|�St�ʥAu��v��gMd8V%X�1�,�,�3ޟ�o�Ħ4�G�z����s���QCp�rN(�9�x��B��	�.e�XQtUd���Cr̿pYz�U�xg.���J�LYk(KU���������ջٍ)�7���-�L\yG�]���{^�<̠򶋖C���A��fMBA��Њ^8'MB�Q��`疫��kbO�W{�n<��%�`��1p4,uz��oy47�PA�N1A6W�&{l��E=I+4�T%�{�$��_��fl�����cH8�0> ������+��+�|�L)�>�gj�E���(���c�

��
b/:��[]����e###LNNR�י���V��$m_���Jt��Lk�()QB��DҜ��Ep"��NtM!��-�=�!�k] C��`�ʑ\P#���4Ֆ����0�C ����$	�Vk����Q�As��?���Emc�4yDv~S>SG�;��a�!

��^]�ʚ��Z�;G%��$M $z\ȍ��^������4��2"n�5_.�<�	��!~C�*f�<�=����T��#	�MMP䓢���E�C�nUx	,+	��f���I���|ݳ�b���v㠑WAa�N

�}�
 ���yNi�I�ԟ�����Z�h4<qz_m�"\��-���*��mM�[m�F+�@ ��2$��(�WJ��t�g�O_�_������WY��5���Y��2D�D�tF�h6[h�lh�h��t:��f�Q�#��&��'_���@�QC)#c�s�r��f^4N�a�<ͤ� �Fy �4%� ,�`�A��j�_��
g�

J����

q��
��v�
�

[�ܩy###DQ�	2w �^JC�RL*�y�,����<��y`��f! � Ͳ�"\�vӫ��#a�Ĝ)FZ�	��Yk�5�qZn�p��<�

o�

��v

��뼁�6��D
���� j ��Xo�|�	���`P7�y�u��[�4

k�

��E

�i�



�P��X�6�?���4c��2��l���Ft�A�(��'965�{�_�Y����Y�>�'��'���4M�����i�����9��H�Hh�k|����ݏ����'x���G�]%KM�mɃ%�@��Z���6GO ��M���IT�!�˴�µF�&��u��a��ՌoWR��a

�t�

?��

����;
�(B+M�>A8]#}���<�zk�8���QQ�J��������	ð�8�+l����U٩$� } ��m�iu{��"G��f���˵�y�8�۝6�n���v�$I��ԧk������[W�G��Lu��?x�����_�H��Ez>d��z��n\aq���

dl9����yLLL�������!dP5VJ�8��b�}޺r�[��x�h�����?훻u�	��@i��QQ�/>���g�zZ��o_�pa޿�L#���{�^t���v��f�P���4��B�_}�%�v�L�"!�S����c��

�

��~�

&�

���

R
G	m�=`c�ų�#@jr�)8D��9$�F���]޸y����䄻�e��#�J�$���鲹�ù���4�T�������<Y�O_����	o^[��(N�I+��>�^�f�K����N���-��]-�}�z5��{���&�!�f�{�|�?������ׄ~���^�[�h��V�M�	^�|�?�{��Zc m]xS6�M\z|��[޼~�z�����>^ŝ�����~GJ���Oþs����a��(G32IP	�}
Bztc����V!��D�.}���	b�l����'kT+!}ݧ�����ȸG��K	���O�����H�z

��

�|:

�

�����

�

L���T< _�W&@X:-���<97���`�!����z��D�<d��D�u�d'VH�=��(%�X���(5��ԁr�0,�O��S=�W�҅���-����.�,�w�h ս��O��|�tE�I<�=ƹ�U���/����H^�?�0�u����w����S�����{\�����$�,���K��lW �ʠ�N�˃��x��^��t����s

a��L2��V�j/$���<^ۤ���~�VhL��+�����W��$�X�HD���8�+�몕�Q� �l�6����ɓ���/��ﱴ0k��	A,�,��C'�y�������[����t�

*�

��
c�

��a

�

% ��"�fY�@I)�ô)�kKTJ�cM�R����� Г���OK�Y72y�݌.�j<JY�r��չ!φ�vM7�B����O���P�g�����͢$\���%�^@�ށ=�~4-��}�==�F��<��2u�{/��6�U)l!8>�G1ϗ���ۏ?���(��x��ǎ��[an~����TϞ2p�d�3k�

�


m����*{�ͼ� ����ݑ��|m���f}m�ƶl�vi��J�cZ��;j=�G���پm4|��?J����Q@=ޅv.B�B �-�� $�@MB��(��������F���f3�w���g�t���S�V!�/����I�}.}}���!�E�q�I�3�YY� �֦DS�����!��;�3X)B������dHE�D� 4����:

?����

�0���-�l���~����=zI�%���*�
U"X �x�)�`�h�J)� �?�����Y^u�C�4��

� R\u��@Ȯ����<��
���'�5Х��;S��w����Ti%�^IR��c��j�������kkFݫܹ�5%"���X�WYz� �N=p�۠ǗV;�gRݾ�7��+D��� y&1���Lv����Iu�$[��W����i��l� +-|�cBv��u	��mj}=�J�}�s�Ðk�"�Jm���Z��8�x��ūW��ŏ9w�'�G�9N�O>%�n�-�@A��f�Ѥ��d�����:��:+�e7�k�}�;XX7ˠ��������4��[�+#O᰸���r�E2��v든�s�� Hfz�I!I;3�<�+p�W�D)��yx���Ҧ0:����r��F}��Sa�H6�6"�ѩ�[�8�|��`EQ{Dj�$m
�(��

���|���Dk:�W��>�O�V̙$�A���ߍ�e d*�ֳBO,ۉ����t�R���Rui_( �-6��qM�ΗC�>��
�m(�^�����$���� �b����_���3|��mf��q�T(�	2���n���`y}�������m�j�ɻ9�n�b>�`_'Jz�E��\��|�1�a�t��*E

�

�*\'H��l����_2'��0�������N�������J�����|�Y�>���G�Z �=4�0�02&�[I�0<�0��ʬ�z(d۔��I�᧹��~����B��(�H����=\�z�ބ(a!1Z��ԝ/�+�#	e���h3��T��G�*ʶ����Tvu���J�X?�t �v�e��'E�/� �����%D�>O�n"@�K[

!����?��?XZZ���)%�f)CpɌ|�����,..233�T�Dt��}n�H��|����Eے�D� ���[��#SA��-, ��0���^D���ͺ#ㇳ=�	XEbg����$��$�c����F��%$���)˒ e�\

�

\Q*@!�7lK࠸|o�b���H5Z�T�U��`�����1����4鉺�HQ�n��T
�0���$A4?;)j�2J��ㄡeh:� �~`/���l�D��W������X)!u��T"E�m��)X;5pϢ�c��A`�hE��b�rڹ��� 4��

\ipɶm>��s<x@?�v em��Y^MMM133�.�x�@�,^��TJB�T Uh	 	���(�qL/n�n�

�����

�L

�

���

��

A

W

�l

�!	�I/��������6�W��'��\Ό�rrl���*W��8>>��rL���6m��P*uxe�/ؒ#������K���GY�����o�A���B��#��Rt�f��z=}�=Xl�?ޡ�h#m|E.P�X�-)9.�BZ!�*	@xX�����L���m�	�X���F~��cY

�D�&mnzķ �(�p��U'>|�������Oդ��w���#%��K����3Q�l�s�z�]��s�u�$��X�0�>�\�D�oB��diK]~����o����M0��	G�'�e�ɇ[B�p|���N�	E��B�̨T������7�ր�2@�4����4��i��o�TJ�?�Ƕ(�v�ۥsDu�A�8�������L���xC��V��� d�G!�^h�K3A�0K�����&f�o�	� �#eA��uk7Y��f]M�'!�: ���v��8 ���ѽ���J (��>z(�,mՕ�ןfB3/�>��ju��癲�7GGG	� ۶����!=1�����ZZ\�o{����ޙ��Ϟdi}���819��i�	�~E�����~�0ˍ�iުT���W�X�h@�Bǅ;��mW�X�4G���y�h5����e�b�V��X

�

��

e�

9
n"��� `��s�\��VL���T!��MۃW��q.E`�G.B�<��v��#^LEV^A� R�JC	��	���H��X߸���g�	b�-\�

���y@ �@�@#X B��<P�,�h�w�֞C�E�ΛEh�f����_�Ѡ�vy��: ��ް

�

;�

�C�

� �L�
�����R L�OF�R$����t>z�l��� ��X�n�,�\��t,��0s1m�z	`��I�

g�
.�x@s��������J��z���:=�"������:�e� �k1�S��8��X\m�r�[�	6
�F����f��-��`ac|d�B��m�P�[,��R��诔p�du��f�E_���+��6(�r��3��B��J%K���s�Ŧ�p��RH��F��f

�
�

�

~���������

>���u���?Y�?������}���33��}�����u��Ona�A�ir��	~p��n=���e������N���7_��+�8^���x���M�d����)Q��{<����#y�8��O�?!)m\�p��$������SO2Y

,��

�
�X4�

m�+�KΒ�T����l&���t���C�Q��*v�5r���,�[c�uY��EJ�?S	�k	%|�/�\.A.������g%/��^�m۶�^c�Ј�L�\��ȝ~bbu+w��Wq��~����س���s�-G$�4���B ���

 ���T��f�

�:�

�

���a�XfZ��Q�%���,�7��mE�uB�����W�n陟Q�}տ�-����G��W���ed(Ov����*J:�	\��̙	��d�c	�l"�í=�*uHzNMH)��<Y^����-��^3�4�@}ނ��%�b����!$��M�J1�-���A�>��Rj�=R����l�\���7x0�89Z i[GXݠ�E���mr	�r�{���c�"���X_۠0���� ���n���prz���k��ӯ��˗y��q;������p
�f&)�3�2���'Y��ah$��X��L��b��^V<Y����S�C	E.���2�t�1�.2�M �)2xFR�����"�������q֊�|�f���_\����

�/
�z�,�nPo4H$3��׏[�f<	R*������D�5EI�~G��X��$�\�m��t����J_�׺n�R���ͺ*Z�h���_�rDI��=��L3p��b.���6�I���N�������[�I�Ӑ�?5���ι1�׵G�����j��ѩAN��x��$�����K�H�HW���P�&�����d>�� !�LY���g����u��Yr���J�Pwd��y�4�����?|�ۨ��l	KD��r��D�����P���o���&��/����i�I#��?	�Ru��m\ 

��
˫��I

E�

11<������vmӦ0�u�E;˸V�^�\���~ɫ(ab��	��f�����|�(�g�Ջ�^�U4���^��kf\�ݞ+ꞸohK_�(&

�{�

��

���
�

��������Ւ�
G
A�
m�

&�NF��+�����Z�����l�B�@:��y_'k!)%��H$�0Xz�X���R$V�{��Tq��Y9E];���~ɥ�E��;j�G`��1����]g�#R��j��Ѝ	B��w�W��~b�+�.��uG�0�C��|��{��B�B:��H�s:>�k5��?E>�	OF�o�6�����d��dF��g���������\�f6��D̠ܲlbU���֔�tj�w�Ѩ7���{��ۆ��Ʉ�K��nu �Z�Z�R����I>��X,�N���q��#.ޓ	۶I$�j��)J^9�{輸8�)j�E'K�N����O��4��u�	+�W�<�Э��#
<(��

E

��=�

��!Ղ�5����7��>����.⭡Å��l��X&yE(D��/H+,	�z�O����S�Iٖ�K�K�:(��=�e)fr;����2ޓ>�Bpwq���H؈ p���Q�l��%]NL��˦�<�c͋�"��ҐRDV�Zeaa�T*E�P�P(�;YI)cw!4'�W)�U/đo��ĹTv:6cQ��E���S��/}4�Nq�������gٰ��*�%�n�hWA�J���+�m�z:���҆z/��GxC��@���!\�����
��2:o��I7Մ|D60W�њ�/��q��neY %��4lT[ӓJz4�&��??�I�7H<2�X���U(�r}}FZ��0�+�Q�}�%a>���j?ot���kȪ�<����]oa;6/�:��o��^��o(�tS���2�@�!�"|�^i�0,x��A�G�	��2h�t�JC=�%ʿ0���&o��_'�I��@�!t�����`㈥(��&KqZ$Vd�I�'��y�D�q]�|�|W� ������2�>x��3��]��{�G8s��P����G�	��|��Q����;�ݸ�^�F2����E!B[v��uk�g�-���1/�M�1���&�l�����=����f���yR�T��B��+�O4�W	Q�(�r�L��

�

��

�

P���K$�.|Ѳ�{_yp�yƑUq�;!��%\:���;�=���Z����ӭ-�.ĕ����n��`=�k
��e����/n�ɗ�pfv�?����\m��E���h}������k)�]��-}B_�m�~��G8B<�כ;����N��{1�T׌�H\\_6���	�%� ��#�bKn,��p&X�V@�xao\���b)��3!��/w��g>q1��l��������p/],��u�fd���)Wt��Y!��a�l��;�Vh;�+^�ݛ`ſ� ��G���F?����N�%�~�L��<.��pq���%�H�mY�fZ�J��j����	�86ŭ{sH��t�������+���R���/9}b�B2�R�j�����k�[AR����w��~��k��&s7�L�F%��J*�:1�p.f/Ju�7-�'U�bYu���ߛ�f�x� �,+�w�TK�5�����tym�w�19>������z��&�뛤�)Jy�J��W�V�R.IHߢQ@��~�~��~�Z^������������c�]�ŻgN2T*x���"��G8�v�+ϻ�5Nk�+��i�zhꟋ��E��*#��(�#%	���m�S��^�� #����;ggy��L�ZG�ݩ��$\u����B(�e'x����������J&���@�TE�VW���|O�x������8�K2�	o���D�`��6�I[�r���򜟝Ŷ�6�O/���։�0�����%F:�ӺԚ���c`�h��e�qd�&��kzի�R��i�e��bh�o�ѩ���V�שV��R��֎p��9�`�v,��S�ո��E2i�

�2������v;

��

`

���x[

��P�בj�.�3U(�����~g�) �`���U,�E
�3 �n [��!w��߉͒���Rit�L�p

�i�

-�

���l�S�ʸ�j�,����a�T�X���~|�Q��JBc��{�����H�%҅
�� ��87p6�	��&@�����^>C������>�����#f �g�(&���=��d����E�K�DQl�U<ϣ�l��v�|-��뎻Br���ᔅ%���i����o�z�h~���{��ǎ!��݋����,.=e����W�2�7���[|����g�p|r�A��eu����w早�c�:݈�˨�bQZ�u�n�Ǜ�e%�����G2�,}&5^;6�婫�Cw����gay�z��`�nΗ�>g}���g��w7��:O�L5�|Ҋ~'����9�k�Nb��n��m<��e']�U* ȑ��qe��V�駞��\��t�g��0�T������L$}"f��=���s_�����;�yW$�o. �f���I=���w'��|F�7����wP)���>�0`�@�i��JD��}���Σf,���c�/c0��t+��k�	s�ύ��{�&�Q��J�ڤ'4Ȥ7a�9�\��R���d*F�*3��<��Z�*�GA�y���0L9���:r�g%hq�M�R��%�}~��#A��.�zY��:x�Oa�?"���-FO�[s�<|:ǟ����%�r�-+D�!��k����i����0�q��R�ּV*[�ѡ-�Cm��~���
}

�
���tۿ�_�&�f�Y'��+|>'��BF�we�Ԗ�"	�n��n��?�-K˫~kxew�5R eH<b��y�o�9�͋�>

���"����t������91Q�|q��6��O��O_]g���/�^f�d�*&F
��OV��o��w.q|r�8����S𷿹C ���?>�/���׃��ۯ�z��څ��s�>6�������ant��������� 4x�/�\"�O(�"�ww�m����Y�9+p(x����G�qj�nO��3?�z���L9��\9
�p���+

�(

sI����Y��FJ	 �p�F���K�^.ܯ~�5�3��;@��L�.�'�ȩ�@�OL���U��7&j)�L'�"p)��ғ� �$�9�<Yi�������������u8�F2 ���[�n�+�B5D E8��R:�	����4�z����7jH{�Z��:�R��c㣼��e��'�盯�dTE��,힠�4�]��op�Q�(&�Fll��	�z��ݡ���h*���Ω�:�K�B����6jSP	A YXYG)�R�I�����&��x�����������S�U��������|�w�����5�M5x�����#\;sA�`�v�S�J�pi�ZM2��/��	�@������	������u��ƽ�%��<z���K
����

�
�z���

t�

7�$w�㘘�H���	p��vY__guu���
�0��j���j5��� (���C�u)P�JB�y�	X+����!���yf2Ӗȭ�;�ܽ/y�@�c�2�2��R	p��#I�ϕè��1�&�Ѧ��6��5`e�X$j
��

+������

"��

9;�
"=6=<��GEv��W�y��4'�����[�Y����_�u��y��#Q�z����&K�M^�c� �J�v�V)q��4��x�ZY$���vv��Y�F*|y��T��^G����x�ť����H]ѡ������W/"����SU�O6��_���Уۆ��c�"TA)�G���*î�:�u�7�X�`�5�����mm,�lj	#7h|xR D����D���5�oͯ5&;@K�э1�& ���s1�ؿ*|[�w����Rac��:�����th<�Ӿ�}5�àe@�َ#��3<ũ�*���D��� %?��<��y����

�

/�������z�ݞL�B(ߣR*qbr2��J��{T*%zqD�����rR~M2@W���x�cU
_���+�F�jsn��xbWO7 �L���u�o]<E �б����(�x�	`v��ԥ�H��+�'WΌiY�j0xޜ����7��bL"��u����

��j

j��

��Z
�<��!�l�a�y��'���/5 fh����	�7�xJ�T��<,D��t�aH;z&4T9�f��H(��[ o�\k�<#�H�0M+È�C�
DD�

l�u

��2�

,

��

�C�

[�KQ����E�oZ��V$u�oJ�JT.Gޖ�~%���J� ���'S�R_}�<��B%,x!	7�ˋ�U���n�q��}�Cy(�%�E�P�<ɻ�Oqj��o���W7���2���������x�(�d�N9 �黖�}+bT��7ȼ��w��Yh�z �Z`����-��c�9�]�����ძ�y��)j��t�t�GX�5 ����v���c&�����|�r���t:���GD�(�S+�"�F!����� wL�V��Ӡp�B�KH���e0_���}���m_�r�K���_W�]U4v[

��
�
\�

��:

�
�*��

MD

8���
�L��&�m�k(3��(�c�+؝�;��'3+�	�K�-X� R��$���g&����y��/r��c������
��.�(&&�H!@%�f"�+J�rbh��� 9��ʴ��56)���$A �׫̎�p��$s�ǘi�	�+m䄷�ʉЫ�B��Ȋ�C5�ل��x���<8ST�NBۊ���+��~&@ߍ�[Q����-��jk/�Q"�[\\�ɓ'��eΝ;G�Tz��

�

�

�
/ �FP�&/.���(DкoR�D��	�O�t)P���=9+�JAc�*F�W!r��Rg7���]����鷪gF���=��WC�}��

?

��=
`�`��sÓ��=�7��r����C�S	��������\�ɗ��L7j\��CJlw��W]�I�|�Z�Σ'�򜟽�:G�;�6�m1b�p�fq���1�������-��)��M���'o6O[� @�G@���D�r�+; ͼ9R"l���������m�yu��P��[ 4
[(�h(-EG��転����y��Z��n����m#�r�,�ā�t���TV�'�H�A�[	����a�#F�1;�����5_]�7_ݤ���o�>��#&�q�6@86�w��Bz�6�� �=9���	�˿��Ooަ��&�t��ww,�7~������%Uc6�	#��5y׮$1b�L>?��'6
/��
�~�����/P"or���1bĈ����z���et]����߅0�A�K�(��e9��L����m��[y�x���e4����`�i���4��z���.�-���2OIg�\���4}�<ui1[�R]�0��C��A�@}Z�����CJ�\�����é�t�����N���*`��]!�|)j� ����G^)�S�\%�딓������ ��T�|x�����.���Cu �4����=JN�

iK�m�l�xR�o;u�^�_���z��i����mwƦ�&�<�t�}C`����`pA>MWAP�^f�7[!��1bĈEt�X]]eii	M���ꊃ������Wޏ�e1�]���wH'u,��g�M���7�B��� �$��-+�~0�Rabj�o��#-�]����

+



���

H'�Wo�ƽ�
�g�\9��n������r$����&��5,�B7A"a`�i���q,�u���h4lV�.�X[��J�&��M:��N |)$ǆ�`$���e2�����S�c��#��$_H��۽4�,��2Y#���� ��H)(�4�c�4�=>���s�/�I�tL%�R&����Nq��a�Egp �{��X^��	�5�}�6���^7�q��vk�S�P�;

�]w

z

! U�"��-%M�BJ�&4t]G`�J�-%�mcZ����k��K�N�/<G�r��jO
�޶�$!r�?��@�4�R�0�r���򎡼��iaKI��C#�mK��	8[��M L�x��BRyB��q��B�o]�^fYӲ��Gz�7�y4Q����߶�[��p[6m��e+��%�>&���l��$�~�\g��$	�T�0n�AU>� �

�š.�G%SH����{q�{�	n���)�Ā�#���A�-��Ӹr��W���n_QK��Q��;��Pz[%L�����]]AJ4lg���$�pe�6):��2w���B;�=�)��	� n����|���Bo=�݅�b���
���[ɋ��Σy���'mUF
��w׹q�	���	�DB�g��pW��5��w�XX����X��`w���W��5���#���٨s��1.�;IW!�Z.:�+�kq+n�B�������ba�8P��Q�'v�D��B�



���V�

�ф��Ujf�L2Ig.K��a$��,W��/-���Y.�X�S����.SH��E�.�i�Z���Ν?A9��T&���b���5k���NN����$�j�Uȁ����#�����G�w���������<WN9q!�`������P�<!0M�F���T*��i1yu�]C�.KIR�����_��tw��`Ͷi�5Z��Z�J����� ��ku,��E;o�����89:��df~	�Ė6O�>E�tnL-ڑ;Q���.�]/��5o�sz��#r\�O���%sp]�X�

N#2
˪�

�

���
���ecf�ePM:'�z2�}��C�~f���2�������|sg��z}���Q�t�_>��@�ݞ�>��?q��ώ#͠�u\�Z+���rG�����5�t�t:��|7��H���^W�ݣ Ӑ���.�����	�)��@�(�i�w=)��'mZ8�C����w!����M�����H!��G�/�_졐u(d�A�4BKNO���0Jy,ךԶ��u��]���t�"�3����p�d�A-q���V=̏qw8�7�؋�����5�W[�=����Bcs�+8\�ʯ���<�4������5��J�dVG-8E�$�޼��:q��u�v�����>I�*b�T�|�4i�[[M�Bv���z�1�:锃e�4��r-"~�ޛ��t���|�[�

�s�~٠��\.�������QR�T���EA0ַJ1��\����3xH���*�=<-J���pG:��Z�I�����:�?��	ω�B���L�1��P�i0����n%�Z&�}9<�N��_��-)�,��l�������\�*P,��-Wpl���A���ڂJ���5f�t^ᘂB�A��B+�&���	z�x�)ty+Y��Y|/3zw����,ۃ�	�9X���{2y��t�~9��1���~�5B��W�f
U

�n��

�3��
C�
��
���V^�t�m�����T��뿾��Y�5&N�s��()�@8&��߾�7��ب0<4���an޹���:�4�g3���Y<�)��X���K��g��EH���A���������B�v��� �)@i�|�U�nV��-��UP��~�u�c�x��Rr�I&�5�z���JS*���O���P�T��m"�djr�������96�,���Q�<��o�gxx���#dLɯ��}Ҧ�^�30�����?����x�erb�b>�/�?Ϲ8G�^�0r�I�ۀ#�Bw.�#�Ͷ{>�.��d��p�N�Bk�/���Q�u"j��ޱ�`_­r�۷�`�L���3m�I���o��9Ҥ�,.m`��e��ُD�B��@s�T�G
d?
ŀL���u	O(t��%}- �w'���d��L��TB��.Z�K�DK u�X�!���˥�]
��

��
�
�C��c-���ǳiە���27�vpd��E��n��A�oa�Kw�]'x����C)�Kw����扨	��#U�H�@ ��[r�1���Ć��YeP�#� �SX�d�_���:��N��O J'Z�H

��1�

z�_�>toBߌ'{D��֫�H���10���>�0���y�����*���,�SRb���}�X[~=��mo�r�n�q����4���jO#�ޏf��'�����d��=v�m���	���=:�c�X�Ih�1'�[����/�ǲ�������oJ�ɨmm%$��z���/�DH�m��!Zʖ|���j�Lt� ���<Y���勭
2�

����Ɔ�

{
�j���

�a	�ZƓ��:��.��cm׽��:��8�����'�� �� G��HV���s؍�����BOD�~� ������,�g#0@

Z?��

����

Ü

<���&

��

~nI
q}�|�!�]u8І]�RM���!�E���������nMK�����@�b*�0t���`���y7�|~��n���!44=E��w�!(����ҩ�M��z����X��D	�
z

~��
���

4/
�

�

�h�
�o��j%P�ݜZX��V!N3h����H1��Z~�E�n.I�h��u#�!ȯ�z�����Oaa��"w-yG�b\*��US�;4&�1��U
���FP]����·�ɉQE�ܭ�u:A��*(�L7/��6�Dh��U@�j< kH��iI
�b�K[�.��V6%���OP��! ��ʴ��Y�P���MX��\�yw&E�(��t��<�}�D����@(�aH<��+�p(�F�w$J�l`�R������E���U��hB��k�|�'�E[������ؾ7��+�-�M�����-l�	��ſ���3^��_b��Mk�e܅2k��%A@^}ug���/�j͗wquf�խ&���=n?^ic):���

��

�

2Q�p��O�����5Ri���ri�ć�gy��2�6���7�x�����K4��ʋ���ӬV�l�������ٍY<���>�>=��s���Y��05T���3�^�w�͐�X][a�$93<Ƨ�-`�]~zi�3�W����Ҩ7xm|��g���>�M����M��◗���g7g�>�z��^�"g9�G�K���&��U`

�
����7

�����<

�

��

��^vr�`���HO4'�����thlҡΑ`�����R��ۼ9J�Msd�����؇����knڎ����Y6td�t����Բ�Hv ��s�'�'���yɤ\�q�n�>?� ����U*[�������;�p���ݹ}�uu��>��5[pz���B�B���(�� ���\�pO4Jx;	�

w��

�

�1

��

{<�X {��a����_��p����C�\�� �s����q�N@�� �Q"���,�J���\+bs#F�G>AeY�J�qH&���qI��U$�Lp��#�����_�����U��UP���

�`?~�>��
�0�

�K���

���

_

�
�m��

ڰ

�

]w�,�����Z+Dc�y�A/�����f�YG��[��6cc��#������f���dÃ���w��.�φ���6�I�w�� �1bĈ���wWBP�V����ɓ'����Yq ���P*�`V��N1:t������8|qg���*��>>�y���P�U���
��T
���uX
u�n
�)
��

�

��t� �tc��@����K�A⤀��٘��4He���BG(f
/���F.%��EWZ��Smrf"�7�5���Օ��F5��6���:Г2 �yrF H't��R0Е	�'�llW�`�BK�[!d���܊6^6m�s�*�&]R dh���[

�
9

���j}�yS�m���smt_�G���-O�;-�թd/�����d~a���sܻ�Dʹ�'��b���l� ��'u*�]��ͻ�=W`��Ұ� �����	r��g�غR��[���(�����_���=���:;;9:�Kw{C*I]/2UV�w�&ݺ+5�w>��ݹEI��O��5��{��m>t�&B�=���m�9L�B����R4�%�U�U-
���3�

u
�

�k��

�

�9

�ʃ

�{�

����uӥK���v�����<�^�������R,s��uVV�����;\�r�Tbzf�V�������!?���aO�]�d�� J��WDc��R��}I��f���k�A89*�qA�!B��o��q�I&��Շ�mG�U�#���e�UtU)�3�AT����P=Ϛ�i~� J�M���z���� &q�P�-��V���Ŷ�+a�_&�+k�p��$7�,3R`����\�:�

�f���y��*m����h��k�k���"�\�A�Rv~w��C��K7l4�c��7
�P ��<�[�.	ر�v��&%�{x�����8��G�A^�9K��7j����P�f�"D��3���65�4�� �$7ddm��D@?��(��@C��f�d����,ܐ�G!��l`�\���j���^kO �n��ӛ��Ռ8
mw=ȯy�ë�KUj��i ��LJ�)ѓ1���&�\� ��u;q��k�0~��Y��7�&�X$�C�2�b1�:3��Ο���+	�]�����+�X��kW0��%]*�ZJ��r|�+���K&')���aZ��:�����P�}5���3t�O
�3���AS��ր@(n\rt����vBt/��%��$�Nі����,�=3�@g�+co
 �T��={��mܸq�|�L:����a������$���l��R�x�)B��WH�ZR!��9Q -�C���g��%>�v���������ıa�Z��������m���\ҒM��/~��C�ܼ9�iJ�zyll��{3\J�I�2�eR{><7B�����q��Ƿt�7y�嗨V��P��d�g�}��g�n�Z/^��^�ҹ6O��B�Pw7���$b1 (	���rCf윋�ruU7���P�`"w˒������7]Gp4��9B

�

i�
��

.�������.�������8���>�n؄���.��F6��P�c#�������?y�k�~��������99��cG��_�����9�K�T�/11}�s��b����_�ԉ1.ߞ�����d!�BC�L���쓧�v�.�K+���I�j322����={���~��q~�Y�mO]hd�	>{������B����u.^�f�;��7�qo�B�ԩ�U>�� ߜgyY�╻
,�+T^����Ξ n !.�=��R��RiJ�*餲�Z .'
y��Ń���� �W{	�nO��}MΏ���0	7�����-+��6��o��J���'�
��81�����d"߁^I���e��@�x듛��4"�J���@����{7�����P/��Kq�����i.A����\R���"ˋU�9�G"��2�d)E�p��6�F\R��F�5�ǿ�Z	ݛ�g��*�'iٓ�+y�S���sh]�%/�D`	��'N�R-�{���6诶F�A�j��X}}������~P<�pb\ex�c�#D��wݑ��t����.����� ��:�uK"a鞪Xf��$.lK^.

�"

M8

��

�
`�

}�

vM�B���i��W��V
Ӭ �rK5*�2�I��Ӛ�DO/��N���H�F\Ϡ'c���K,�?����B��q����E^��|�l6���a#�N������>;���?�P* �,؛��Hy{X�����޷��o�����ȍ�{���gq}BJ�SS3�f��޻5��B��D���27�'�ƹ3�j\_X�s�r{z��w���`�\����

Z�
��(�

��e�

|#

�sM�<X

��۵'����q��
ܹsg�EIX2|�嗸v�666\����DL���^[�:zfJzk�]�>�����#ةr��bIx	B��wb�����W宫���/�\ܒNn��:��k�c�)�d��rƷ+�U���.	��ؒ6��L�A.�ƕy;x�yQ]N�9��Ȭ�ҐV�X)

)�V�<���)�<��bD^���D94ƐWL�U`�Ջat���E� ��ِ���x	��
�T�)�x�1~!c�U�V�|9D�ـuJ ���	�fzCjfV��}�Ng���LH�h�3G�yK�2n	��􁕶r/?�����?�'�<�j�>�_��`�'O�������w�l�����b,��
�J9pQ���Ž�%lXu�2vJe`��P�I�T��Y�h��C6���pe���B֨��ل�r�z=|����٩u�BK��z=<z��ք[�b!�����b��A�� ���	��KWQ��^����]����&������a�BZ/a.��~a�����E�DR ��۰YDw�9��xL�g�/�k�7ٸK�VMah��"���/��_;�o7-�

{WFr�&¥�����6�+��X�2���*���f4V֨�ԡ�-|�]<Y��rnr��
5D������;�Z-�����n��l���!�Rh���ց��KO7��H)f�*�D�R���kT�.*e|n"�.�~�?������MI:�O|�[�-!!ay������S<���Au\B��������`3[�e���*�w�����ۨ�����)��TU

�N�

�_�J�J+���ۙ�	9�����C���x�頴��"��^F}:�b�x����ADȲ�V˅f�;m%����>vb�����(�b̜�tܕa��+��������IeB&�VD��6E~����� nUa ?��<C���5wXSw���������|}1���73S�|x��������s!�쪤��%���`B²�����SKE�a����vn#�

U��
��V

��

���

�Ph��
�

��0

�0	
7

3�

����

���b���Xwc�-�������m�c� Nܳ�牸�Ѧ�Ϣ�֩���� ��7�n�·	$j,���<��gW�H�jn���x�Gɽ`��vs���Ƣ��X�non;�4������7O����D�ߦ�5@f=���N�G

���

�

�!Ib��0�⯇~�sU�YZ^�7}�;o����������O1��^෤	HUk �L��&�

/C�

`��

/

���

t��{�,
�t��������$��ʞ=4���z��l�ef~�R���9:���dR)2���بBej�̾CS��+Q�x�4�6HZ�a��׊&�o�:cg�� ��=��+ĳ157I8=���؂~@}�Oc�d�Y�'��S �6Fm,Ҭ����^󼶼ړQ@�H�NV� �

�^

�\��֐�`�h�tj
���H�����K�E�%�s렃���WX/��a���������& �ւh��v��j�:�� ������l��cm��E<x����E^=��fm�Z
���X

�

���X��

�
��-z�\�c<"'V�=ί%Y��U<�-#�n<����:�Mǀ犥���\L�� �E\;蠃�# t�7��#���%~�y@v+��mm@h�	�"r�x�i{�"���G���������[��C�P�"b��!+b�]�"iC𾳦w���

��

t�#��WR��'�%bB2�	�Jpս�'�>�!BJ��9aH�o�WZ��Jڵ[%�64���Wۈ�����Ӎ�ꠃ���n-�%QO* ��	�a)%���8+++�?���)��:�t�ӧO�ꫯ�)���M0�n0��`cYA�����1i�/��

[�
qS����,WJ�M
��t��d5h � ��FxCնI�*i]M�	�S��L��Pk�]����D����}��i�)B.v�-[R�\�.�$�2JA��$�j���2���7��Pe�SL��}���G�:����J(Y

wV�|m���>@_���eΏ/0�8��@F7��_���!z�j�@�3Xq�
�tq���j�����CZW���ѻ��pa��\�O�q�6�����v����7�K�gϽm;|qc�/��s��~�=v��\�����14�?�8�W��\�7���*B���u���}�dt�7B�D{R�p���1U��c�hjӱ

�

�m����

���

#

�

�Y-Q�e*��u�(p�Lʠ�ϰ��G���m�=lS͙�,��K��'{����g�כ�vk���ŧOv�j}�v�f᭛�Mv�V����6o޻�4~���M���R΁0�9�Ŗ�,�P�S&% ���K��Ml���)@� �:����F����ۏ��u���;K,�
������;�Ցi����t��տ`B�󜈫 ��o�wjH|��Ҹp�p�Wg�Q�� ˪�O����;R����.S&Ý�

����

�

G���

���-Vjyn,��n��϶xq(9����-R�r͋�u���y j�% M$B:8	��x��	,C

�V
����

�j�:
�'�K����K�و"�}˘�"�U(�D��O�q���zǿi��8� �'㑗2�3�^y�R�-̽g�L�pUA�SƓ�O/�Z��F�\������{���6��� �?������w�c�$K��!-�QƟ$��Ѥ�\��6�3�DR����>�;#:����> m�	r��T����c//

��r

��
0�

�Q=���X��G�P`vv�Di���s��m����J5=�-J&�I�����q%ո}"��j��#�'���"�M�_"i��M�C���q���W�Y�z��ת����X_Oέ_���� c����3&	�+~EzD��[u������!c���O�]:*A�

�s�
�_

EO=��z�'�U�$�~3l�$}�/�U~�@ ��ٖ�~���GV%d%�n;��:2��!�]z������/��p����|���H�5L��ó�!��rK"� ,��S�muFX'`1�l`d��$v����;a��ɳA��"����&�4444444444440Xg�(���ȫ��1�fm�Nq��W'�#��hq4�������R̪OP��� f�4���^~�:�j-'���

��*�
44444444444.2�|������Zo���4nZHJ��<t�
���^0t	ض�a`�����dM�;%�7�r����  ����ݮ��q��*���V��U���(�,�X @�X�#�:ϑ�<D���#�.@n� �C1

�

\�

����T���xٗ�_��b�s��׵�rMc��Z1U��sf�ę�S��	��cxi2�zA�A?��lb�dQ�P댮ܫ嶧�l3x����(մŽtT?�

���
��i�;

����

!5�=�

f

�����f

��
���
5 DMJ"E)q��Z����t�W�s�ڹ� ���������r�P_����Yhv��ۥuY�D�.�_�����}f��u��1�N��w�\&��ZR�sM�xpR`֍	���ea���ĥ�1�H5#��b�E{_��c���T�H,@��4|(��s���"o��V=Oղٹ�M��`4P�wb���bg\��ۺn��,�D8�4��(�)ڔ�.�����3���h����X'P��

9s

`���8��aeK�1��-
� �8|vպ��>W����2��c|5�e��ԓ��#z��jl�w>�<�C�هO���-n�����2�³cX���������˹qp� fE�

U

�N��R

�
{�
��

�O�

m�

�
g�

#�

.��S��

ף���B�tP'e&q T�{�11[}*�~l��o��b]l��z�e���B���T�[	-�	�UZ^=�H`�W-���c ��yNM�o	`��*�<�
�

�

�p�

?=��Ap���:���XSF.�$V�Gp$d�d@�b�����E.῱�Mt$��>����p`�}ӷ���#����uZ ��ϓ����W�V�yG 
��C�y

?�����

#

���!

�
aa
&�j��{��\V,�n����X����F������v�Ϗ	U-R(���tB��z/_��Gbj�E�����Z,�2��F�M��WN��"��+��&/ �j U�

�ϡi
an��-�����7��]���u�O�����&������p���Q�n#"��r�{<��Ny�wL�c�}���/��	b��'�^���W���	�#�^}�x�w�9y0x����쑂�&���d9���J� ~��Ahȇbc���������C���o�0��'�[��rW�����$>Q�_�y�r>GAN��`�߅��QvP��C%�cX= l��\���j�%������(�(+N�~�3���"ğ�'!q<\-�� 	�/��ݝ�Uv��B��M�A>��"���7 �3��Xk�^]��G/�

�

�������

BP�S�	�:�I��	j3�ޱ�Z��;�1�E{��N��t�[z��

߆4���o����t��a#R=h��1�%��inA������ꍒI�9��Y�x@X���-�\�'�^��?K��@{&��:X7&R�-�4�mc�jLrd�ӝ�&� ΁��8��Y �j���>�&c�L"�J�$Ubv]y��A���nW/��*<����d�9�_�*��R�[{�ܻ'�r�BM��`�Y%Ȳ�#�+�t����Pa6�:��R�+�x:�>qՋp�lh<l��w��eQ������<:�lL�:C�د�8ΎC�d����؜�����EY��JE,��T6�����ؓST�:T<�2���̒�4>��	N�3�H$ ٻn�k�?;�q�cz��O3b6���fP�����"^c�g��-:-�AWC=Ӹ�A�;���⻜cR�5R[d����Y��E��0X�e�"�M
)�2-\�֏��WҚG������%����>���Sm�Yj��_�>��iT�RX��9Kk#f8[�{���#��u�2�4m���q�m�����qq��HN�M�h[�R���u{:	Åp````�#�q����Æʸt����ԵU	}�N>0���(�S����"�PΕk�+1T�q��N�&�␙�81�ʭY�7�i+�~�Y��n��zX�s!�Y��J�Je���qi��2�s�7

���o�S����Nx��EK �ϓ�Y\(IW�DG�B�{���I��@��fK�S�у'`�Y3���P}&���� �F�j�G��!Y��C,����

�

�

�\��"�g'�8��1E� ��4=6\,�:���xsb8�\��XGu�yH|7�.6kz��u�d� ��A\�wQ�q	�V��	�zZ�?�r���G�U���x8��?H�Y��K��Ӊ>��ɫ�ۇ߻7�&��č~ �!A��W,� �Źl	�<
|

,

��0��Q�A&Ϭ�;���h���,w�	f�ו�g��DV�k+N/(8Y�����+Ťߪ�����1v��'�*o�f/J��xC�-��͂��e�j�5닟��ȶ��Ѐ)�ϥy��顑��L���a��7'�(ƌ�	�Ł$���j�|i�[Ԋ��w�;X\=VW����o�8={`�� $��3��zj���ļ�0��
l{%H�-��]��-A>�#�����l�+�h����~1���ܫT�g炻���Z��Z!}�I�!.�JK��Nrz�Zg���,�%��X�/T�G�'��	d�r�	�=��R_��+��^`�+@����.Xa�.`�5��u�V8N�2��Isf�-�h�r�N�v��B�����P���.�xk������}2���rAm�9)׿�N0��e��Dܳn-�� ��

��
z��-Z�W�n�߂�.2�Zzj�ț4b�z�"ً���Y4������N��mc�"���ש��]8M^m�'#
��c_�-�\�R6B ������X��ֹ�YدD�w.��2/J��]��M��
H
��A��E�ĭ�W��2�h_�;ɫ����7d>�nCTm�V�D&P��*]�V�7^`6�,uS;��Ϥ�	o��MZ�k��j�E��R7�����Bf:�Fả�"���3fͻ�7��2?Z&�L��'����;ڨ[� ���߫�m�YuQ���L��g$���bsl�,� �G�Q~_��

��
�|
��U�

k`�S�VMv��P%&����O�as�    IEND�B`�



42_ONCODNA-COM-FOR-PHARMA-COMPANIES-MRD-FOR-PHARMA

DiscoverhowMRDisusedinclinicaltrialswithOncoDNA

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Molecular Residual Disease (MRD) for Pharma 

MRD allows a faster time to market for pharmaceutical companies by increasing clinical trials efficiency while reducing overall cost 

MRD (Molecular Residual Disease) allows a faster time to market for pharmaceutical companies by increasing clinical trials efficiency while reducing overall cost. MRD which refers to the presence of circulating tumor DNA in the blood, can be tested at multiple time points in the patient journey and might be used for several applications during the clinical trial, increasing its efficiency, reducing overall costs, and demonstrating the durability of treatment response.

Why conduct clinical trials with MRD monitoring? 

To ensure an accurate enrolment 

Guide patient selection based on biopsy mutation signature and blood-based MRD. 

To evaluate treatment efficacy most quickly

Tested at multiple time-points during the course of treatment, MRD assessment is used to monitor patient response over time. 

To compare two treatment approaches

Providing deep insights on treatment efficiency enables the development of an informed treatment strategy. 

AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test 

To adapt therapy intensity according to MRD follow-up

With the accurate tumor burden measurement as indicator, clinicians can precisely adapt the treatment intensity. 

To adapt maintenance duration

Collect enough data to ensure that the trial stays on track  and that the drug or therapy is working as intended. 

To introduce Early Rescue Intervention (ERI) strategy

The implementation of MRD testing supports the prevention of over and under treatment and may become a surrogate biomarker for accelerated drug development and operational cure. 

Clinical utility of the MRD testing 

MRD testing eliminates uncertainty throughout the treatment journey and provides a simple way of monitoring how patients are responding to their current treatment in real time. 

Stage II-IIIA Bladder Cancer

Stage III Colon Cancer

Stage IV Lung Cancer (width>50% PD-L1 expression)

Our standardized workflow from the test shipment to providing MRD report has been designed to ensure consistency, accuracy, and efficiency at every stage of the process. 

After confirmation of the order, we dispatch the test kits 

After confirmation of the order, we dispatch the test kits, which include a solid biopsy block/slides holder and a barcoded blood collection tube, to the designated medical institution. 

Filter out noise and derive patient specific cancer mutational signature 

We identify the genetic pattern of a patient’s tumor using thousands of data points across the entire genome. 

MRD technology utilizes artificial intelligence that recognizes patient-specific cancer patterns 

AI & Advanced Signal Processing

MRD technology utilizes artificial intelligence that recognizes tumor specific genomic patterns to provide unprecedented acuity in cancer detection and monitoring. 

Our team of oncology experts reviews each report          

Clinical validation by scientific team

Our team of oncology experts reviews each report before making it available for the clinician 

AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer
Sensitive detection of circulating tumor DNA by whole genome sequencing (AACR)
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers (AACR)
Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC) (AACR)

What is MRD (powered by C2i Genomics) test and what does it test for?

C2inform is a personalized qualitative diagnostic tumor informed test for the circulating tumor DNA (ctDNA) – based Molecular Residual Disease (MRD) assessment by using whole-genome sequencing (WGS) data for patients previously diagnosed with solid cancer.

How accurate is C2i Genomics MRD test?

MRD test is designed to be highly sensitive and specific. It can detect extremely low levels of circulating tumor DNA (ctDNA) in a patient’s blood, allowing for the identification of residual cancer cells that might go undetected by conventional biomarker tests.

What information does the test report provide?

MRD test provides results in the form of a binary score (positive or negative).

What does a positive C2i Genomics MRD test result mean?

Test Positive: Estimated detection score is above or equal to a pre-defined threshold value – indicates MRD detection

What does a negative C2i Genomics MRD test result mean?

Test Negative: Estimated detection score is below a pre-defined threshold value – indicates MRD non-detection. A negative test result does not definitely indicate the absence of cancer. 

What type of samples are needed for MRD testing?

Data is generated from WGS analysis of the following specimen types from each patient: Tumor tissue sample (Formalin Fixed Paraffin Embedded (FFPE)), whole blood for both germline DNA from Peripheral Blood Mononuclear Cells (PBMCs), and plasma for circulating tumor DNA (ctDNA).

What is the turnaround time for my MRD test results?

The turnaround time is 14 Days.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712106933



43_ONCODNA-COM-WEBINAR-ADVANCING-PERSONALIZED-CANCER-TREATMENT-WEBINAR-REPLAY

WebinarReplay:PersonalizedCancerTreatment

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Advancing personalized cancer treatment: Webinar Replay 

Webinar replay available now: Unlocking precision medicine through expert NGS panel design 

Discover the Future of Personalized Cancer Treatment

Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research and treatment. If you missed the live session or wish to revisit the insightful presentations, we’re offering exclusive access to the replay.

This webinar featured leading experts in the field, discussing how our OncoDEEP® Kit and innovative technologies like Twist hybrid capture are transforming the landscape of cancer treatment through personalized medicine and precision diagnostics.

What you’ll learn:Revolutionary personalized treatments: Insights into OncoDEEP’s approach to cancer therapy and its potential to change patient care.Expert perspectives on genomic signatures: An exploration of complex genomic signatures, including HRD, TMB, MSI, and LOH, and their significance in cancer research.Innovative technology: The impact of Twist hybrid capture technology on cancer research and its role in improving test efficiency.Real-world impact: Case studies from leading German healthcare providers, showcasing the practical application and effectiveness of these innovations.Maximizing NGS data: Strategies for exploiting next-generation sequencing data to improve research outcomes and patient care. 

To view the replay, please enter your details below. 

Position / Job Title 

Assistant Professor & Head Molecular Diagnostics and Research — Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster 

Head of Scientific & KDO, OncoDNA 

Staff Product Manager, Twist Bioscience 

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Press Release
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, NetherlandsNov 7th

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...Read more →

 Press Release
OncoDNA wins the Biotech Award of Deloitte’s 2020 Technology Fast50 competitionNov 27th

Gosselies, 27 november 2020 – Already celebrated by Deloitte’s Technology Fast50 in 2015 and 2018, OncoDNA is thrilled to announce that it has received this year’s Award in the biotechnology and pharmaceutical category. Deloitte’s Technology...Read more →

 Scientific Application Note
LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectivelyMay 11th

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129247



44_ONCODNA-COM-CONTENT-UPLOADS-2024-01-BANNIERES-EMAIL-5-JPG

 FIF      Comressed by peg-recompress Exif  II*               V       ^   (              i    f       `      `            010          0100      �    �  �           

2

Bannières email - 1

    �  H  ���      ��    �( P  KE$�D� %(   H�U���H� �)|c�`�	  )H   J(X

 

 Pg�3-̥ QE  <%T�  �Q@ �(�3@ Z1�    % �H ($ )e   ( ��  e U�  e @�� �ڊIJ�%g���r �Q )�9c5l�
�DU0�	J�) X1� (  R (  �@�(  �e�@ �*�  @P)@ �Z�� IEP��g�u�@% 	"	��d(�QT@@J�*"� Ռue   ,T ( ��

P(  

�

J

 �

:�Oa����g߯?���s��~Zɱ��z}{ǎ��ց�;��1�MOG�wY�]��<]�Ƿ
�n��.�Me����$�=��Jm�����o�nh�o�� $� �L��r �E� %�q��*�

 �������@�U!IQ&b�U�8�,�GHP �@,�   ^ψc}���MNTX  ���g[��,� 2ƕ!JJ��e��ڻ

   YP(  �%Q� P����(  +<sE��Qe YE�AA2fj-�J"��R�r��;-,YAE���xB���H  ̎}�R�{������1�tZ�uΓ�]��5��k]��<�����9�Ug���k>͖����������6޾�o��{�o���i��?��u���}���{;���{����E���{������sx��-���/ jn�׬���:)e�3r�[Qe a�W,s��PT PR0g�L��-�̘�s��R2�1 ��� 





�(

,��

��

���

~

Y

�G�+ #\�a�%�e�% :߸�	R3�[��s.�\^Z�� :� ��~2"�
�����

��x��DY�qj{)OW/(Db��(��>Sې�+-�N���˵�[��M_TQk�,�ѣ'�Ye��㩋����g��Jy_܏�K~����,�!e��+�F�'H�HA����i9:t����I�|C��$D�jL��ל�#�� 5��
L��2"�������9P")F�Os1[���5:���Gl��-|e袌�	A�Z��i0*&���¾P������H�iFy�Ey0�.z͆O��'��X���u��)��Mf�k-F�M�	R�Y�D�O#��<�W>�|��,8

@

�Y
���

��3��(�7l���O7M$���)��RE:�e�6��Z�p[9� t���!Ε�4b��&I���;���v��SƄʯ�^���2S$�R�y2�,�9��H�%�w4y�,�Dۭ"�]դ֫O-�g�`k%1A�� ��=�e�Y�ӱu.l���d��v���l�vͻ���C�UbY�HN�ӯW�c2Sr*�e6E�M��.Em��I�d���[�����	���ebλ��>�A�����WF;���7%g/N��y�"�Y;��1b���I��P�꫞M�fjT�s_� �#�!���ce+�|��D_��tk��(�70AL�*�.zC����@�Td��9�VJ�HE��
�3Ơ{РL�G(T��1}���md��Z����ַ�Q��� HO�����k�[�6Wx��Rre���T*3At�� �%���Y<��E��>-8,�J9)񹖃S�1ˇ=�y YZ��L����Db��	9��9O�\��

��

p
�[�

�[

�V����O�S��Ըt2��c9�iQV25��k!H3�|�H؝��V��B�]�C�V���.-}.�0��fG�ɪ���U><���TV���0%,)����ս�i��
.��Y��	b�9�B�M���\���^�Jޯݮ��]��V~�O�3{;��[!U�t�j����}�A�le+99�hK�������ʝy	0�q\�]%��^d�R�%&�c���'&�~R=���g

S
��t>�

�3WW���6U�|`��ʓ��{�������=U �,���6�ɠb�V?j� ��F���� ��	���7 '� �sA8�

��ao:��ft�2sTXI$�d�ď��ňM��wΏHn��QlLx�F*}���|$jD�t��xٓ �y��
���Ƿ�y���8��/c�@&,H[�����RfE��k: �x�ef�9�	:�{:����W�b#`y�V_ �ԬV �ȍ����T�g�U��gXW��Q
�

�
�

�D�

����l

����5u��a⢔�m�`��������[�j���"� v�qM��n;	�W��8��h�w

�

Y

j

�
Oi�IU�36�{�f��#XA̱��t'Z{w��){���p1Z� �b�4���T\{���Z���qg 7��� EQ���T+j���&:�ӊ�h�qG`#b?Up�u�����^�=l�S�L��J"�F� �&b�O��a��w��� ��7��8���$
�;Jx�L�P�<ۉ����h7"rQ���J:����*�� �Υ��Yds5�������y����cq"h+�p�	kX��Ճ��Fr �Q�`�b���pPx,�i���[:����k����>���G������jq"_s�}��/��<_&����?T�H��Gi��p-�ݙV���[0�c�

�Y

3�横P�:_���>Z��; ���b;#�Glv���%˕�N0v����Ў�������?-R��G`��k�;c�GJ�+�D�~PvH�>D��d@|�	��C�����x�WpeB.���&��0,�}g��W���X����]3^������TP�

do	)w�.X-|0+�CM1���9�A&Ϧ�8&�#0+D�3PA\��� &��HN �5��}"k�J1h��U���J�q�к�z�HQ��E�T�  q�M˗� �@{C���],�Fɤ^ ��q�_�W�3����p�Ly�F�I��

C� ��@z\����ݩ^J���� 5     !10 AQ"@P2Br#3CR`aq�b��4��� ? ��?�g�����~Pk�{�eFQ�eFQ�eFQ�eG���5u=��f6w���joy�������joy�������joy�������jox����59�r��#�9�����>� �&����� }�O��ߤe�>�C�#�{@B|��;B7'ɭ��Yޮ6�P��f�c�Qdz�cs�c�j��pa��x}*(t��A��)�g�G�

�h


���Q
�
��
(�

�0��T�R��/�y��ہ�r��������



45_ONCODNA-COM-CASE-MONTH-JANUARY-45-YEAR-OLD-MALE-WITH-AN-INTRAHEPATIC-CHOLANGIOCARCINOMA

Cholangiocarcinoma:FGFR2-BICC1FusionIdentified

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

January: 45-year-old male with an intrahepatic cholangiocarcinoma 

Cholangiocarcinoma can be classified into subtypes depending on the primary anatomic: intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma (perihilar cholangiocarcinoma and distal cholangiocarcinoma).

Intrahepatic cholangiocarcinoma is the most common primary liver cancer after hepatocellular carcinoma. The early diagnosis of this cancer remains a challenge because of the silent clinical manifestation. The prognosis of both subtypes of cholangiocarcinoma is poor. Current therapeutic option remains on first complete surgical resection but the situation of the primary tumor constitutes a challenge to proceed. Indeed, small tumor can be located in difficult access localisation, multiple lesions can also be identified. The 5-year overall survival for patients with intrahepatic cholangiocarcinoma is around 10% [PMID: 33735689].

The use of adjuvant therapy is needed. The most common chemotherapy is gemcitabine alone or in combination with cytotoxic agent such as cisplatin. The better knowledge of the genomic landscape of the tumor allows the use of targeted therapies. The main two are targeting alteration in isocitrate dehydrogenase (IDH) and fibroblast growth factor receptor (FGFR). [PMID: 36260350].

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance to the adjuvant therapy. Therefore a genomic profile of the tumor has been performed using the OncoDEEP solution. 

Clinical interpretation and analysis results
IDH1 variant analysis in intrahepatic cholangiocarcinoma

The OncoDEEP panel did not identify the presence of IDH1 variant for this patient.

IDH1 alteration is found in about 20% of patients with intrahepatic cholangiocarcinoma [PMID: 37746315]. Isocitrate dehydrogenase (IDH) is a key metabolism enzyme that is responsible of the conversion of isocitrate into alpha-ketoglutarate, involved in the Krebs Cycle.

The IDH mutation usually leads to a gain of function of the protein leading to the increase of alpha-ketoglutarate conversion into D-2-hydroxyglutarate, an oncometabolite. The high concentration of the D-2- hydroxyglutarate leads to dysregulation of histone and DNA methylation (alpha-ketoglutarate enzyme dependent) promoting malignant transformation. This oncometabolites also lead to the promotion of cellular proliferation by stabilisation of the hypoxia-inductible factor 1 alpha (HIF-1α) [PMID: 33182517 ; PMID: 37746315].

Ivosidenib (also called AG-120) is an inhibitor of IDH1, FDA approved drug for patients with IDH1 mutation and previously treated locally advanced or metastatic cholangiocarcinoma. The Ivosidenib allows to decrease the level of D-2-hydroxyglutarate to restore the level of alpha-ketoglutarate and the activity of alpha-ketoglutarate enzymes dependent, involved in the regulation of histone and DNA methylation [PMID: 33683991]. For this patient, Ivosidenib is therefore not recommended since there is no mutation in IDH1.
Detection of FGFR2-BICC1 fusion and its implications

Nevertheless, we detected a fusion FGFR2-BICC1 with our OncoDEEP RNA panel. Indeed, our oncoDEEP solution includes a DNA panel allowing us to identify genomic alterations but also a RNA panel targeting splicing event and fusion in 22 genes involved tumor development. The detection of gene fusion is performed by specific primers pairs designed for the identification of rearrangements.

A fusion FGFR2 – BICC1 has been identified in the RNA for this patient.

Fibroblast growth factor receptor (FGFR) family belongs to the family of the tyrosine kinase receptors. There are four family member: FGFR1, FGFR2, FGFR3 and FGFR4. Those receptors are involved in several cellular processes such as proliferation, survival, migration, angiogenesis. FGFR signalling pathways is triggered by the binding of the ligand that allows the recruitment of intermediate proteins leading to the activation of the downstream pathway. FGFR fusion lead to a constitutive activity of the receptor independent of the ligand. FGFR2 fusion is characteristic of the intrahepatic cholangiocarcinoma. About 14% of cholangiocarcinoma shows a FGFR2 fusion [PMID: 23900974 ; PMID: 36497187 ; PMID: 29848569].

The FGFR receptor is composed by 3 domains:the extracellular domain that allows the ligation of the ligand,the transmembrane domain andthe intracellular domain which contains the tyrosine kinase activity.variant 

In case of FGFR2 fusion, the extracellular domain and the kinase domain is conserved. The fusion partner, in this case BICC1, allows dimerization signal and lead to the activation of the downstream pathway. FGFR2 translocation can be targeted by tyrosine kinase inhibitor [PMID: 32983265]. Pemigatinib, an oral selective inhibitor, is approved for the treatment of cholangiocarcinoma with FGFR2 fusion. [ PMID: 36497187].

In conclusion, the OncoDEEP kit analysis reveals the absence of mutation in IDH1 but highlight the detection of an FGFR2 fusion. The treatment of intrahepatic cholangiocarcinoma remains a challenge and is still associated with poor prognostic for the patient. The use of targeted therapy such as FGFR2 inhibitors paved the way to a better chance of survival for the patient. 

Fig : Isocitrate is converted into alpha ketoglutarate by the Isocitrate dehydrogenase in normal condition. In case of IDH1 mutated, the alpha-ketoglutarate is converted into an oncometabolite, D-2-hydroxyglutarate. The accumulation of this oncometabolite leads to dysregulation of alpha-ketoglutarate enzyme dependent which leads to dysregulation of histone and DNA methylation. In addition, the HIF factor is also stabilised by the high concentration of D-2-hydroxyglutarate. 

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Case of the Month
November: 68 year-old man with a Stage IV Prostate cancer2 min readingNov 14th

Case description: Prostate cancer is the fifth leading cause of cancer death in the world. When the cancer is localized, it is usually indolent, with a 5-year survival rate of nearly 100%. However, when the...Read more →

 Press Release
OncoDNA supports BSMO project to advance precision medicine for late stage cancer patients across BelgiumFeb 4th

Nation-wide study will measure the impact of comprehensive genomic profiling on access to, and uptake of, personalised medicines and on clinical outcomes for patients across Belgium GOSSELIES, FEBRUARY 4, 2021 – Today, the Belgian Society of...Read more → Lab Case
Revolutionizing laboratory operations with OncoDEEP® Kit4 min readingJun 18th

Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129289



46_ONCODNA-COM-CONTENT-UPLOADS-2024-01-INTRAHEPATIC-CHOLANGIOCARCINOMA-STUDY-JPG

JFIF     Compresed by jpeg-recompress� �Exif  II*                       ^   (              i�    f       `      `        �    010�      �    0100�      �    �  �           ��htp://ns.adobe.com/xap/1.0/ xpacket begin='﻿' id='W5M0MpCehiHzreSzNTczkc9d'?

2

Tempates Posts Website - intrahepatic-cholangiocarcinoma-study

(=&-&&-&=6B525B6aLDDLap^Y^p�z�  �" 2                        ��     ҇���             )JX    !@	b�) P ,�KE @J 1���Z"�P  �TU�DQ 

  

@

 

G

�/U�tI�o��'�!<{�}oǛ[����*t+��O�"�i���Wu���m41j��&wo.J�JXm? ��O�߬�I�8b��m3BM:�Xáxس>	��7�85��kt}qu���
is�9�c#��C��H�{����T�[n�G����Yf�U'	<#�u9���!U	b?G���'1�~m��b�F�ijέ<6����9�h�
�\

���F5[fUT���m����Gd\�5�i���w;r��(;u+�:d�4�.�$��V��I���*�T�ٛt	���5��W�l:�0�P��	BK��Ui�#L4$3�2 IV"0���K6UU`M��P�5�� d$4g�`9�(Z�3Qv�_6�� AA�z�

��R������g��x�Q��]Ni�C`r���\r���Y#��9x	Y`w�b(��b�X� {5������$�AIٓ��mKb>��M��Ǡ�Z��	��j�]EUc4	�Z�"|��

�

�����z�uq"6?���2���+���]���1���	��&���pM'������=���C7o.��X� �����F�?l�������"#�Ȭ�TG0�;ݘI��cn��V��T��O���7���_:8�+ё���>�$\~�DM�"#[�gg$��N�Ꭼ2��OU��,3�[_wL�A�	���N	��ͭ��_l���9�F��&}�0*��g(�T��+�n

�s��9��]t)9�ĩ�N�-n��bOزY��+U���k�q�zB� �D$,�+k�Y$(���������q����]M+ �I��H�z�Ro\�b˵����ֳ.��0?B4N�iI3!%G�0��	�@+$��1�Y}����$�ϙ�T�DDDN�'M�X��h�d���R�X�솯��V0���w�$B�a����=�Ys�2�7

����
�5���U,	s�l��S��_�m
k ���-5�������]+Uf��Ul`c�	��DD�� ���f�b�����$U����:ԗ�/)s
i�1຅��g���a��/�=�(�ܗ>6GYc3y���c��H� v��}�yr�SaI��`Ď@=�[#`X���̽�}�M'ĆF1���+�_
~�����L�� �!@��v�O v� c�E$k$�D�n��

��

����

�-

�

%�

�_Z���������b��v^��!R~�[U���A���
��`�>.]Oԭ��𦻻O�b����[)��J��ea�kz)�&�t);�D (�Lz ����k+�v/μ�#^D�+Ϲ��'����w��b�����������=�W�O��

�� ��

����

t

�6

� 

����d

�
10�Cm�Lj���Ǩ: ���roP
���uܱ�1��x~$�L(�ק,Y��Ŏ��:$x߉�a�T�m��� ۴\Db�91�*�=;0Af�!���K�`E��h��%����pa x����=Rƀ�����O�!�1a	�s�C�� 7-v�P�C5���Q���:��� L�M��2��{�>y�	�l�(ox2��Nc壤
���

��

��M

 �&r�I&L�� P��@���~��Yz����lH	�D��>�X�'�_6Rq�􃴚�I�r��x{I��bg ��=��)[L�NJۈ����"�l�5��gj�c�q�5�Ǚ�E�9a�

V

L$���^ƶ��u{P�Fd�#��<�f	3.S����c c'���}�)��O�ߓ ]��|�� ���|�#P�G����� �:��	� ���c���>RN�{����� �A�I��қ�EԳ��|���<	��&������ˋ�ZcP�d�h�N���ߥ��ǥ�!� ��n�i�[*��� �� �VQ�"��8KP��q �q���N�e�r��6�8�]�2���G\���Ӽ�W"�]�tʎ�T"�uG���W�^�| �

l
�0���z#�y��9�%��P2���J�%�ˎ>\}�����



47_ONCODNA-COM-FOR-LABORATORIES-LIQUID-BIOPSY-ONCOSELEC

AdecentralizedOncologyLiquidBiopsyKit:OncoSELECT

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

EndGoogle Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Liquid Biopsy (OncoSELECT Kit) 

Targeted liquid biopsy to support your clinical decisions

Compatible with Illumina technology

Clear data insight and clinical interpretation

Targeted Liquid Biopsy to Your Clinical Decisions

The OncoSELECT Kit is OncoDNA’s first decentralised RUO (Research Use Only) solution for liquid biopsies , it benefits from having been used in a routine centralised setting for many years ensuring that laboratories can leverage OncoDNA’s extensive expertise locally. The OncoSELECT Kit encompasses more than 70 genes, including pertinent HRR genes, reporting genomic alterations and enabling the identification of MSI and CNV.

When a solid biopsy is impossible or unavailable, the OncoSELECT Kit is recommended as a non-invasive solution to detect ctDNA in the blood of cancer patients. Underpinning the kit is Twist Bioscience reagents, and OncoDNA’s data analysis and clinical interpretation tool, OncoKDMTM. Using the data gathered in OncoKDMTM, molecular biologists can create a report that will ensure oncologists increase patient access to precision oncology. 

10 years of knowledge that matters 

Since 2013, OncoDNA has performed more than 35,000 tests, enabling us to build a comprehensive database (OncoKDO®) comprising 4,5 million variants across 22,000 genes, along with information on 1,400 drugs and 9,000 clinical trials. This vast repository of information allows OncoDNA to provide our clients with the most accurate and up-to-date molecular profiling for personalized cancer treatment. 

A unique capture method for high quality data with less sequencing 

OncoSELECT® Kit uses a unique Twist Biosciences’ capture method allowing high coverage and uniformity with less DNA input and less sequencing needed. 

An easy process automatization 

Thanks to the compatibility with Illumina’s technology, the easy automation process simplifies tasks by continuing using the current tools without disturbing the automate routine activities and losing time in extra training and manipulations. 

Compatible with Illumina Technology 

	OncoSELECT® Kit has been meticulously designed to seamlessly integrate Illumina’s cutting-edge sequencing platforms, ensuring a streamlined and efficient workflow. This singular compatibility empowers researchers to concentrate on their scientific goals, free from the burden of technical obstacles. By optimizing the compatibility of
OncoSELECT® Kit, we strike the perfect balance between cost efficiency and constand precision, guaranteeing reliable results without compromising accuracy.	

Achieving high-performance sequencing is now more accessible than ever, thanks to the OncoSELECT® Kit and Illumina sequencers. By utilizing these cutting-edge technologies, laboratories can process multiple samples per flow cell, as outlined in the Table above. This streamlined process allows faster and more efficient sequencing, resulting in more accurate data and better outcomes. 

From sample preparation to clinical insights in just 5 days 

OncoSELECT® Kit revolutionizes the diagnostic process by significantly reducing the timeline from DNA extraction to clinical and biological interpretation to just 5 days. This accelerated timeframe enables healthcare professionals to make faster decisions, resulting in enhanced patient care and improved outcomes. 

Clear data insight and clinical interpretation 

Easy sequencing files upload

After the sequencing, output files (FASTQ + Medata files) are uploaded 

Easy sequencing files upload

After the sequencing, output files (Fastq + medata files) are uploaded on a secured storage to automatically launch a batch of samples. 

Variants identification & annotation

Our BioIT pipeline performs the secondary analysis of genomic data 

Variants identification & annotation

Our BioIT pipeline performs the secondary analysis of genomic data by aligning the data, identifying, annotating and classifying the variants, and cleaning the bias. 

Data cross-referencing with our proprietary knowledge base

We use our proprietary knowledge base 

Data cross-referencing with our proprietary knowledge base

We use our proprietary knowledge base OncoKDO to perform tertiary analysis by cross-referencing molecular data, resulting in the clinical interpretation of the data. 

Clinical validation by scientific team

Our team of oncology experts reviews each report 

Clinical validation by scientific team

Our team of oncology experts reviews each report before making it available on OncoKDM 

OncoKDM® ’s comprehensive interpretation reports provide labs with eight essential assets to enhance the understanding of NGS data, including detailed annotations, a list of actionable variants, a list of therapies recommendation and a summary of relevant clinical trials. 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712109564

